

(51) International Patent Classification:
C12N 1/00 (2006.01)

(21) International Application Number:

PCT/US2014/014747

(22) International Filing Date:

4 February 2014 (04.02.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/760,574	4 February 2013 (04.02.2013)	US
61/760,585	4 February 2013 (04.02.2013)	US
61/760,606	4 February 2013 (04.02.2013)	US
61/760,584	4 February 2013 (04.02.2013)	US
61/798,606	15 March 2013 (15.03.2013)	US
61/926,918	13 January 2014 (13.01.2014)	US

(71) Applicant: SERES HEALTH, INC. [US/US]; 161 First Street, Suite 1A, Cambridge, MA 02142 (US).

(72) Inventors: AFEYAN, Noubar, B.; c/o Seres Health, Inc., 161 First Street, Suite 1A, Cambridge, MA 02142 (US). MCKENZIE, Mary-Jane, Lombardo; c/o Seres Health, Inc., 161 First Street, Suite 1A, Cambridge, MA 02142 (US). LITCOFSKY, Kevin, Daniel; c/o Seres Health, Inc., 161 First Street, Suite 1A, Cambridge, MA 02142 (US). COOK, David, N.; c/o Seres Health, Inc., 161 First Street, Suite 1A, Cambridge, MA 02142 (US). AFEYAN, Noubar, B.; c/o Seres Health, Inc., 161 First Street, Suite

1A, Cambridge, MA 02142 (US). GOODMAN, Brian; c/o Seres Health, Inc., 161 First Street, Suite 1A, Cambridge, MA 02142 (US).

(74) Agents: HUBL, Susan T. et al.; Fenwick & West LLP, Silicon Valley Center, 801 California Street, Mountain View, CA 94041 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS




Figure 6

(57) Abstract: Provided are defined bacterial compositions for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for populating the gastrointestinal tract of a subject. Provided also are bacterial formulations for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.



Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

TITLE

[001] Compositions and Methods

RELATED APPLICATIONS

[002] This application is related to U.S. Provisional Application No. 61/760,584, filed on Feb. 4, 2013, and to U.S. Provisional Application No. 61/760,585, filed on Feb. 4, 2013, and to U.S. Provisional Application No. 61/760,574, filed on Feb. 4, 2013, and to U.S. Provisional Application No. 61/760,606, filed on Feb. 4, 2013, and to U.S. Provisional Application No. 61/926,928, filed on Jan. 13, 2014, which are each incorporated by reference in its entirety for all purposes.

REFERENCE TO A SEQUENCE LISTING

[003] This application includes a Sequence Listing submitted electronically as a text file named 25968PCT_CRF_sequencelisting.txt, created on Feb. 4, 2014, with a size of 911,051 bytes. The sequence listing is incorporated by reference.

BACKGROUND

[004] Mammals are colonized by microbes in the gastrointestinal (GI) tract, on the skin, and in other epithelial and tissue niches such as the oral cavity, eye surface and vagina. The gastrointestinal tract harbors an abundant and diverse microbial community. It is a complex system, providing an environment or niche for a community of many different species or organisms, including diverse strains of bacteria. Hundreds of different species may form a commensal community in the GI tract in a healthy person, and this complement of organisms evolves from the time of birth to ultimately form a functionally mature microbial population by about 3 years of age. Interactions

between microbial strains in these populations and between microbes and the host, *e.g.* the host immune system, shape the community structure, with availability of and competition for resources affecting the distribution of microbes. Such resources may be food, location and the availability of space to grow or a physical structure to which the microbe may attach. For example, host diet is involved in shaping the GI tract flora.

[005] A healthy microbiota provides the host with multiple benefits, including colonization resistance to a broad spectrum of pathogens, essential nutrient biosynthesis and absorption, and immune stimulation that maintains a healthy gut epithelium and an appropriately controlled systemic immunity. In settings of ‘dysbiosis’ or disrupted symbiosis, microbiota functions can be lost or deranged, resulting in increased susceptibility to pathogens, altered metabolic profiles, or induction of proinflammatory signals that can result in local or systemic inflammation or autoimmunity. Thus, the intestinal microbiota plays a significant role in the pathogenesis of many diseases and disorders, including a variety of pathogenic infections of the gut. For instance, subjects become more susceptible to pathogenic infections when the normal intestinal microbiota has been disturbed due to use of broad-spectrum antibiotics. Many of these diseases and disorders are chronic conditions that significantly decrease a subject’s quality of life and can be ultimately fatal.

[006] Manufacturers of probiotics have asserted that their preparations of bacteria promote mammalian health by preserving the natural microflora in the GI tract and reinforcing the normal controls on aberrant immune responses. See, *e.g.*, U.S. Patent No. 8,034,601. Probiotics, however, have been limited to a very narrow group of

genera and a correspondingly limited number of species; as such, they do not adequately replace the missing natural microflora of the GI tract in many situations.

[007] Thus, there is a need for a method of populating a subject's gastrointestinal tract with a diverse and useful selection of microbiota in order to alter a dysbiosis. In response to the need for durable, efficient, and effective compositions and methods for treatment of GI diseases by way of restoring or enhancing microbiota functions, Applicants address these and other shortcomings of the art by providing compositions and methods for treating subjects.

SUMMARY OF THE INVENTION

[008] Disclosed herein are therapeutic compositions comprising a bacterial population comprising at least three but fewer than nine bacterial strains selected from the group consisting of *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*, wherein the composition is formulated for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition. In some embodiments, the bacterial strains are not a colonic bacterium and/or are not obtained from a fecal culture. In some embodiments, at least one *Bacteroides* species is detectably present in the mammalian subject prior to administration of the composition or, in other embodiments at least one *Bacteroides* species is not detectably present in the mammalian subject prior to administration of the composition, but is detectably present in the mammalian subject at least one hour after administration of the composition. In some embodiments, the mammalian subject has not received at

least two doses of vancomycin, metronidazole and/or or similar antibiotic compound within one week prior to administration of the therapeutic composition. In some embodiments, a single administration is substantially effective to reduce *C. difficile* and/or *C. difficile* toxin content in a mammalian subject to whom the composition is administered. In some embodiments, one strain of *E. coli* is present in amounts at least 2, 5, 10, 50, 100 or more than 100 times greater than any other strain of *E. coli* present in the composition. In some embodiments, at least three bacterial strains are not present in the composition in equal ratios or are present in a ratio equivalent to the ratio of the bacterial strains in a reference mammalian subject. In some embodiments, at least one of the bacterial strains is provided in a concentration of greater than 1×10^9 viable bacteria per gram of composition or is provided in a concentration of less than 1×10^8 viable bacteria per gram of composition. In some embodiments, a plurality of the bacterial strains is provided in a concentration of less than 1×10^8 viable bacteria per gram of composition. In some embodiments, no more than nine different bacterial strains are used, wherein at least two strains are from the group selected from: *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*. In some embodiments, the composition is formulated for oral administration as a solid, semi-solid, gel, or liquid form; in the form of a pill, tablet, capsule, or lozenge; the bacterial strains are substantially encapsulated in an enteric coating; and/or the bacterial strains are substantially inactive prior to localization in the gastrointestinal tract of a mammalian subject to whom the composition is administered. In some embodiments, no more than two of the bacterial

strains are strains whose growth is substantially inhibited by an equivalent amount of *C. difficile* bacteria.

[009] Also disclosed is a method of treating a mammalian subject suffering from or at risk of developing a gastrointestinal disease, disorder or condition, comprising the step of administering to the mammalian subject a therapeutic composition comprising a bacterial population as described herein, wherein the composition is formulated for oral or gastric administration. In some embodiments, the gastrointestinal disease, disorder or condition is selected from the group consisting of relapsing diarrhea caused by *C. difficile*, ulcerative colitis, colitis, Crohn's disease, and irritable bowel disease. In some embodiments, the mammalian subject is an agricultural mammal. In some embodiments, the bacterial population comprises at least six bacterial strains or comprises at least six but fewer than ten bacterial strains. In some embodiments, the therapeutic composition is administered only once prior to improvement of the disease, disorder or condition; wherein the therapeutic composition is administered at intervals greater than two days; the mammalian subject has not received at least two doses of vancomycin, metronidazole and/or or similar antibiotic compound within one week prior to administration of the therapeutic composition; the mammalian subject is not suffering from relapsing diarrhea caused by *C. difficile*; and/or the mammalian subject has not previously received an antibiotic compound in the one month prior to administration of the therapeutic composition.

[010] Also disclosed is a method of treating a mammalian subject suffering from or at risk of developing a gastrointestinal disease, disorder or condition, comprising

the step of administering to the mammalian subject any therapeutic composition disclosed herein.

[011] Also disclosed is a method of treating a mammalian subject suffering from or at risk of developing a gastrointestinal disease, disorder or condition, or a metabolic disease, disorder or condition selected from the group consisting of diabetes and autism, comprising the step of administering to the mammalian subject a therapeutic composition comprising a bacterial population comprising at least three bacterial strains, wherein no greater than nine of the bacterial strains are members of a bacterial species selected from the group consisting of *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*, wherein the composition is formulated for oral or gastric administration. In some embodiments, the method further comprises the step of detecting one or more of the administered bacterial strains in the mammalian subject subsequent to administration, for example, detecting a 16S nucleic acid sequence in at least one administered bacterial strain.

[012] Also disclosed is a therapeutic composition comprising a bacterial population comprising at least three but fewer than nine bacterial strains, wherein the bacterial strains comprise 16S nucleic acid sequences at least 97% identical to reference 16S nucleic acid sequences in bacterial strains selected from the group consisting of *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*, wherein the composition is

formulated for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.

[013] Also disclosed is a therapeutic composition comprising a bacterial population comprising at least three but fewer than nine bacterial strains, wherein the bacterial strains comprise *Clostridium innocuum*, *Clostridium ramosum*, and *Clostridium bifermentans*, wherein the composition is formulated for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.

[014] Also disclosed is a therapeutic composition comprising a bacterial population comprising at least three but fewer than nine bacterial strains, wherein the bacterial strains do not comprise detectable amounts of *Bacteroides ovatus*, *Bacteroides vulgatus*, or *Bacteroides thetaiotaomicron*, wherein the composition is formulated for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.

[015] Also disclosed is a method of increasing diversity of a gastrointestinal microbiota in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutic composition comprising a bacterial population comprising at least three but fewer than nine bacterial strains, wherein the bacterial strains comprise 16S nucleic acid sequences at least 97% identical to reference 16S nucleic acid sequences in bacterial strains selected from the group consisting of *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*, wherein the composition is formulated for oral

or gastric administration to a mammalian subject in an effective amount for increasing the diversity of the gastrointestinal microbiota of the mammalian subject subsequent to administration. In some embodiments, the diversity is increased for at least 1 day after administration or for at least 4 days after administration or for at least 7 days after administration or for at least 14 days after administration or for at least 21 days after administration. In some embodiments, wherein the mammalian subject is suffering from or at risk of developing a disease, disorder or condition other than a gastrointestinal disease, disorder or condition.

BRIEF DESCRIPTION OF THE DRAWINGS

[016] Figure 1A provides a schematic of 16S rRNA gene and denotes the coordinates of hypervariable regions 1-9 (V1-V9). Coordinates of V1-V9 are 69-99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1117-1173, 1243-1294, and 1435-1465 respectively, based on numbering using *E. coli* system of nomenclature defined by Brosius et al., Complete nucleotide sequence of a 16S ribosomal RNA gene (16S rRNA) from *Escherichia coli*, PNAS 75(10):4801-4805 (1978).

[017] Figure 1B highlights in bold the nucleotide sequences for each hypervariable region in the exemplary reference *E. coli* 16S sequence described by Brosius et al.

[018] Figure 2 shows a photograph of a CsCl gradient demonstrating the spore separation from other residual habitat material.

[019] Figure 3 shows three phase contrast image demonstrating the progressive enrichment of spores from a fecal suspension; ethanol treated, CsCl

purified spore preparation; and an ethanol treated, CsCl purified, sucrose purified spore preparation.

[020] Figure 4 shows a set of survival curves demonstrating efficacy of the spore population in a hamster prophylaxis model of *C. difficile*.

[021] Figure 5 provides a set of survival curves demonstrating efficacy of the spore population in a hamster relapse prevention model of *C. difficile*.

[022] Figure 6 shows the strong correlation and linear correspondence between the measurement of DPA concentration by a coupled fluorescence assay and the viable spore colony forming units.

[023] The figures depict various embodiments of the present invention for purposes of illustration only. One skilled in the art will readily recognize from the following discussion that alternative embodiments of the structures and methods illustrated herein may be employed without departing from the principles of the invention described herein.

DETAILED DESCRIPTION

DEFINITIONS

[024] “Microbiota” refers to the community of microorganisms that occur (sustainably or transiently) in and on an animal subject, typically a mammal such as a human, including eukaryotes, archaea, bacteria, and viruses (including bacterial viruses i.e., phage).

[025] “Microbiome” refers to the genetic content of the communities of microbes that live in and on the human body, both sustainably and transiently, including eukaryotes, archaea, bacteria, and viruses (including bacterial viruses (i.e., phage)),

wherein “genetic content” includes genomic DNA, RNA such as ribosomal RNA, the epigenome, plasmids, and all other types of genetic information.

[026] “Microbial Carriage” or simply “Carriage” refers to the population of microbes inhabiting a niche within or on humans. Carriage is often defined in terms of relative abundance. For example, OTU1 comprises 60% of the total microbial carriage, meaning that OTU1 has a relative abundance of 60% compared to the other OTUs in the sample from which the measurement was made. Carriage is most often based on genomic sequencing data where the relative abundance or carriage of a single OTU or group of OTUs is defined by the number of sequencing reads that are assigned to that OTU/s relative to the total number of sequencing reads for the sample.

[027] “Microbial Augmentation” or simply “augmentation” refers to the establishment or significant increase of a population of microbes that are (i) absent or undetectable (as determined by the use of standard genomic and microbiological techniques) from the administered therapeutic microbial composition, (ii) absent, undetectable, or present at low frequencies in the host niche (as example: gastrointestinal tract, skin, anterior-nares, or vagina) before the delivery of the microbial composition, and (iii) are found after the administration of the microbial composition or significantly increase, for instance 2-fold, 5-fold, 1×10^2 , 1×10^3 , 1×10^4 , 1×10^5 , 1×10^6 , 1×10^7 , or greater than 1×10^8 , in cases where they were present at low frequencies. The microbes that comprise an augmented ecology can be derived from exogenous sources such as food and the environment, or grow out from micro-niches within the host where they reside at low frequency.

[028] The administration of the therapeutic microbial composition induces an environmental shift in the target niche that promotes favorable conditions for the growth of these commensal microbes. In the absence of treatment with a therapeutic microbial composition, the host can be constantly exposed to these microbes; however, sustained growth and the positive health effects associated with the stable population of increased levels of the microbes comprising the augmented ecology are not observed.

[029] “Microbial Engraftment” or simply “engraftment” refers to the establishment of OTUs comprising a therapeutic microbial composition in a target niche that are absent in the treated host prior to treatment. The microbes that comprise the engrafted ecology are found in the therapeutic microbial composition and establish as constituents of the host microbial ecology upon treatment. Engrafted OTUs can establish for a transient period of time, or demonstrate long-term stability in the microbial ecology that populates the host post treatment with a therapeutic microbial composition. The engrafted ecology can induce an environmental shift in the target niche that promotes favorable conditions for the growth of commensal microbes capable of catalyzing a shift from a dysbiotic ecology to one representative of a health state.

[030] “Ecological Niche” or simply “Niche” refers to the ecological space in which a an organism or group of organisms occupies. Niche describes how an organism or population or organisms responds to the distribution of resources, physical parameters (e.g., host tissue space) and competitors (e.g., by growing when resources are abundant, and when predators, parasites and pathogens are scarce) and how it in turn alters those same factors (e.g., limiting access to resources by other organisms, acting as a food source for predators and a consumer of prey).

[031] “Dysbiosis” refers to a state of the microbiota of the gut or other body area in a subject, including mucosal or skin surfaces in which the normal diversity and/or function of the ecological network is disrupted. This unhealthy state can be due to a decrease in diversity, the overgrowth of one or more pathogens or pathobionts, symbiotic organisms able to cause disease only when certain genetic and/or environmental conditions are present in a subject, or the shift to an ecological microbial network that no longer provides an essential function to the host subject, and therefore no longer promotes health.

[032] “Pathobionts” or “Opportunistic Pathogens” refers to symbiotic organisms able to cause disease only when certain genetic and/or environmental conditions are present in a subject.

[033] “Phylogenetic tree” refers to a graphical representation of the evolutionary relationships of one genetic sequence to another that is generated using a defined set of phylogenetic reconstruction algorithms (e.g. parsimony, maximum likelihood, or Bayesian). Nodes in the tree represent distinct ancestral sequences and the confidence of any node is provided by a bootstrap or Bayesian posterior probability, which measures branch uncertainty.

[034] “Operational taxonomic units,” “OTU” (or plural, “OTUs”) refer to a terminal leaf in a phylogenetic tree and is defined by a nucleic acid sequence, e.g., the entire genome, or a specific genetic sequence, and all sequences that share sequence identity to this nucleic acid sequence at the level of species. In some embodiments the specific genetic sequence may be the 16S sequence or a portion of the 16S sequence. In other embodiments, the entire genomes of two entities are sequenced and

compared. In another embodiment, select regions such as multilocus sequence tags (MLST), specific genes, or sets of genes may be genetically compared. In 16S embodiments, OTUs that share $\geq 97\%$ average nucleotide identity across the entire 16S or some variable region of the 16S are considered the same OTU (see e.g. Claesson MJ, Wang Q, O'Sullivan O, Greene-Diniz R, Cole JR, Ross RP, and O'Toole PW. 2010. Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions. *Nucleic Acids Res* **38**: e200. Konstantinidis KT, Ramette A, and Tiedje JM. 2006. The bacterial species definition in the genomic era. *Philos Trans R Soc Lond B Biol Sci* **361**: 1929–1940.). In embodiments involving the complete genome, MLSTs, specific genes, or sets of genes OTUs that share $\geq 95\%$ average nucleotide identity are considered the same OTU (see e.g. Achtman M, and Wagner M. 2008. Microbial diversity and the genetic nature of microbial species. *Nat. Rev. Microbiol.* **6**: 431–440. Konstantinidis KT, Ramette A, and Tiedje JM. 2006. The bacterial species definition in the genomic era. *Philos Trans R Soc Lond B Biol Sci* **361**: 1929–1940.). OTUs are frequently defined by comparing sequences between organisms. Generally, sequences with less than 95% sequence identity are not considered to form part of the same OTU. OTUs may also be characterized by any combination of nucleotide markers or genes, in particular highly conserved genes (e.g., “house-keeping” genes), or a combination thereof. Such characterization employs, e.g., WGS data or a whole genome sequence.

[035] Table 1 below shows a List of Operational Taxonomic Units (OTU) with taxonomic assignments made to Genus, Species, and Phylogenetic Clade. Clade membership of bacterial OTUs is based on 16S sequence data. Clades are defined

based on the topology of a phylogenetic tree that is constructed from full-length 16S sequences using maximum likelihood methods familiar to individuals with ordinary skill in the art of phylogenetics. Clades are constructed to ensure that all OTUs in a given clade are: (i) within a specified number of bootstrap supported nodes from one another, and (ii) within 5% genetic similarity. OTUs that are within the same clade can be distinguished as genetically and phylogenetically distinct from OTUs in a different clade based on 16S-V4 sequence data, while OTUs falling within the same clade are closely related. OTUs falling within the same clade are evolutionarily closely related and may or may not be distinguishable from one another using 16S-V4 sequence data. Members of the same clade, due to their evolutionary relatedness, play similar functional roles in a microbial ecology such as that found in the human gut. Compositions substituting one species with another from the same clade are likely to have conserved ecological function and therefore are useful in the present invention. All OTUs are denoted as to their putative capacity to form spores and whether they are a Pathogen or Pathobiont (see Definitions for description of "Pathobiont"). NIAID Priority Pathogens are denoted as 'Category-A', 'Category-B', or 'Category-C', and Opportunistic Pathogens are denoted as 'OP'. OTUs that are not pathogenic or for which their ability to exist as a pathogen is unknown are denoted as 'N'. The 'SEQ ID Number' denotes the identifier of the OTU in the Sequence Listing File and 'Public DB Accession' denotes the identifier of the OTU in a public sequence repository.

[036] "Residual habitat products" refers to material derived from the habitat for microbiota within or on a human or animal. For example, microbiota live in feces in the gastrointestinal tract, on the skin itself, in saliva, mucus of the respiratory tract, or

secretions of the genitourinary tract (i.e., biological matter associated with the microbial community). Substantially free of residual habitat products means that the bacterial composition no longer contains the biological matter associated with the microbial environment on or in the human or animal subject and is 100% free, 99% free, 98% free, 97% free, 96% free, or 95% free of any contaminating biological matter associated with the microbial community. Residual habitat products can include abiotic materials (including undigested food) or it can include unwanted microorganisms. Substantially free of residual habitat products may also mean that the bacterial composition contains no detectable cells from a human or animal and that only microbial cells are detectable. In one embodiment, substantially free of residual habitat products may also mean that the bacterial composition contains no detectable viral (including bacterial viruses (i.e., phage)), fungal, mycoplasmal contaminants. In another embodiment, it means that fewer than $1 \times 10^{-2}\%$, $1 \times 10^{-3}\%$, $1 \times 10^{-4}\%$, $1 \times 10^{-5}\%$, $1 \times 10^{-6}\%$, $1 \times 10^{-7}\%$, $1 \times 10^{-8}\%$ of the viable cells in the bacterial composition are human or animal, as compared to microbial cells. There are multiple ways to accomplish this degree of purity, none of which are limiting. Thus, contamination may be reduced by isolating desired constituents through multiple steps of streaking to single colonies on solid media until replicate (such as, but not limited to, two) streaks from serial single colonies have shown only a single colony morphology. Alternatively, reduction of contamination can be accomplished by multiple rounds of serial dilutions to single desired cells (e.g., a dilution of 10^{-8} or 10^{-9}), such as through multiple 10-fold serial dilutions. This can further be confirmed by showing that multiple isolated colonies have similar cell shapes and Gram staining behavior. Other methods for confirming adequate purity include genetic analysis (e.g. PCR, DNA

sequencing), serology and antigen analysis, enzymatic and metabolic analysis, and methods using instrumentation such as flow cytometry with reagents that distinguish desired constituents from contaminants.

[037] “Clade” refers to the OTUs or members of a phylogenetic tree that are downstream of a statistically valid node in a phylogenetic tree. The clade comprises a set of terminal leaves in the phylogenetic tree that is a distinct monophyletic evolutionary unit and that share some extent of sequence similarity.

[038] 16s Sequencing, 16s, 16s-rRNA, 16s-NGS: In microbiology, “16S sequencing” or “16S-rRNA” or “16S” refers to sequence derived by characterizing the nucleotides that comprise the 16S ribosomal RNA gene(s). The bacterial 16S rDNA is approximately 1500 nucleotides in length and is used in reconstructing the evolutionary relationships and sequence similarity of one bacterial isolate to another using phylogenetic approaches. 16S sequences are used for phylogenetic reconstruction as they are in general highly conserved, but contain specific hypervariable regions that harbor sufficient nucleotide diversity to differentiate genera and species of most bacteria.

[039] The “V1-V9 regions” of the 16S rRNA refers to the first through ninth hypervariable regions of the 16S rRNA gene that are used for genetic typing of bacterial samples. These regions in bacteria are defined by nucleotides 69-99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1117-1173, 1243-1294 and 1435-1465 respectively using numbering based on the *E. coli* system of nomenclature. Brosius et al., Complete nucleotide sequence of a 16S ribosomal RNA gene from *Escherichia coli*, PNAS 75(10):4801-4805 (1978). In some embodiments, at least one of the V1, V2, V3, V4, V5,

V6, V7, V8, and V9 regions are used to characterize an OTU. In one embodiment, the V1, V2, and V3 regions are used to characterize an OTU. In another embodiment, the V3, V4, and V5 regions are used to characterize an OTU. In another embodiment, the V4 region is used to characterize an OTU. A person of ordinary skill in the art can identify the specific hypervariable regions of a candidate 16S rRNA by comparing the candidate sequence in question to a reference sequence and identifying the hypervariable regions based on similarity to the reference hypervariable regions, or alternatively, one can employ Whole Genome Shotgun (WGS) sequence characterization of microbes or a microbial community.

[040] The term “subject” refers to any animal subject including humans, laboratory animals (e.g., primates, rats, mice), livestock (e.g., cows, sheep, goats, pigs, turkeys, and chickens), and household pets (e.g., dogs, cats, and rodents). The subject may be suffering from a dysbiosis, including, but not limited to, an infection due to a gastrointestinal pathogen or may be at risk of developing or transmitting to others an infection due to a gastrointestinal pathogen.

[041] The term “phenotype” refers to a set of observable characteristics of an individual entity. As example an individual subject may have a phenotype of “health” or “disease”. Phenotypes describe the state of an entity and all entities within a phenotype share the same set of characteristics that describe the phenotype. The phenotype of an individual results in part, or in whole, from the interaction of the entities genome and/or microbiome with the environment.

[042] The term “Network Ecology” refers to a consortium of OTUs that co-occur in some number of subjects. As used herein, a “network” is defined

mathematically by a graph delineating how specific nodes (i.e. OTUs) and edges (connections between specific OTUs) relate to one another to define the structural ecology of a consortium of OTUs. Any given Network Ecology will possess inherent phylogenetic diversity and functional properties. A Network Ecology can also be defined in terms of function where for example the nodes would be comprised of elements such as, but not limited to, enzymes, clusters of orthologous groups (COGS; <http://www.ncbi.nlm.nih.gov/books/NBK21090/>), or KEGG pathways (www.genome.jp/kegg/).

[043] Network Class, Core Network, Core Network Ecology: The terms “Network Class”, “Core Network” and “Core Network Ecology” refer to a group of network ecologies that in general are computationally determined to comprise ecologies with similar phylogenetic and/or functional characteristics. A Core Network therefore contains important biological features, defined either phylogenetically or functionally, of a group (i.e., a cluster) of related network ecologies. One representation of a Core Network Ecology is a designed consortium of microbes, typically non-pathogenic bacteria, that represents core features of a set of phylogenetically or functionally related network ecologies seen in many different subjects. In many occurrences, a Core Network, while designed as described herein, exists as a Network Ecology observed in one or more subjects. Core Network ecologies are useful for reversing or reducing a dysbiosis in subjects where the underlying, related Network Ecology has been disrupted.

[044] The term “Keystone OTU” refers to one or more OTUs that are common to many network ecologies and are members of networks ecologies that occur in many

subjects (i.e. are pervasive). Due to the ubiquitous nature of Keystone OTUs, they are central to the function of network ecologies in healthy subjects and are often missing or at reduced levels in subjects with disease. Keystone OTUs may exist in low, moderate, or high abundance in subjects.

[045] The term “non-Keystone OTU” refers to an OTU that is observed in a Network Ecology and is not a keystone OTU.

[046] The term “Phylogenetic Diversity” refers to the biodiversity present in a given Network Ecology or Core Network Ecology based on the OTUs that comprise the network. Phylogenetic diversity is a relative term, meaning that a Network Ecology or Core Network that is comparatively more phylogenetically diverse than another network contains a greater number of unique species, genera, and taxonomic families.

Uniqueness of a species, genera, or taxonomic family is generally defined using a phylogenetic tree that represents the genetic diversity all species, genera, or taxonomic families relative to one another. In another embodiment phylogenetic diversity may be measured using the total branch length or average branch length of a phylogenetic tree.

[047] “Spore” or “endospore” refers to an entity, particularly a bacterial entity, which is in a dormant, non-vegetative and non-reproductive stage. Spores are generally resistant to environmental stress such as radiation, desiccation, enzymatic treatment, temperature variation, nutrient deprivation, and chemical disinfectants.

[048] A “spore population” refers to a plurality of spores present in a composition. Synonymous terms used herein include spore composition, spore preparation, *ethanol treated spore fraction* and spore ecology. A spore population may be purified from a fecal donation, e.g. via ethanol or heat treatment, or a density

gradient separation or any combination of methods described herein to increase the purity, potency and/or concentration of spores in a sample. Alternatively, a spore population may be derived through culture methods starting from isolated *spore former species* or *spore former OTUs* or from a mixture of such species, either in vegetative or spore form.

[049] In one embodiment, the spore preparation comprises spore forming species wherein residual non-spore forming species have been inactivated by chemical or physical treatments including ethanol, detergent, heat, sonication, and the like; or wherein the non-spore forming species have been removed from the spore preparation by various separations steps including density gradients, centrifugation, filtration and/or chromatography; or wherein inactivation and separation methods are combined to make the spore preparation. In yet another embodiment, the spore preparation comprises spore forming species that are enriched over viable non-spore formers or vegetative forms of spore formers. In this embodiment, spores are enriched by 2-fold, 5-fold, 10-fold, 50-fold, 100-fold, 1000-fold, 10,000-fold or greater than 10,000-fold compared to all vegetative forms of bacteria. In yet another embodiment, the spores in the spore preparation undergo partial germination during processing and formulation such that the final composition comprises spores and vegetative bacteria derived from spore forming species.

[050] A “germinant” is a material or composition or physical-chemical process capable of inducing vegetative growth of a bacterium that is in a dormant spore form, or group of bacteria in the spore form, either directly or indirectly in a host organism and/or in vitro.

[051] A “sporulation induction agent” is a material or physical-chemical process that is capable of inducing sporulation in a bacterium, either directly or indirectly, in a host organism and/or in vitro.

[052] To “increase production of bacterial spores” includes an activity or a sporulation induction agent. “Production” includes conversion of vegetative bacterial cells into spores and augmentation of the rate of such conversion, as well as decreasing the germination of bacteria in spore form, decreasing the rate of spore decay *in vivo*, or *ex vivo*, or to increasing the total output of spores (e.g. via an increase in volumetric output of fecal material).

[053] The “colonization” of a host organism includes the non-transitory residence of a bacterium or other microscopic organism. As used herein, “reducing colonization” of a host subject’s gastrointestinal tract (or any other microbiotal niche) by a pathogenic bacterium includes a reduction in the residence time of the pathogen in the gastrointestinal tract as well as a reduction in the number (or concentration) of the pathogen in the gastrointestinal tract or adhered to the luminal surface of the gastrointestinal tract. Measuring reductions of adherent pathogens may be demonstrated, e.g., by a biopsy sample, or reductions may be measured indirectly, e.g., by measuring the pathogenic burden in the stool of a mammalian host.

[054] A “combination” of two or more bacteria includes the physical co-existence of the two bacteria, either in the same material or product or in physically connected products, as well as the temporal co-administration or co-localization of the two bacteria.

[055] A “cytotoxic” activity or bacterium includes the ability to kill a bacterial cell, such as a pathogenic bacterial cell. A “cytostatic” activity or bacterium includes the ability to inhibit, partially or fully, growth, metabolism, and/or proliferation of a bacterial cell, such as a pathogenic bacterial cell.

[056] To be free of “non-comestible products” means that a bacterial composition or other material provided herein does not have a substantial amount of a non-comestible product, e.g., a product or material that is inedible, harmful or otherwise undesired in a product suitable for administration, e.g., oral administration, to a human subject. Non-comestible products are often found in preparations of bacteria from the prior art.

[057] As used herein the term "vitamin" is understood to include any of various fat-soluble or water-soluble organic substances (non-limiting examples include *vitamin A*, Vitamin B1 (thiamine), Vitamin B2 (riboflavin), Vitamin B3 (*niacin* or niacinamide), Vitamin B5 (pantothenic acid), Vitamin B6 (pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride), Vitamin B7 (biotin), Vitamin B9 (folic acid), and Vitamin B12 (various cobalamins; commonly cyanocobalamin in vitamin supplements), vitamin C, vitamin D, vitamin E, vitamin K, K1 and K2 (i.e. MK-4, MK-7), folic acid and biotin) essential in minute amounts for normal growth and activity of the body and obtained naturally from plant and animal foods or synthetically made, pro-vitamins, derivatives, analogs.

[058] As used herein, the term "minerals" is understood to include boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, nickel, phosphorus, potassium, selenium, silicon, tin, vanadium, zinc, or combinations thereof.

[059] As used herein, the term "antioxidant" is understood to include any one or more of various substances such as beta-carotene (a *vitamin A* precursor), vitamin C, vitamin E, and selenium) that inhibit oxidation or reactions promoted by Reactive Oxygen Species ("ROS") and other radical and non-radical species. Additionally, antioxidants are molecules capable of slowing or preventing the oxidation of other molecules. Non-limiting examples of antioxidants include astaxanthin, carotenoids, coenzyme Q10 ("CoQ10"), flavonoids, glutathione, Goji (wolfberry), hesperidin, lactowolfberry, lignan, lutein, lycopene, polyphenols, selenium, *vitamin A*, vitamin C, vitamin E, zeaxanthin, or combinations thereof.

COMPOSITIONS OF THE INVENTION

Bacterial Compositions

[060] We have identified combinations of commensal bacteria of the human gut microbiota with the capacity to meaningfully provide functions of a healthy microbiota when administered to mammalian hosts. Without being limited to a specific mechanism, it is thought that such compositions inhibit the growth of a pathogen such as *C. difficile*, *Salmonella* spp., enteropathogenic *E coli*, and vancomycin-resistant *Enterococcus* spp. and other pathobionts, so that a healthy, diverse and protective microbiota can be maintained or, in the case of pathogenic bacterial infections such as recurrent *C. difficile* infection, repopulate the intestinal lumen to reestablish ecological control over potential pathogens. Furthermore, the bacterial compositions have the ability to shift the state of the gut microbiota toward a healthy state allowing for augmentation of the microbiota with commensal bacteria found in healthy microbiomes. The bacterial compositions may also engraft in the host themselves and remain present in the gut for 1 day, 1 week, 1 month, 1 year, or longer than 1 year.

[061] Preferred bacterial species include *Escherichia coli*, *Streptococcus faecalis*, *Clostridium Innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*. As used herein, a “type” or more than one “types” of bacteria may be differentiated at the genus level, the species level, the sub-species level, the strain level or by any other taxonomic method, as described herein and otherwise known in the art. Preferred bacterial species also include species that share 97% homology in the 16s rDNA region to the species of *Escherichia coli*, *Streptococcus faecalis*, *Clostridium Innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta* as defined by the provided 16s sequences (See Table 1).

[062] Bacterial compositions may consist essentially of no greater than a number of types of these preferred bacteria. For instance, a bacterial composition may comprise no more than 2, no more than 3, no more than 4, no more than 5, no more than 6, no more than 7, no more than 8, no more than 9, no more than 10, no more than 11, no more than 12, no more than 13, no more than 14, no more than 15, no more than 16, no more than 17, no more than 18, no more than 19, or no more than 20 types of bacteria, as defined by above species or operational taxonomic unit (OTU) encompassing such species.

[063] Bacterial compositions may consist essentially of a range of numbers of species of these preferred bacteria, but the precise number of species in a given composition is not known. For instance, a bacterial composition may consist essentially of between 2 and 10, 3 and 10, 4 and 10, 5 and 10, 6 and 10, 7 and 10, 8 and 10, or 9

and 10; or 2 and 9, 3 and 9, 4 and 9, 5 and 9, 6 and 9, 7 and 8 or 8 and 9; or 2 and 8, 3 and 8, 4 and 8, 5 and 8, 6 and 8 or 7 and 8; or 2 and 7, 3 and 7, 4 and 7, 5 and 7, or 6 and 7; or 2 and 6, 3 and 6, 4 and 6 or 5 and 6; or 2 and 5, 3 and 5 or 4 and 5; or 2 and 4 or 3 and 4; or 2 and 3, as defined by above species or operational taxonomic unit (OTU) encompassing such species.

[064] Bacterial compositions containing a plurality of species may be provided such that the relative concentration of a given species in the composition to any other species in the composition is known or unknown. Such relative concentrations of any two species, or OTUs, may be expressed as a ratio, where the ratio of a first species or OTU to a second species or OTU is 1:1 or any ratio other than 1:1, such as 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:15, 1:20, 1:25; 1:50; 1:75, 1:100, 1:200, 1:500; 1:1000, 1:10,000, 1:100,000 or greater than 1:100,000. The ratio of bacterial strains present in a bacterial composition may be determined by the ratio of the bacterial strains in a reference mammalian subject, e.g., a healthy human not suffering from or at known risk of developing a dysbiosis.

[065] Bacterial compositions comprising a plurality of species may be provided such that the concentration of a given strain, or the aggregate of all strains, is between 1×10^4 and 1×10^{15} viable bacteria per gram of composition or per administered dose. For example the concentration of a given strain, or the aggregate of all strains, is e.g., 1×10^4 , 1×10^5 , 1×10^6 , 1×10^7 , 1×10^8 , 1×10^9 , 1×10^{10} , 1×10^{11} , 1×10^{12} , 1×10^{13} , 1×10^{14} , 1×10^{15} , or greater than 1×10^{15} viable bacteria per gram of composition or per administered dose. Alternatively, the concentration of a given strain, or the aggregate of all strains, is below a given concentration e.g., below 1×10^4 , 1×10^5 , 1×10^6 , 1×10^7 ,

1×10^8 , 1×10^9 , 1×10^{10} , 1×10^{11} , 1×10^{12} , 1×10^{13} , 1×10^{14} , 1×10^{15} , or below 1×10^{15} viable bacteria per gram of composition or per administered dose.

[066] In certain embodiments, the bacterial compositions comprise a plurality of strains of the same species of bacteria. In certain embodiments, the strain of bacteria is present in amounts at least 2, 5, 10, 50, 100 or more than 100 times greater than any other strain of that species present in the composition. For example, provided are compositions containing one strain of *E. coli*, where this strain is present in amounts at least 2, 5, 10, 50, 100 or more than 100 times greater than any other strain of *E. coli* present in the composition.

[067] Because pathogenic bacteria such as *C. difficile* bacteria may inhibit growth of the bacterial strains present in the composition, it is generally beneficial such that no more than two of the bacterial strains in the bacterial composition are strains whose growth is substantially inhibited, e.g., *in vitro*, by an equivalent amount of *C. difficile* bacteria.

[068] In one embodiment, the bacterial composition comprises at least one and preferably more than one of the following species or a species that is 97% identical based on the 16s rDNA: *Barnesiella intestinihominis*; *Lactobacillus reuteri*; a species characterized as one of *Enterococcus hirae*, *Enterococcus faecium*, or *Enterococcus durans*; a species characterized as one of *Anaerostipes caccae* or *Clostridium indolis*; a species characterized as one of *Staphylococcus warneri* or *Staphylococcus pasteurii*; and *Adlercreutzia equolifaciens*. In an alternative embodiment, at least one of the preceding species is not substantially present in the bacterial composition.

[069] In one embodiment, the bacterial composition comprises at least one and preferably more than one of the following species or a species that is 97% identical based on the 16s rDNA: *Clostridium absonum*, *Clostridium argentinense*, *Clostridium baratii*, *Clostridium bifermentans*, *Clostridium botulinum*, *Clostridium butyricum*, *Clostridium cadaveris*, *Clostridium camis*, *Clostridium celatum*, *Clostridium chauvoei*, *Clostridium clostridioforme*, *Clostridium cochlearium*, *Clostridium difficile*, *Clostridium fallax*, *Clostridium felsineum*, *Clostridium ghonii*, *Clostridium glycolicum*, *Clostridium haemolyticum*, *Clostridium hastiforme*, *Clostridium histolyticum*, *Clostridium indolis*, *Clostridium innocuum*, *Clostridium irregulare*, *Clostridium limosum*, *Clostridium malenominatum*, *Clostridium novyi*, *Clostridium oroticum*, *Clostridium paraputrificum*, *Clostridium perfringens*, *Clostridium piliforme*, *Clostridium putrefaciens*, *Clostridium putrificum*, *Clostridium ramosum*, *Clostridium sardiniense*, *Clostridium sartagoforme*, *Clostridium scindens*, *Clostridium septicum*, *Clostridium sordellii*, *Clostridium sphenoides*, *Clostridium spiroforme*, *Clostridium sporogenes*, *Clostridium subterminale*, *Clostridium symbiosum*, *Clostridium tertium*, *Clostridium tetani*, *Clostridium welchii*, and *Clostridium villosum*. In an alternative embodiment, at least one of the preceding species is not substantially present in the bacterial composition.

[070] In one embodiment, the bacterial composition comprises at least one and preferably more than one of the following species or a species that is 97% identical based on the 16s rDNA: *Clostridium innocuum*, *Clostridium bifermentans*, *Clostridium butyricum*, *Bacteroides fragilis*, *Bacteroides thetaiotaomicron*, *Bacteroides uniformis*, three strains of *Escherichia coli*, and *Lactobacillus* sp. In an alternative embodiment, at

least one of the preceding species is not substantially present in the bacterial composition.

[071] In one embodiment, the bacterial composition comprises at least one and preferably more than one of the following species or a species that is 97% identical based on the 16s rDNA: *Clostridium bifermentans*, *Clostridium innocuum*, *Clostridium butyricum*, three strains of *Escherichia coli*, three strains of *Bacteroides*, and *Blautia producta*. In an alternative embodiment, at least one of the preceding species is not substantially present in the bacterial composition.

[072] In one embodiment, the bacterial composition comprises at least one and preferably more than one of the following species or a species that is 97% identical based on the 16s rDNA: *Bacteroides sp.*, *Escherichia coli*, and non pathogenic *Clostridia*, including *Clostridium innocuum*, *Clostridium bifermentans* and *Clostridium ramosum*. In an alternative embodiment, at least one of the preceding species is not substantially present in the bacterial composition.

[073] In one embodiment, the bacterial composition comprises at least one and preferably more than one of the following species or a species that is 97% identical based on the 16s rDNA: *Bacteroides* species, *Escherichia coli* and non-pathogenic *Clostridia*, such as *Clostridium butyricum*, *Clostridium bifermentans* and *Clostridium innocuum*. In an alternative embodiment, at least one of the preceding species is not substantially present in the bacterial composition.

[074] In one embodiment, the bacterial composition comprises at least one and preferably more than one of the following species or a species that is 97% identical based on the 16s rDNA: *Bacteroides caccae*, *Bacteroides capillosus*, *Bacteroides*

coagulans, *Bacteroides distasonis*, *Bacteroides eggerthii*, *Bacteroides forsythus*, *Bacteroides fragilis*, *Bacteroides fragilis-ryhm*, *Bacteroides gracilis*, *Bacteroides levii*, *Bacteroides macacae*, *Bacteroides merdae*, *Bacteroides ovatus*, *Bacteroides pneumosintes*, *Bacteroides putredinis*, *Bacteroides pyogenes*, *Bacteroides splanchnicus*, *Bacteroides stercoris*, *Bacteroides tectum*, *Bacteroides thetaiotaomicron*, *Bacteroides uniformis*, *Bacteroides ureolyticus*, and *Bacteroides vulgatus*. In an alternative embodiment, at least one of the preceding species is not substantially present in the bacterial composition.

[075] In one embodiment, the bacterial composition comprises at least one and preferably more than one of the following species or a species that is 97% identical based on the 16s rDNA: *Bacteroides*, *Eubacteria*, *Fusobacteria*, *Propionibacteria*, *Lactobacilli*, *anaerobic cocci*, *Ruminococcus*, *Escherichia coli*, *Gemmiger*, *Desulfomonas*, and *Peptostreptococcus*. In an alternative embodiment, at least one of the preceding species is not substantially present in the bacterial composition.

[076] In one embodiment, the bacterial composition comprises at least one and preferably more than one of the following species or a species that is 97% identical based on the 16s rDNA: *Bacteroides fragilis* ss. *Vulgatus*, *Eubacterium aerofaciens*, *Bacteroides fragilis* ss. *Thetaiotaomicron*, *Blautia producta* (previously known as *Peptostreptococcus productus* II), *Bacteroides fragilis* ss. *Distasonis*, *Fusobacterium prausnitzii*, *Coprococcus eutactus*, *Eubacterium aerofaciens* III, *Blautia producta* (previously known as *Peptostreptococcus productus* I), *Ruminococcus bronii*, *Bifidobacterium adolescentis*, *Gemmiger formicilis*, *Bifidobacterium longum*, *Eubacterium siraeum*, *Ruminococcus torques*, *Eubacterium rectale* III-H, *Eubacterium*

rectale IV, Eubacterium eligens, Bacteroides eggerthii, Clostridium leptum, Bacteroides fragilis ss. A, Eubacterium bifforme, Bifidobacterium infantis, Eubacterium rectale III-F, Coprococcus comes, Bacteroides capillosus, Ruminococcus albus, Eubacterium formicigenerans, Eubacterium hallii, Eubacterium ventriosum I, Fusobacterium russii, Ruminococcus obeum, Eubacterium rectale II, Clostridium ramosum I, Lactobacillus leichmanii, Ruminococcus cailidus, Butyrivibrio crossotus, Acidaminococcus fermentans, Eubacterium ventriosum, Bacteroides fragilis ss. fragilis, Bacteroides AR, Coprococcus catus, Eubacterium hadrum, Eubacterium cylindroides, Eubacterium ruminantium, Eubacterium CH-1, Staphylococcus epidermidis, Peptostreptococcus BL, Eubacterium limosum, Bacteroides praeacutus, Bacteroides L, Fusobacterium mortiferum I, Fusobacterium naviforme, Clostridium innocuum, Clostridium ramosum, Propionibacterium acnes, Ruminococcus flavefaciens, Ruminococcus AT, Peptococcus AU-1, Eubacterium AG, -AK, -AL, -AL-1, -AN; Bacteroides fragilis ss. ovatus, -ss. d, -ss. f; Bacteroides L-1, L-5; Fusobacterium nucleatum, Fusobacterium mortiferum, Escherichia coli, Streptococcus morbillorum, Peptococcus magnus, Peptococcus G, AU-2; Streptococcus intermedius, Ruminococcus lactaris, Ruminococcus CO Gemmiger X, Coprococcus BH, -CC; Eubacterium tenue, Eubacterium ramulus, Eubacterium AE, -AG-H, -AG-M, -AJ, -BN-1; Bacteroides clostridiiformis ss. clostridiiformis, Bacteroides coagulans, Bacteroides orails, Bacteroides ruminicola ss. brevis, -ss. ruminicola, Bacteroides splanchnicus, Desulfomonas pigra, Bacteroides L-4, -N-i; Fusobacterium H, Lactobacillus G, and Succinivibrio A. In an alternative embodiment, at least one of the preceding species is not substantially present in the bacterial composition.

Bacterial Compositions Described by Operational Taxonomic Unit (OTUs)

[077] Bacterial compositions may be prepared comprising at least two types of isolated bacteria, chosen from the species in Table 1.

[078] A bacterial composition may be prepared comprising at least two types of isolated bacteria, wherein a first type is a first OTU comprising a species of *E. coli*, *S. faecalis*, *Cl. Innocuum*, *Cl. ramosum*, *Cl. bifermentans*, *Bact. ovatus*, *Bact. vulgatus*, *Bact. thetaiotaomicron*, or *Blautia producta* and the type is a second OTU is characterized by, i.e., at least 95%, 96%, 97%, 98%, 99% or including 100% sequence identity to, the first OTU. In some embodiments, two types of bacteria are provided in a composition, and the first bacteria and the second bacteria are not the same OTU.

[079] OTUs can be defined either by full 16S sequencing of the rRNA gene (Table 1), by sequencing of a specific hypervariable region of this gene (i.e. V1, V2, V3, V4, V5, V6, V7, V8, or V9), or by sequencing of any combination of hypervariable regions from this gene (e.g. V1-3 or V3-5). The bacterial 16S rDNA is approximately 1500 nucleotides in length and is used in reconstructing the evolutionary relationships and sequence similarity of one bacterial isolate to another using phylogenetic approaches. 16S sequences are used for phylogenetic reconstruction as they are in general highly conserved, but contain specific hypervariable regions that harbor sufficient nucleotide diversity to differentiate genera and species of most microbes.

[080] Using well known techniques, in order to determine the full 16S sequence or the sequence of any hypervariable region of the 16S sequence, genomic DNA is extracted from a bacterial sample, the 16S rDNA (full region or specific hypervariable regions) amplified using polymerase chain reaction (PCR), the PCR

products cleaned, and nucleotide sequences delineated to determine the genetic composition of 16S gene or subdomain of the gene. If full 16S sequencing is performed, the sequencing method used may be, but is not limited to, Sanger sequencing. If one or more hypervariable regions are used, such as the V4 region, the sequencing can be, but is not limited to being, performed using the Sanger method or using a next-generation sequencing method, such as an Illumina (sequencing by synthesis) method using barcoded primers allowing for multiplex reactions.

[081] OTUs can be defined by a combination of nucleotide markers or genes, in particular highly conserved genes (e.g., “house-keeping” genes), or a combination thereof, full-genome sequence, or partial genome sequence generated using amplified genetic products, or whole genome sequence (WGS). Using well defined methods DNA extracted from a bacterial sample will have specific genomic regions amplified using PCR and sequenced to determine the nucleotide sequence of the amplified products. In the whole genome shotgun (WGS) method, extracted DNA will be directly sequenced without amplification. Sequence data can be generated using any sequencing technology including, but not limited to Sanger, Illumina, 454 Life Sciences, Ion Torrent, ABI, Pacific Biosciences, and/or Oxford Nanopore.

[082] In one embodiment, the OTUs can be characterized by one or more of the variable regions of the 16S sequence (V1-V9). These regions in bacteria are defined by nucleotides 69-99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1117-1173, 1243-1294 and 1435-1465 respectively using numbering based on the *E. coli* system of nomenclature. (See, e.g., Brosius *et al.*, Complete nucleotide sequence of a 16S ribosomal RNA gene from *Escherichia coli*, PNAS 75(10):4801-4805 (1978)). In some

embodiments, at least one of the V1, V2, V3, V4, V5, V6, V7, V8, and V9 regions are used to characterize an OTU. In one embodiment, the V1, V2, and V3 regions are used to characterize an OTU. In another embodiment, the V3, V4, and V5 regions are used to characterize an OTU. In another embodiment, the V4 region is used to characterize an OTU.

Inhibition of Bacterial Pathogens

[083] In some embodiments, the bacterial composition provides a protective or therapeutic effect against infection by one or more GI pathogens of interest. A list of exemplary bacterial pathogens and pathobionts is provided in Table 1.

[084] In some embodiments, the pathogenic bacterium is selected from the group consisting of Yersinia, Vibrio, Treponema, Streptococcus, Staphylococcus, Shigella, Salmonella, Rickettsia, Orientia, Pseudomonas, Neisseria, Mycoplasma, Mycobacterium, Listeria, Leptospira, Legionella, Klebsiella, Helicobacter, Haemophilus, Francisella, Escherichia, Ehrlichia, Enterococcus, Coxiella, Corynebacterium, Clostridium, Chlamydia, Chlamydophila, Campylobacter, Burkholderia, Brucella, Borrelia, Bordetella, Bifidobacterium, Bacillus, multi-drug resistant bacteria, extended spectrum beta-lactam resistant Enterococci (ESBL), Carbapenem-resistant Enterobacteriaceae (CRE), and vancomycin-resistant Enterococci (VRE).

[085] In some embodiments, these pathogens include, but are not limited to, Aeromonas hydrophila, Campylobacter fetus, Plesiomonas shigelloides, Bacillus cereus, Campylobacter jejuni, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, enteroaggregative Escherichia coli, enterohemorrhagic Escherichia coli, enteroinvasive Escherichia coli, enterotoxigenic Escherichia coli (such as, but not limited to, LT and/or ST), Escherichia coli O157:H7, Helicobacter pylori, Klebsiella

pneumonia, *Lysteria monocytogenes*, *Plesiomonas shigelloides*, *Salmonella* spp., *Salmonella typhi*, *Salmonella paratyphi*, *Shigella* spp., *Staphylococcus* spp., *Staphylococcus aureus*, vancomycin-resistant *enterococcus* spp., *Vibrio* spp., *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificus*, and *Yersinia enterocolitica*.

[086] In one embodiment, the pathogen of interest is at least one pathogen chosen from *Clostridium difficile*, *Salmonella* spp., pathogenic *Escherichia coli*, vancomycin-resistant *Enterococcus* spp., and extended spectrum beta-lactam resistant *Enterococci* (ESBL).

Generation and Formulation of Bacterial Compositions

[087] The bacterial compositions are generally formulated for oral or gastric administration, typically to a mammalian subject. Preferably, such formulations contain or are coated by an enteric coating to protect the bacteria through the stomach and small intestine. In particular embodiments, the composition is formulated for oral administration as a solid, semi-solid, powder, gel, or liquid form, such as in the form of a pill, tablet, capsule, or lozenge.

[088] The bacterial strains may, individually or together, be substantially inactive prior to localization in the gastrointestinal tract of the mammalian subject to whom the composition is administered. The bacterial strains may be lyophilized or otherwise acted upon to increase long-term storage viability.

[089] Preferential species include *E. coli*, *S. faecalis*, *Cl. Innocuum*, *Cl. ramosum*, *Cl. bifermentans*, *Bact. ovatus*, *Bact. vulgatus*, *Bact. thetaiotaomicron*, and *Blautia producta*, or species 97% identical to the 16s rDNA sequences of these species and are generally provided in bacterial compositions containing at least three strains. In certain embodiments, at least one of the bacterial strains is not a colonic bacterium. In

another embodiment, at least one of the bacterial strains is not obtained from a fecal culture, e.g., the bacterial strain is obtained from culturing a non-fecal biological material from a subject, from an environmental source, or from repeatedly streaking and purifying strains from any source. Alternatively, at least one bacterial strain is genetically engineered. In another embodiment, at least one species is present in the composition in spore form. In an alternative embodiment, all of the species are present as vegetative forms, substantially free of spores.

[090] The bacterial compositions may be formulated to be effective in a given mammalian subject in a single administration or over multiple administrations. For example, a single administration is substantially effective to reduce *C. difficile* and/or *C. difficile* toxin content in a mammalian subject to whom the composition is administered. Alternatively, a single administration is substantially effective to reduce vancomycin resistant Enterococci, carbapenem resistant bacteria, or another pathobiont in a mammalian subject to whom the composition is administered (See Table 1). Substantially effective means that *C. difficile* and/or *C. difficile* toxin and/or pathobiont content in the subject is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99% or greater than 99% following administration of the composition.

[091] In some embodiments, the bacterial compositions comprise purified spore populations. Purified spore populations comprise one or more commensal bacteria of the human gut microbiota present in the form of a spore. Without being limited to a specific mechanism, it is thought that such compositions inhibit the growth of a pathogen such as *C. difficile*, *Salmonella* spp., enteropathogenic *E. coli*, and

vancomycin-resistant *Enterococcus* spp., so that a healthy, diverse and protective microbiota can be maintained or, in the case of pathogenic bacterial infections such as *C. difficile* infection, repopulate the intestinal lumen to reestablish ecological control over potential pathogens.

[092] In some embodiments, spore-forming bacteria are identified by the presence of nucleic acid sequences that modulate sporulation. In particular, signature sporulation genes are highly conserved across members of distantly related genera including *Clostridium* and *Bacillus*. Traditional approaches of forward genetics have identified many, if not all, genes that are essential for sporulation (spo). The developmental program of sporulation is governed in part by the successive action of four compartment-specific sigma factors (appearing in the order σ_F , σ_E , σ_G and σ_K), whose activities are confined to the forespore (σ_F and σ_G) or the mother cell (σ_E and σ_K).

[093] Provided are bacterial compositions comprising more than one type of spore forming bacterium. As used herein, a “type” or more than one “types” of bacteria may be differentiated at the genus level, the species, level, the sub-species level, the strain level or by any other taxonomic method, as described herein and otherwise known in the art.

PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS OF THE INVENTION

[094] Provided are formulations for administration to humans and other subjects in need thereof. Generally the bacterial compositions are combined with additional active and/or inactive materials in order to produce a final product, which may be in single dosage unit or in a multi-dose format.

[095] In some embodiments, the composition comprises at least one carbohydrate. A “carbohydrate” refers to a sugar or polymer of sugars. The terms “saccharide,” “polysaccharide,” “carbohydrate,” and “oligosaccharide” may be used interchangeably. Most carbohydrates are aldehydes or ketones with many hydroxyl groups, usually one on each carbon atom of the molecule. Carbohydrates generally have the molecular formula $C_nH_{2n}O_n$. A carbohydrate can be a monosaccharide, a disaccharide, trisaccharide, oligosaccharide, or polysaccharide. The most basic carbohydrate is a monosaccharide, such as glucose, sucrose, galactose, mannose, ribose, arabinose, xylose, and fructose. Disaccharides are two joined monosaccharides. Exemplary disaccharides include sucrose, maltose, cellobiose, and lactose. Typically, an oligosaccharide includes between three and six monosaccharide units (e.g., raffinose, stachyose), and polysaccharides include six or more monosaccharide units. Exemplary polysaccharides include starch, glycogen, and cellulose. Carbohydrates can contain modified saccharide units, such as 2'-deoxyribose wherein a hydroxyl group is removed, 2'-fluororibose wherein a hydroxyl group is replaced with a fluorine, or N-acetylglucosamine, a nitrogen-containing form of glucose (e.g., 2'-fluororibose, deoxyribose, and hexose). Carbohydrates can exist in many different forms, for example, conformers, cyclic forms, acyclic forms, stereoisomers, tautomers, anomers, and isomers.

[096] In some embodiments, the composition comprises at least one lipid. As used herein, a “lipid” includes fats, oils, triglycerides, cholesterol, phospholipids, fatty acids in any form including free fatty acids. Fats, oils and fatty acids can be saturated, unsaturated (cis or trans) or partially unsaturated (cis or trans). In some embodiments,

the lipid comprises at least one fatty acid selected from lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), palmitoleic acid (16:1), margaric acid (17:0), heptadecenoic acid (17:1), stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2), linolenic acid (18:3), octadecatetraenoic acid (18:4), arachidic acid (20:0), eicosenoic acid (20:1), eicosadienoic acid (20:2), eicosatetraenoic acid (20:4), eicosapentaenoic acid (20:5) (EPA), docosanoic acid (22:0), docosenoic acid (22:1), docosapentaenoic acid (22:5), docosahexaenoic acid (22:6) (DHA), and tetracosanoic acid (24:0). In other embodiments, the composition comprises at least one modified lipid, for example, a lipid that has been modified by cooking.

[097] In some embodiments, the composition comprises at least one supplemental mineral or mineral source. Examples of minerals include, without limitation: chloride, sodium, calcium, iron, chromium, copper, iodine, zinc, magnesium, manganese, molybdenum, phosphorus, potassium, and selenium. Suitable forms of any of the foregoing minerals include soluble mineral salts, slightly soluble mineral salts, insoluble mineral salts, chelated minerals, mineral complexes, non-reactive minerals such as carbonyl minerals, and reduced minerals, and combinations thereof.

[098] In certain embodiments, the composition comprises at least one supplemental vitamin. In one embodiment, at least one vitamin can be fat-soluble or water soluble vitamins. Suitable vitamins include but are not limited to vitamin C, vitamin A, vitamin E, vitamin B12, vitamin K, riboflavin, niacin, vitamin D, vitamin B6, folic acid, pyridoxine, thiamine, pantothenic acid, and biotin. Suitable forms of any of the foregoing are salts of the vitamin, derivatives of the vitamin, compounds having the same or similar activity of the vitamin, and metabolites of the vitamin.

[0099] In other embodiments, the composition comprises an excipient. Non-limiting examples of suitable excipients include a buffering agent, a preservative, a stabilizer, a binder, a compaction agent, a lubricant, a dispersion enhancer, a disintegration agent, a flavoring agent, a sweetener, and a coloring agent.

[0100] In another embodiment, the excipient is a buffering agent. Non-limiting examples of suitable buffering agents include sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, and calcium bicarbonate.

[0101] In some embodiments, the excipient comprises a preservative. Non-limiting examples of suitable preservatives include antioxidants, such as alpha-tocopherol and ascorbate, and antimicrobials, such as parabens, chlorobutanol, and phenol.

[0102] In other embodiments, the composition comprises a binder as an excipient. Non-limiting examples of suitable binders include starches, pregelatinized starches, gelatin, polyvinylpyrrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamides, polyvinylloxazolidone, polyvinylalcohols, C₁₂-C₁₈ fatty acid alcohol, polyethylene glycol, polyols, saccharides, oligosaccharides, and combinations thereof.

[0103] In another embodiment, the composition comprises a lubricant as an excipient. Non-limiting examples of suitable lubricants include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oils, sterotex, polyoxyethylene monostearate, talc, polyethyleneglycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and light mineral oil.

[0104] In other embodiments, the composition comprises a dispersion enhancer as an excipient. Non-limiting examples of suitable dispersants include starch, alginic acid, polyvinylpyrrolidones, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose as high HLB emulsifier surfactants.

[0105] In some embodiments, the composition comprises a disintegrant as an excipient. In other embodiments, the disintegrant is a non-effervescent disintegrant. Non-limiting examples of suitable non-effervescent disintegrants include starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays, such as bentonite, micro-crystalline cellulose, alginates, sodium starch glycolate, gums such as agar, guar, locust bean, karaya, pectin, and tragacanth. In another embodiment, the disintegrant is an effervescent disintegrant. Non-limiting examples of suitable effervescent disintegrants include sodium bicarbonate in combination with citric acid, and sodium bicarbonate in combination with tartaric acid.

[0106] In another embodiment, the excipient comprises a flavoring agent. Flavoring agents can be chosen from synthetic flavor oils and flavoring aromatics; natural oils; extracts from plants, leaves, flowers, and fruits; and combinations thereof. In some embodiments the flavoring agent is selected from cinnamon oils; oil of wintergreen; peppermint oils; clover oil; hay oil; anise oil; eucalyptus; vanilla; citrus oil such as lemon oil, orange oil, grape and grapefruit oil; and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.

[0107] In other embodiments, the excipient comprises a sweetener. Non-limiting examples of suitable sweeteners include glucose (corn syrup), dextrose, invert

sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as the sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (Stevioside); chloro derivatives of sucrose such as sucralose; and sugar alcohols such as sorbitol, mannitol, xylitol, and the like. Also contemplated are hydrogenated starch hydrolysates and the synthetic sweetener 3,6-dihydro-6-methyl-1,2,3-oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K), and sodium and calcium salts thereof.

[0108] In yet other embodiments, the composition comprises a coloring agent. Non-limiting examples of suitable color agents include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), and external drug and cosmetic colors (Ext. D&C). The coloring agents can be used as dyes or their corresponding lakes.

[0109] The weight fraction of the excipient or combination of excipients in the formulation is usually about 99% or less, such as about 95% or less, about 90% or less, about 85% or less, about 80% or less, about 75% or less, about 70% or less, about 65% or less, about 60% or less, about 55% or less, 50% or less, about 45% or less, about 40% or less, about 35% or less, about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2% or less, or about 1% or less of the total weight of the composition.

[0110] The bacterial compositions disclosed herein can be formulated into a variety of forms and administered by a number of different means. The compositions can be administered orally, rectally, or parenterally, in formulations containing conventionally acceptable carriers, adjuvants, and vehicles as desired. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, or

intrasternal injection and infusion techniques. In an exemplary embodiment, the bacterial composition is administered orally.

[0111] Solid dosage forms for oral administration include capsules, tablets, caplets, pills, troches, lozenges, powders, and granules. A capsule typically comprises a core material comprising a bacterial composition and a shell wall that encapsulates the core material. In some embodiments, the core material comprises at least one of a solid, a liquid, and an emulsion. In other embodiments, the shell wall material comprises at least one of a soft gelatin, a hard gelatin, and a polymer. Suitable polymers include, but are not limited to: cellulosic polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose (HPMC), methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose succinate and carboxymethylcellulose sodium; acrylic acid polymers and copolymers, such as those formed from acrylic acid, methacrylic acid, methyl acrylate, ammonio methacrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate (e.g., those copolymers sold under the trade name "Eudragit"); vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, polyvinylacetate phthalate, vinylacetate crotonic acid copolymer, and ethylene-vinyl acetate copolymers; and shellac (purified lac). In yet other embodiments, at least one polymer functions as taste-masking agents.

[0112] Tablets, pills, and the like can be compressed, multiply compressed, multiply layered, and/or coated. The coating can be single or multiple. In one embodiment, the coating material comprises at least one of a saccharide, a

polysaccharide, and glycoproteins extracted from at least one of a plant, a fungus, and a microbe. Non-limiting examples include corn starch, wheat starch, potato starch, tapioca starch, cellulose, hemicellulose, dextrans, maltodextrin, cyclodextrins, inulins, pectin, mannans, gum arabic, locust bean gum, mesquite gum, guar gum, gum karaya, gum ghatti, tragacanth gum, funori, carrageenans, agar, alginates, chitosans, or gellan gum. In some embodiments the coating material comprises a protein. In another embodiment, the coating material comprises at least one of a fat and an oil. In other embodiments, the at least one of a fat and an oil is high temperature melting. In yet another embodiment, the at least one of a fat and an oil is hydrogenated or partially hydrogenated. In one embodiment, the at least one of a fat and an oil is derived from a plant. In other embodiments, the at least one of a fat and an oil comprises at least one of glycerides, free fatty acids, and fatty acid esters. In some embodiments, the coating material comprises at least one edible wax. The edible wax can be derived from animals, insects, or plants. Non-limiting examples include beeswax, lanolin, bayberry wax, carnauba wax, and rice bran wax. Tablets and pills can additionally be prepared with enteric coatings.

[0113] Alternatively, powders or granules embodying the bacterial compositions disclosed herein can be incorporated into a food product. In some embodiments, the food product is a drink for oral administration. Non-limiting examples of a suitable drink include fruit juice, a fruit drink, an artificially flavored drink, an artificially sweetened drink, a carbonated beverage, a sports drink, a liquid dairy product, a shake, an alcoholic beverage, a caffeinated beverage, infant formula and so forth. Other suitable means for oral administration include aqueous and nonaqueous solutions, emulsions,

suspensions and solutions and/or suspensions reconstituted from non-effervescent granules, containing at least one of suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, coloring agents, and flavoring agents.

[0114] In some embodiments, the food product can be a solid foodstuff. Suitable examples of a solid foodstuff include without limitation a food bar, a snack bar, a cookie, a brownie, a muffin, a cracker, an ice cream bar, a frozen yogurt bar, and the like.

[0115] In other embodiments, the compositions disclosed herein are incorporated into a therapeutic food. In some embodiments, the therapeutic food is a ready-to-use food that optionally contains some or all essential macronutrients and micronutrients. In another embodiment, the compositions disclosed herein are incorporated into a supplementary food that is designed to be blended into an existing meal. In one embodiment, the supplemental food contains some or all essential macronutrients and micronutrients. In another embodiment, the bacterial compositions disclosed herein are blended with or added to an existing food to fortify the food's protein nutrition. Examples include food staples (grain, salt, sugar, cooking oil, margarine), beverages (coffee, tea, soda, beer, liquor, sports drinks), snacks, sweets and other foods.

[0116] In one embodiment, the formulations are filled into gelatin capsules for oral administration. An example of an appropriate capsule is a 250 mg gelatin capsule containing from 10 (up to 100 mg) of lyophilized powder (10^8 to 10^{11} bacteria), 160 mg microcrystalline cellulose, 77.5 mg gelatin, and 2.5 mg magnesium stearate. In an alternative embodiment, from 10^5 to 10^{12} bacteria may be used, 10^5 to 10^7 , 10^6 to 10^7 ,

or 10^8 to 10^{10} , with attendant adjustments of the excipients if necessary. In an alternative embodiment, an enteric-coated capsule or tablet or with a buffering or protective composition can be used.

METHODS OF THE INVENTION

Administration of Bacterial Compositions

[0117] The bacterial compositions of the invention are suitable for administration to mammals and non-mammalian animals in need thereof. The bacterial compositions can be administered to animals, including humans, laboratory animals (e.g., primates, rats, mice), livestock (e.g., cows, sheep, goats, pigs, turkeys, chickens), and household pets (e.g., dogs, cats, rodents). In certain embodiments, the mammalian subject is a human subject who has one or more symptoms of a dysbiosis.

[0118] When the mammalian subject is suffering from a disease, disorder or condition characterized by an aberrant microbiota, the bacterial compositions described herein are suitable for treatment thereof. In some embodiments, the mammalian subject has not received antibiotics in advance of treatment with the bacterial compositions. For example, the mammalian subject has not been administered at least two doses of vancomycin, metronidazole and/or or similar antibiotic compound within one week prior to administration of the therapeutic composition. In other embodiments, the mammalian subject has not previously received an antibiotic compound in the one month prior to administration of the therapeutic composition.

[0119] The bacterial compositions are useful in methods of treating a mammalian subject suffering from or at risk of developing a gastrointestinal disease, disorder or condition. Therefore, a therapeutic benefit is provided by orally administering to the mammalian subject a therapeutic composition containing a bacterial population

comprising at least three bacterial strains, wherein each bacterial strain is a member of a bacterial species selected from the group consisting of *E. coli*, *S. faecalis*, *C. ramosum*, *C. bifermentans*, *Bact. ovatus*, *Bact. vulgatus*, *Bact. thetaiotaomicron*, and *Blautia producta*, wherein the therapeutic composition is formulated for oral administration. In some embodiments, the gastrointestinal disease, disorder or condition is relapsing diarrhea caused by *C. difficile*, ulcerative colitis, colitis, Crohn's disease, or irritable bowel disease. Beneficially, the therapeutic composition is administered only once prior to improvement of the disease, disorder or condition. In some embodiments the therapeutic composition is administered at intervals greater than two days, such as once every three, four, five or six days, or every week or less frequently than every week.

[0120] Also provided are methods of treating or preventing a mammalian subject suffering from or at risk of developing a metabolic disease, disorder or condition selected from the group consisting of diabetes, metabolic syndrome, obesity, and autism using the therapeutic compositions provided herein. The bacterial compositions can be administered as a complementary treatment to antibiotics when a patient is suffering from an acute infection, to reduce the risk of recurrence after an acute infection has subsided, or when a patient will be in close proximity to others with or at risk of serious gastrointestinal infections (physicians, nurses, hospital workers, family members of those who are ill or hospitalized).

An In Vivo Assay Establishing that a Bacterial Composition Populates a Subject's Gastrointestinal Tract

[0121] In order to determine that the bacterial composition populates the gastrointestinal tract of a subject, an animal model, such as a mouse model, may be

used. The model may begin by evaluating the microbiota of the mice. Qualitative assessments may be accomplished using 16S profiling of the microbial community in the feces of normal mice. It may also be accomplished by full genome sequencing, whole genome shotgun sequencing (WGS), or traditional microbiological techniques. Quantitative assessments may be conducted using quantitative PCR (qPCR), described in section below, or by using traditional microbiological techniques and counting colony formation.

[0122] Optionally, the mice may receive an antibiotic treatment to mimic the condition of dysbiosis. Antibiotic treatment can decrease the taxonomic richness, diversity, and evenness of the community, including a reduction of abundance of a significant number of bacterial taxa. Dethlefsen *et al.*, The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing, PLoS Biology 6(11):3280 (2008). At least one antibiotic may be used and antibiotics are well known. Antibiotics may include aminoglycoside antibiotics (amikacin, arbekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, rhodostreptomycin, streptomycin, tobramycin, and apramycin), amoxicillin, ampicillin, Augmentin (an amoxicillin/clavulanate potassium combination), cephalosporin (cefactor, defadroxil, cefazolin, cefixime, fefoxitin, cefprozil, ceftazimide, cefuroxime, cephalexin), clavulanate potassium, clindamycin, colistin, gentamycin, kanamycin, metronidazole, or vancomycin. As an individual, nonlimiting specific example, the mice may be provided with drinking water containing a mixture of the antibiotics kanamycin, colistin, gentamycin, metronidazole and vancomycin at 40 mg/kg, 4.2 mg/kg, 3.5 mg/kg, 21.5 mg/kg, and 4.5 mg/kg (mg per average mouse body weight), respectively, for 7 days.

Alternatively, mice may be administered ciprofloxacin at a dose of 15-20 mg/kg (mg per average mouse body weight), for 7 days.

[0123] If the mice are provided with an antibiotic, a wash out period of from one day to three days may be provided with no antibiotic treatment and no bacterial composition treatment.

[0124] Subsequently, the test bacterial composition is administered to the mice by oral gavage. The test bacterial composition may be administered in a volume of 0.2 ml containing 10^4 CFUs of each type of bacteria in the bacterial composition. Dose-response may be assessed by using a range of doses, including, but not limited to 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , and/or 10^{10} .

[0125] The mice may be evaluated using 16S sequencing, full genome sequencing, whole genome shotgun sequencing (WGS), or traditional microbiological techniques to determine whether the test bacterial composition has populated the gastrointestinal tract of the mice. For example only, one day, three days, one week, two weeks, and one month after administration of the bacterial composition to the mice, 16S profiling is conducted to determine whether the test bacterial composition has populated the gastrointestinal tract of the mice. Quantitative assessments, including qPCR and traditional microbiological techniques such as colony counting, may additionally or alternatively be performed, at the same time intervals.

[0126] Furthermore, the number of sequence counts that correspond exactly to those in the bacterial composition over time may be assessed to determine specifically which components of the bacterial composition reside in the gastrointestinal tract over a particular period of time. In one embodiment, the strains of the bacterial composition

persist for a desired period of time; in another embodiment, the components of the bacterial composition persist for a desired period of time while also increasing the ability of other microbes (such as those present in the environment, food, etc.) to populate the gastrointestinal tract, further increasing overall diversity, as discussed below.

Ability of Bacterial cCompositions to Populate Different Regions of the Gastrointestinal Tract

[0127] The present bacterial compositions may also be assessed for their ability to populate different regions on the gastrointestinal tract. In one embodiment, a bacterial composition may be chosen for its ability to populate one or more than one region of the gastrointestinal tract, including, but not limited to the stomach, the small intestine (duodenum, jejunum, and ileum), the large intestine (the cecum, the colon (the ascending, transverse, descending, and sigmoid colon), and the rectum).

[0128] An *in vivo* study may be conducted to determine which regions of the gastrointestinal tract a given bacterial composition will populate. A mouse model similar to the one described above in section II.A may be conducted, except instead of assessing the feces produced by the mice, particular regions of the gastrointestinal tract may be removed and studied individually. For example, at least one particular region of the gastrointestinal tract may be removed and a qualitative or quantitative determination may be performed on the contents of that region of the gastrointestinal tract. In another embodiment, the contents may optionally be removed and the qualitative or quantitative determination may be conducted on the tissue removed from the mouse.

Methods for Testing Sensitivity of Bacterial composition

[0129] In certain embodiments, methods for testing the sensitivity of bacterial compositions in order to select for particular desirable characteristics may be employed.

For example, the constituents in the bacterial composition may be tested for pH resistance, bile acid resistance, and/or antibiotic sensitivity, either individually on a constituent-by-constituent basis or collectively as a bacterial composition comprised of multiple bacterial constituents (collectively referred to in this section as bacterial composition).

1. pH Sensitivity Testing

[0130] For oral administration of the bacterial compositions, optionally testing for pH resistance enhances the selection of bacterial compositions that will survive at the highest yield possible through the varying pH environments of the distinct regions of the GI tract. Understanding how the bacterial compositions react to the pH of the GI tract also assists in formulation, so that the number of bacteria in a dosage form can be increased if beneficial and/or so that the composition may be administered in an enteric-coated capsule or tablet or with a buffering composition. As the pH of the stomach can drop to a pH of 1 to 2 after a high-protein meal for a short time before physiological mechanisms adjust it to a pH of 3 to 4 and often resides at a resting pH of 4 to 5, and as the pH of the small intestine can range from a pH of 6 to 7.4, bacterial compositions can be prepared that survive these varying pH ranges (specifically wherein at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or as much as 100% of the bacteria can survive gut transit times through various pH ranges).

[0131] This may be tested by exposing the bacterial composition to varying pH ranges for the expected gut transit times through those pH ranges. Therefore, as a nonlimiting example only, 18-hour cultures of bacterial compositions may be grown in standard media, such as gut microbiota medium ("GMM", see Goodman et al., Extensive personal human gut microbiota culture collections characterized and

manipulated in gnotobiotic mice, PNAS 108(15):6252-6257 (2011)) or another animal-products-free medium, with the addition of pH adjusting agents for a pH of 1 to 2 for 30 minutes, a pH of 3 to 4 for 1 hour, a pH of 4 to 5 for 1 to 2 hours, and a pH of 6 to 7.4 for 2.5 to 3 hours.

[0132] Alternatively, bacterial cells may be grown in a standard media, such as the GMM media described above, and adjusted to pH 2.5 with 1M HCl. The cells may be incubated anaerobically at 37°C and their survival measured at intervals of 0, 30, 60, 120, 240, and/or 360 minutes.

[0133] A further alternative method for testing stability to acid is described in U.S. Patent No. 4,839,281.

[0134] Survival of bacteria may be determined by culturing the bacteria and counting colonies on appropriate selective or non-selective media.

2. Bile Acid Sensitivity Testing

[0135] Additionally, in some embodiments, testing for bile-acid resistance enhances the selection of bacterial compositions that will survive exposures to bile acid during transit through the GI tract. Bile acids are secreted into the small intestine and can, like pH, affect the survival of bacterial compositions.

[0136] This may be tested by exposing the bacterial compositions to bile acids for the expected gut exposure time to bile acids. For example, bile acid solutions may be prepared at desired concentrations using 0.05 mM Tris at pH 9 as the solvent. After the bile acid is dissolved, the pH of the solution may be adjusted to 7.2 with 10% HCl. Bacterial compositions may be cultured in 2.2 ml of a bile acid composition mimicking the concentration and type of bile acids in the subject, 1.0 ml of 10% sterile-filtered feces media and 0.1 ml of an 18-hour culture of the given strain of bacteria. Incubations

may be conducted for from 2.5 to 3 hours or longer. Survival of bacteria may be determined by culturing the bacteria and counting colonies on appropriate selective or non-selective media.

[0137] As another alternative, bacterial strains may be streaked onto agar plates supplemented with porcine bile (Sigma) at 0.5%, 1%, and 5% (w/v). Plates may be incubated at 37°C under anaerobic conditions and the growth recorded after 48 hours. Growth may be compared with control plates by an experienced observer and the growth of colonies scored as: 0=no growth, 1=hazy translucent growth (<33% control plates with 0% bile), 2=definite growth but not as good as controls (>33% but <66%), 3=growth equivalent to controls (>66%).

[0138] A further alternative method for testing stability to bile acid is described in U.S. Patent No. 4,839,281. Survival of bacteria may be determined by culturing the bacteria and counting colonies on appropriate selective or non-selective media.

3. Antibiotic Sensitivity Testing

[0139] As a further optional sensitivity test, bacterial compositions may be tested for sensitivity to antibiotics. In one embodiment, bacterial compositions may be chosen so that the bacterial constituents are sensitive to antibiotics such that if necessary they can be eliminated or substantially reduced from the subject's gastrointestinal tract by at least one antibiotic targeting the bacterial composition.

4. Adherence to Gastrointestinal Cells

[0140] The bacterial compositions may optionally be tested for the ability to adhere to gastrointestinal cells. Without being bound by theory, in some instances, adherence can enhance the ability to repopulate a subject's gastrointestinal tract and thus may be used as a criterion in some embodiments. As a first embodiment, this may

be conducted in a tissue culture model, where gastrointestinal epithelial cells, such as but not limited to CACO-2 cells (ATCC HTB-37), are grown in tissue culture flasks to differentiation in an antibiotic containing media, grown for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7 days in an antibiotic-free medium, incubated with bacterial cells for 30 minutes, 60 minutes, 90 minutes, or 120 minutes, and washed three times. After washing, the number of adherent bacteria may be assessed by lysing the epithelial cells and enumerating the bacteria using the plate count method or qPCR, as described herein.

[0141] As another mode, bacterial adherence may be evaluated using an engineered tissue model of the lining of the gastrointestinal tract. Viney et al., "Co-culture of Intestinal Epithelial and Stromal Cells in 3D Collagen-based Environments," Regen Med 4(3):397-406 (2009). After preparation of the engineered tissue model, the bacterial cells may be incubated, washed, and adherence enumerated, as described above.

[0142] Furthermore, bacterial adherence may be evaluated using a tissue explant from the gastrointestinal tract of a subject. Gastrointestinal tract tissue may be surgically removed from a healthy donor. Alternatively, gastrointestinal tract tissue may be surgically removed from a donor who has a gastrointestinal disease, such as from an unused portion of a biopsy. After surgical excision, the bacterial cells may be incubated, washed, and adherence enumerated, as described above.

[0143] As an alternative, one technique involves the collection of the effluent from a subject with a well functioning ileostomy by saline lavage, as described in U.S. Patent No. 4,839,281.

Assessment of Microbiota Diversity

[0144] Microbiota diversity, as assessed by deep 16S rRNA sequencing or metagenomic sequencing, may be evaluated at a variety of time points to assess the effect of microbial compositions on restoring microbiota diversity. Microbial diversity may optionally be assessed before administration of an antibiotic or removal of microbiota by a colon-cleansing preparation. Microbial diversity may also be assessed before administration of a microbial composition and after administration of a microbial composition at any frequency (e.g., more frequently than 1 day, 1 day, 3 days, 1 week, 2 weeks, one month, or more than one month). One may provide for any temporal resolution that has more or less frequent sampling intervals, and/or samples taken for a longer time period (e.g., at least 1 week, at least 1 month, at least three months, at least six months, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or over more than 10 years).

[0145] Diversity may be measured according to known sequencing methods, including, but not limited to Dethlefsen *et al.*, The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing, PLoS Biology 6(11):3280 (2008). Sequence data used for diversity analysis may comprise 16S rRNA, whole genome sequence, any subset of a genome as well as whole genome shotgun metagenomic sequence (WGS). Sequence data may be generated using any sequencing technology including, but not limited to Sanger, Illumina, 454 Life Sciences, Ion Torrent, ABI, Pacific Biosciences, and/or Oxford Nanopore. Subjects may be assessed for a variety of diversity metrics, including, but not limited to, observed taxon richness, Shannon diversity index, Shannon equitability index, alpha diversity, beta diversity, Chao1 index, Simpson diversity index, normalized abundance over time, and/or phylogenetic breadth.

[0146] In another embodiment, subjects may be assessed for a variety of diversity metrics, including, but not limited to, Simpson diversity or by plotting rarefaction curve comparisons of reference OTUs for subjects before and after treatment with microbial compositions. Phylogenetic diversity may be plotted against the number of sequence reads (full 16S sequence or one or any combination of more hypervariable regions of the 16S sequence, whole genome sequence, or specific marker loci). Shahinas, et al., Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA Gene Deep Sequencing, mBio 3(5):e00338-12 (2012).

[0147] In another embodiment, diversity may be shown by graphing a bar plot of abundance at the family level and showing an increase in either the number of families or the balance of abundance between families.

[0148] In another embodiment, diversity may be shown by plotting heatmaps of the abundance of an OTU, species, genus, and/or higher taxonomic assignment showing sets of samples that are enriched or depleted for specific constituents.

[0149] In another embodiment, diversity may be shown by generation of a phylogenetic tree of OTUs, species, genera, and/or higher or lower clade assignments. In this embodiment genetic distances may be computed between all OTUs, and summary statistics including, but not limited to average genetic distance and number of unique clades may be computed.

[0150] In another embodiment, beta-diversity may be computed using diversity metrics familiar to those with ordinary skill in the art that include but are not limited to

Bray-Curtis Dissimilarity Indices or Jaccard Distances and plotted using Principal Coordinates Analysis.

[0151] Beneficial bacterial compositions may result in an increase in diversity after their administration that is 10%, 20%, 30%, 40%, or 50% higher than diversity before their administration. In another embodiment bacterial compositions may result in restoration of diversity to at least 70%, 80%, 90%, 95%, or up to 100% of the diversity either measured before administration of an antibiotic or removal of microbiota by a colon-cleansing preparation, or alternatively, as compared to the diversity of a reference mammalian subject.

Methods for Preparing a Bacterial Composition for Administration to a Subject

[0152] Methods for producing bacterial compositions may include three main processing steps, combined with one or more mixing steps. The steps are: organism banking, organism production, and preservation.

[0153] For banking, the strains included in the bacterial composition may be (1) isolated directly from a specimen or taken from a banked stock, (2) optionally cultured on a nutrient agar or broth that supports growth to generate viable biomass, and (3) the biomass optionally preserved in multiple aliquots in long-term storage.

[0154] In embodiments using a culturing step, the agar or broth may contain nutrients that provide essential elements and specific factors that enable growth. An example would be a medium composed of 20 g/L glucose, 10 g/L yeast extract, 10 g/L soy peptone, 2 g/L citric acid, 1.5 g/L sodium phosphate monobasic, 100 mg/L ferric ammonium citrate, 80 mg/L magnesium sulfate, 10 mg/L hemin chloride, 2 mg/L calcium chloride, 1 mg/L menadione. Medium can be added to the culture at the start,

may be added during the culture, or may be intermittently/continuously flowed through the culture. The strains in the bacterial composition may be cultivated alone, as a subset of the bacterial composition, or as an entire collection comprising the bacterial composition. As an example, a first strain may be cultivated together with a second strain in a mixed continuous culture, at a dilution rate lower than the maximum growth rate of either cell to prevent the culture from washing out of the cultivation.

[0155] The inoculated culture is incubated under favorable conditions for a time sufficient to build biomass. For bacterial compositions for human use this is often at 37°C temperature, pH, and other parameter with values similar to the normal human niche. The environment may be actively controlled, passively controlled (e.g., via buffers), or allowed to drift. For example, for anaerobic bacterial compositions (e.g., gut applications), an anoxic/reducing environment may be employed. This can be accomplished by addition of reducing agents such as cysteine to the broth, and/or stripping it of oxygen. As an example, a culture of a bacterial composition may be grown at 37°C, pH 7, in the medium above, pre-reduced with 1 g/L cysteine·HCl.

[0156] When the culture has generated sufficient biomass, it may be preserved for banking. The organisms may be placed into a chemical milieu that protects from freezing (adding 'cryoprotectants'), drying ('lyoprotectants'), and/or osmotic shock ('osmoprotectants'), dispensing into multiple (optionally identical) containers to create a uniform bank, and then treating the culture for preservation. Containers are generally impermeable and have closures that assure isolation from the environment. Cryopreservation treatment is accomplished by freezing a liquid at ultra-low temperatures (e.g., at or below -80°C). Dried preservation removes water from the

culture by evaporation (in the case of spray drying or 'cool drying') or by sublimation (e.g., for freeze drying, spray freeze drying). Removal of water improves long-term bacterial composition storage stability at temperatures elevated above cryogenic. Bacterial composition banking may be done by culturing and preserving the strains individually, or by mixing the strains together to create a combined bank. As an example of cryopreservation, a bacterial composition culture may be harvested by centrifugation to pellet the cells from the culture medium, the supernatant decanted and replaced with fresh culture broth containing 15% glycerol. The culture can then be aliquoted into 1 mL cryotubes, sealed, and placed at -80°C for long-term viability retention. This procedure achieves acceptable viability upon recovery from frozen storage.

[0157] Organism production may be conducted using similar culture steps to banking, including medium composition and culture conditions. It may be conducted at larger scales of operation, especially for clinical development or commercial production. At larger scales, there may be several subcultivations of the bacterial composition prior to the final cultivation. At the end of cultivation, the culture is harvested to enable further formulation into a dosage form for administration. This can involve concentration, removal of undesirable medium components, and/or introduction into a chemical milieu that preserves the bacterial composition and renders it acceptable for administration via the chosen route. For example, a bacterial composition may be cultivated to a concentration of 10^{10} CFU/mL, then concentrated 20-fold by tangential flow microfiltration; the spent medium may be exchanged by diafiltering with a preservative medium consisting of 2% gelatin, 100 mM trehalose, and 10 mM sodium phosphate buffer. The suspension can then be freeze-dried to a powder and titrated. After drying,

the powder may be blended to an appropriate potency, and mixed with other cultures and/or a 'filler' such as microcrystalline cellulose for consistency and ease of handling, and the bacterial composition filled into gelatin capsules for oral administration.

[0158] An example of an appropriate capsule is a 250 mg gelatin capsule containing from 10 (up to 100 mg) of lyophilized powder (10^8 to 10^{11} bacteria), 160 mg microcrystalline cellulose, 77.5 mg gelatin, and 2.5 mg magnesium stearate. In an alternative embodiment, from 10^5 to 10^{12} bacteria may be used, 10^5 to 10^7 , 10^6 to 10^7 , or 10^8 to 10^{10} , with attendant adjustments of the excipients if necessary.

[0159] In one embodiment, the number of bacteria of each type may be present in the same amount or in different amounts. For example, in a bacterial composition with two types of bacteria, the bacteria may be present in from a 1:10,000 ratio to a 1:1 ratio, from a 1:10,000 ratio to a 1:1,000 ratio, from a 1:1,000 ratio to a 1:100 ratio, from a 1:100 ratio to a 1:50 ratio, from a 1:50 ratio to a 1:20 ratio, from a 1:20 ratio to a 1:10 ratio, from a 1:10 ratio to a 1:1 ratio. For bacterial compositions comprising at least three types of bacteria, the ratio of type of bacteria may be chosen pairwise from ratios for bacterial compositions with two types of bacteria. For example, in a bacterial composition comprising bacteria A, B, and C, at least one of the ratio between bacteria A and B, the ratio between bacteria B and C, and the ratio between bacteria A and C may be chosen, independently, from the pairwise combinations above.

Methods of Treating a Subject

A. Overview of Method

[0160] The bacterial compositions may be used to populate the gastrointestinal tract of a subject, resulting in one or more of a changed constitution of a subject's microbiota and improvement or correction of a dysbiosis. Without being bound by

theory, bacterial compositions can promote mammalian health by restoring the natural microflora in the GI tract and reinforcing the normal controls on aberrant immune responses.

[0161] Bacterial compositions can also improve fiber and protein digestion. Improving fiber and protein digestion is desirable as it promotes the growth of microbiota. A probiotic composition with multiple species has been shown to reduce production of toxic metabolites from protein fermentation. Rehman, Effects of Probiotics and antibiotics on intestinal homeostasis in a computer controlled model of the large intestine, BMC Microbiology 12:47 (2012). Carbohydrate fermentation is, for the most part, believed to be a beneficial process in the large gut, because the growth of saccharolytic bacteria stimulates their requirements for toxic products associated with putrefaction, for incorporation into cellular proteins, thereby protecting the host. However, as digestive materials move along the gut, carbohydrates become depleted, which may be linked to the increased prevalence of colonic disease in the distal bowel. Macfarlane, *et al.*, Bacteria, colonic fermentation, and gastrointestinal health, J AOAC Int. 95(1):50-60 (2012). Thus, restoring microbiota, including, but not limited to, restoring microbiota in the distal bowel can provide health benefits.

[0162] Fiber digestion may be determined using the method described in Vickers et al., Comparison of fermentation of selected fructooligosaccharides and other fiber substrates by canine colonic microflora, Am. J. Vet. Res. 61 (4), 609-615 (2001), with the exception that instead of inoculating using diluted fecal samples each experiment may use the bacterial compositions of interest.

[0163] In one embodiment, the pathogen may be *Clostridium difficile*, *Salmonella* spp., pathogenic *Escherichia coli*, or vancomycin-resistant *Enterococcus* spp. In yet another embodiment, the pathogen may be *Clostridium difficile*, or other pathogen or pathobiont listed in Table 1.

[0164] The present bacterial compositions may be useful in a variety of clinical situations. For example, the bacterial compositions may be administered as a complementary treatment to antibiotics when a subject is suffering from an acute infection, to reduce the risk of recurrence after an acute infection has subsided, or when a subject will be in close proximity to others with or at risk of serious gastrointestinal infections (physicians, nurses, hospital workers, family members of those who are ill or hospitalized).

[0165] The present bacterial compositions may be administered to animals, including humans, laboratory animals (e.g., primates, rats, mice), livestock (e.g., cows, sheep, goats, pigs, turkeys, chickens), and household pets (e.g., dogs, cats, rodents).

[0166] In the present method, the bacterial composition is administered enterically, in other words by a route of access to the gastrointestinal tract. This includes oral administration, rectal administration (including enema, suppository, or colonoscopy), by an oral or nasal tube (nasogastric, nasojejunal, oral gastric, or oral jejunal), as detailed more fully in the section below.

B. Pretreatment Protocols

[0167] Prior to administration of the bacterial composition, the subject may optionally have a pretreatment protocol to prepare the gastrointestinal tract to receive the bacterial composition. In certain embodiments, the pretreatment protocol is advisable, such as when a subject has an acute infection with a highly resilient

pathogen or when the microbiota resident in the subject's gastrointestinal tract is likely to resist colonization by the bacterial composition. In other embodiments, the pretreatment protocol is entirely optional, such as when the dysbiosis is not associated with a pathogenic infection; when, if an infection is present, the pathogen causing the infection is not resilient, or when the subject has had an acute infection that has been successfully treated but where the physician is concerned that the infection may recur. In these instances, the pretreatment protocol may enhance the ability of the bacterial composition to affect the subject's microbiome.

[0168] As one way of preparing the subject for administration of the microbial ecosystem, a standard colon-cleansing preparation may be administered to the subject to substantially empty the contents of the colon, such as used to prepare a subject for a colonoscopy. By "substantially emptying the contents of the colon," this application means removing at least 75%, at least 80%, at least 90%, at least 95%, or about 100% of the contents of the ordinary volume of colon contents.

[0169] If a subject has received an antibiotic for treatment of an infection, or if a subject has received an antibiotic as part of a specific pretreatment protocol, in one embodiment the antibiotic should be stopped in sufficient time to allow the antibiotic to be substantially reduced in concentration in the gut before the bacterial composition is administered. In one embodiment, the antibiotic may be discontinued 1, 2, or 3 days before the administration of the bacterial composition. In one embodiment, the antibiotic may be discontinued 3, 4, 5, 6, or 7 antibiotic half-lives before administration of the bacterial composition. In another embodiment, the antibiotic may be chosen so the

constituents in the bacterial composition have an MIC₅₀ that is higher than the concentration of the antibiotic in the gut.

[0170] MIC₅₀ of a bacterial composition or the elements in the composition may be determined by methods well known in the art. Reller et al., Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices, Clinical Infectious Diseases 49(11):1749-1755 (2009). In such an embodiment, the additional time between antibiotic administration and administration of the bacterial composition is not necessary. If the pretreatment protocol is part of treatment of an acute infection, the antibiotic may be chosen so that the infection is sensitive to the antibiotic, but the constituents in the bacterial composition are not sensitive to the antibiotic.

C. Routes of Administration

[0171] In the present method, the bacterial composition is administered enterically, in other words by a route of access to the gastrointestinal tract. This preferentially includes oral administration, or by an oral or nasal tube (including nasogastric, nasojejunal, oral gastric, or oral jejunal). In other embodiments, administration includes rectal administration (including enema, suppository, or colonoscopy). The bacterial composition may be administered to at least one region of the gastrointestinal tract, including the mouth, esophagus, stomach, small intestine, large intestine, and rectum. In some embodiments it is administered to all regions of the gastrointestinal tract. The bacterial compositions may be administered orally in the form of medicaments such as powders, capsules, tablets, gels or liquids. The bacterial compositions may also be administered in gel or liquid form by the oral route or through

a nasogastric tube, or by the rectal route in a gel or liquid form, by enema or instillation through a colonoscope or by a suppository.

[0172] If the composition is administered colonoscopically and, optionally, if the bacterial composition is administered by other rectal routes (such as an enema or suppository) or even if the subject has an oral administration, the subject may have a colonic-cleansing preparation. The colon-cleansing preparation can facilitate proper use of the colonoscope or other administration devices, but even when it does not serve a mechanical purpose it can also maximize the proportion of the bacterial composition relative to the other organisms previously residing in the gastrointestinal tract of the subject. Any ordinarily acceptable colonic-cleansing preparation may be used such as those typically provided when a subject undergoes a colonoscopy.

D. Dosages and Schedule for Administration

[0173] In one embodiment, from 10^8 and 10^{11} microorganisms total may be administered to the subject in a given dosage form. In one mode, an effective amount may be provided in from 1 to 500 ml or from 1 to 500 grams of the bacterial composition having from 10^8 to 10^{11} bacteria per ml or per gram, or a capsule, tablet or suppository having from 1 mg to 1000 mg lyophilized powder having from 10^8 to 10^{15} bacteria. Those receiving acute treatment may receive higher doses than those who are receiving chronic administration (such as hospital workers or those admitted into long-term care facilities).

[0174] Any of the preparations described herein may be administered once on a single occasion or on multiple occasions, such as once a day for several days or more than once a day on the day of administration (including twice daily, three times daily, or up to five times daily). Or the preparation may be administered intermittently according

to a set schedule, e.g., once a day, once weekly, or once monthly, or when the subject relapses from the primary illness. In another embodiment, the preparation may be administered on a long-term basis to individuals who are at risk for infection with or who may be carriers of these pathogens, including individuals who will have an invasive medical procedure (such as surgery), who will be hospitalized, who live in a long-term care or rehabilitation facility, who are exposed to pathogens by virtue of their profession (livestock and animal processing workers), or who could be carriers of pathogens (including hospital workers such as physicians, nurses, and other health care professionals).

E. Subject Selection

[0175] Particular bacterial compositions may be selected for individual subjects or for subjects with particular profiles. For example, 16S sequencing may be performed for a given subject to identify the bacteria present in his or her microbiota. The sequencing may either profile the subject's entire microbiome using 16S sequencing (to the family, genera, or species level), a portion of the subject's microbiome using 16S sequencing, or it may be used to detect the presence or absence of specific candidate bacteria that are biomarkers for health or a particular disease state. Based on the biomarker data, a particular composition may be selected for administration to a subject to supplement or complement a subject's microbiota in order to restore health or treat or prevent disease.

[0176] The specification is most thoroughly understood in light of the teachings of the references cited within the specification. The embodiments within the specification provide an illustration of embodiments and should not be construed to limit the scope. The skilled artisan readily recognizes that many other embodiments are

encompassed. All publications and patents cited in this disclosure are incorporated by reference in their entirety. To the extent the material incorporated by reference contradicts or is inconsistent with this specification, the specification will supersede any such material. The citation of any references herein is not an admission that such references are prior art.

[0177] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification, including claims, are to be understood as being modified in all instances by the term “about.” Accordingly, unless otherwise indicated to the contrary, the numerical parameters are approximations and may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

[0178] Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series.

EXAMPLES

[0179] Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

[0180] The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA

techniques and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., T.E. Creighton, *Proteins: Structures and Molecular Properties* (W.H. Freeman and Company, 1993); A.L. Lehninger, *Biochemistry* (Worth Publishers, Inc., current addition); Sambrook, et al., *Molecular Cloning: A Laboratory Manual* (2nd Edition, 1989); *Methods In Enzymology* (S. Colowick and N. Kaplan eds., Academic Press, Inc.); *Remington's Pharmaceutical Sciences*, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); Carey and Sundberg *Advanced Organic Chemistry 3rd Ed.* (Plenum Press) Vols A and B(1992).

Example 1: Administration of bacterial compositions to mammalian subjects having *C. difficile* infection.

[0181] An *in vivo* mouse model was employed to demonstrate the protective effect of the bacterial compositions against *C. difficile*. In this model (based on Chen, et al., A mouse model of *Clostridium difficile* associated disease, *Gastroenterology* 135(6):1984-1992 (2008)), mice were made susceptible to *C. difficile* by a 7 or 9 day treatment (days -14 or -12 until -5 of experiment) with 5 to 7 antibiotics (kanamycin, colistin, gentamycin, metronidazole and vancomycin, and optionally including ampicillin and ciprofloxacin) delivered via their drinking water, followed by a single dose with clindamycin on day -3. The mice were then challenged three days later (on day 0) with 10⁴ spores of *C. difficile* via oral gavage (i.e., oro-gastric lavage). The outcomes assessed each day from day 0 to day 6 were weight, clinical signs, mortality and shedding of *C. difficile* in the feces. Weight, clinical signs and mortality were also evaluated on day -1. Weight loss, clinical signs of disease, and *C. difficile* shedding were typically observed without treatment. Vancomycin treatment protects against these outcomes and serves as a positive control when provided by oral gavage on days -1 to

4. Clinical signs were subjective, and scored each day by the same experienced observer. Mortality includes euthanasia of animals that lose greater than or equal to 25% of their body weight or that display severe morbidity as assessed by clinical signs. Feces were gathered from the mouse cages (5 mice per cage) each day, and suspended in 5 mL of PBS by vortexing. The shedding of *C. difficile* spores is detected in the feces using a selective plating assay as described for the *in vitro* assay above, after a 1 hour treatment with 50% ethanol at room temperature to kill *C. difficile* vegetative cells. *C. difficile* may also be detected in the mouse fecal suspension via qPCR for the toxin gene as described herein. The effects of various administrations, including 10% suspension of human feces in PBS (as a positive control), microbial compositions, or PBS (as a negative vehicle control), were determined by introducing the bacterial composition in a 0.2 mL volume into the mice via oral gavage on day -1, one day prior to *C. difficile* challenge. Vancomycin, as discussed above, is given on days -1 to -4 as another positive control. Alternative dosing schedules can be employed, including multiple doses of bacterial composition, and 10^3 to 10^{10} of a given organism or composition may be delivered.

[0182] Exemplary bacterial compositions as described herein were administered as follows.

[0183] In a first demonstration, the results of which are provided in tabular form as Table 2, Treatment 1 is the vehicle control of phosphate buffered saline (PBS), Treatment 2 is a positive control of 10% fecal suspension in PBS which has total anaerobic cfu/ml of 4.5×10^9 , Treatment 3 is a positive control of 10% fecal suspension in PBS which has total anaerobic cfu/ml of 6.2×10^8 , Treatment 4 is a bacterial

composition comprising *Escherichia coli* (family *Enterobacteriaceae*, ATCC 35320), *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Blautia producta* (family *Lachnospiraceae*, DSM 14466), *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*, ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), *Clostridium innocuum* (family *Erysipelotrichaceae*, DSM 22910) with a total anaerobic cfu/ml of 7.1×10^9 . Treatment 5 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, ATCC 35320), *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Blautia producta* (family *Lachnospiraceae*, DSM 14466), *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*, ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), *Clostridium innocuum* (family *Erysipelotrichaceae*, DSM 22910) with a total anaerobic cfu/ml of 7.1×10^8 . Treatment 6 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, ATCC 35320), *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Blautia producta* (family *Lachnospiraceae*, DSM 14466), *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*, ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), *Clostridium innocuum* (family *Erysipelotrichaceae*,

DSM 22910) with a total anaerobic cfu/ml of 7.1×10^7 . Treatment 7 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, ATCC 35320), *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Blautia producta* (family *Lachnospiraceae*, DSM 14466), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), *Clostridium innocuum* (family *Erysipelotrichaceae*, DSM 22910) with a total anaerobic cfu/ml of 3.7×10^9 . Treatment 8 is a bacterial composition comprising *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*, ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483) with a total anaerobic cfu/ml of 3.5×10^9 . Treatment 9 is a bacterial composition comprising *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*, ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), *Clostridium innocuum* (family *Erysipelotrichaceae*, DSM 22910) with a total anaerobic cfu/ml of 6.7×10^9 . Treatment 10 is a bacterial composition comprising *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), and *Clostridium innocuum* (family *Erysipelotrichaceae*, DSM 22910) with a total anaerobic cfu/ml of 1.2×10^9 . Treatment 11 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, ATCC 35320), *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Blautia producta* (family *Lachnospiraceae*, DSM 14466), *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*,

ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483), *Clostridium celatum* (family *Clostridiaceae*, SPC21278) with a total anaerobic cfu/ml of 6.1×10^9 .

Treatment 12 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, ATCC 35320), *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*, ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), *Clostridium innocuum* (family *Erysipelotrichaceae*, DSM 22910) with a total anaerobic cfu/ml of 1×10^{10} .

[0184] In a second demonstration, the results of which are provided in tabular form as Table 3A, Treatment 1 is the vehicle control of phosphate buffered saline (PBS), Treatment 2 is a positive control of 10% fecal suspension in PBS which has total anaerobic cfu/ml of 5×10^9 , Treatment 3 is a positive control of 10% fecal suspension in PBS which has total anaerobic cfu/ml of 7×10^8 .

[0185] Treatment 4 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, ATCC 35320), *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Blautia producta* (family *Lachnospiraceae*, DSM 14466), *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*, ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), *Clostridium innocuum* (family *Erysipelotrichaceae*, DSM 22910) with a total anaerobic

cfu/ml of 2.2×10^9 , Treatment 5 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, ATCC 35320), *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Blautia producta* (family *Lachnospiraceae*, DSM 14466), *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*, ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), *Clostridium innocuum* (family *Erysipelotrichaceae*, DSM 22910) with a total anaerobic cfu/ml of 2.2×10^8 . Treatment 6 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, ATCC 35320), *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Blautia producta* (family *Lachnospiraceae*, DSM 14466), *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*, ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), *Clostridium innocuum* (family *Erysipelotrichaceae*, DSM 22910) with a total anaerobic cfu/ml of 2.2×10^7 , Treatment 7 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, ATCC 35320), *Enterococcus faecalis* (family *Enterococcaceae* ATCC, 19433), *Blautia producta* (family *Lachnospiraceae*, DSM 14466), *Bacteroides vulgatus* (family *Bacteroidaceae*, ATCC 8482), *Bacteroides thetaiotaomicron* (family *Bacteroidaceae*, ATCC 29148), *Bacteroides ovatus* (family *Bacteroidaceae*, ATCC 8483), *Clostridium innocuum* (family *Erysipelotrichaceae*, DSM 22910) with a total anaerobic cfu/ml of 5×10^9 , Treatment 8 is a bacterial composition

comprising *Escherichia coli* (family, *Enterobacteriaceae*, SPC21221), *Escherichia coli* (family, *Enterobacteriaceae*, SPC21248), *Enterococcus faecalis* (family, *Enterococcaceae*, SPC21240), *Enterococcus faecalis* (family, *Enterococcaceae*, SPC21252), *Blautia producta* (family, *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21122), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes thetaiotaomicron*, (family *Bacteroidaceae*, SPC21133), *Bacteriodes ovatus* (family, *Bacteroidaceae*, SPC21141), *Bacteriodes ovatus* (family, *Bacteroidaceae*, SPC21181), *Clostridium innocuum* (family, *Erysipelotrichaceae*, SPC21112), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), with a total anaerobic cfu/ml of 1.7×10^{10} , Treatment 9 is a bacterial composition comprising *Escherichia coli* (family, *Enterobacteriaceae*, SPC21221), *Escherichia coli* (family, *Enterobacteriaceae*, SPC21248), *Enterococcus faecalis* (family, *Enterococcaceae*, SPC21240), *Enterococcus faecalis* (family, *Enterococcaceae*, SPC21252), *Blautia producta* (family, *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21122), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes thetaiotaomicron*, (family *Bacteroidaceae*, SPC21133), *Bacteriodes ovatus* (family, *Bacteroidaceae*, SPC21141), *Bacteriodes ovatus* (family, *Bacteroidaceae*, SPC21181), *Clostridium innocuum* (family, *Erysipelotrichaceae*, SPC21112), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), with a total anaerobic cfu/ml of 1.7×10^9 , Treatment 10 is a bacterial

composition comprising *Escherichia coli* (family, *Enterobacteriaceae*, SPC21221), *Escherichia coli* (family, *Enterobacteriaceae*, SPC21248), *Enterococcus faecalis* (family, *Enterococcaceae*, SPC21240), *Enterococcus faecalis* (family, *Enterococcaceae*, SPC21252), *Blautia producta* (family, *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21122), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes thetaiotaomicron*, (family *Bacteroidaceae*, SPC21133), *Bacteriodes ovatus* (family, *Bacteroidaceae*, SPC21141), *Bacteriodes ovatus* (family, *Bacteroidaceae*, SPC21181), *Clostridium innocuum* (family, *Erysipelotrichaceae*, SPC21112), *Clostridium bifermentans* (family *Peptostreptococcaceae*, ATCC 638), and *Clostridium ramosum* (family *Erysipelotrichaceae*, ATCC 25582), with a total anaerobic cfu/ml of 1.7×10^8 , Treatment 11 is a bacterial composition comprising *Escherichia coli* (family, *Enterobacteriaceae*, SPC21221), *Escherichia coli* (family, *Enterobacteriaceae*, SPC21248), *Enterococcus faecalis* (family, *Enterococcaceae*, SPC21240), *Enterococcus faecalis* (family, *Enterococcaceae*, SPC21252), *Blautia producta* (family, *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21122), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes thetaiotaomicron*, (family *Bacteroidaceae*, SPC21133), *Bacteriodes ovatus* (family, *Bacteroidaceae*, SPC21141), *Bacteriodes ovatus* (family, *Bacteroidaceae*, SPC21181), and *Clostridium innocuum* (family, *Erysipelotrichaceae*, SPC21112) with a total anaerobic cfu/ml of 1.2×10^{10} , Treatment 12 is a bacterial composition comprising *Escherichia coli* (family, *Enterobacteriaceae*, SPC21221), *Escherichia coli* (family, *Enterobacteriaceae*,

SPC21248), *Enterococcus faecalis* (family, *Enterococcaceae*, SPC21240), *Enterococcus faecalis* (family, *Enterococcaceae*, SPC21252), *Blautia producta* (family, *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21122), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes thetaiotaomicron*, (family *Bacteroidaceae*, SPC21133), *Bacteriodes ovatus* (family, *Bacteroidaceae*, SPC21141), *Bacteriodes ovatus* (family, *Bacteroidaceae*, SPC21181), *Clostridium innocuum* (family, *Erysipelotrichaceae*, SPC21112), and *Clostridium celatum* (family *Clostridiaceae*, SPC21278) with a total anaerobic cfu/ml of 9×10^9 , Treatment 13 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21221), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21240), *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family *Bacteroidaceae*, SPC21122), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21141), and *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112) with a total anaerobic cfu/ml of 6×10^9 . Treatment 14 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21248), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21252), *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family, *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21133), *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21181), and *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112) with a total anaerobic cfu/ml of 5×10^9 .

[0186] In a third demonstration, the results of which are provided in tabular form as Table 3B, Treatment 1 is the vehicle control of phosphate buffered saline (PBS), Treatment 2 is a positive control of 10% fecal suspension in PBS which has total anaerobic cfu/ml of 2.3×10^{11} , Treatment 3 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21221), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21240), *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21141), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), and *Clostridium celatum* (family *Clostridiaceae*, SPC21278) with a total anaerobic cfu/ml of 2.5×10^9 , Treatment 4 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21221), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21240), *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21141), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), and *Clostridium celatum* (family *Clostridiaceae*, SPC21278) with a total anaerobic cfu/ml of 2.5×10^8 , Treatment 5 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21221), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21240), *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21141), *Clostridium innocuum* (family *Erysipelotrichaceae*,

SPC21112), and *Clostridium celatum* (family *Clostridiaceae*, SPC21278) with a total anaerobic cfu/ml of 2.5×10^7 , Treatment 6 is a bacterial composition comprising *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21141), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), and *Clostridium celatum* (family *Clostridiaceae*, SPC21278) with a total anaerobic cfu/ml of 2.8×10^9 , Treatment 7 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21221), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21240), *Bacteriodes vulgatus* (family *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21141), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), and *Clostridium celatum* (family *Clostridiaceae*, SPC21278) with a total anaerobic cfu/ml of 6×10^9 , Treatment 8 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21221), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21240), *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), and *Clostridium celatum* (family *Clostridiaceae*, SPC21278) with a total anaerobic cfu/ml of 1.8×10^9 , Treatment 9 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21221), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21240), *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), and *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21141) with a total anaerobic cfu/ml of

2×10^9 , Treatment 10 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21221), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21240), *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21141), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), *Clostridium celatum* (family *Clostridiaceae*, SPC21278), *Clostridium butyricum* (family *Clostridiaceae*, SPC21367), and *Clostridium glycolicum* (family *Peptostreptococcaceae*, SPC21349) with a total anaerobic cfu/ml of 8×10^9 , Treatment 11 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21221), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21240), *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21141), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), *Clostridium celatum* (family *Clostridiaceae*, SPC21278), *Clostridium butyricum* (family *Clostridiaceae*, SPC21367), *Clostridium glycolicum* (family *Peptostreptococcaceae*, SPC21349), *Dorea formicigerans* (family *Lachnospiraceae*, SPC21308), *Ruminococcus torques* (family *Ruminococcaceae*, SPC21344), *Eubacterium tenue* (family *Peptostreptococcaceae*, SPC21391) and *Eubacterium cylindroides* (family *Erysipelotrichaceae*, SPC21300) with a total anaerobic cfu/ml of 2.5×10^9 . Treatment 12 is a bacterial composition comprising *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), and *Clostridium celatum* (family *Clostridiaceae*,

SPC21278), with a total anaerobic cfu/ml of 2.1×10^7 . Treatment 13 is a bacterial composition comprising *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), *Clostridium celatum* (family *Clostridiaceae*, SPC21278), *Clostridium butyricum* (family *Clostridiaceae*, SPC21367), and *Clostridium glycolicum* (family *Peptostreptococcaceae*, SPC21349) with a total anaerobic cfu/ml of 1.4×10^8 . Treatment 14 is a bacterial composition comprising *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), *Clostridium celatum* (family *Clostridiaceae*, SPC21278), *Clostridium butyricum* (family *Clostridiaceae*, SPC21367), *Clostridium glycolicum* (family *Peptostreptococcaceae*, SPC21349), *Dorea formicigerans* (family *Lachnospiraceae*, SPC21308), *Ruminococcus torques* (family *Ruminococcaceae*, SPC21344), *Eubacterium tenue* (family *Peptostreptococcaceae*, SPC21391) and *Eubacterium cylindroides* (family *Erysipelotrichaceae*, SPC21300) with a total anaerobic cfu/ml of 3.1×10^7 . Treatment 15 is a bacterial composition comprising *Escherichia coli* (family *Enterobacteriaceae*, SPC21221), *Enterococcus faecalis* (family *Enterococcaceae*, SPC21240), *Blautia producta* (family *Lachnospiraceae*, SPC2115104), *Bacteriodes vulgatus* (family *Bacteroidaceae*, SPC21192), *Bacteriodes thetaiotaomicron* (family *Bacteroidaceae*, SPC21132), *Bacteriodes ovatus* (family *Bacteroidaceae*, SPC21141), *Clostridium innocuum* (family *Erysipelotrichaceae*, SPC21112), *Clostridium celatum* (family *Clostridiaceae*, SPC21278), *Clostridium butyricum* (family *Clostridiaceae*, SPC21367), *Clostridium glycolicum* (family *Peptostreptococcaceae*, SPC21349), *Dorea formicigerans* (family *Lachnospiraceae*, SPC21308), *Ruminococcus torques* (family *Ruminococcaceae*, SPC21344),

Eubacterium tenue (family *Peptostreptococcaceae*, SPC21391) and *Eubacterium cylindroides* (family *Erysipelotrichaceae*, SPC21300) that was treated with 50% EtOH for 1 hour at 37C, centrifuged to pellet the bacterial cells and resuspended in sterile PBS at the equivalent original volume and having a total anaerobic cfu/ml of 1.3×10^7 .

[0187] For each of the three demonstrations, scores for each treatment range from 0 to 9. Scores were calculated as follows. Groups of animals (N=10/group) were scored for % mortality. Mortality was normalized in a given demonstration by setting the observed mortality of the PBS vehicle control group = 3. A treatment group was then scored based on the observed mortality for that group divided by the mortality of the PBS vehicle control times 3. Thus, if the mortality of the PBS vehicle group was 60% (score = 3), then a treatment group with mortality of 30% would receive a score of 1.5. Similarly, mean weight loss on Day 3 was normalized to a score of 3 for the PBS vehicle control group. A score for each treatment was calculated by dividing the actual mean weight loss by the mean weight loss for the PBS vehicle control group and multiplying by 3. A similar procedure was used for the clinical scores evaluation. Finally, the individual values for mortality, mean weight loss on Day 3 and clinical scores were summed to give a final value of 0-9 for each treatment, with 0 being best (no death, no weight loss, no clinical symptoms) and 9 being equivalent to the vehicle control.

Example 2: Species Identification

[0188] The identity of the bacterial species which grew up from a complex fraction can be determined in multiple ways. First, individual colonies can be picked into liquid media in a 96 well format, grown up and saved as 15% glycerol stocks at -80C. Aliquots of the cultures can be placed into cell lysis buffer and colony PCR methods can be used to amplify and sequence the 16S rDNA gene (described below in Example 3).

Alternatively, colonies may be streaked to purity in several passages on solid media. Well separated colonies are streaked onto the fresh plates of the same kind and incubated for 48-72 hours at 37C. The process is repeated multiple times in order to ensure purity. Pure cultures can be analyzed by phenotypic- or sequence-based methods, including 16S rDNA amplification and sequencing as described in Examples 3 and 4. Sequence characterization of pure isolates or mixed communities e.g. plate scrapes and spore fractions can also include whole genome shotgun sequencing. The latter is valuable to determine the presence of genes associated with sporulation, antibiotic resistance, pathogenicity, and virulence. Colonies can also be scraped from plates en masse and sequenced using a massively parallel sequencing method as described in Examples 3 & 4 such that individual 16S signatures can be identified in a complex mixture. Optionally, the sample can be sequenced prior to germination (if appropriate DNA isolation procedures are used to lyse and release the DNA from spores) in order to compare the diversity of germinable species with the total number of species in a spore sample. As an alternative or complementary approach to 16S analysis, MALDI-TOF-mass spec can also be used for species identification (as reviewed in Anaerobe 22:123).

Example 3: 16s Sequencing to Determine Operational Taxonomic Unit (OTU)

Method for Determining 16S Sequence

[0189] OTUs may be defined either by full 16S sequencing of the rRNA gene, by sequencing of a specific hypervariable region of this gene (i.e. V1, V2, V3, V4, V5, V6, V7, V8, or V9), or by sequencing of any combination of hypervariable regions from this gene (e.g. V1-3 or V3-5). The bacterial 16S rDNA is approximately 1500

nucleotides in length and is used in reconstructing the evolutionary relationships and sequence similarity of one bacterial isolate to another using phylogenetic approaches. 16S sequences are used for phylogenetic reconstruction as they are in general highly conserved, but contain specific hypervariable regions that harbor sufficient nucleotide diversity to differentiate genera and species of most microbes.

[0190] Using well known techniques, in order to determine the full 16S sequence or the sequence of any hypervariable region of the 16S sequence, genomic DNA is extracted from a bacterial sample, the 16S rDNA (full region or specific hypervariable regions) amplified using polymerase chain reaction (PCR), the PCR products cleaned, and nucleotide sequences delineated to determine the genetic composition of 16S gene or subdomain of the gene. If full 16S sequencing is performed, the sequencing method used may be, but is not limited to, Sanger sequencing. If one or more hypervariable regions are used, such as the V4 region, the sequencing may be, but is not limited to being, performed using the Sanger method or using a next-generation sequencing method, such as an Illumina (sequencing by synthesis) method using barcoded primers allowing for multiplex reactions.

[0191] In addition to the 16S rRNA gene, one may define an OTU by sequencing a selected set of genes that are known to be marker genes for a given species or taxonomic group of OTUs. These genes may alternatively be assayed using a PCR-based screening strategy. As example, various strains of pathogenic *Escherichia coli* can be distinguished using DNAs from the genes that encode heat-labile (LTl, LTIIa, and LTIIb) and heat-stable (STI and STII) toxins, verotoxin types 1, 2, and 2e (VT1, VT2, and VT2e, respectively), cytotoxic necrotizing factors (CNF1 and

CNF2), attaching and effacing mechanisms (*eaeA*), enteroaggregative mechanisms (Eagg), and enteroinvasive mechanisms (Einv). The optimal genes to utilize for taxonomic assignment of OTUs by use of marker genes will be familiar to one with ordinary skill of the art of sequence based taxonomic identification and may include, but will not be limited, to highly conserved “house-keeping” genes or a combination thereof, full-genome sequence, or partial genome sequence generated using amplified genetic products, or whole genome sequence (WGS). Using well defined methods DNA extracted from a bacterial sample will have specific genomic regions amplified using PCR and sequenced to determine the nucleotide sequence of the amplified products. In the whole genome shotgun (WGS) method, extracted DNA will be directly sequenced without amplification. Sequence data can be generated using any sequencing technology including, but not limited to Sanger, Illumina, 454 Life Sciences, Ion Torrent, ABI, Pacific Biosciences, and/or Oxford Nanopore.

Genomic DNA Extraction

[0192] Genomic DNA is extracted from pure microbial cultures using a hot alkaline lysis method. 1 µl of microbial culture is added to 9 µl of Lysis Buffer (25mM NaOH, 0.2 mM EDTA) and the mixture is incubated at 95°C for 30 minutes. Subsequently, the samples are cooled to 4°C and neutralized by the addition of 10 µl of Neutralization Buffer (40 mM Tris-HCl) and then diluted 10-fold in Elution Buffer (10 mM Tris-HCl). Alternatively, genomic DNA is extracted from pure microbial cultures using commercially available kits such as the Mo Bio Ultraclean® Microbial DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA) or by standard methods known to those skilled in the art.

Amplification of 16S Sequences for downstream Sanger Sequencing

[0193] To amplify bacterial 16S rDNA (Figure 1A), 2 µl of extracted gDNA is added to a 20 µl final volume PCR reaction. For full-length 16 sequencing the PCR reaction also contains 1x HotMasterMix (5PRIME, Gaithersburg, MD), 250 nM of 27f (AGRGTTTGATCMTGGCTCAG, IDT, Coralville, IA), and 250 nM of 1492r (TACGGYTACCTTGTTAYGACTT, IDT, Coralville, IA), with PCR Water (Mo Bio Laboratories, Carlsbad, CA) for the balance of the volume. Alternatively, other universal bacterial primers or thermostable polymerases known to those skilled in the art are used. For example primers are available to those skilled in the art for the sequencing of the the “V1-V9 regions” of the 16S rRNA (Figure 1A). These regions refer to the first through ninth hypervariable regions of the 16S rRNA gene that are used for genetic typing of bacterial samples. These regions in bacteria are defined by nucleotides 69-99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1117-1173, 1243-1294 and 1435-1465 respectively using numbering based on the *E. coli* system of nomenclature. Brosius et al., Complete nucleotide sequence of a 16S ribosomal RNA gene from Escherichia coli, PNAS 75(10):4801-4805 (1978). In some embodiments, at least one of the V1, V2, V3, V4, V5, V6, V7, V8, and V9 regions are used to characterize an OTU. In one embodiment, the V1, V2, and V3 regions are used to characterize an OTU. In another embodiment, the V3, V4, and V5 regions are used to characterize an OTU. In another embodiment, the V4 region is used to characterize an OTU. A person of ordinary skill in the art can identify the specific hypervariable regions of a candidate 16S rRNA (in Figure 1A) by comparing the candidate sequence in question to the reference sequence

(Figure 1B) and identifying the hypervariable regions based on similarity to the reference hypervariable regions.

[0194] The PCR is performed on commercially available thermocyclers such as a BioRad MyCycler™ Thermal Cycler (BioRad, Hercules, CA). The reactions are run at 94°C for 2 minutes followed by 30 cycles of 94°C for 30 seconds, 51°C for 30 seconds, and 68°C for 1 minute 30 seconds, followed by a 7 minute extension at 72°C and an indefinite hold at 4°C. Following PCR, gel electrophoresis of a portion of the reaction products is used to confirm successful amplification of a ~1.5 kb product.

[0195] To remove nucleotides and oligonucleotides from the PCR products, 2 µl of HT ExoSap-IT (Affymetrix, Santa Clara, CA) is added to 5 µl of PCR product followed by a 15 minute incubation at 37°C and then a 15 minute inactivation at 80°C.

**Amplification of 16S Sequences for downstream
characterization by massively parallel sequencing
technologies**

[0196] Amplification performed for downstream sequencing by short read technologies such as Illumina require amplification using primers known to those skilled in the art that additionally include a sequence-based barcoded tag. As example, to amplify the 16s hypervariable region V4 region of bacterial 16S rDNA, 2 µl of extracted gDNA is added to a 20 µl final volume PCR reaction. The PCR reaction also contains 1x HotMasterMix (5PRIME, Gaithersburg, MD), 200 nM of V4_515f_adapt (AATGATACGGCGACCAACGAGATCTACACTATGGTAATTGTGTGCCAGCMGCCGCGGTAA, IDT, Coralville, IA), and 200 nM of barcoded 806rbc (CAAGCAGAAGACGGCATACGAGAT_12bpGolayBarcode_AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT, IDT, Coralville, IA), with PCR Water (Mo Bio Laboratories, Carlsbad, CA) for the balance of the volume. These primers incorporate barcoded

adapters for Illumina sequencing by synthesis. Optionally, identical replicate, triplicate, or quadruplicate reactions may be performed. Alternatively other universal bacterial primers or thermostable polymerases known to those skilled in the art are used to obtain different amplification and sequencing error rates as well as results on alternative sequencing technologies.

[0197] The PCR amplification is performed on commercially available thermocyclers such as a BioRad MyCycler™ Thermal Cycler (BioRad, Hercules, CA). The reactions are run at 94°C for 3 minutes followed by 25 cycles of 94°C for 45 seconds, 50°C for 1 minute, and 72°C for 1 minute 30 seconds, followed by a 10 minute extension at 72°C and a indefinite hold at 4°C. Following PCR, gel electrophoresis of a portion of the reaction products is used to confirm successful amplification of a ~1.5 kb product. PCR cleanup is performed as specified in the previous example.

Sanger Sequencing of Target Amplicons from Pure Homogeneous Samples

[0198] To detect nucleic acids for each sample, two sequencing reactions are performed to generate a forward and reverse sequencing read. For full-length 16S sequencing primers 27f and 1492r are used.. 40 ng of ExoSap-IT-cleaned PCR products are mixed with 25 pmol of sequencing primer and Mo Bio Molecular Biology Grade Water (Mo Bio Laboratories, Carlsbad, CA) to 15 µl total volume. This reaction is submitted to a commercial sequencing organization such as Genewiz (South Plainfield, NJ) for Sanger sequencing.

Massively Parallel Sequencing of Target Amplicons from Heterogeneous Samples

[0199] *DNA Quantification & Library Construction.* The cleaned PCR amplification products are quantified using the Quant-iT™ PicoGreen® dsDNA Assay

Kit (Life Technologies, Grand Island, NY) according to the manufacturer's instructions. Following quantification, the barcoded cleaned PCR products are combined such that each distinct PCR product is at an equimolar ratio to create a prepared Illumina library.

[0200] *Nucleic Acid Detection.* The prepared library is sequenced on Illumina HiSeq or MiSeq sequencers (Illumina, San Diego, CA) with cluster generation, template hybridization, iso-thermal amplification, linearization, blocking and denaturization and hybridization of the sequencing primers performed according to the manufacturer's instructions. 16SV4SeqFw (TATGGTAATTGTGTGCCAGCMGCCGCGGTAA), 16SV4SeqRev (AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT), and 16SV4Index (ATTAGAWACCCBDGTAGTCCGGCTGACTGACT) (IDT, Coralville, IA) are used for sequencing. Other sequencing technologies can be used such as but not limited to 454, Pacific Biosciences, Helicos, Ion Torrent, and Nanopore using protocols that are standard to someone skilled in the art of genomic sequencing.

Example 4: Sequence Read Annotation

Primary Read Annotation

[0201] Nucleic acid sequences are analyzed and annotations are to define taxonomic assignments using sequence similarity and phylogenetic placement methods or a combination of the two strategies. A similar approach can be used to annotate protein names, transcription factor names, and any other classification schema for nucleic acid sequences. Sequence similarity based methods include those familiar to individuals skilled in the art including, but not limited to BLAST, BLASTx, tBLASTn, tBLASTx, RDP-classifier, DNAClust, and various implementations of these algorithms such as Qiime or Mothur. These methods rely on mapping a sequence read to a reference database and selecting the match with the best score and e-value. Common

databases include, but are not limited to the Human Microbiome Project, NCBI non-redundant database, Greengenes, RDP, and Silva. Phylogenetic methods can be used in combination with sequence similarity methods to improve the calling accuracy of an annotation or taxonomic assignment. Here tree topologies and nodal structure are used to refine the resolution of the analysis. In this approach we analyze nucleic acid sequences using one of numerous sequence similarity approaches and leverage phylogenetic methods that are well known to those skilled in the art, including but not limited to maximum likelihood phylogenetic reconstruction (see e.g. Liu K, Linder CR, and Warnow T. 2011. RAxML and FastTree: Comparing Two Methods for Large-Scale Maximum Likelihood Phylogeny Estimation. PLoS ONE 6: e27731. McGuire G, Denham MC, and Balding DJ. 2001. Models of sequence evolution for DNA sequences containing gaps. Mol. Biol. Evol 18: 481–490. Wróbel B. 2008. Statistical measures of uncertainty for branches in phylogenetic trees inferred from molecular sequences by using model-based methods. J. Appl. Genet. 49: 49–67.) Sequence reads are placed into a reference phylogeny comprised of appropriate reference sequences. Annotations are made based on the placement of the read in the phylogenetic tree. The certainty or significance of the OTU annotation is defined based on the OTU's sequence similarity to a reference nucleic acid sequence and the proximity of the OTU sequence relative to one or more reference sequences in the phylogeny. As an example, the specificity of a taxonomic assignment is defined with confidence at the the level of Family, Genus, Species, or Strain with the confidence determined based on the position of bootstrap supported branches in the reference phylogenetic tree relative to the placement of the OTU sequence being interrogated.

Clade Assignments

[0202] The ability of 16S-V4 OTU identification to assign an OTU as a specific species depends in part on the resolving power of the 16S-V4 region of the 16S gene for a particular species or group of species. Both the density of available reference 16S sequences for different regions of the tree as well as the inherent variability in the 16S gene between different species will determine the definitiveness of a taxonomic annotation. Given the topological nature of a phylogenetic tree and the fact that tree represents hierarchical relationships of OTUs to one another based on their sequence similarity and an underlying evolutionary model, taxonomic annotations of a read can be rolled up to a higher level using a clade-based assignment procedure (Table 1). Using this approach, clades are defined based on the topology of a phylogenetic tree that is constructed from full-length 16S sequences using maximum likelihood or other phylogenetic models familiar to individuals with ordinary skill in the art of phylogenetics. Clades are constructed to ensure that all OTUs in a given clade are: (i) within a specified number of bootstrap supported nodes from one another (generally, 1-5 bootstraps), and (ii) within a 5% genetic similarity. OTUs that are within the same clade can be distinguished as genetically and phylogenetically distinct from OTUs in a different clade based on 16S-V4 sequence data. OTUs falling within the same clade are evolutionarily closely related and may or may not be distinguishable from one another using 16S-V4 sequence data. The power of clade based analysis is that members of the same clade, due to their evolutionary relatedness, are likely to play similar functional roles in a microbial ecology such as that found in the human gut. Compositions substituting one species with another from the same clade are likely to have conserved ecological function and therefore are useful in the present invention.

[0203] Notably, 16S sequences of isolates of a given OTU are phylogenetically placed within their respective clades, sometimes in conflict with the microbiological-based assignment of species and genus that may have preceded 16S-based assignment. Discrepancies between taxonomic assignment based on microbiological characteristics versus genetic sequencing are known to exist from the literature.

Example 5: Germinating Spores

[0204] Mixtures of bacteria can include species that are in spore form. Germinating a spore fraction increases the number of viable bacteria that will grow on various media types. To germinate a population of spores, the sample is moved to the anaerobic chamber, resuspended in prereduced PBS, mixed and incubated for 1 hour at 37C to allow for germination. Germinants can include amino-acids (e.g., alanine, glycine), sugars (e.g., fructose), nucleosides (e.g., inosine), bile salts (e.g., cholate and taurocholate), metal cations (e.g., Mg^{2+} , Ca^{2+}), fatty acids, and long-chain alkyl amines (e.g., dodecylamine, Germination of bacterial spores with alkyl primary amines” J. Bacteriology, 1961.). Mixtures of these or more complex natural mixtures, such as rumen fluid or Oxgall, can be used to induce germination. Oxgall is dehydrated bovine bile composed of fatty acids, bile acids, inorganic salts, sulfates, bile pigments, cholesterol, mucin, lecithin, glycuronic acids, porphyrins, and urea. The germination can also be performed in a growth medium like prereduced BHIS/oxgall germination medium, in which BHIS (Brain heart infusion powder (37 g/L), yeast extract (5 g/L), L-cysteine HCl (1 g/L)) provides peptides, amino acids, inorganic ions and sugars in the complex BHI and yeast extract mixtures and Oxgall provides additional bile acid germinants.

[0205] In addition, pressure may be used to germinate spores. The selection of germinants can vary with the microbe being sought. Different species require different germinants and different isolates of the same species can require different germinants for optimal germination. Finally, it is important to dilute the mixture prior to plating because some germinants are inhibitory to growth of the vegetative-state microorganisms. For instance, it has been shown that alkyl amines must be neutralized with anionic lipophiles in order to promote optimal growth. Bile acids can also inhibit growth of some organisms despite promoting their germination, and must be diluted away prior to plating for viable cells.

[0206] For example, BHIS/oxgall solution is used as a germinant and contains 0.5X BHIS medium with 0.25% oxgall (dehydrated bovine bile) where 1x BHIS medium contains the following per L of solution: 6g Brain Heart Infusion from solids, 7g peptic digest of animal tissue, 14.5g of pancreatic digest of casein, 5g of yeast extract, 5g sodium chloride, 2g glucose, 2.5g disodium phosphate, and 1g cysteine. Additionally, Ca-DPA is a germinant and contains 40mM CaCl_2 , and 40mM dipicolinic acid (DPA). Rumen fluid (Bar Diamond, Inc.) is also a germinant. Simulated gastric fluid (Ricca Chemical) is a germinant and is 0.2% (w/v) Sodium Chloride in 0.7% (v/v) Hydrochloric Acid. Mucin medium is a germinant and prepared by adding the following items to 1L of distilled sterile water: 0.4 g KH_2PO_4 , 0.53 g Na_2HPO_4 , 0.3 g NH_4Cl , 0.3 g NaCl , 0.1 g $\text{MgCl}_2 \times 6\text{H}_2\text{O}$, 0.11 g CaCl_2 , 1 ml alkaline trace element solution, 1 ml acid trace element solution, 1 ml vitamin solution, 0.5 mg resazurin, 4 g NaHCO_3 , 0.25 g $\text{Na}_2\text{S} \times 9\text{H}_2\text{O}$. The trace element and vitamin solutions prepared as described previously (Stams et al., 1993). All compounds were autoclaved, except the vitamins, which were filter-

sterilized. The basal medium was supplemented with 0.7% (v/v) clarified, sterile rumen fluid and 0.25% (v/v) commercial hog gastric mucin (Type III; Sigma), purified by ethanol precipitation as described previously (Miller & Hoskins, 1981). This medium is referred herein as mucin medium.

[0207] Fetal Bovine Serum (Gibco) can be used as a germinant and contains 5% FBS heat inactivated, in Phosphate Buffered Saline (PBS, Fisher Scientific) containing 0.137M Sodium Chloride, 0.0027M Potassium Chloride, 0.0119M Phosphate Buffer. Thioglycollate is a germinant as described previously (Kamiya et al Journal of Medical Microbiology 1989) and contains 0.25M (pH10) sodium thioglycollate. Dodecylamine solution containing 1mM dodecylamine in PBS is a germinant. A sugar solution can be used as a germinant and contains 0.2% fructose, 0.2% glucose, and 0.2% mannitol. Amino acid solution can also be used as a germinant and contains 5mM alanine, 1mM arginine, 1mM histidine, 1mM lysine, 1mM proline, 1mM asparagine, 1mM aspartic acid, 1mM phenylalanine. A germinant mixture referred to herein as Germix 3 can be a germinant and contains 5mM alanine, 1mM arginine, 1mM histidine, 1mM lysine, 1mM proline, 1mM asparagine, 1mM aspartic acid, 1mM phenylalanine, 0.2%taurocholate, 0.2% fructose, 0.2% mannitol, 0.2% glucose, 1mM inosine, 2.5mM Ca-DPA, and 5mM KCl. BHIS medium + DPA is a germinant mixture and contains BHIS medium and 2mM Ca-DPA. Escherichia coli spent medium supernatant referred to herein as EcSN is a germinant and is prepared by growing E. coli MG1655 in SweetB/Fos inulin medium anaerobically for 48 hr, spinning down cells at 20,000rcf for 20 minutes, collecting the supernatant and heating to 60C for 40 min. Finally, the solution is filter sterilized and used as a germinant solution.

Example 6: Selection of Media for Growth

[0208] It is important to select appropriate media to support growth, including preferred carbon sources. For example, some organisms prefer complex sugars such as cellobiose over simple sugars. Examples of media used in the isolation of sporulating organisms include EYA, BHI, BHIS, and GAM (see below for complete names and references). Multiple dilutions are plated out to ensure that some plates will have well isolated colonies on them for analysis, or alternatively plates with dense colonies may be scraped and suspended in PBS to generate a mixed diverse community.

[0209] Plates are incubated anaerobically or aerobically at 37°C for 48-72 or more hours, targeting anaerobic or aerobic spore formers, respectively.

[0210] Solid plate media include:

[0211] • Gifu Anaerobic Medium (GAM, Nissui) without dextrose supplemented with fructooligosaccharides/inulin (0.4%), mannitol (0.4%), inulin (0.4%), or fructose (0.4%), or a combination thereof.

[0212] • Sweet GAM [Gifu Anaerobic Medium (GAM, Nissui)] modified, supplemented with glucose, cellobiose, maltose, L-arabinose, fructose, fructooligosaccharides/inulin, mannitol and sodium lactate)

[0213] • Brucella Blood Agar (BBA, Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010)

[0214] • PEA sheep blood (Anaerobe Systems; 5% Sheep Blood Agar with Phenylethyl Alcohol)

[0215] • Egg Yolk Agar (EYA) (Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010)

- [0216] • Sulfite polymyxin milk agar (Mevisse-Verhage et al., J. Clin. Microbiol. 25:285-289 (1987))
- [0217] • Mucin agar (Derrien et al., IJSEM 54: 1469-1476 (2004))
- [0218] • Polygalacturonate agar (Jensen & Canale-Parola, Appl. Environ. Microbiol. 52:880-997 (1986))
- [0219] • M2GSC (Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010)
- [0220] • M2 agar (Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010) supplemented with starch (1%), mannitol (0.4%), lactate (1.5g/L) or lactose (0.4%)
- [0221] • Sweet B - Brain Heart Infusion agar (Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010) supplemented with yeast extract (0.5%), hemin, cysteine (0.1%), maltose (0.1%), cellobiose (0.1%), soluble starch (sigma, 1%), MOPS (50mM, pH 7).
- [0222] • PY-salicin (peptone-yeast extract agar supplemented with salicin) (Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010).
- [0223] • Modified Brain Heart Infusion (M-BHI) [[sweet and sour]] contains the following per L: 37.5g Brain Heart Infusion powder (Remel), 5g yeast extract, 2.2g meat extract, 1.2g liver extract, 1g cystein HCl, 0.3g sodium thioglycolate, 10mg hemin, 2g soluble starch, 2g FOS/Inulin, 1g cellobiose, 1g L-arabinose, 1g mannitol, 1 Na-lactate, 1mL Tween 80, 0.6g MgSO₄·7H₂O, 0.6g CaCl₂, 6g (NH₄)₂SO₄, 3g KH₂PO₄, 0.5g K₂HPO₄, 33mM Acetic acid, 9mM propionic acid, 1mM

Isobutyric acid, 1mM isovaleric acid, 15g agar, and after autoclaving add 50mL of 8% NaHCO₃ solution and 50mL 1M MOPS-KOH (pH 7).

[0224] • Noack-Blaut Eubacterium agar (See Noack et al. J. Nutr. (1998) 128:1385-1391)

[0225] • BHIS az1/ge2 - BHIS az/ge agar (Reeves et. al. Infect. Immun. 80:3786-3794 (2012)) [Brain Heart Infusion agar (Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010) supplemented with yeast extract 0.5%, cysteine 0.1%, 0.1% cellobiose, 0.1% inulin, 0.1% maltose, aztreonam 1 mg/L, gentamycin 2 mg/L]

[0226] • BHIS CInM az1/ge2- BHIS CInM [Brain Heart Infusion agar (Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010) supplemented with yeast extract 0.5%, cysteine 0.1%, 0.1% cellobiose, 0.1% inulin, 0.1% maltose, aztreonam 1 mg/L, gentamycin 2 mg/L]

Example 7: The purification and isolation of a spore forming fraction from feces

[0227] To purify and selectively isolate efficacious spores from fecal material a donation is first blended with saline using a homogenization device (e.g., laboratory blender) to produce a 20% slurry (w/v). 100% ethanol is added for an inactivation treatment that lasts 10 seconds to 1 hour. The final alcohol concentration can range from 30-90%, preferably 50-70%. High speed centrifugation (3200 rcf for 10min) is performed to remove solvent and the pellet is retained and washed. Subsequently, once the washed pellet is resuspended, a low speed centrifugation step (200 rcf for 4 min) is performed to remove large particulate vegetative matter and the supernatant containing the spores is retained. High speed centrifugation (3200 rcf for 10 min) is

performed on the supernatant to concentrate the spore material. The pellet is then washed and resuspended to generate a 20% slurry. This is the ethanol treated spore preparation. The concentrated slurry is then separated with a density based gradient e.g. a CsCl gradient, sucrose gradient or combination of the two generating a ethanol treated, gradient-purified spore preparation. For example, a CsCl gradient is performed by loading a 20% volume of spore suspension on top a 80% volume of a stepwise CsCl gradient (w/v) containing the steps of 64%, 50%, 40% CsCl (w/v) and centrifuging for 20 min at 3200 rcf. The spore fraction is then run on a sucrose step gradient with steps of 67%, 50%, 40%, and 30% (w/v). When centrifuged in a swinging bucket rotor for 10 min at 3200 rcf. The spores run roughly in the 30% and 40% sucrose fractions. The lower spore fraction (Figure 2) is then removed and washed to produce a concentrated ethanol treated, gradient-purified spore preparation. Taking advantage of the refractive properties of spores observed by phase contrast microscopy (spores are bright and refractive while germinated spores and vegetative cells are dark) one can see an enrichment of the spore fraction from a fecal bacterial cell suspension (Figure 3, left) compared to an ethanol treated, CsCl gradient purified, spore preparation (Figure 3, center), and to an ethanol treated, CsCl gradient purified, sucrose gradient purified, spore preparation (Figure 3, right).

[0228] Furthermore, growth of spores after treatment with a germinant can also be used to quantify a viable spore population. Briefly, samples were incubated with a germinant (Oxgall, 0.25% for up to 1 hour), diluted and plated anaerobically on BBA (Brucella Blood Agar) or similar media (e.g. see Examples 5 and 6). Individual colonies were picked and DNA isolated for full-length 16S sequencing to identify the species

composition (e.g. see Examples 3 and 4). Analysis revealed that 22 species were observed in total (Table 4) with a vast majority present in both the material purified with the gradient and without the gradient, indicating no or inconsequential shift in the ecology as a result of gradient purification. Spore yield calculations demonstrate an efficient recovery of 38% of the spores from the initial fecal material as measured by germination and plating of spores on BBA or measuring DPA count in the sample.

Example 8: Bacterial compositions prevent C. difficile infection in a mouse model

[0229] To test the therapeutic potential of the bacterial composition such as but not limited to a spore population, a prophylactic mouse model of C. difficile infection (model based on Chen, et al., A mouse model of Clostridium difficile associated disease, Gastroenterology 135(6):1984-1992) was used. Two cages of five mice each were tested for each arm of the experiment. All mice received an antibiotic cocktail consisting of 10% glucose, kanamycin (0.5 mg/ml), gentamicin (0.044 mg/ml), colistin (1062.5 U/ml), metronidazole (0.269 mg/ml), ciprofloxacin (0.156 mg/ml), ampicillin (0.1 mg/ml) and Vancomycin (0.056 mg/ml) in their drinking water on days -14 through -5 and a dose of 10mg/kg Clindamycin by oral gavage on day -3. On day -1, they received either the test article or vehicle control via oral gavage. On day 0 they were challenged by administration of approximately 4.5 log₁₀ cfu of C. difficile (ATCC 43255) via oral gavage. Optionally a positive control group received vancomycin from day -1 through day 3 in addition to the antibiotic protocol and C. difficile challenge specified above. Feces were collected from the cages for analysis of bacterial carriage, mortality was assessed every day from day 0 to day 6 and the weight and subsequent weight change of the animal was assessed with weight loss being associated with C. difficile infection.

Mortality and reduced weight loss of the test article compared to the vehicle were used to assess the success of the test article. Additionally, a *C. difficile* symptom scoring was performed each day from day -1 through day 6. Clinical Score was based on a 0-4 scale by combining scores for Appearance (0-2 pts based on normal, hunched, piloerection, or lethargic), and Clinical Signs (0-2 points based on normal, wet tail, cold-to-the-touch, or isolation from other animals).

[0230] In a naive control arm, animals were challenged with *C. difficile*. In the vancomycin positive control arm animals were dosed with *C. difficile* and treated with vancomycin from day -1 through day 3. The negative control was gavaged with PBS alone and no bacteria. The test arms of the experiment tested 1x, 0.1x, 0.01x dilutions derived from a single donor preparation of ethanol treated spores (e.g. see Example 7) or the heat treated feces prepared by treating a 20% slurry for 30min at 80C. Dosing for CFU counts was determined from the final ethanol treated spores and dilutions of total spores were administered at 1x, 0.1x, 0.01x of the spore mixture for the ethanol treated fraction and a 1x dose for the heat treated fraction.

[0231] Weight loss and mortality were assessed on day 3. The negative control, treated with *C. difficile* only, exhibits 20% mortality and weight loss on Day 3, while the positive control of 10% human fecal suspension displays no mortality or weight loss on Day 3 (Table 5). EtOH-treated feces prevents mortality and weight loss at three dilutions, while the heat-treated fraction was protective at the only dose tested. These data indicate that the spore fraction is efficacious in preventing *C. difficile* infection in the mouse.

Example 9: The prophylactic and relapse prevention hamster models

[0232] Previous studies with hamsters using toxigenic and nontoxigenic strains of *C. difficile* demonstrated the utility of the hamster model in examining relapse post antibiotic treatment and the effects of prophylaxis treatments with cecal flora in *C. difficile* infection (Wilson et al. 1981, Wilson et al. 1983, Borriello et al. 1985) and more broadly gastrointestinal infectious disease. To demonstrate prophylactic use of a bacterial composition such as but not limited to a spore population, spore preparation, vegetative cell population, to ameliorate *C. difficile* infection, the following hamster model is used. In a prophylactic model, Clindamycin (10mg/kg s.c.) is given on day -5, the bacterial composition or control is administered on day -3, and *C. difficile* challenge occurs on day 0. In the positive control arm, vancomycin is then administered on day 1-5 (and vehicle control is delivered on day -3). Feces are collected on day -5, -4, -1, 1, 3, 5, 7, 9 and fecal samples are assessed for pathogen carriage and reduction by microbiological methods, 16S sequencing approaches or other methods utilized by one skilled in the art. Mortality is assessed throughout the experiment through 21 days post *C. difficile* challenge. The percentage survival curves show that ethanol treated spores and ethanol treated, gradient-purified spores better protect the hamsters compared to the Vancomycin control, and vehicle control.

[0233] Figure 4 shows prophylaxis model with the ethanol treated spore preparation and the ethanol treated, gradient-purified spore preparation.

[0234] In the relapse prevention model, hamsters are challenged with toxigenic *C. difficile* strains on day 0, and treated with clindamycin by oral gavage on day 1, and vancomycin dosing day 2-6. Test or control treatment was then administered on day 7, 8, and 9. The groups of hamsters for each arm consist of 8 hamsters per group. Fecal

material is collected on day -1, 1, 3, 5, 7, 10 and 13 and hamster mortality is assessed throughout. Survival curves are used to assess the success of the test article e.g. ethanol treated or ethanol treated, gradient purified spores versus the control treatment in preventing hamster death. The survival curves demonstrate maximum efficacy for the ethanol treated, gradient-purified spores followed by the ethanol treated spores. Both treatments improved survival percentage over vancomycin treatment alone.

[0235] Figure 5 shows relapse prevention model with ethanol treated spores and ethanol treated, gradient purified spores

Example 10: Clinical treatment of recurrent *C. difficile* in patients

[0236] To assess the efficacy of test articles like bacterial compositions including but not limited to a ethanol treated spore preparations (e.g. see Example 7) to treat recurrent *C. difficile* in human patients, the following procedure was performed to take feces from a healthy donor, inactivate via the ethanol treated spore preparation protocol described below, and treat recurrent *C. difficile* in patients presenting with this indication. Non-related donors were screened for general health history for absence of chronic medical conditions (including inflammatory bowel disease; irritable bowel syndrome; Celiac disease; or any history of gastrointestinal malignancy or polyposis), absence of risk factors for transmissible infections, antibiotic non-use in the previous 6 months, and negative results in laboratory assays for blood-borne pathogens (HIV, HTLV, HCV, HBV, CMV, HAV and *Treponema pallidum*) and fecal bacterial pathogens (*Salmonella*, *Shigella*, *Yersinia*, *Campylobacter*, *E. coli* 0157), ova and parasites, and other infectious agents (*Giardia*, *Cryptosporidium* *Cyclospora*, *Isospora*) prior to stool donation.

[0237] Donor stool was frozen shortly after donation and sampled for testing. At the time of use, approximately 75 g of donor stool was thawed and resuspended in 500 mL of non-bacteriostatic normal saline and mixed in a single use glass or plastic blender. The resulting slurry was sequentially passed through sterile, disposable mesh screens that remove particles of size 600, 300 and 200 microns. The slurry was then centrifuged briefly (200 rcf for 4 min) to separate fibrous and particulate materials, and the supernatant (containing bacterial cells and spores) was transferred to a fresh container. Ethanol was added to a final concentration of 50% and the resulting ~1500 ml slurry was incubated at room temperature for 1 hr with continuous mixing to inactivate vegetative bacterial cells. Midway through inactivation the slurry was transferred to a new bottle to ensure complete contact with the ethanol. The solid matter was pelleted in a centrifuge and washed 3 times with normal saline to remove residual ethanol. The final pellet was resuspended in 100% sterile, USP glycerol at a minimum volume, and filled into approximately 30 size 0 delayed release capsules (hypromellose DRcaps, Capsugel, Inc.) at 0.65 mL suspension each. The capsules were immediately capped and placed onto an aluminum freezing block held at -80° C via dry ice to freeze. The frozen capsules were in turn over-capsulated with size 00 DRcaps to enhance capsule stability, labeled, and placed into < -65° C storage immediately. The final product was stored at < -65° C until the day and time of use. Encapsulated product may be stored for indefinitely at < -65° C. On the day of dosing capsules were warmed on wet ice for 1 to 2 hours to improve tolerability, and were then dosed with water ad libitum.

[0238] Patient 1 is a 45-year old woman with a history of *C. difficile* infection and diarrhea for at least 1 year prior to treatment. She has been previously treated with multiple courses of antibiotics followed each time by recurrence of *C. difficile*-associated diarrhea.

[0239] Patient 2 is an 81-year old female who has experienced recurrent *C. difficile* infection for 6 months prior to treatment despite adequate antibiotic therapy following each recurrence.

[0240] 24 hours prior to starting oral treatment, CDAD antibiotic therapy was discontinued. Each patient received a colon preparation procedure intended to reduce the competing microbial burden in the gastrointestinal tract and to facilitate repopulation by the spore forming organisms in the investigational product.

[0241] On the morning of the first treatment day, the patients received a dose of delayed release capsules containing the investigational product with water ad libitum. Patients were requested to avoid food for 1 hour thereafter. The next day, the patient returned to the clinic to receive an additional dose. Patients were asked to avoid food for 4 hours prior to receiving their second dose and for 1 hour following dosing.

[0242] Both patients were followed closely for evidence of relapse or adverse symptoms following treatment. Patients were contacted by phone on Day 2, Day 4, and Weeks 1, 2 and 4 and each was queried about her general status and the condition of her CDAD and related symptoms. Stool samples were collected at baseline and Weeks 1, 2, 4 and 8 post-treatment to assess changes in the gut microbiota via 16S sequencing and spore count with methods explained previously (e.g. see Examples

AAAB and AAAC). Through 4 weeks post treatment, each patient has gradually improved with no evidence of *C. difficile* recurrence.

[0243] Six other patients with recurrent *C. difficile*-associated diarrhea were treated in a similar fashion, with no CDI recurrence and no requirement for resumption of antibiotics (total of 8 patients). Additionally, there were no treatment-related serious adverse events.

[0244] The above protocol could be modified to deliver other bacterial compositions e.g. vegetative cells, spore preparations, combinations thereof.

Example 11. Enrichment and Purification of bacteria.

[0245] To purify individual bacterial strains, dilution plates were selected in which the density enables distinct separation of single colonies. Colonies were picked with a sterile implement (either a sterile loop or toothpick) and re-streaked to BBA or other solid media. Plates were incubated at 37°C for 3-7 days. One or more well-isolated single colonies of the major morphology type were re-streaked. This process was repeated at least three times until a single, stable colony morphology is observed. The isolated microbe was then cultured anaerobically in liquid media for 24 hours or longer to obtain a pure culture of 10^6 - 10^{10} cfu/ml. Liquid growth medium might include Brain Heart Infusion-based medium (Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010) supplemented with yeast extract, hemin, cysteine, and carbohydrates (for example, maltose, cellobiose, soluble starch) or other media described previously (e.g. see example 6). The culture was centrifuged at 10,000 x g for 5 min to pellet the bacteria, the spent culture media was removed, and the bacteria were resuspended in sterile PBS. Sterile 75% glycerol was added to a final concentration of 20%. An aliquot of glycerol stock was titered by serial dilution and

plating. The remainder of the stock was frozen on dry ice for 10-15 min and then placed at -80C for long term storage.

Example 12. Cell Bank Preparation.

[0246] Cell banks (RCBs) of bacterial strains were prepared as follows. Bacterial strains were struck from -80°C frozen glycerol stocks to Brucella blood agar with Hemin or Vitamin K (Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010), M2GSC (Atlas, Handbook of Microbiological Media, 4th ed, ASM Press, 2010) or other solid growth media and incubated for 24 to 48 h at 37°C in an anaerobic chamber with a gas mixture of H₂:CO₂:N₂ of 10:10:80. Single colonies were then picked and used to inoculate 250 ml to 1 L of Wilkins-Chalgren broth, Brain-Heart Infusion broth, M2GSC broth or other growth media, and grown to mid to late exponential phase or into the stationary phase of growth. Alternatively, the single colonies may be used to inoculate a pilot culture of 10 ml, which were then used to inoculate a large volume culture. The growth media and the growth phase at harvest were selected to enhance cell titer, sporulation (if desired) and phenotypes that might be associated desired in vitro or in vivo. Optionally, Cultures were grown static or shaking, depending which yielded maximal cell titer. The cultures were then concentrated 10 fold or more by centrifugation at 5000 rpm for 20 min, and resuspended in sterile phosphate buffered saline (PBS) plus 15% glycerol. 1 ml aliquots were transferred into 1.8 ml cryovials which were then frozen on dry ice and stored at -80C. The identity of a given cell bank was confirmed by PCR amplification of the 16S rDNA gene, followed by Sanger direct cycle sequencing, and comparison to a curated rDNA database to determine a taxonomic ID. Each bank was confirmed to yield colonies of a single morphology upon streaking to Brucella blood agar or M2GSC agar. When more than one morphology was

observed, colonies were confirmed to be the expected species by PCR and sequencing analysis of the 16S rDNA gene. Variant colony morphologies can be observed within pure cultures, and in a variety of bacteria the mechanisms of varying colony morphologies have been well described (van der Woude, Clinical Microbiology Reviews, 17:518, 2004), including in Clostridium species (Wadsworth-KTL Anaerobic Bacteriology Manual, 6th Ed, Jousimie-Somer, et al 2002). For obligate anaerobes, RCBs were confirmed to lack aerobic colony forming units at a limit of detection of 10 cfu/ml.

Example 13. Titer Determination.

[0247] The number of viable cells per ml was determined on the freshly harvested, washed and concentrated culture by plating serial dilutions of the RCB to Brucella blood agar or other solid media, and varied from 10^6 to 10^{10} cfu/ml. The impact of freezing on viability was determined by titering the banks after one or two freeze-thaw cycles on dry ice or at -80°C , followed by thawing in an anaerobic chamber at room temperature. Some strains displayed a 1-3 log drop in viable cfu/ml after the 1st and/or 2nd freeze thaw, while the viability of others were unaffected.

Example 14. Preparation of bacterial compositions.

[0248] Individual strains were typically thawed on ice and combined in an anaerobic chamber to create mixtures, followed by a second freeze at -80°C to preserve the mixed samples. When making combinations of strains for in vitro or in vivo assays, the cfu in the final mixture was estimated based on the second freeze-thaw titer of the individual strains. For experiments in rodents, strains may be combined at equal counts in order to deliver between 10^4 and 10^{10} per strain. Additionally, some bacteria may

not grow to sufficient titer to yield cell banks that allowed the production of compositions where all bacteria were present at 1×10^{10} .

Example 15. Provision of gut microbiome sample material.

[0249] For sourcing of microbial cultures and for use as a positive control in *in vivo* studies, fresh gut microbiome samples, e.g. fecal samples, were obtained from healthy human donors who have been screened for general good health and for the absence of infectious diseases, and meet inclusion and exclusion criteria, inclusion criteria include being in good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities, regular bowel movements with stool appearance typically Type 2, 3, 4, 5 or 6 on the Bristol Stool Scale, and having a BMI $\geq 18 \text{ kg/m}^2$ and $\leq 25 \text{ kg/m}^2$. Exclusion criteria generally included significant chronic or acute medical conditions including renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic or hematological disease, a family history of, inflammatory bowel disease including Crohn's disease and ulcerative colitis, Irritable bowel syndrome, colon, stomach or other gastrointestinal malignancies, or gastrointestinal polyposis syndromes, or recent use of yogurt or commercial probiotic materials in which an organism(s) is a primary component. Samples were collected directly using a commode specimen collection system, which contains a plastic support placed on the toilet seat and a collection container that rests on the support. Gut microbiome samples e.g. feces were deposited into the container, and the lid was then placed on the container and sealed tightly. The sample was then delivered on ice within 1-4 hours for processing. Samples were mixed with a sterile disposable tool, and 2-4 g aliquots were weighed and placed into tubes

and flash frozen in a dry ice/ethanol bath. Aliquots are frozen at -80 degrees Celsius until use.

[0250] Optionally, the microbiome sample was suspended in a solution, and/or fibrous and/or particulate materials were removed. A frozen aliquot containing a known weight of sample was removed from storage at -80 degrees Celsius and allowed to thaw at room temperature. Sterile 1x PBS was added to create a 10% w/v suspension, and vigorous vortexing was performed to suspend the sample until the material appeared homogeneous. The sample was then left to sit for 10 minutes at room temperature to sediment fibrous and particulate matter. The suspension above the sediment was then carefully removed into a new tube and contains a purified spore population. Optionally, the suspension was then centrifuged at a low speed, e.g., 1000 x g, for 5 minutes to pellet particulate matter including fibers. The pellet was discarded and the supernatant, which contained vegetative organisms and spores, was removed into a new tube. The supernatant was then centrifuged at 6000 x g for 10 minutes to pellet the vegetative organisms and spores. The pellet was then resuspended in 1x PBS with vigorous vortexing until the sample material appears homogenous.

Example 16: Quantification of Spore Concentrations using DPA assay

[0251] Methods to assess spore concentration in complex mixtures typically require the separation and selection of spores and subsequent growth of individual species to determine the colony forming units. The art does not teach how to quantitatively germinate all the spores in a complex mixture as there are many species for which appropriate germinants have not been identified. Furthermore, sporulation is thought to be a stochastic process as a result of evolutionary selection, meaning that not all spores from a single species germinate with same response to germinant concentration, time

and other environmental conditions. Alternatively, a key metabolite of bacterial spores, dipicolinic acid (DPA) has been developed to quantify spores particles in a sample and avoid interference from fecal contaminants. The assay utilizes the fact that DPA chelates Terbium 3+ to form a luminescent complex (Fichtel et al, FEMS Microbiology Ecology, 2007; Kort et al, Applied and Environmental Microbiology, 2005; Shafaat and Ponce, Applied and Environmental Microbiology, 2006; Yang and Ponce, International Journal of Food Microbiology, 2009; Hindle and Hall, Analyst, 1999). A time-resolved fluorescence assay detects terbium luminescence in the presence of DPA giving a quantitative measurement of DPA concentration in a solution.

[0252] To perform the assay 1mL of the spore standard to be measured was transferred to a 2mL microcentrifuge tube. The samples were centrifuged at 13000 RCF for 10 min and the sample is washed in 1mL sterile deionized H₂O. Wash an additional time by repeating the centrifugation. Transfer the 1mL solution to hungate tubes and autoclave samples on a steam cycle for 30 min at 250C. Add 100uL of 30uM TbCl₃ solution (400mM sodium acetate, pH 5.0, 30uM TbCl₃) to the sample. Make serial dilutions of of the autoclaved material and measure the fluorescence of each sample by exciting with 275nm light and measuring the emission wavelength of 543nm for an integration time of 1.25ms and a 0.1ms delay.

[0253] Purified spores are produced as described previously (e.g. see <http://www.epa.gov/pesticides/methods/MB-28-00.pdf>). Serial dilutions of purified spores from *C. bifermentans*, *C. sporogenes*, and *C. butyricum* cultures were prepared and measured by plating on BBA media and incubating overnight at 37C to determine CFU/ml. Figure 6 shows the linear correspondence across different spore producing

bacteria across several logs demonstrating the DPA assay as means to assess spore content (linear range of DPA assay compared to CFU counts/ml).

[0254] The discrepancy for complex spore populations between spore counts measured by germinable spore CFU and by DPA has important implications for determining the potency of an ethanol treated spore preparation for clinical use. Table 6 shows spore content data from 3 different ethanol treated spore preparations used to successfully treat 3 patients suffering from recurrent *C. difficile* infection. The spore content of each spore preparation is characterized using the two described methods.

[0255] What is immediately apparent is that spore content varies greatly per 30 capsules. As measured by germinable SCFU, spore content varies by greater than 10,000-fold. As measured by DPA, spore content varies by greater than 100-fold. In the absence of the DPA assay, it would be difficult to set a minimum dose for administration to a patient. For instance, without data from the DPA assay, one would conclude that a minimum effective dose of spores is 4×10^5 or less using the SCFU assay (e.g. Preparation 1, Table 7). If that SCFU dose was used to normalize dosing in a clinical setting, however, then the actual spore doses given to patients would be much lower for other ethanol treated spore preparations as measured as by the DPA assay (Table 7).

[0256] It becomes immediately obvious from the variability of SCFU and DPA counts across various donations that using SCFU as the measure of potency would lead to significant underdosing in certain cases. For instance, setting a dose specification of 4×10^5 SCFU (the apparent effective dose from donor Preparation 1) for product Preparation 3 would lead to a potential underdosing of more than 100-fold. This can be

rectified only by setting potency specifications based on the DPA assay which better reflects total spore counts in an ethanol treated spore preparation. The unexpected finding of this work is that the DPA assay is uniquely suited to set potency and determine dosing for an ethanol treated spore preparation.

Example 17: Identification of Keystone OTUs and Functions

[0257] The human body is an ecosystem in which the microbiota, and the microbiome, play a significant role in the basic healthy function of human systems (e.g. metabolic, immunological, and neurological). The microbiota and resulting microbiome comprise an ecology of microorganisms that co-exist within single subjects interacting with one another and their host (i.e., the mammalian subject) to form a dynamic unit with inherent biodiversity and functional characteristics. Within these networks of interacting microbes (i.e. ecologies), particular members can contribute more significantly than others; as such these members are also found in many different ecologies, and the loss of these microbes from the ecology can have a significant impact on the functional capabilities of the specific ecology. Robert Paine coined the concept “Keystone Species” in 1969 (see Paine RT. 1969. A note on trophic complexity and community stability. The American Naturalist 103: 91–93.) to describe the existence of such lynchpin species that are integral to a given ecosystem regardless of their abundance in the ecological community. Paine originally describe the role of the starfish *Pisaster ochraceus* in marine systems and since the concept has been experimentally validated in numerous ecosystems.

[0258] Keystone OTUs and/or Functions are computationally-derived by analysis of network ecologies elucidated from a defined set of samples that share a specific phenotype. Keystone OTUs and/or Functions are defined as all Nodes within a defined

set of networks that meet two or more of the following criteria. Using Criterion 1, the node is frequently observed in networks, and the networks in which the node is observed are found in a large number of individual subjects; the frequency of occurrence of these Nodes in networks and the pervasiveness of the networks in individuals indicates these Nodes perform an important biological function in many individuals. Using Criterion 2, the node is frequently observed in networks, and each the networks in which the node is observed contain a large number of Nodes -- these Nodes are thus “super-connectors”, meaning that they form a nucleus of a majority of networks and as such have high biological significance with respect to their functional contributions to a given ecology. Using Criterion 3, the node is found in networks containing a large number of Nodes (i.e. they are large networks), and the networks in which the node is found occur in a large number of subjects; these networks are potentially of high interest as it is unlikely that large networks occurring in many individuals would occur by chance alone strongly suggesting biological relevance. Optionally, the required thresholds for the frequency at which a node is observed in network ecologies, the frequency at which a given network is observed across subject samples, and the size of a given network to be considered a Keystone node are defined by the 50th, 70th, 80th, or 90th percentiles of the distribution of these variables. Optionally, the required thresholds are defined by the value for a given variable that is significantly different from the mean or median value for a given variable using standard parametric or non-parametric measures of statistical significance. In another embodiment a Keystone node is defined as one that occurs in a sample phenotype of interest such as but not limited to “health” and simultaneously does not occur in a

sample phenotype that is not of interest such as but not limited to “disease.” Optionally, a Keystone Node is defined as one that is shown to be significantly different from what is observed using permuted test datasets to measure significance.

Example 18: Prophylactic use and treatment in a Mouse model of vancomycin resistant enterococcus (VRE) colonization.

[0259] The emergence and spread of highly antibiotic-resistant bacteria represent a major clinical challenge (Snitkin et al Science Translational Medicine, 2012). In recent years, the numbers of infections caused by organisms such as methicillin- resistant *Staphylococcus aureus*, carbapenem-resistant *Enterobacteriaceae*, vancomycin-resistant *Enterococcus* (VRE), and *Clostridium difficile* have increased markedly, and many of these strains are acquiring resistance to the few remaining active antibiotics. Most infections produced by highly antibiotic-resistant bacteria are acquired during hospitalizations, and preventing patient- to-patient transmission of these pathogens is one of the major challenges confronting hospitals and clinics. Most highly antibiotic-resistant bacterial strains belong to genera that colonize mucosal surfaces, usually at low densities. The highly complex microbiota that normally colonizes mucosal surfaces inhibits expansion of and domination by bacteria such as *Enterobacteriaceae* and *Enterococcaceae*. Destruction of the normal flora by antibiotic administration, however, disinhibition antibiotic-resistant members of these bacterial families, leading to their expansion to very high densities (Ubeda et al Journal of Clinical Investigation 2010). High-density colonization by these organisms can be calamitous for the susceptible patient, resulting in bacteremia and sepsis (Taur et al, Clinical Infectious Disease, 2012).

[0260] To test prophylactic use and treatment of a bacterial composition test article, a VRE infection mouse model is used as previously described (Ubeda et al, Infectious Immunity 2013, Ubeda et al, Journal of clinical investigation, 2010). Briefly, experiments are done with 7-week-old C57BL/6J female mice purchased from Jackson Laboratory, housed with irradiated food, and provided with acidified water. Mice are individually housed to avoid contamination between mice due to coprophagia. For experimental infections with VRE, mice are treated with ampicillin (0.5 g/liter) in their drinking water, which is changed every 3 days.

[0261] In the treatment model, on day 1, mice are infected by means of oral gavage with 10⁸ CFU of the vancomycin-resistant *Enterococcus faecium* strain purchased from ATCC (ATCC 700221). One day after infection (day 1), antibiotic treatment is stopped and VRE levels are determined at different time points by plating serial dilutions of fecal pellets on Enterococcosel agar plates (Difco) with vancomycin (8 ug/ml; Sigma). VRE colonies are identified by appearance and confirmed by Gram staining or other methods previously described (e.g. see examples 2, 3 and 4). In addition, as previously described (Ubeda et al, Journal of Clinical Investigation 2010), PCR of the *vanA* gene, which confers resistance to vancomycin, confirms the presence of VRE in infected mice. The bacterial composition test article such as but not limited to an ethanol treated, gradient purified spore preparation (as described herein), fecal suspension, or antibiotic treatment is delivered in PBS on days 1-3 while the negative control contains only PBS and is also delivered on days 1-3 by oral gavage. Fresh fecal stool pellets are obtained daily for the duration of the experiment from days -7 to day 10. The samples are

immediately frozen and stored at -80°C. DNA was extracted using standard techniques and analyzed with 16S or comparable methods (e.g. see example 3 and 4).

[0262] In the colonization model, ampicillin is administered as described above for day -7 to day 1, treatment with the test article or vehicle control is administered on day 0-2 and the VRE resistant bacteria at 10⁸ CFU are administered on day 14. Fecal samples are taken throughout the experiment daily from -7 to day 21 and submitted for 16S sequencing as previously described (e.g. see examples 3 and 4).

[0263] In both models titers of VRE in feces are used to evaluate the success of the test article versus the negative control. Furthermore, microbiota composition is assessed for the ability of the bacterial composition test article to induce a healthy microbiome.

Example 19: Prophylactic use and treatment of a Mouse model of Carbapenem resistant klebsiella (CRKB) colonization

[0264] The emergence of *Klebsiella pneumoniae* strains with decreased susceptibility to carbapenems is a significant threat to hospitalized patients. Resistance to carbapenems in these organisms is most frequently mediated by *K. pneumoniae* carbapenemase (KPC), a class A beta-lactamase that also confers resistance to broad-spectrum cephalosporins and commercially available beta-lactam/beta-lactamase inhibitor combinations (Queenan et al, Clinical Microbiology Review, 2007). KPC-producing *K. pneumoniae* (KPC-Kp) strains often harbor resistance determinants against several other classes of antimicrobials, including aminoglycosides and fluoroquinolones, resulting in truly multidrug-resistant (MDR) organisms (Hirsch et al, Journal of Antimicrobial Chemotherapy, 2009). Considering the limited antimicrobial

options, infections caused by KPC-Kp pose a tremendous therapeutic challenge and are associated with poor clinical outcomes

[0265] A treatment protocol in a mouse model as previously described (e.g. Perez et al, Antimicrobial Agents Chemotherapy, 2011) is used to evaluate the bacterial composition (test article) for treating carbapenem resistant *Klebsiella* and reducing carriage in the GI tract. Female CF1 mice (Harlan Sprague-Dawley, Indianapolis, IN) are used and are individually housed and weighed between 25 and 30 g.

[0266] The thoroughly characterized strain of *K. pneumoniae*, VA-367 (8, 9, 25) is used in this study. This clinical isolate is genetically related to the KPC-Kp strain circulating in the Eastern United States. Characterization of the resistance mechanisms in *K. pneumoniae* VA-367 with PCR and DNA sequence analysis revealed the presence of bla_{KPC-3}, bla_{TEM-1}, bla_{SHV-11}, and bla_{SHV-12} as well as qnrB19 and aac(6')-Ib. Additionally, PCR and DNA sequencing revealed disruptions in the coding sequences of the following outer membrane protein genes: ompK35, ompK36, and ompK37. Antibiotic susceptibility testing (AST) was performed with the agar dilution method and interpreted according to current recommendations from the Clinical and Laboratory Standards Institute (CLSI). A modified Hodge test were performed, according to a method described previously (e.g. see Anderson et al, Journal of Clinical Microbiology, 2007) with ertapenem, meropenem, and imipenem. Tigecycline and polymyxin E were evaluated by Etest susceptibility assays (AB bioMérieux, Solna, Sweden). Results for tigecycline were interpreted as suggested by the U.S. Food and Drug Administration (FDA) and according to CLSI recommendations (criteria for *Pseudomonas*) for polymyxin E.

[0267] Mice (10 per group) are assigned to either a bacterial composition (test article), ethanol treated, spore preparation (e.g. see example 7), antibiotic clindamycin, piperacillin-tazobactam, tigecycline, ertapenem, cefepime, ciprofloxacin, or combination thereof or control group receiving only the vehicle. They are administered the test article daily from day -10 to day 0, On day 0, 10^3 CFU of KPC-Kp VA-367 diluted in 0.5 ml phosphate-buffered saline (PBS) was administered by oral gavage using a stainless-steel feeding tube (Perfektum; Popper & Sons, New Hyde Park, NY). Stool samples were collected 1, 4, 6, and 11 days after the administration of KPC-Kp in order to measure the concentration of carbapenem-resistant *K. pneumoniae*. Stool samples (100 mg diluted in 800 ml of PBS) are plated onto MacConkey agar with and without 0.5 ug/ml of imipenem, and the number of CFU per gram of stool was determined.

Alternatively other methods may be used to measure the levels of carbapenem-resistant *K. pneumoniae* e.g. pcr, antigen testing, as one who's skilled in the art could perform.

[0268] Stool samples were collected after 5 days of treatment to assess the effects of the antibiotics on the stool microflora and to measure antibiotic levels in stool. To assess the effects on the microflora, fresh stool samples as previously described (e.g. see examples AAAB and AAAC). Additional experiments are performed to examine whether the administration the bacterial composition (test article) resulted in the elimination or persistence of colonization with KPC-Kp VA-367.

[0269] Mice are treated with subcutaneous clindamycin to reduce the normal intestinal flora 1 day before receiving 10^4 CFU of KPC-Kp VA-367 by oral gavage, and the mice continued to receive subcutaneous clindamycin every other day for 7 days. Concurrently, for 7 days after oral gavage with KPC-Kp, mice received oral gavage of

normal saline (control group), or the bacterial composition as specified. An additional dose of subcutaneous clindamycin was administered 20 days after the administration of KPC-Kp VA-367 to assess whether low levels of carbapenem-resistant *K. pneumoniae* were present that could be augmented by the elimination of the anaerobic microflora. Stool samples were collected at baseline and at 3, 6, 8, 11, 16, and 21 days after KPC-Kp VA-367 was given by gavage. The bacterial composition will be examined by the reduction of CRKB in feces.

Example 20: Methods of Construction and Quantification

Construction of binary pairs in a high-throughput 96-well format.

[0270] To allow high-throughput screening of binary pairs, vials of -80 °C glycerol stock banks were thawed and diluted to 1e8 CFU/mL. Each strain was then diluted 10x (to a final concentration of 1e7 CFU/mL of each strain) into 200 uL of PBS + 15% glycerol in the wells of a 96-well plate. Plates were then frozen at -80 °C. When needed, plates were removed from -80°C and thawed at room temperature under anaerobic conditions when testing in an In vitro inhibition assay with *Clostridium difficile*.

Construction of ternary combinations in a high-throughput 96-well format

[0271] To allow high-throughput screening of ternary combinations, vials of -80 °C glycerol stock banks were thawed and diluted to 1e8 CFU/mL. Each strain was then diluted 10x (to a final concentration of 1e7 CFU/mL of each strain) into 200 uL of PBS + 15% glycerol in the wells of a 96-well plate. Plates were then frozen at -80 °C. When needed for the assay, plates were removed from -80 °C and thawed at room temperature under anaerobic conditions when testing in an In vitro inhibition assay with *Clostridium difficile*.

Construction of an In vitro inhibition Assay to Screen for Ecobiotic™ compositions Inhibitory to the Growth of Clostridium difficile

[0272] An overnight culture of *Clostridium difficile* was grown under anaerobic conditions in SweetB-FosIn or other suitable media for the growth of *C. difficile*.

SweetB-FosIn is a complex media composed of brain heart infusion, yeast extract, cysteine, cellobiose, maltose, soluble starch, and fructooligosaccharides/inulin, and hemin, and is buffered with MOPs. After 24 hr of growth the culture was diluted 100,000 fold into a complex media such as SweetB-FosIn which is suitable for the growth of a wide variety of anaerobic bacterial species. The diluted *C. difficile* mixture was then aliquoted to wells of a 96-well plate (180 uL to each well). 20 uL of a unique binary pair of potential inhibitory species was then added to each well at a final concentration of 1e6 CFU/mL of each species. Alternatively the assay can be tested with binary pairs at different initial concentrations (1e9 CFU/mL, 1e8 CFU/mL, 1e7 CFU/mL, 1e5 CFU/mL, 1e4 CFU/mL, 1e3 CFU/mL, 1e2 CFU/mL). Control wells only inoculated with *C. difficile* were included for a comparison to the growth of *C. difficile* without inhibition. Additional wells were used for controls that either inhibit or do not inhibit the growth of *C. difficile*. One example of a positive control that inhibits growth was a combination of *Blautia producta*, *Clostridium bifermentans* and *Escherichia coli*. One example of a control that shows reduced inhibition of *C. difficile* growth as a combination of *Bacteroides thetaiotaomicron*, *Bacteroides ovatus* and *Bacteroides vulgatus*. Plates were wrapped with parafilm and incubated for 24 hr at 37 °C under anaerobic conditions. After 24 hr the wells containing *C. difficile* alone were serially diluted and plated to determine titer. The 96-well plate was then frozen at -80C before quantifying *C. difficile* by qPCR assay.

Construction of an In vitro inhibition Assay to Screen for bacterial compositions that produce diffusible products inhibitory to the growth of Clostridium difficile using a filter insert .

[0273] The In vitro inhibition assay described above was modified by using a 0.22 μ M filter insert (Millipore™ MultiScreen™ 96-Well Assay Plates - Item MAGVS2210) in 96-well format to physically separate C. difficile from the bacterial compositions. The C. difficile was aliquoted into the 96-well plate while the bacterial compositions were aliquoted into media on the filter overlay. The nutrient media as in contact on both sides of the 0.22 μ M filter, allowing exchange of nutrients, small molecules and many macromolecules (e.g., bacteriocins, cell-surface proteins, or polysaccharides) by diffusion. In this embodiment, after 24 hr incubation, the filter insert containing the bacterial compositions was removed. The plate containing C. difficile was then transferred to a 96-well plate reader suitable for measuring optical density (OD) at 600 nm. The growth of C. difficile in the presence of different bacterial compositions was compared based on the OD measurement.

Construction of an In vitro inhibition Assay to Screen for bacterial compositions inhibitory to the growth of Clostridium difficile using Clostridium difficile selective media for quantification

[0274] The In vitro inhibition assay described above can be modified to determine final C. difficile titer by serially diluting and plating to C. difficile selective media (Bloedt et al 2009) such as CCFA (cycloserine cefoxitin fructose agar, Anaerobe Systems), CDSA (Clostridium difficile selective agar, which is cycloserine cefoxitin mannitol agar, Becton Dickinson).

Quantification of C. difficile using Quantitative PCR (qPCR)

Standard Curve Preparation

[0275] The standard curve was generated from a well on each assay plate containing only pathogenic *C. difficile* grown in SweetB + FosIn media as provided herein and quantified by selective spot plating. Serial dilutions of the culture were performed in sterile phosphate-buffered saline. Genomic DNA was extracted from the standard curve samples along with the other wells.

Genomic DNA Extraction

[0276] Genomic DNA was extracted from 5 µl of each sample using a dilution, freeze/thaw, and heat lysis protocol. 5 µL of thawed samples were added to 45 µL of UltraPure water (Life Technologies, Carlsbad, CA) and mixed by pipetting. The plates with diluted samples were frozen at -20 °C until use for qPCR which includes a heated lysis step prior to amplification. Alternatively the genomic DNA could be isolated using the Mo Bio Powersoil®-htp 96 Well Soil DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA), Mo Bio Powersoil® DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA), or the QIAamp DNA Stool Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer's instructions.

qPCR Composition and Conditions

[0277] The qPCR reaction mixture contained 1x SsoAdvanced Universal Probes Supermix, 900 nM of Wr-tcdB-F primer (AGCAGTTGAATATAGTGGTTTAGTTAGAGTTG, IDT, Coralville, IA), 900 nM of Wr-tcdB-R primer (CATGCTTTTTTAGTTTCTGGATTGAA, IDT, Coralville, IA), 250 nM of Wr-tcdB-P probe (6FAM-CATCCAGTCTCAATTGTATATGTTTCTCCA-MGB, Life Technologies, Grand Island, NY), and Molecular Biology Grade Water (Mo Bio Laboratories, Carlsbad, CA) to 18 µl (Primers adapted from: Wroblewski, D. et al., Rapid Molecular Characterization of *Clostridium difficile* and Assessment of Populations

of *C. difficile* in Stool Specimens, Journal of Clinical Microbiology 47:2142–2148 (2009)). This reaction mixture was aliquoted to wells of a Hard-shell Low-Profile Thin Wall 96-well Skirted PCR Plate (BioRad, Hercules, CA). To this reaction mixture, 2 μ l of diluted, frozen, and thawed samples were added and the plate sealed with a Microseal 'B' Adhesive Seal (BioRad, Hercules, CA). The qPCR was performed on a BioRad C1000™ Thermal Cycler equipped with a CFX96™ Real-Time System (BioRad, Hercules, CA). The thermocycling conditions were 95°C for 15 minutes followed by 45 cycles of 95°C for 5 seconds, 60°C for 30 seconds, and fluorescent readings of the FAM channel. Alternatively, the qPCR could be performed with other standard methods known to those skilled in the art.

Data Analysis

[0278] The C_q value for each well on the FAM channel was determined by the CFX Manager™ 3.0 software. The log₁₀(cfu/mL) of *C. difficile* each experimental sample was calculated by inputting a given sample's C_q value into a linear regression model generated from the standard curve comparing the C_q values of the standard curve wells to the known log₁₀(cfu/mL) of those samples. The log inhibition was calculated for each sample by subtracting the log₁₀(cfu/mL) of *C. difficile* in the sample from the log₁₀(cfu/mL) of *C. difficile* in the sample on each assay plate used for the generation of the standard curve that has no additional bacteria added. The mean log inhibition was calculated for all replicates for each composition.

[0279] A histogram of the range and standard deviation of each composition was plotted. Ranges or standard deviations of the log inhibitions that were distinct from the overall distribution were examined as possible outliers. If the removal of a single log inhibition datum from one of the binary pairs that were identified in the histograms would

bring the range or standard deviation in line with those from the majority of the samples, that datum was removed as an outlier, and the mean log inhibition was recalculated.

[0280] The pooled variance of all samples evaluated in the assay was estimated as the average of the sample variances weighted by the sample's degrees of freedom. The pooled standard error was then calculated as the square root of the pooled variance divided by the square root of the number of samples. Confidence intervals for the null hypothesis were determined by multiplying the pooled standard error to the z score corresponding to a given percentage threshold. Mean log inhibitions outside the confidence interval were considered to be inhibitory if positive or stimulatory if negative with the percent confidence corresponding to the interval used. Samples with mean log inhibition greater than the 99% confidence interval (C.I.) of the null hypothesis are reported as +++, those with a 95% < C.I. <99% as ++, those with a 90% < C.I. <95% as +, those with a 80% < C.I. <90% as - while samples with mean log inhibition less than than the 99% confidence interval (C.I.) of the null hypothesis are reported as ----, those with a 95% < C.I. <99% as ---, those with a 90% < C.I. <95% as --, those with a 80% < C.I. <90% as -.

[0281] Many binary pairs inhibit *C. difficile* Table 8. 622 of 989 combinations show inhibition with a confidence interval >80%; 545 of 989 with a C.I. > 90%; 507 of 989 with a C.I. > 95%; 430 of 989 with a C.I. of >99%. Non-limiting but exemplary binary pairs include those with mean log reduction greater than 0.366, e.g. *Allistipes shahii* paired with *Blautia producta*, *Clostridium hathawayi*, or *Colinsella aerofaciens*, or *Clostridium mayombeii* paired with *C. innocuum*, *C. tertium*, *Colinsella aerofaciens*, or any of the other 424 combinations shown in Table 8. Equally important, the In vitro inhibition assay

describes binary pairs that do not effectively inhibit *C. difficile*. 188 of 989 combinations promote growth with >80% confidence; 52 of 989 show a lack of inhibition with >90% confidence; 22 of 989 show a lack of inhibition with >95% confidence; 3 of 989, including *B. producta* combined with *Coprococcus catus*, *Alistipes shahii* combined with *Dorea formicigenerans*, and *Eubacterium rectale* combined with *Roseburia intestinalis*, show a lack of inhibition with >99% confidence. 249 of 989 combinations are neutral in the assay, meaning they neither promote nor inhibit *C. difficile* growth to the limit of measurement.

[0282] Ternary combinations with mean log inhibition greater than 0.312 are reported as ++++ ($\geq 99\%$ confidence interval (C.I.) of the null hypothesis), those with mean log inhibition between 0.221 and 0.312 as +++ ($95\% < \text{C.I.} < 99\%$), those with mean log inhibition between 0.171 and 0.221 as ++ ($90\% < \text{C.I.} < 95\%$), those with mean log inhibition between 0.113 and 0.171 as + ($80\% < \text{C.I.} < 90\%$), those with mean log inhibition between -0.113 and -0.171 as - ($80\% < \text{C.I.} < 90\%$), those with mean log inhibition between -0.171 and -0.221 as -- ($90\% < \text{C.I.} < 95\%$), those with mean log inhibition between -0.221 and -0.312 as --- ($95\% < \text{C.I.} < 99\%$), and those with mean log inhibition less than -0.312 as ---- ($99\% < \text{C.I.}$).

[0283] The In vitro inhibition assay shows that many ternary combinations inhibit *C. difficile*. 39 of 56 combinations show inhibition with a confidence interval >80%; 36 of 56 with a C.I. > 90%; 36 of 56 with a C.I. > 95%; 29 of 56 with a C.I. of >99%. Non-limiting but exemplary ternary combinations include those with mean log reduction greater than 0.171, e.g. any combination shown in Table 9 with a score of ++++, such as *Colinsella aerofaciens*, *Coprococcus comes*, and *Blautia producta*. Equally

important, the In vitro inhibition assay describes ternary combinations that do not effectively inhibit *C. difficile*. 5 of 56 combinations promote growth with >80% confidence; 2 of 56 promote growth with >90% confidence; 1 of 56, *Coprococcus comes*, *Clostridium symbiosum* and *Eubacterium rectale*, promote growth with >95% confidence. 12 of 56 combinations are neutral in the assay, meaning they neither promote nor inhibit *C. difficile* growth to the limit of measurement.

[0284] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification, including claims, are to be understood as being modified in all instances by the term “about.” Accordingly, unless otherwise indicated to the contrary, the numerical parameters are approximations and may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

[0285] Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series.

[0286] While the invention has been particularly shown and described with reference to a preferred embodiment and various alternate embodiments, it will be understood by persons skilled in the relevant art that various changes in form and details can be made therein without departing from the spirit and scope of the invention.

[0287] All references, issued patents and patent applications cited within the body of the instant specification are hereby incorporated by reference in their entirety, for all purposes.

TABLES**Table 1**

List of Operational Taxonomic Units (OTU) with taxonomic assignments made to Genus, Species, and Phylogenetic Clade. Clade membership of bacterial OTUs is based on 16S sequence data. Clades are defined based on the topology of a phylogenetic tree that is constructed from full-length 16S sequences using maximum likelihood methods familiar to individuals with ordinary skill in the art of phylogenetics.

Clades are constructed to ensure that all OTUs in a given clade are: (i) within a specified number of bootstrap supported nodes from one another, and (ii) within 5% genetic similarity. OTUs that are within the same clade can be distinguished as genetically and phylogenetically distinct from OTUs in a different clade based on 16S-V4 sequence data, while OTUs falling within the same clade are closely related. OTUs falling within the same clade are evolutionarily closely related and may or may not be distinguishable from one another using 16S-V4 sequence data. Members of the same clade, due to their evolutionary relatedness, play similar functional roles in a microbial ecology such as that found in the human gut. Compositions substituting one species with another from the same clade are likely to have conserved ecological function and therefore are useful in the present invention. All OTUs are denoted as to their putative capacity to form spores and whether they are a Pathogen or Pathobiont (see Definitions for description of "Pathobiont"). NIAID Priority Pathogens are denoted as 'Category-A', 'Category-B', or 'Category-C', and Opportunistic Pathogens are denoted as 'OP'. OTUs that are not pathogenic or for which their ability to exist as a pathogen is unknown are denoted as 'N'. The 'SEQ ID Number' denotes the identifier of the OTU in the Sequence Listing File and 'Public DB Accession' denotes the identifier of the OTU in a public sequence repository.

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Eubacterium saburreum	858	AB525414	clade_178	Y	N
Eubacterium sp. oral clone IR009	866	AY349376	clade_178	Y	N
Lachnospiraceae bacterium ICM62	1061	HQ616401	clade_178	Y	N
Lachnospiraceae bacterium MSX33	1062	HQ616384	clade_178	Y	N
Lachnospiraceae bacterium oral taxon 107	1063	ADDS01000069	clade_178	Y	N
Alicyclobacillus acidocaldarius	122	NR_074721	clade_179	Y	N
Clostridium baratii	555	NR_029229	clade_223	Y	N
Clostridium colicanis	576	FJ957863	clade_223	Y	N
Clostridium paraputrificum	611	AB536771	clade_223	Y	N
Clostridium sardiniense	621	NR_041006	clade_223	Y	N
Eubacterium budayi	837	NR_024682	clade_223	Y	N
Eubacterium moniliforme	851	HF558373	clade_223	Y	N
Eubacterium multiforme	852	NR_024683	clade_223	Y	N
Eubacterium nitritogenes	853	NR_024684	clade_223	Y	N
Anoxybacillus flavithermus	173	NR_074667	clade_238	Y	N
Bacillus aerophilus	196	NR_042339	clade_238	Y	N
Bacillus aestuarii	197	GQ980243	clade_238	Y	N
Bacillus amyloliquefaciens	199	NR_075005	clade_238	Y	N
Bacillus anthracis	200	AAEN01000020	clade_238	Y	Category -A
Bacillus atrophaeus	201	NR_075016	clade_238	Y	OP
Bacillus badius	202	NR_036893	clade_238	Y	OP
Bacillus cereus	203	ABDJ01000015	clade_238	Y	OP
Bacillus circulans	204	AB271747	clade_238	Y	OP
Bacillus firmus	207	NR_025842	clade_238	Y	OP
Bacillus flexus	208	NR_024691	clade_238	Y	OP
Bacillus fordii	209	NR_025786	clade_238	Y	OP
Bacillus halmapalus	211	NR_026144	clade_238	Y	OP
Bacillus herbersteinensis	213	NR_042286	clade_238	Y	OP
Bacillus idriensis	215	NR_043268	clade_238	Y	OP
Bacillus lentus	216	NR_040792	clade_238	Y	OP
Bacillus licheniformis	217	NC_006270	clade_238	Y	OP
Bacillus megaterium	218	GU252124	clade_238	Y	OP
Bacillus nealsonii	219	NR_044546	clade_238	Y	OP
Bacillus niabensis	220	NR_043334	clade_238	Y	OP
Bacillus niacini	221	NR_024695	clade_238	Y	OP
Bacillus pocheonensis	222	NR_041377	clade_238	Y	OP
Bacillus pumilus	223	NR_074977	clade_238	Y	OP
Bacillus safensis	224	JQ624766	clade_238	Y	OP
Bacillus simplex	225	NR_042136	clade_238	Y	OP
Bacillus sonorensis	226	NR_025130	clade_238	Y	OP
Bacillus sp. 10403023 MM10403188	227	CAET01000089	clade_238	Y	OP
Bacillus sp. 2_A_57_CT2	230	ACWD01000095	clade_238	Y	OP
Bacillus sp. 2008724126	228	GU252108	clade_238	Y	OP
Bacillus sp. 2008724139	229	GU252111	clade_238	Y	OP
Bacillus sp. 7_16AIA	231	FN397518	clade_238	Y	OP
Bacillus sp. AP8	233	JX101689	clade_238	Y	OP

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Bacillus sp. B27(2008)	234	EU362173	clade_238	Y	OP
Bacillus sp. BT1B_CT2	235	ACWC01000034	clade_238	Y	OP
Bacillus sp. GB1.1	236	FJ897765	clade_238	Y	OP
Bacillus sp. GB9	237	FJ897766	clade_238	Y	OP
Bacillus sp. HU19.1	238	FJ897769	clade_238	Y	OP
Bacillus sp. HU29	239	FJ897771	clade_238	Y	OP
Bacillus sp. HU33.1	240	FJ897772	clade_238	Y	OP
Bacillus sp. JC6	241	JF824800	clade_238	Y	OP
Bacillus sp. oral taxon F79	248	HM099654	clade_238	Y	OP
Bacillus sp. SRC_DSF1	243	GU797283	clade_238	Y	OP
Bacillus sp. SRC_DSF10	242	GU797292	clade_238	Y	OP
Bacillus sp. SRC_DSF2	244	GU797284	clade_238	Y	OP
Bacillus sp. SRC_DSF6	245	GU797288	clade_238	Y	OP
Bacillus sp. tc09	249	HQ844242	clade_238	Y	OP
Bacillus sp. zh168	250	FJ851424	clade_238	Y	OP
Bacillus sphaericus	251	DQ286318	clade_238	Y	OP
Bacillus sporothermodurans	252	NR_026010	clade_238	Y	OP
Bacillus subtilis	253	EU627588	clade_238	Y	OP
Bacillus thermoamylavorans	254	NR_029151	clade_238	Y	OP
Bacillus thuringiensis	255	NC_008600	clade_238	Y	OP
Bacillus weihenstephanensis	256	NR_074926	clade_238	Y	OP
Geobacillus kaustophilus	933	NR_074989	clade_238	Y	N
Geobacillus stearothermophilus	936	NR_040794	clade_238	Y	N
Geobacillus thermodenitrificans	938	NR_074976	clade_238	Y	N
Geobacillus thermoglucosidasius	939	NR_043022	clade_238	Y	N
Lysinibacillus sphaericus	1193	NR_074883	clade_238	Y	N
Clostridiales sp. SS3_4	543	AY305316	clade_246	Y	N
Clostridium beijerinckii	557	NR_074434	clade_252	Y	N
Clostridium botulinum	560	NC_010723	clade_252	Y	Category -A
Clostridium butyricum	561	ABDT01000017	clade_252	Y	N
Clostridium chauvoei	568	EU106372	clade_252	Y	N
Clostridium favosporum	582	X76749	clade_252	Y	N
Clostridium histolyticum	592	HF558362	clade_252	Y	N
Clostridium isatidis	597	NR_026347	clade_252	Y	N
Clostridium limosum	602	FR870444	clade_252	Y	N
Clostridium sartagoforme	622	NR_026490	clade_252	Y	N
Clostridium septicum	624	NR_026020	clade_252	Y	N
Clostridium sp. 7_2_43FAA	626	ACDK01000101	clade_252	Y	N
Clostridium sporogenes	645	ABKW02000003	clade_252	Y	N
Clostridium tertium	653	Y18174	clade_252	Y	N
Clostridium carnis	564	NR_044716	clade_253	Y	N
Clostridium celatum	565	X77844	clade_253	Y	N
Clostridium disporicum	579	NR_026491	clade_253	Y	N
Clostridium gasigenes	585	NR_024945	clade_253	Y	N
Clostridium quinii	616	NR_026149	clade_253	Y	N
Clostridium hylemonae	593	AB023973	clade_260	Y	N
Clostridium scindens	623	AF262238	clade_260	Y	N
Lachnospiraceae bacterium 5_1_57FAA	1054	ACTR01000020	clade_260	Y	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
<i>Clostridium glycyrrhizinilyticum</i>	588	AB233029	clade_262	Y	N
<i>Clostridium nexile</i>	607	X73443	clade_262	Y	N
<i>Coprococcus comes</i>	674	ABVR01000038	clade_262	Y	N
<i>Lachnospiraceae bacterium 1_1_57FAA</i>	1048	ACTM01000065	clade_262	Y	N
<i>Lachnospiraceae bacterium 1_4_56FAA</i>	1049	ACTN01000028	clade_262	Y	N
<i>Lachnospiraceae bacterium 8_1_57FAA</i>	1057	ACWQ01000079	clade_262	Y	N
<i>Ruminococcus lactaris</i>	1663	ABOU02000049	clade_262	Y	N
<i>Ruminococcus torques</i>	1670	AAVP02000002	clade_262	Y	N
<i>Paenibacillus lautus</i>	1397	NR_040882	clade_270	Y	N
<i>Paenibacillus polymyxa</i>	1399	NR_037006	clade_270	Y	N
<i>Paenibacillus sp. HGF5</i>	1402	AEXS01000095	clade_270	Y	N
<i>Paenibacillus sp. HGF7</i>	1403	AFDH01000147	clade_270	Y	N
<i>Eubacterium sp. oral clone JI012</i>	868	AY349379	clade_298	Y	N
<i>Alicyclobacillus contaminans</i>	124	NR_041475	clade_301	Y	N
<i>Alicyclobacillus herbarius</i>	126	NR_024753	clade_301	Y	N
<i>Alicyclobacillus pomorum</i>	127	NR_024801	clade_301	Y	N
<i>Blautia coccooides</i>	373	AB571656	clade_309	Y	N
<i>Blautia glucerasea</i>	374	AB588023	clade_309	Y	N
<i>Blautia glucerasei</i>	375	AB439724	clade_309	Y	N
<i>Blautia hansenii</i>	376	ABYU02000037	clade_309	Y	N
<i>Blautia luti</i>	378	AB691576	clade_309	Y	N
<i>Blautia producta</i>	379	AB600998	clade_309	Y	N
<i>Blautia schinkii</i>	380	NR_026312	clade_309	Y	N
<i>Blautia sp. M25</i>	381	HM626178	clade_309	Y	N
<i>Blautia stercoris</i>	382	HM626177	clade_309	Y	N
<i>Blautia wexlerae</i>	383	EF036467	clade_309	Y	N
<i>Bryantella formatexigens</i>	439	ACCL02000018	clade_309	Y	N
<i>Clostridium coccooides</i>	573	EF025906	clade_309	Y	N
<i>Eubacterium cellulosolvens</i>	839	AY178842	clade_309	Y	N
<i>Lachnospiraceae bacterium 6_1_63FAA</i>	1056	ACTV01000014	clade_309	Y	N
<i>Ruminococcus hansenii</i>	1662	M59114	clade_309	Y	N
<i>Ruminococcus obeum</i>	1664	AY169419	clade_309	Y	N
<i>Ruminococcus sp. 5_1_39BFAA</i>	1666	ACII01000172	clade_309	Y	N
<i>Ruminococcus sp. K_1</i>	1669	AB222208	clade_309	Y	N
<i>Syntrophococcus sucromutans</i>	1911	NR_036869	clade_309	Y	N
<i>Bacillus alcalophilus</i>	198	X76436	clade_327	Y	N
<i>Bacillus clausii</i>	205	FN397477	clade_327	Y	OP
<i>Bacillus gelatini</i>	210	NR_025595	clade_327	Y	OP
<i>Bacillus halodurans</i>	212	AY144582	clade_327	Y	OP
<i>Bacillus sp. oral taxon F26</i>	246	HM099642	clade_327	Y	OP
<i>Clostridium innocuum</i>	595	M23732	clade_351	Y	N
<i>Clostridium sp. HGF2</i>	628	AENW01000022	clade_351	Y	N
<i>Clostridium perfringens</i>	612	ABDW01000023	clade_353	Y	Category -B
<i>Sarcina ventriculi</i>	1687	NR_026146	clade_353	Y	N
<i>Clostridium bartlettii</i>	556	ABEZ02000012	clade_354	Y	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
<i>Clostridium bifermentans</i>	558	X73437	clade_354	Y	N
<i>Clostridium ghonii</i>	586	AB542933	clade_354	Y	N
<i>Clostridium glycolicum</i>	587	FJ384385	clade_354	Y	N
<i>Clostridium mayombeii</i>	605	FR733682	clade_354	Y	N
<i>Clostridium sordellii</i>	625	AB448946	clade_354	Y	N
<i>Clostridium</i> sp. MT4 E	635	FJ159523	clade_354	Y	N
<i>Eubacterium tenue</i>	872	M59118	clade_354	Y	N
<i>Clostridium argentinense</i>	553	NR_029232	clade_355	Y	N
<i>Clostridium</i> sp. JC122	630	CAEV01000127	clade_355	Y	N
<i>Clostridium</i> sp. NMBHI_1	636	JN093130	clade_355	Y	N
<i>Clostridium subterminale</i>	650	NR_041795	clade_355	Y	N
<i>Clostridium sulfidigenes</i>	651	NR_044161	clade_355	Y	N
<i>Dorea formicigenerans</i>	773	AAXA02000006	clade_360	Y	N
<i>Dorea longicatena</i>	774	AJ132842	clade_360	Y	N
<i>Lachnospiraceae</i> bacterium 2_1_46FAA	1050	ADLB01000035	clade_360	Y	N
<i>Lachnospiraceae</i> bacterium 2_1_58FAA	1051	ACTO01000052	clade_360	Y	N
<i>Lachnospiraceae</i> bacterium 4_1_37FAA	1053	ADCR01000030	clade_360	Y	N
<i>Lachnospiraceae</i> bacterium 9_1_43BFAA	1058	ACTX01000023	clade_360	Y	N
<i>Ruminococcus gnavus</i>	1661	X94967	clade_360	Y	N
<i>Ruminococcus</i> sp. ID8	1668	AY960564	clade_360	Y	N
<i>Blautia hydrogenotrophica</i>	377	ACBZ01000217	clade_368	Y	N
<i>Lactonifactor longoviformis</i>	1147	DQ100449	clade_368	Y	N
<i>Robinsoniella peoriensis</i>	1633	AF445258	clade_368	Y	N
<i>Eubacterium infirmum</i>	849	U13039	clade_384	Y	N
<i>Eubacterium</i> sp. WAL 14571	864	FJ687606	clade_384	Y	N
<i>Erysipelotrichaceae</i> bacterium 5_2_54FAA	823	ACZW01000054	clade_385	Y	N
<i>Eubacterium bifforme</i>	835	ABYT01000002	clade_385	Y	N
<i>Eubacterium cylindroides</i>	842	FP929041	clade_385	Y	N
<i>Eubacterium dolichum</i>	844	L34682	clade_385	Y	N
<i>Eubacterium</i> sp. 3_1_31	861	ACTL01000045	clade_385	Y	N
<i>Eubacterium tortuosum</i>	873	NR_044648	clade_385	Y	N
<i>Bulleidia extructa</i>	441	ADFR01000011	clade_388	Y	N
<i>Solobacterium moorei</i>	1739	AECQ01000039	clade_388	Y	N
<i>Coprococcus catus</i>	673	EU266552	clade_393	Y	N
<i>Lachnospiraceae</i> bacterium oral taxon F15	1064	HM099641	clade_393	Y	N
<i>Clostridium cochlearium</i>	574	NR_044717	clade_395	Y	N
<i>Clostridium malenominatum</i>	604	FR749893	clade_395	Y	N
<i>Clostridium tetani</i>	654	NC_004557	clade_395	Y	N
<i>Acetivibrio ethanolignens</i>	6	FR749897	clade_396	Y	N
<i>Anaerosporeobacter mobilis</i>	161	NR_042953	clade_396	Y	N
<i>Bacteroides pectinophilus</i>	288	ABVQ01000036	clade_396	Y	N
<i>Clostridium aminovalericum</i>	551	NR_029245	clade_396	Y	N
<i>Clostridium phytofermentans</i>	613	NR_074652	clade_396	Y	N
<i>Eubacterium hallii</i>	848	L34621	clade_396	Y	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Eubacterium xylanophilum	875	L34628	clade_396	Y	N
Ruminococcus callidus	1658	NR_029160	clade_406	Y	N
Ruminococcus champanellensis	1659	FP929052	clade_406	Y	N
Ruminococcus sp. 18P13	1665	AJ515913	clade_406	Y	N
Ruminococcus sp. 9SE51	1667	FM954974	clade_406	Y	N
Anaerostipes caccae	162	ABAX03000023	clade_408	Y	N
Anaerostipes sp. 3_2_56FAA	163	ACWB01000002	clade_408	Y	N
Clostridiales bacterium 1_7_47FAA	541	ABQR01000074	clade_408	Y	N
Clostridiales sp. SM4_1	542	FP929060	clade_408	Y	N
Clostridiales sp. SSC_2	544	FP929061	clade_408	Y	N
Clostridium aerotolerans	546	X76163	clade_408	Y	N
Clostridium aldenense	547	NR_043680	clade_408	Y	N
Clostridium algidixylanolyticum	550	NR_028726	clade_408	Y	N
Clostridium amygdalinum	552	AY353957	clade_408	Y	N
Clostridium asparagiforme	554	ACCJ01000522	clade_408	Y	N
Clostridium bolteae	559	ABCC02000039	clade_408	Y	N
Clostridium celerecrescens	566	JQ246092	clade_408	Y	N
Clostridium citroniae	569	ADLJ01000059	clade_408	Y	N
Clostridium clostridiiformes	571	M59089	clade_408	Y	N
Clostridium clostridioforme	572	NR_044715	clade_408	Y	N
Clostridium hathewayi	590	AY552788	clade_408	Y	N
Clostridium indolis	594	AF028351	clade_408	Y	N
Clostridium lavalense	600	EF564277	clade_408	Y	N
Clostridium saccharolyticum	620	CP002109	clade_408	Y	N
Clostridium sp. M62_1	633	ACFX02000046	clade_408	Y	N
Clostridium sp. SS2_1	638	ABGC03000041	clade_408	Y	N
Clostridium sphenoides	643	X73449	clade_408	Y	N
Clostridium symbiosum	652	ADLQ01000114	clade_408	Y	N
Clostridium xylanolyticum	658	NR_037068	clade_408	Y	N
Eubacterium hadrum	847	FR749933	clade_408	Y	N
Lachnospiraceae bacterium 3_1_57FAA_CT1	1052	ACTP01000124	clade_408	Y	N
Lachnospiraceae bacterium 5_1_63FAA	1055	ACTS01000081	clade_408	Y	N
Lachnospiraceae bacterium A4	1059	DQ789118	clade_408	Y	N
Lachnospiraceae bacterium DJF VP30	1060	EU728771	clade_408	Y	N
Lachnospiraceae genomosp. C1	1065	AY278618	clade_408	Y	N
Clostridium difficile	578	NC_013315	clade_409	Y	OP
Eubacterium sp. AS15b	862	HQ616364	clade_428	Y	N
Eubacterium sp. OBRC9	863	HQ616354	clade_428	Y	N
Eubacterium sp. oral clone OH3A	871	AY947497	clade_428	Y	N
Eubacterium yurii	876	AEES01000073	clade_428	Y	N
Clostridium acetobutylicum	545	NR_074511	clade_430	Y	N
Clostridium algidicarnis	549	NR_041746	clade_430	Y	N
Clostridium cadaveris	562	AB542932	clade_430	Y	N
Clostridium carboxidivorans	563	FR733710	clade_430	Y	N
Clostridium estertheticum	580	NR_042153	clade_430	Y	N
Clostridium fallax	581	NR_044714	clade_430	Y	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Clostridium felsineum	583	AF270502	clade_430	Y	N
Clostridium frigidicarnis	584	NR_024919	clade_430	Y	N
Clostridium kluyveri	598	NR_074165	clade_430	Y	N
Clostridium magnum	603	X77835	clade_430	Y	N
Clostridium putrefaciens	615	NR_024995	clade_430	Y	N
Clostridium sp. HPB_46	629	AY862516	clade_430	Y	N
Clostridium tyrobutyricum	656	NR_044718	clade_430	Y	N
Sutterella parvirubra	1899	AB300989	clade_432	Y	N
Acetanaerobacterium elongatum	4	NR_042930	clade_439	Y	N
Clostridium cellulosi	567	NR_044624	clade_439	Y	N
Ethanoligenens harbinense	832	AY675965	clade_439	Y	N
Eubacterium rectale	856	FP929042	clade_444	Y	N
Eubacterium sp. oral clone GI038	865	AY349374	clade_444	Y	N
Lachnobacterium bovis	1045	GU324407	clade_444	Y	N
Roseburia cecicola	1634	GU233441	clade_444	Y	N
Roseburia faecalis	1635	AY804149	clade_444	Y	N
Roseburia faecis	1636	AY305310	clade_444	Y	N
Roseburia hominis	1637	AJ270482	clade_444	Y	N
Roseburia intestinalis	1638	FP929050	clade_444	Y	N
Roseburia inulinivorans	1639	AJ270473	clade_444	Y	N
Brevibacillus brevis	410	NR_041524	clade_448	Y	N
Brevibacillus laterosporus	414	NR_037005	clade_448	Y	N
Bacillus coagulans	206	DQ297928	clade_451	Y	OP
Sporolactobacillus inulinus	1752	NR_040962	clade_451	Y	N
Kocuria palustris	1041	EU333884	clade_453	Y	N
Nocardia farcinica	1353	NC_006361	clade_455	Y	N
Bacillus sp. oral taxon F28	247	HM099650	clade_456	Y	OP
Catenibacterium mitsuokai	495	AB030224	clade_469	Y	N
Clostridium sp. TM_40	640	AB249652	clade_469	Y	N
Coprobaillus cateniformis	670	AB030218	clade_469	Y	N
Coprobaillus sp. 29_1	671	ADKX01000057	clade_469	Y	N
Clostridium rectum	618	NR_029271	clade_470	Y	N
Eubacterium nodatum	854	U13041	clade_476	Y	N
Eubacterium saphenum	859	NR_026031	clade_476	Y	N
Eubacterium sp. oral clone JH012	867	AY349373	clade_476	Y	N
Eubacterium sp. oral clone JS001	870	AY349378	clade_476	Y	N
Faecalibacterium prausnitzii	880	ACOP02000011	clade_478	Y	N
Gemmiger formicilis	932	GU562446	clade_478	Y	N
Subdoligranulum variabile	1896	AJ518869	clade_478	Y	N
Clostridiaceae bacterium JC13	532	JF824807	clade_479	Y	N
Clostridium sp. MLG055	634	AF304435	clade_479	Y	N
Erysipelotrichaceae bacterium 3_1_53	822	ACTJ01000113	clade_479	Y	N
Clostridium cocleatum	575	NR_026495	clade_481	Y	N
Clostridium ramosum	617	M23731	clade_481	Y	N
Clostridium saccharogumia	619	DQ100445	clade_481	Y	N
Clostridium spiroforme	644	X73441	clade_481	Y	N
Coprobaillus sp. D7	672	ACDT01000199	clade_481	Y	N
Clostridiales bacterium SY8519	535	AB477431	clade_482	Y	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Clostridium sp. SY8519	639	AP012212	clade_482	Y	N
Eubacterium ramulus	855	AJ011522	clade_482	Y	N
Erysipelothrix inopinata	819	NR_025594	clade_485	Y	N
Erysipelothrix rhusiopathiae	820	ACLK01000021	clade_485	Y	N
Erysipelothrix tonsillarum	821	NR_040871	clade_485	Y	N
Holdemania filiformis	1004	Y11466	clade_485	Y	N
Mollicutes bacterium pACH93	1258	AY297808	clade_485	Y	N
Coxiella burnetii	736	CP000890	clade_486	Y	Category -B
Clostridium hiranonis	591	AB023970	clade_487	Y	N
Clostridium irregulare	596	NR_029249	clade_487	Y	N
Clostridium orbiscindens	609	Y18187	clade_494	Y	N
Clostridium sp. NML 04A032	637	EU815224	clade_494	Y	N
Flavonifractor plautii	886	AY724678	clade_494	Y	N
Pseudoflavonifractor capillosus	1591	AY136666	clade_494	Y	N
Ruminococcaceae bacterium D16	1655	ADDX01000083	clade_494	Y	N
Acetivibrio cellulolyticus	5	NR_025917	clade_495	Y	N
Clostridium aldrichii	548	NR_026099	clade_495	Y	N
Clostridium clariflavum	570	NR_041235	clade_495	Y	N
Clostridium stercorarium	647	NR_025100	clade_495	Y	N
Clostridium straminisolvens	649	NR_024829	clade_495	Y	N
Clostridium thermocellum	655	NR_074629	clade_495	Y	N
Fusobacterium nucleatum	901	ADVK01000034	clade_497	Y	N
Eubacterium barkeri	834	NR_044661	clade_512	Y	N
Eubacterium callanderi	838	NR_026330	clade_512	Y	N
Eubacterium limosum	850	CP002273	clade_512	Y	N
Anaerotruncus colihominis	164	ABGD02000021	clade_516	Y	N
Clostridium methylpentosum	606	ACEC01000059	clade_516	Y	N
Clostridium sp. YIT 12070	642	AB491208	clade_516	Y	N
Hydrogenoanaerobacterium saccharovorans	1005	NR_044425	clade_516	Y	N
Ruminococcus albus	1656	AY445600	clade_516	Y	N
Ruminococcus flavefaciens	1660	NR_025931	clade_516	Y	N
Clostridium haemolyticum	589	NR_024749	clade_517	Y	N
Clostridium novyi	608	NR_074343	clade_517	Y	N
Clostridium sp. LMG 16094	632	X95274	clade_517	Y	N
Eubacterium ventriosum	874	L34421	clade_519	Y	N
Bacteroides galacturonicus	280	DQ497994	clade_522	Y	N
Eubacterium eligens	845	CP001104	clade_522	Y	N
Lachnospira multipara	1046	FR733699	clade_522	Y	N
Lachnospira pectinoschiza	1047	L14675	clade_522	Y	N
Lactobacillus rogosae	1114	GU269544	clade_522	Y	N
Bacillus horti	214	NR_036860	clade_527	Y	OP
Bacillus sp. 9_3AIA	232	FN397519	clade_527	Y	OP
Eubacterium brachy	836	U13038	clade_533	Y	N
Filifactor alocis	881	CP002390	clade_533	Y	N
Filifactor villosus	882	NR_041928	clade_533	Y	N
Clostridium leptum	601	AJ305238	clade_537	Y	N
Clostridium sp. YIT 12069	641	AB491207	clade_537	Y	N
Clostridium sporosphaeroides	646	NR_044835	clade_537	Y	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Eubacterium coprostanoligenes	841	HM037995	clade_537	Y	N
Ruminococcus bromii	1657	EU266549	clade_537	Y	N
Eubacterium siraeum	860	ABCA03000054	clade_538	Y	N
Clostridium viride	657	NR_026204	clade_540	Y	N
Oscillibacter sp. G2	1386	HM626173	clade_540	Y	N
Oscillibacter valericigenes	1387	NR_074793	clade_540	Y	N
Oscillospira guilliermondii	1388	AB040495	clade_540	Y	N
Butyrivibrio crossotus	455	ABWN01000012	clade_543	Y	N
Clostridium sp. L2_50	631	AAYW02000018	clade_543	Y	N
Coprococcus eutactus	675	EF031543	clade_543	Y	N
Coprococcus sp. ART55_1	676	AY350746	clade_543	Y	N
Eubacterium ruminantium	857	NR_024661	clade_543	Y	N
Collinsella aerofaciens	659	AAVN02000007	clade_553	Y	N
Alkaliphilus metalliredigenes	137	AY137848	clade_554	Y	N
Alkaliphilus oremlandii	138	NR_043674	clade_554	Y	N
Clostridium sticklandii	648	L04167	clade_554	Y	N
Turicibacter sanguinis	1965	AF349724	clade_555	Y	N
Fulvimonas sp. NML 060897	892	EF589680	clade_557	Y	N
Desulfitobacterium frappieri	753	AJ276701	clade_560	Y	N
Desulfitobacterium hafniense	754	NR_074996	clade_560	Y	N
Desulfotomaculum nigrificans	756	NR_044832	clade_560	Y	N
Lutispora thermophila	1191	NR_041236	clade_564	Y	N
Brachyspira pilosicoli	405	NR_075069	clade_565	Y	N
Eggerthella lenta	778	AF292375	clade_566	Y	N
Streptomyces albus	1888	AJ697941	clade_566	Y	N
Chlamydiales bacterium NS11	505	JN606074	clade_567	Y	N
Anaerofustis stercorihominis	159	ABIL02000005	clade_570	Y	N
Butyricoccus pullicaecorum	453	HH793440	clade_572	Y	N
Eubacterium desmolans	843	NR_044644	clade_572	Y	N
Papillibacter cinnamivorans	1415	NR_025025	clade_572	Y	N
Sporobacter termitidis	1751	NR_044972	clade_572	Y	N
Deferribacteres sp. oral clone JV006	744	AY349371	clade_575	Y	N
Clostridium colinum	577	NR_026151	clade_576	Y	N
Clostridium lactatifermentans	599	NR_025651	clade_576	Y	N
Clostridium piliforme	614	D14639	clade_576	Y	N
Saccharomonospora viridis	1671	X54286	clade_579	Y	N
Thermobifida fusca	1921	NC_007333	clade_579	Y	N
Leptospira licherasiae	1164	EF612284	clade_585	Y	OP
Moorella thermoacetica	1259	NR_075001	clade_590	Y	N
Thermoanaerobacter pseudethanolicus	1920	CP000924	clade_590	Y	N
Flexistipes sinuarabici	888	NR_074881	clade_591	Y	N
Gloeobacter violaceus	942	NR_074282	clade_596	Y	N
Eubacterium sp. oral clone JN088	869	AY349377	clade_90	Y	N
Clostridium oroticum	610	FR749922	clade_96	Y	N
Clostridium sp. D5	627	ADBG01000142	clade_96	Y	N
Eubacterium contortum	840	FR749946	clade_96	Y	N
Eubacterium fissicatena	846	FR749935	clade_96	Y	N
Corynebacterium coyleae	692	X96497	clade_100	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
<i>Corynebacterium mucifaciens</i>	711	NR_026396	clade_100	N	N
<i>Corynebacterium ureicelerivorans</i>	733	AM397636	clade_100	N	N
<i>Corynebacterium appendicis</i>	684	NR_028951	clade_102	N	N
<i>Corynebacterium genitalium</i>	698	ACLJ01000031	clade_102	N	N
<i>Corynebacterium glaucum</i>	699	NR_028971	clade_102	N	N
<i>Corynebacterium imitans</i>	703	AF537597	clade_102	N	N
<i>Corynebacterium riegliei</i>	719	EU848548	clade_102	N	N
<i>Corynebacterium</i> sp. L_2012475	723	HE575405	clade_102	N	N
<i>Corynebacterium</i> sp. NML 93_0481	724	GU238409	clade_102	N	N
<i>Corynebacterium sundsvallense</i>	728	Y09655	clade_102	N	N
<i>Corynebacterium tuscaniae</i>	730	AY677186	clade_102	N	N
<i>Prevotella maculosa</i>	1504	AGEK01000035	clade_104	N	N
<i>Prevotella oris</i>	1513	ADDV01000091	clade_104	N	N
<i>Prevotella salivae</i>	1517	AB108826	clade_104	N	N
<i>Prevotella</i> sp. ICM55	1521	HQ616399	clade_104	N	N
<i>Prevotella</i> sp. oral clone AA020	1528	AY005057	clade_104	N	N
<i>Prevotella</i> sp. oral clone GI032	1538	AY349396	clade_104	N	N
<i>Prevotella</i> sp. oral taxon G70	1558	GU432179	clade_104	N	N
<i>Prevotella corporis</i>	1491	L16465	clade_105	N	N
<i>Bacteroides</i> sp. 4_1_36	312	ACTC01000133	clade_110	N	N
<i>Bacteroides</i> sp. AR20	315	AF139524	clade_110	N	N
<i>Bacteroides</i> sp. D20	319	ACPT01000052	clade_110	N	N
<i>Bacteroides</i> sp. F_4	322	AB470322	clade_110	N	N
<i>Bacteroides uniformis</i>	329	AB050110	clade_110	N	N
<i>Prevotella nanceiensis</i>	1510	JN867228	clade_127	N	N
<i>Prevotella</i> sp. oral taxon 299	1548	ACWZ01000026	clade_127	N	N
<i>Prevotella bergensis</i>	1485	ACKS01000100	clade_128	N	N
<i>Prevotella buccalis</i>	1489	JN867261	clade_129	N	N
<i>Prevotella timonensis</i>	1564	ADEF01000012	clade_129	N	N
<i>Prevotella oralis</i>	1512	AEPE01000021	clade_130	N	N
<i>Prevotella</i> sp. SEQ072	1525	JN867238	clade_130	N	N
<i>Leuconostoc carnosum</i>	1177	NR_040811	clade_135	N	N
<i>Leuconostoc gasicomitatum</i>	1179	FN822744	clade_135	N	N
<i>Leuconostoc inhae</i>	1180	NR_025204	clade_135	N	N
<i>Leuconostoc kimchii</i>	1181	NR_075014	clade_135	N	N
<i>Edwardsiella tarda</i>	777	CP002154	clade_139	N	N
<i>Photorhabdus asymbiotica</i>	1466	Z76752	clade_139	N	N
<i>Psychrobacter arcticus</i>	1607	CP000082	clade_141	N	N
<i>Psychrobacter cibarius</i>	1608	HQ698586	clade_141	N	N
<i>Psychrobacter cryohalolentis</i>	1609	CP000323	clade_141	N	N
<i>Psychrobacter faecalis</i>	1610	HQ698566	clade_141	N	N
<i>Psychrobacter nivimaris</i>	1611	HQ698587	clade_141	N	N
<i>Psychrobacter pulmonis</i>	1612	HQ698582	clade_141	N	N
<i>Pseudomonas aeruginosa</i>	1592	AABQ07000001	clade_154	N	N
<i>Pseudomonas</i> sp. 2_1_26	1600	ACWU01000257	clade_154	N	N
<i>Corynebacterium confusum</i>	691	Y15886	clade_158	N	N
<i>Corynebacterium propinquum</i>	712	NR_037038	clade_158	N	N
<i>Corynebacterium pseudodiphtheriticum</i>	713	X84258	clade_158	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
<i>Bartonella bacilliformis</i>	338	NC_008783	clade_159	N	N
<i>Bartonella grahamii</i>	339	CP001562	clade_159	N	N
<i>Bartonella henselae</i>	340	NC_005956	clade_159	N	N
<i>Bartonella quintana</i>	341	BX897700	clade_159	N	N
<i>Bartonella tamiae</i>	342	EF672728	clade_159	N	N
<i>Bartonella washoensis</i>	343	FJ719017	clade_159	N	N
<i>Brucella abortus</i>	430	ACBJ01000075	clade_159	N	Category -B
<i>Brucella canis</i>	431	NR_044652	clade_159	N	Category -B
<i>Brucella ceti</i>	432	ACJD01000006	clade_159	N	Category -B
<i>Brucella melitensis</i>	433	AE009462	clade_159	N	Category -B
<i>Brucella microti</i>	434	NR_042549	clade_159	N	Category -B
<i>Brucella ovis</i>	435	NC_009504	clade_159	N	Category -B
<i>Brucella</i> sp. 83_13	436	ACBQ01000040	clade_159	N	Category -B
<i>Brucella</i> sp. BO1	437	EU053207	clade_159	N	Category -B
<i>Brucella suis</i>	438	ACBK01000034	clade_159	N	Category -B
<i>Ochrobactrum anthropi</i>	1360	NC_009667	clade_159	N	N
<i>Ochrobactrum intermedium</i>	1361	ACQA01000001	clade_159	N	N
<i>Ochrobactrum pseudintermedium</i>	1362	DQ365921	clade_159	N	N
<i>Prevotella genomosp. C2</i>	1496	AY278625	clade_164	N	N
<i>Prevotella multisaccharivorax</i>	1509	AFJE01000016	clade_164	N	N
<i>Prevotella</i> sp. oral clone IDR_CEC_0055	1543	AY550997	clade_164	N	N
<i>Prevotella</i> sp. oral taxon 292	1547	GQ422735	clade_164	N	N
<i>Prevotella</i> sp. oral taxon 300	1549	GU409549	clade_164	N	N
<i>Prevotella marshii</i>	1505	AEEI01000070	clade_166	N	N
<i>Prevotella</i> sp. oral clone IK053	1544	AY349401	clade_166	N	N
<i>Prevotella</i> sp. oral taxon 781	1554	GQ422744	clade_166	N	N
<i>Prevotella stercorea</i>	1562	AB244774	clade_166	N	N
<i>Prevotella brevis</i>	1487	NR_041954	clade_167	N	N
<i>Prevotella ruminicola</i>	1516	CP002006	clade_167	N	N
<i>Prevotella</i> sp. sp24	1560	AB003384	clade_167	N	N
<i>Prevotella</i> sp. sp34	1561	AB003385	clade_167	N	N
<i>Prevotella albensis</i>	1483	NR_025300	clade_168	N	N
<i>Prevotella copri</i>	1490	ACBX02000014	clade_168	N	N
<i>Prevotella oulorum</i>	1514	L16472	clade_168	N	N
<i>Prevotella</i> sp. BI_42	1518	AJ581354	clade_168	N	N
<i>Prevotella</i> sp. oral clone P4PB_83 P2	1546	AY207050	clade_168	N	N
<i>Prevotella</i> sp. oral taxon G60	1557	GU432133	clade_168	N	N
<i>Prevotella amnii</i>	1484	AB547670	clade_169	N	N
<i>Bacteroides caccae</i>	268	EU136686	clade_170	N	N
<i>Bacteroides finegoldii</i>	277	AB222699	clade_170	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Bacteroides intestinalis	283	ABJL02000006	clade_171	N	N
Bacteroides sp. XB44A	326	AM230649	clade_171	N	N
Bifidobacteriaceae genomosp. C1	345	AY278612	clade_172	N	N
Bifidobacterium adolescentis	346	AAXD02000018	clade_172	N	N
Bifidobacterium angulatum	347	ABYS02000004	clade_172	N	N
Bifidobacterium animalis	348	CP001606	clade_172	N	N
Bifidobacterium breve	350	CP002743	clade_172	N	N
Bifidobacterium catenulatum	351	ABXY01000019	clade_172	N	N
Bifidobacterium dentium	352	CP001750	clade_172	N	OP
Bifidobacterium gallicum	353	ABXB03000004	clade_172	N	N
Bifidobacterium infantis	354	AY151398	clade_172	N	N
Bifidobacterium kashiwanohense	355	AB491757	clade_172	N	N
Bifidobacterium longum	356	ABQQ01000041	clade_172	N	N
Bifidobacterium pseudocatenulatum	357	ABXX02000002	clade_172	N	N
Bifidobacterium pseudolongum	358	NR_043442	clade_172	N	N
Bifidobacterium scardovii	359	AJ307005	clade_172	N	N
Bifidobacterium sp. HM2	360	AB425276	clade_172	N	N
Bifidobacterium sp. HMLN12	361	JF519685	clade_172	N	N
Bifidobacterium sp. M45	362	HM626176	clade_172	N	N
Bifidobacterium sp. MSX5B	363	HQ616382	clade_172	N	N
Bifidobacterium sp. TM_7	364	AB218972	clade_172	N	N
Bifidobacterium thermophilum	365	DQ340557	clade_172	N	N
Leuconostoc citreum	1178	AM157444	clade_175	N	N
Leuconostoc lactis	1182	NR_040823	clade_175	N	N
Alicyclobacillus acidoterrestris	123	NR_040844	clade_179	N	N
Alicyclobacillus cycloheptanicus	125	NR_024754	clade_179	N	N
Acinetobacter baumannii	27	ACYQ01000014	clade_181	N	N
Acinetobacter calcoaceticus	28	AM157426	clade_181	N	N
Acinetobacter genomosp. C1	29	AY278636	clade_181	N	N
Acinetobacter haemolyticus	30	ADMT01000017	clade_181	N	N
Acinetobacter johnsonii	31	ACPL01000162	clade_181	N	N
Acinetobacter junii	32	ACPM01000135	clade_181	N	N
Acinetobacter lwoffii	33	ACPN01000204	clade_181	N	N
Acinetobacter parvus	34	AIEB01000124	clade_181	N	N
Acinetobacter schindleri	36	NR_025412	clade_181	N	N
Acinetobacter sp. 56A1	37	GQ178049	clade_181	N	N
Acinetobacter sp. CIP 101934	38	JQ638573	clade_181	N	N
Acinetobacter sp. CIP 102143	39	JQ638578	clade_181	N	N
Acinetobacter sp. M16_22	41	HM366447	clade_181	N	N
Acinetobacter sp. RUH2624	42	ACQF01000094	clade_181	N	N
Acinetobacter sp. SH024	43	ADCH01000068	clade_181	N	N
Lactobacillus jensenii	1092	ACQD01000066	clade_182	N	N
Alcaligenes faecalis	119	AB680368	clade_183	N	N
Alcaligenes sp. CO14	120	DQ643040	clade_183	N	N
Alcaligenes sp. S3	121	HQ262549	clade_183	N	N
Oligella ureolytica	1366	NR_041998	clade_183	N	N
Oligella urethralis	1367	NR_041753	clade_183	N	N
Eikenella corrodens	784	ACEA01000028	clade_185	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Kingella denitrificans	1019	AEWV01000047	clade_185	N	N
Kingella genomosp. P1 oral clone MB2_C20	1020	DQ003616	clade_185	N	N
Kingella kingae	1021	AFHS01000073	clade_185	N	N
Kingella oralis	1022	ACJW02000005	clade_185	N	N
Kingella sp. oral clone ID059	1023	AY349381	clade_185	N	N
Neisseria elongata	1330	ADBF01000003	clade_185	N	N
Neisseria genomosp. P2 oral clone MB5_P15	1332	DQ003630	clade_185	N	N
Neisseria sp. oral clone JC012	1345	AY349388	clade_185	N	N
Neisseria sp. SMC_A9199	1342	FJ763637	clade_185	N	N
Simonsiella muelleri	1731	ADCY01000105	clade_185	N	N
Corynebacterium glucuronolyticum	700	ABYP01000081	clade_193	N	N
Corynebacterium pyruviciproducens	716	FJ185225	clade_193	N	N
Rothia aeria	1649	DQ673320	clade_194	N	N
Rothia dentocariosa	1650	ADDW01000024	clade_194	N	N
Rothia sp. oral taxon 188	1653	GU470892	clade_194	N	N
Corynebacterium accolens	681	ACGD01000048	clade_195	N	N
Corynebacterium macginleyi	707	AB359393	clade_195	N	N
Corynebacterium pseudogenitalium	714	ABYQ01000237	clade_195	N	N
Corynebacterium tuberculostrictum	729	ACVP01000009	clade_195	N	N
Lactobacillus casei	1074	CP000423	clade_198	N	N
Lactobacillus paracasei	1106	ABQV01000067	clade_198	N	N
Lactobacillus zeae	1143	NR_037122	clade_198	N	N
Prevotella dentalis	1492	AB547678	clade_205	N	N
Prevotella sp. oral clone ASCG10	1529	AY923148	clade_206	N	N
Prevotella sp. oral clone HF050	1541	AY349399	clade_206	N	N
Prevotella sp. oral clone ID019	1542	AY349400	clade_206	N	N
Prevotella sp. oral clone IK062	1545	AY349402	clade_206	N	N
Prevotella genomosp. P9 oral clone MB7_G16	1499	DQ003633	clade_207	N	N
Prevotella sp. oral clone AU069	1531	AY005062	clade_207	N	N
Prevotella sp. oral clone CY006	1532	AY005063	clade_207	N	N
Prevotella sp. oral clone FL019	1534	AY349392	clade_207	N	N
Actinomyces genomosp. C1	56	AY278610	clade_212	N	N
Actinomyces genomosp. C2	57	AY278611	clade_212	N	N
Actinomyces genomosp. P1 oral clone MB6_C03	58	DQ003632	clade_212	N	N
Actinomyces georgiae	59	GU561319	clade_212	N	N
Actinomyces israelii	60	AF479270	clade_212	N	N
Actinomyces massiliensis	61	AB545934	clade_212	N	N
Actinomyces meyeri	62	GU561321	clade_212	N	N
Actinomyces odontolyticus	66	ACYT01000123	clade_212	N	N
Actinomyces orihominis	68	AJ575186	clade_212	N	N
Actinomyces sp. CCUG 37290	71	AJ234058	clade_212	N	N
Actinomyces sp. ICM34	75	HQ616391	clade_212	N	N
Actinomyces sp. ICM41	76	HQ616392	clade_212	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Actinomyces sp. ICM47	77	HQ616395	clade_212	N	N
Actinomyces sp. ICM54	78	HQ616398	clade_212	N	N
Actinomyces sp. oral clone IP081	87	AY349366	clade_212	N	N
Actinomyces sp. oral taxon 178	91	AEUH01000060	clade_212	N	N
Actinomyces sp. oral taxon 180	92	AEPP01000041	clade_212	N	N
Actinomyces sp. TeJ5	80	GU561315	clade_212	N	N
Haematobacter sp. BC14248	968	GU396991	clade_213	N	N
Paracoccus denitrificans	1424	CP000490	clade_213	N	N
Paracoccus marcusii	1425	NR_044922	clade_213	N	N
Grimontia hollisae	967	ADAQ01000013	clade_216	N	N
Shewanella putrefaciens	1723	CP002457	clade_216	N	N
Afipia genomosp. 4	111	EU117385	clade_217	N	N
Rhodopseudomonas palustris	1626	CP000301	clade_217	N	N
Methylobacterium extorquens	1223	NC_010172	clade_218	N	N
Methylobacterium podarium	1224	AY468363	clade_218	N	N
Methylobacterium radiotolerans	1225	GU294320	clade_218	N	N
Methylobacterium sp. 1sub	1226	AY468371	clade_218	N	N
Methylobacterium sp. MM4	1227	AY468370	clade_218	N	N
Achromobacter denitrificans	18	NR_042021	clade_224	N	N
Achromobacter piechaudii	19	ADMS01000149	clade_224	N	N
Achromobacter xylosoxidans	20	ACRC01000072	clade_224	N	N
Bordetella bronchiseptica	384	NR_025949	clade_224	N	OP
Bordetella holmesii	385	AB683187	clade_224	N	OP
Bordetella parapertussis	386	NR_025950	clade_224	N	OP
Bordetella pertussis	387	BX640418	clade_224	N	OP
Microbacterium chokolatum	1230	NR_037045	clade_225	N	N
Microbacterium flavescens	1231	EU714363	clade_225	N	N
Microbacterium lacticum	1233	EU714351	clade_225	N	N
Microbacterium oleivorans	1234	EU714381	clade_225	N	N
Microbacterium oxydans	1235	EU714348	clade_225	N	N
Microbacterium paraoxydans	1236	AJ491806	clade_225	N	N
Microbacterium phyllosphaerae	1237	EU714359	clade_225	N	N
Microbacterium schleiferi	1238	NR_044936	clade_225	N	N
Microbacterium sp. 768	1239	EU714378	clade_225	N	N
Microbacterium sp. oral strain C24KA	1240	AF287752	clade_225	N	N
Microbacterium testaceum	1241	EU714365	clade_225	N	N
Corynebacterium atypicum	686	NR_025540	clade_229	N	N
Corynebacterium mastitidis	708	AB359395	clade_229	N	N
Corynebacterium sp. NML 97_0186	725	GU238411	clade_229	N	N
Mycobacterium elephantis	1275	AF385898	clade_237	N	OP
Mycobacterium paraterrae	1288	EU919229	clade_237	N	OP
Mycobacterium phlei	1289	GU142920	clade_237	N	OP
Mycobacterium sp. 1776	1293	EU703152	clade_237	N	N
Mycobacterium sp. 1781	1294	EU703147	clade_237	N	N
Mycobacterium sp. AQ1GA4	1297	HM210417	clade_237	N	N
Mycobacterium sp. GN_10546	1299	FJ497243	clade_237	N	N
Mycobacterium sp. GN_10827	1300	FJ497247	clade_237	N	N
Mycobacterium sp. GN_11124	1301	FJ652846	clade_237	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Mycobacterium sp. GN_9188	1302	FJ497240	clade_237	N	N
Mycobacterium sp. GR_2007_210	1303	FJ555538	clade_237	N	N
Anoxybacillus contaminans	172	NR_029006	clade_238	N	N
Bacillus aeolius	195	NR_025557	clade_238	N	N
Brevibacterium frigoritolerans	422	NR_042639	clade_238	N	N
Geobacillus sp. E263	934	DQ647387	clade_238	N	N
Geobacillus sp. WCH70	935	CP001638	clade_238	N	N
Geobacillus thermocatenulatus	937	NR_043020	clade_238	N	N
Geobacillus thermoleovorans	940	NR_074931	clade_238	N	N
Lysinibacillus fusiformis	1192	FN397522	clade_238	N	N
Planomicrobium koreense	1468	NR_025011	clade_238	N	N
Sporosarcina newyorkensis	1754	AFPZ01000142	clade_238	N	N
Sporosarcina sp. 2681	1755	GU994081	clade_238	N	N
Ureibacillus composti	1968	NR_043746	clade_238	N	N
Ureibacillus suwonensis	1969	NR_043232	clade_238	N	N
Ureibacillus terrenus	1970	NR_025394	clade_238	N	N
Ureibacillus thermophilus	1971	NR_043747	clade_238	N	N
Ureibacillus thermosphaericus	1972	NR_040961	clade_238	N	N
Prevotella micans	1507	AGWK01000061	clade_239	N	N
Prevotella sp. oral clone DA058	1533	AY005065	clade_239	N	N
Prevotella sp. SEQ053	1523	JN867222	clade_239	N	N
Treponema socranskii	1937	NR_024868	clade_240	N	OP
Treponema sp. 6:H:D15A_4	1938	AY005083	clade_240	N	N
Treponema sp. oral taxon 265	1953	GU408850	clade_240	N	N
Treponema sp. oral taxon G85	1958	GU432215	clade_240	N	N
Porphyromonas endodontalis	1472	ACNN01000021	clade_241	N	N
Porphyromonas sp. oral clone BB134	1478	AY005068	clade_241	N	N
Porphyromonas sp. oral clone F016	1479	AY005069	clade_241	N	N
Porphyromonas sp. oral clone P2PB_52 P1	1480	AY207054	clade_241	N	N
Porphyromonas sp. oral clone P4GB_100 P2	1481	AY207057	clade_241	N	N
Acidovorax sp. 98_63833	26	AY258065	clade_245	N	N
Comamonadaceae bacterium NML000135	663	JN585335	clade_245	N	N
Comamonadaceae bacterium NML790751	664	JN585331	clade_245	N	N
Comamonadaceae bacterium NML910035	665	JN585332	clade_245	N	N
Comamonadaceae bacterium NML910036	666	JN585333	clade_245	N	N
Comamonas sp. NSP5	668	AB076850	clade_245	N	N
Delftia acidovorans	748	CP000884	clade_245	N	N
Xenophilus aerolatus	2018	JN585329	clade_245	N	N
Oribacterium sp. oral taxon 078	1380	ACIQ02000009	clade_246	N	N
Oribacterium sp. oral taxon 102	1381	GQ422713	clade_246	N	N
Weissella cibaria	2007	NR_036924	clade_247	N	N
Weissella confusa	2008	NR_040816	clade_247	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Weissella hellenica	2009	AB680902	clade_247	N	N
Weissella kandleri	2010	NR_044659	clade_247	N	N
Weissella koreensis	2011	NR_075058	clade_247	N	N
Weissella paramesenteroides	2012	ACKU01000017	clade_247	N	N
Weissella sp. KLDS 7.0701	2013	EU600924	clade_247	N	N
Mobiluncus curtisii	1251	AEPZ01000013	clade_249	N	N
Enhydrobacter aerosaccus	785	ACYI01000081	clade_256	N	N
Moraxella osloensis	1262	JN175341	clade_256	N	N
Moraxella sp. GM2	1264	JF837191	clade_256	N	N
Brevibacterium casei	420	JF951998	clade_257	N	N
Brevibacterium epidermidis	421	NR_029262	clade_257	N	N
Brevibacterium sanguinis	426	NR_028016	clade_257	N	N
Brevibacterium sp. H15	427	AB177640	clade_257	N	N
Acinetobacter radioresistens	35	ACVR01000010	clade_261	N	N
Lactobacillus alimentarius	1068	NR_044701	clade_263	N	N
Lactobacillus farciminis	1082	NR_044707	clade_263	N	N
Lactobacillus kimchii	1097	NR_025045	clade_263	N	N
Lactobacillus nodensis	1101	NR_041629	clade_263	N	N
Lactobacillus tucseti	1138	NR_042194	clade_263	N	N
Pseudomonas mendocina	1595	AAUL01000021	clade_265	N	N
Pseudomonas pseudoalcaligenes	1598	NR_037000	clade_265	N	N
Pseudomonas sp. NP522b	1602	EU723211	clade_265	N	N
Pseudomonas stutzeri	1603	AM905854	clade_265	N	N
Paenibacillus barcinonensis	1390	NR_042272	clade_270	N	N
Paenibacillus barengoltzii	1391	NR_042756	clade_270	N	N
Paenibacillus chibensis	1392	NR_040885	clade_270	N	N
Paenibacillus cookii	1393	NR_025372	clade_270	N	N
Paenibacillus durus	1394	NR_037017	clade_270	N	N
Paenibacillus glucanolyticus	1395	D78470	clade_270	N	N
Paenibacillus lactis	1396	NR_025739	clade_270	N	N
Paenibacillus pabuli	1398	NR_040853	clade_270	N	N
Paenibacillus popilliae	1400	NR_040888	clade_270	N	N
Paenibacillus sp. CIP 101062	1401	HM212646	clade_270	N	N
Paenibacillus sp. JC66	1404	JF824808	clade_270	N	N
Paenibacillus sp. R_27413	1405	HE586333	clade_270	N	N
Paenibacillus sp. R_27422	1406	HE586338	clade_270	N	N
Paenibacillus timonensis	1408	NR_042844	clade_270	N	N
Rothia mucilaginosa	1651	ACVO01000020	clade_271	N	N
Rothia nasimurium	1652	NR_025310	clade_271	N	N
Prevotella sp. oral taxon 302	1550	ACZK01000043	clade_280	N	N
Prevotella sp. oral taxon F68	1556	HM099652	clade_280	N	N
Prevotella tanneriae	1563	ACIJ02000018	clade_280	N	N
Prevotellaceae bacterium P4P_62 P1	1566	AY207061	clade_280	N	N
Porphyromonas asaccharolytica	1471	AENO01000048	clade_281	N	N
Porphyromonas gingivalis	1473	AE015924	clade_281	N	N
Porphyromonas macacae	1475	NR_025908	clade_281	N	N
Porphyromonas sp. UQD 301	1477	EU012301	clade_281	N	N
Porphyromonas uenonis	1482	ACLR01000152	clade_281	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Leptotrichia buccalis	1165	CP001685	clade_282	N	N
Leptotrichia hofstadii	1168	ACVB02000032	clade_282	N	N
Leptotrichia sp. oral clone HE012	1173	AY349386	clade_282	N	N
Leptotrichia sp. oral taxon 223	1176	GU408547	clade_282	N	N
Bacteroides fluxus	278	AFBN01000029	clade_285	N	N
Bacteroides helcogenes	281	CP002352	clade_285	N	N
Parabacteroides johnsonii	1419	ABYH01000014	clade_286	N	N
Parabacteroides merdae	1420	EU136685	clade_286	N	N
Treponema denticola	1926	ADEC01000002	clade_288	N	OP
Treponema genomsp. P5 oral clone MB3_P23	1929	DQ003624	clade_288	N	N
Treponema putidum	1935	AJ543428	clade_288	N	OP
Treponema sp. oral clone P2PB_53 P3	1942	AY207055	clade_288	N	N
Treponema sp. oral taxon 247	1949	GU408748	clade_288	N	N
Treponema sp. oral taxon 250	1950	GU408776	clade_288	N	N
Treponema sp. oral taxon 251	1951	GU408781	clade_288	N	N
Anaerococcus hydrogenalis	144	ABXA01000039	clade_289	N	N
Anaerococcus sp. 8404299	148	HM587318	clade_289	N	N
Anaerococcus sp. gpac215	156	AM176540	clade_289	N	N
Anaerococcus vaginalis	158	ACXU01000016	clade_289	N	N
Propionibacterium acidipropionici	1569	NC_019395	clade_290	N	N
Propionibacterium avidum	1571	AJ003055	clade_290	N	N
Propionibacterium granulorum	1573	FJ785716	clade_290	N	N
Propionibacterium jensenii	1574	NR_042269	clade_290	N	N
Propionibacterium propionicum	1575	NR_025277	clade_290	N	N
Propionibacterium sp. H456	1577	AB177643	clade_290	N	N
Propionibacterium thoenii	1581	NR_042270	clade_290	N	N
Bifidobacterium bifidum	349	ABQP01000027	clade_293	N	N
Leuconostoc mesenteroides	1183	ACKV01000113	clade_295	N	N
Leuconostoc pseudomesenteroides	1184	NR_040814	clade_295	N	N
Johnsonella ignava	1016	X87152	clade_298	N	N
Propionibacterium acnes	1570	ADJM01000010	clade_299	N	N
Propionibacterium sp. 434_HC2	1576	AFIL01000035	clade_299	N	N
Propionibacterium sp. LG	1578	AY354921	clade_299	N	N
Propionibacterium sp. S555a	1579	AB264622	clade_299	N	N
Alicyclobacillus sp. CCUG 53762	128	HE613268	clade_301	N	N
Actinomyces cardiffensis	53	GU470888	clade_303	N	N
Actinomyces funkei	55	HQ906497	clade_303	N	N
Actinomyces sp. HKU31	74	HQ335393	clade_303	N	N
Actinomyces sp. oral taxon C55	94	HM099646	clade_303	N	N
Kerstersia gyiorum	1018	NR_025669	clade_307	N	N
Pigmentiphaga daeguensis	1467	JN585327	clade_307	N	N
Aeromonas allosaccharophila	104	S39232	clade_308	N	N
Aeromonas enteropelogenes	105	X71121	clade_308	N	N
Aeromonas hydrophila	106	NC_008570	clade_308	N	N
Aeromonas jandaei	107	X60413	clade_308	N	N
Aeromonas salmonicida	108	NC_009348	clade_308	N	N
Aeromonas trota	109	X60415	clade_308	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Aeromonas veronii	110	NR_044845	clade_308	N	N
Marvinbryantia formatexigens	1196	AJ505973	clade_309	N	N
Rhodobacter sp. oral taxon C30	1620	HM099648	clade_310	N	N
Rhodobacter sphaeroides	1621	CP000144	clade_310	N	N
Lactobacillus antri	1071	ACLL01000037	clade_313	N	N
Lactobacillus coleohominis	1076	ACOH01000030	clade_313	N	N
Lactobacillus fermentum	1083	CP002033	clade_313	N	N
Lactobacillus gastricus	1085	AICN01000060	clade_313	N	N
Lactobacillus mucosae	1099	FR693800	clade_313	N	N
Lactobacillus oris	1103	AEKL01000077	clade_313	N	N
Lactobacillus pontis	1111	HM218420	clade_313	N	N
Lactobacillus reuteri	1112	ACGW02000012	clade_313	N	N
Lactobacillus sp. KLDS 1.0707	1127	EU600911	clade_313	N	N
Lactobacillus sp. KLDS 1.0709	1128	EU600913	clade_313	N	N
Lactobacillus sp. KLDS 1.0711	1129	EU600915	clade_313	N	N
Lactobacillus sp. KLDS 1.0713	1131	EU600917	clade_313	N	N
Lactobacillus sp. KLDS 1.0716	1132	EU600921	clade_313	N	N
Lactobacillus sp. KLDS 1.0718	1133	EU600922	clade_313	N	N
Lactobacillus sp. oral taxon 052	1137	GQ422710	clade_313	N	N
Lactobacillus vaginalis	1140	ACGV01000168	clade_313	N	N
Brevibacterium aurantiacum	419	NR_044854	clade_314	N	N
Brevibacterium linens	423	AJ315491	clade_314	N	N
Lactobacillus pentosus	1108	JN813103	clade_315	N	N
Lactobacillus plantarum	1110	ACGZ02000033	clade_315	N	N
Lactobacillus sp. KLDS 1.0702	1123	EU600906	clade_315	N	N
Lactobacillus sp. KLDS 1.0703	1124	EU600907	clade_315	N	N
Lactobacillus sp. KLDS 1.0704	1125	EU600908	clade_315	N	N
Lactobacillus sp. KLDS 1.0705	1126	EU600909	clade_315	N	N
Agrobacterium radiobacter	115	CP000628	clade_316	N	N
Agrobacterium tumefaciens	116	AJ389893	clade_316	N	N
Corynebacterium argenteoroseum	685	EF463055	clade_317	N	N
Corynebacterium diphtheriae	693	NC_002935	clade_317	N	OP
Corynebacterium pseudotuberculosis	715	NR_037070	clade_317	N	N
Corynebacterium renale	717	NR_037069	clade_317	N	N
Corynebacterium ulcerans	731	NR_074467	clade_317	N	N
Aurantimonas coralicida	191	AY065627	clade_318	N	N
Aureimonas altamirensis	192	FN658986	clade_318	N	N
Lactobacillus acidipiscis	1066	NR_024718	clade_320	N	N
Lactobacillus salivarius	1117	AEBA01000145	clade_320	N	N
Lactobacillus sp. KLDS 1.0719	1134	EU600923	clade_320	N	N
Lactobacillus buchneri	1073	ACGH01000101	clade_321	N	N
Lactobacillus genomosp. C1	1086	AY278619	clade_321	N	N
Lactobacillus genomosp. C2	1087	AY278620	clade_321	N	N
Lactobacillus hilgardii	1089	ACGP01000200	clade_321	N	N
Lactobacillus kefir	1096	NR_042230	clade_321	N	N
Lactobacillus parabuchneri	1105	NR_041294	clade_321	N	N
Lactobacillus parakefir	1107	NR_029039	clade_321	N	N
Lactobacillus curvatus	1079	NR_042437	clade_322	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
<i>Lactobacillus sakei</i>	1116	DQ989236	clade_322	N	N
<i>Aneurinibacillus aneurinilyticus</i>	167	AB101592	clade_323	N	N
<i>Aneurinibacillus danicus</i>	168	NR_028657	clade_323	N	N
<i>Aneurinibacillus migulanus</i>	169	NR_036799	clade_323	N	N
<i>Aneurinibacillus terranovensis</i>	170	NR_042271	clade_323	N	N
<i>Staphylococcus aureus</i>	1757	CP002643	clade_325	N	Category -B
<i>Staphylococcus auricularis</i>	1758	JQ624774	clade_325	N	N
<i>Staphylococcus capitis</i>	1759	ACFR01000029	clade_325	N	N
<i>Staphylococcus caprae</i>	1760	ACRH01000033	clade_325	N	N
<i>Staphylococcus carnosus</i>	1761	NR_075003	clade_325	N	N
<i>Staphylococcus cohnii</i>	1762	JN175375	clade_325	N	N
<i>Staphylococcus condimentii</i>	1763	NR_029345	clade_325	N	N
<i>Staphylococcus epidermidis</i>	1764	ACHE01000056	clade_325	N	N
<i>Staphylococcus equorum</i>	1765	NR_027520	clade_325	N	N
<i>Staphylococcus haemolyticus</i>	1767	NC_007168	clade_325	N	N
<i>Staphylococcus hominis</i>	1768	AM157418	clade_325	N	N
<i>Staphylococcus lugdunensis</i>	1769	AEQA01000024	clade_325	N	N
<i>Staphylococcus pasteurii</i>	1770	FJ189773	clade_325	N	N
<i>Staphylococcus pseudintermedius</i>	1771	CP002439	clade_325	N	N
<i>Staphylococcus saccharolyticus</i>	1772	NR_029158	clade_325	N	N
<i>Staphylococcus saprophyticus</i>	1773	NC_007350	clade_325	N	N
<i>Staphylococcus</i> sp. clone bottae7	1777	AF467424	clade_325	N	N
<i>Staphylococcus</i> sp. H292	1775	AB177642	clade_325	N	N
<i>Staphylococcus</i> sp. H780	1776	AB177644	clade_325	N	N
<i>Staphylococcus succinus</i>	1778	NR_028667	clade_325	N	N
<i>Staphylococcus warneri</i>	1780	ACPZ01000009	clade_325	N	N
<i>Staphylococcus xylosus</i>	1781	AY395016	clade_325	N	N
<i>Cardiobacterium hominis</i>	490	ACKY01000036	clade_326	N	N
<i>Cardiobacterium valvarum</i>	491	NR_028847	clade_326	N	N
<i>Pseudomonas fluorescens</i>	1593	AY622220	clade_326	N	N
<i>Pseudomonas gessardii</i>	1594	FJ943496	clade_326	N	N
<i>Pseudomonas monteilii</i>	1596	NR_024910	clade_326	N	N
<i>Pseudomonas poae</i>	1597	GU188951	clade_326	N	N
<i>Pseudomonas putida</i>	1599	AF094741	clade_326	N	N
<i>Pseudomonas</i> sp. G1229	1601	DQ910482	clade_326	N	N
<i>Pseudomonas tolaasii</i>	1604	AF320988	clade_326	N	N
<i>Pseudomonas viridiflava</i>	1605	NR_042764	clade_326	N	N
<i>Listeria grayi</i>	1185	ACCR02000003	clade_328	N	OP
<i>Listeria innocua</i>	1186	JF967625	clade_328	N	N
<i>Listeria ivanovii</i>	1187	X56151	clade_328	N	N
<i>Listeria monocytogenes</i>	1188	CP002003	clade_328	N	Category -B
<i>Listeria welshimeri</i>	1189	AM263198	clade_328	N	OP
<i>Capnocytophaga</i> sp. oral clone ASCH05	484	AY923149	clade_333	N	N
<i>Capnocytophaga sputigena</i>	489	ABZV01000054	clade_333	N	N
<i>Leptotrichia genomsp. C1</i>	1166	AY278621	clade_334	N	N
<i>Leptotrichia shahii</i>	1169	AY029806	clade_334	N	N
<i>Leptotrichia</i> sp. neutropenicPatient	1170	AF189244	clade_334	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Leptotrichia sp. oral clone GT018	1171	AY349384	clade_334	N	N
Leptotrichia sp. oral clone GT020	1172	AY349385	clade_334	N	N
Bacteroides sp. 20_3	296	ACRQ01000064	clade_335	N	N
Bacteroides sp. 3_1_19	307	ADCJ01000062	clade_335	N	N
Bacteroides sp. 3_2_5	311	ACIB01000079	clade_335	N	N
Parabacteroides distasonis	1416	CP000140	clade_335	N	N
Parabacteroides goldsteinii	1417	AY974070	clade_335	N	N
Parabacteroides gordonii	1418	AB470344	clade_335	N	N
Parabacteroides sp. D13	1421	ACPW01000017	clade_335	N	N
Capnocytophaga genomsp. C1	477	AY278613	clade_336	N	N
Capnocytophaga ochracea	480	AEOH01000054	clade_336	N	N
Capnocytophaga sp. GEJ8	481	GU561335	clade_336	N	N
Capnocytophaga sp. oral strain A47ROY	486	AY005077	clade_336	N	N
Capnocytophaga sp. S1b	482	U42009	clade_336	N	N
Paraprevotella clara	1426	AFFY01000068	clade_336	N	N
Bacteroides heparinolyticus	282	JN867284	clade_338	N	N
Prevotella heparinolytica	1500	GQ422742	clade_338	N	N
Treponema genomsp. P4 oral clone MB2_G19	1928	DQ003618	clade_339	N	N
Treponema genomsp. P6 oral clone MB4_G11	1930	DQ003625	clade_339	N	N
Treponema sp. oral taxon 254	1952	GU408803	clade_339	N	N
Treponema sp. oral taxon 508	1956	GU413616	clade_339	N	N
Treponema sp. oral taxon 518	1957	GU413640	clade_339	N	N
Chlamydia muridarum	502	AE002160	clade_341	N	OP
Chlamydia trachomatis	504	U68443	clade_341	N	OP
Chlamydia psittaci	503	NR_036864	clade_342	N	Category -B
Chlamydophila pneumoniae	509	NC_002179	clade_342	N	OP
Chlamydophila psittaci	510	D85712	clade_342	N	OP
Anaerococcus octavius	146	NR_026360	clade_343	N	N
Anaerococcus sp. 8405254	149	HM587319	clade_343	N	N
Anaerococcus sp. 9401487	150	HM587322	clade_343	N	N
Anaerococcus sp. 9403502	151	HM587325	clade_343	N	N
Gardnerella vaginalis	923	CP001849	clade_344	N	N
Campylobacter lari	466	CP000932	clade_346	N	OP
Anaerobiospirillum succiniciproducens	142	NR_026075	clade_347	N	N
Anaerobiospirillum thomasi	143	AJ420985	clade_347	N	N
Ruminobacter amylophilus	1654	NR_026450	clade_347	N	N
Succinatimonas hippei	1897	AEVO01000027	clade_347	N	N
Actinomyces europaeus	54	NR_026363	clade_348	N	N
Actinomyces sp. oral clone GU009	82	AY349361	clade_348	N	N
Moraxella catarrhalis	1260	CP002005	clade_349	N	N
Moraxella lincolni	1261	FR822735	clade_349	N	N
Moraxella sp. 16285	1263	JF682466	clade_349	N	N
Psychrobacter sp. 13983	1613	HM212668	clade_349	N	N
Actinobaculum massiliae	49	AF487679	clade_350	N	N
Actinobaculum schaalii	50	AY957507	clade_350	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Actinobaculum sp. BM#101342	51	AY282578	clade_350	N	N
Actinobaculum sp. P2P_19 P1	52	AY207066	clade_350	N	N
Actinomyces sp. oral clone IO076	84	AY349363	clade_350	N	N
Actinomyces sp. oral taxon 848	93	ACUY01000072	clade_350	N	N
Actinomyces neuui	65	X71862	clade_352	N	N
Mobiluncus mulieris	1252	ACKW01000035	clade_352	N	N
Blastomonas natatoria	372	NR_040824	clade_356	N	N
Novosphingobium aromaticivorans	1357	AAAV03000008	clade_356	N	N
Sphingomonas sp. oral clone FI012	1745	AY349411	clade_356	N	N
Sphingopyxis alaskensis	1749	CP000356	clade_356	N	N
Oxalobacter formigenes	1389	ACDQ01000020	clade_357	N	N
Veillonella atypica	1974	AEDS01000059	clade_358	N	N
Veillonella dispar	1975	ACIK02000021	clade_358	N	N
Veillonella genomosp. P1 oral clone MB5_P17	1976	DQ003631	clade_358	N	N
Veillonella parvula	1978	ADFU01000009	clade_358	N	N
Veillonella sp. 3_1_44	1979	ADCV01000019	clade_358	N	N
Veillonella sp. 6_1_27	1980	ADCW01000016	clade_358	N	N
Veillonella sp. ACP1	1981	HQ616359	clade_358	N	N
Veillonella sp. AS16	1982	HQ616365	clade_358	N	N
Veillonella sp. BS32b	1983	HQ616368	clade_358	N	N
Veillonella sp. ICM51a	1984	HQ616396	clade_358	N	N
Veillonella sp. MSA12	1985	HQ616381	clade_358	N	N
Veillonella sp. NVG 100cf	1986	EF108443	clade_358	N	N
Veillonella sp. OK11	1987	JN695650	clade_358	N	N
Veillonella sp. oral clone ASCG01	1990	AY923144	clade_358	N	N
Veillonella sp. oral clone ASCG02	1991	AY953257	clade_358	N	N
Veillonella sp. oral clone OH1A	1992	AY947495	clade_358	N	N
Veillonella sp. oral taxon 158	1993	AENU01000007	clade_358	N	N
Kocuria marina	1040	GQ260086	clade_365	N	N
Kocuria rhizophila	1042	AY030315	clade_365	N	N
Kocuria rosea	1043	X87756	clade_365	N	N
Kocuria varians	1044	AF542074	clade_365	N	N
Clostridiaceae bacterium END_2	531	EF451053	clade_368	N	N
Micrococcus antarcticus	1242	NR_025285	clade_371	N	N
Micrococcus luteus	1243	NR_075062	clade_371	N	N
Micrococcus lylae	1244	NR_026200	clade_371	N	N
Micrococcus sp. 185	1245	EU714334	clade_371	N	N
Lactobacillus brevis	1072	EU194349	clade_372	N	N
Lactobacillus parabrevis	1104	NR_042456	clade_372	N	N
Pediococcus acidilactici	1436	ACXB01000026	clade_372	N	N
Pediococcus pentosaceus	1437	NR_075052	clade_372	N	N
Lactobacillus dextrinicus	1081	NR_036861	clade_373	N	N
Lactobacillus perolens	1109	NR_029360	clade_373	N	N
Lactobacillus rhamnosus	1113	ABWJ01000068	clade_373	N	N
Lactobacillus saniviri	1118	AB602569	clade_373	N	N
Lactobacillus sp. BT6	1121	HQ616370	clade_373	N	N
Mycobacterium mageritense	1282	FR798914	clade_374	N	OP
Mycobacterium neoaurum	1286	AF268445	clade_374	N	OP

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Mycobacterium smegmatis	1291	CP000480	clade_374	N	OP
Mycobacterium sp. HE5	1304	AJ012738	clade_374	N	N
Dysgonomonas gadei	775	ADLV01000001	clade_377	N	N
Dysgonomonas mossii	776	ADLW01000023	clade_377	N	N
Porphyromonas levii	1474	NR_025907	clade_377	N	N
Porphyromonas somerae	1476	AB547667	clade_377	N	N
Bacteroides barnesiae	267	NR_041446	clade_378	N	N
Bacteroides coprocola	272	ABLY02000050	clade_378	N	N
Bacteroides coprophilus	273	ACBW01000012	clade_378	N	N
Bacteroides dorei	274	ABWZ01000093	clade_378	N	N
Bacteroides massiliensis	284	AB200226	clade_378	N	N
Bacteroides plebeius	289	AB200218	clade_378	N	N
Bacteroides sp. 3_1_33FAA	309	ACPS01000085	clade_378	N	N
Bacteroides sp. 3_1_40A	310	ACRT01000136	clade_378	N	N
Bacteroides sp. 4_3_47FAA	313	ACDR02000029	clade_378	N	N
Bacteroides sp. 9_1_42FAA	314	ACAA01000096	clade_378	N	N
Bacteroides sp. NB_8	323	AB117565	clade_378	N	N
Bacteroides vulgatus	331	CP000139	clade_378	N	N
Bacteroides ovatus	287	ACWH01000036	clade_38	N	N
Bacteroides sp. 1_1_30	294	ADCL01000128	clade_38	N	N
Bacteroides sp. 2_1_22	297	ACPQ01000117	clade_38	N	N
Bacteroides sp. 2_2_4	299	ABZZ01000168	clade_38	N	N
Bacteroides sp. 3_1_23	308	ACRS01000081	clade_38	N	N
Bacteroides sp. D1	318	ACAB02000030	clade_38	N	N
Bacteroides sp. D2	321	ACGA01000077	clade_38	N	N
Bacteroides sp. D22	320	ADCK01000151	clade_38	N	N
Bacteroides xylanisolvens	332	ADKP01000087	clade_38	N	N
Treponema lecithinolyticum	1931	NR_026247	clade_380	N	OP
Treponema parvum	1933	AF302937	clade_380	N	OP
Treponema sp. oral clone JU025	1940	AY349417	clade_380	N	N
Treponema sp. oral taxon 270	1954	GQ422733	clade_380	N	N
Parascardovia denticolens	1428	ADEB01000020	clade_381	N	N
Scardovia inopinata	1688	AB029087	clade_381	N	N
Scardovia wiggisiae	1689	AY278626	clade_381	N	N
Clostridiales bacterium 9400853	533	HM587320	clade_384	N	N
Mogibacterium diversum	1254	NR_027191	clade_384	N	N
Mogibacterium neglectum	1255	NR_027203	clade_384	N	N
Mogibacterium pumilum	1256	NR_028608	clade_384	N	N
Mogibacterium timidum	1257	Z36296	clade_384	N	N
Borrelia burgdorferi	389	ABGI01000001	clade_386	N	OP
Borrelia garinii	392	ABJV01000001	clade_386	N	OP
Borrelia sp. NE49	397	AJ224142	clade_386	N	OP
Caldimonas manganoxidans	457	NR_040787	clade_387	N	N
Comamonadaceae bacterium oral taxon F47	667	HM099651	clade_387	N	N
Lautropia mirabilis	1149	AEQP01000026	clade_387	N	N
Lautropia sp. oral clone AP009	1150	AY005030	clade_387	N	N
Peptoniphilus asaccharolyticus	1441	D14145	clade_389	N	N
Peptoniphilus duerdenii	1442	EU526290	clade_389	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Peptoniphilus harei	1443	NR_026358	clade_389	N	N
Peptoniphilus indolicus	1444	AY153431	clade_389	N	N
Peptoniphilus lacrimalis	1446	ADDO01000050	clade_389	N	N
Peptoniphilus sp. gpac077	1450	AM176527	clade_389	N	N
Peptoniphilus sp. JC140	1447	JF824803	clade_389	N	N
Peptoniphilus sp. oral taxon 386	1452	ADCS01000031	clade_389	N	N
Peptoniphilus sp. oral taxon 836	1453	AEAA01000090	clade_389	N	N
Peptostreptococcaceae bacterium ph1	1454	JN837495	clade_389	N	N
Dialister pneumosintes	765	HM596297	clade_390	N	N
Dialister sp. oral taxon 502	767	GQ422739	clade_390	N	N
Cupriavidus metallidurans	741	GU230889	clade_391	N	N
Herbaspirillum seropedicae	1001	CP002039	clade_391	N	N
Herbaspirillum sp. JC206	1002	JN657219	clade_391	N	N
Janthinobacterium sp. SY12	1015	EF455530	clade_391	N	N
Massilia sp. CCUG 43427A	1197	FR773700	clade_391	N	N
Ralstonia pickettii	1615	NC_010682	clade_391	N	N
Ralstonia sp. 5_7_47FAA	1616	ACUF01000076	clade_391	N	N
Francisella novicida	889	ABSS01000002	clade_392	N	N
Francisella philomiragia	890	AY928394	clade_392	N	N
Francisella tularensis	891	ABAZ01000082	clade_392	N	Category -A
Ignatzschineria indica	1009	HQ823562	clade_392	N	N
Ignatzschineria sp. NML 95_0260	1010	HQ823559	clade_392	N	N
Streptococcus mutans	1814	AP010655	clade_394	N	N
Lactobacillus gasseri	1084	AC0Z01000018	clade_398	N	N
Lactobacillus hominis	1090	FR681902	clade_398	N	N
Lactobacillus iners	1091	AEKJ01000002	clade_398	N	N
Lactobacillus johnsonii	1093	AE017198	clade_398	N	N
Lactobacillus senioris	1119	AB602570	clade_398	N	N
Lactobacillus sp. oral clone HT002	1135	AY349382	clade_398	N	N
Weissella beninensis	2006	EU439435	clade_398	N	N
Sphingomonas echinoides	1744	NR_024700	clade_399	N	N
Sphingomonas sp. oral taxon A09	1747	HM099639	clade_399	N	N
Sphingomonas sp. oral taxon F71	1748	HM099645	clade_399	N	N
Zymomonas mobilis	2032	NR_074274	clade_399	N	N
Arcanobacterium haemolyticum	174	NR_025347	clade_400	N	N
Arcanobacterium pyogenes	175	GU585578	clade_400	N	N
Trueperella pyogenes	1962	NR_044858	clade_400	N	N
Lactococcus garvieae	1144	AF061005	clade_401	N	N
Lactococcus lactis	1145	CP002365	clade_401	N	N
Brevibacterium mcbrellneri	424	ADNU01000076	clade_402	N	N
Brevibacterium paucivorans	425	EU086796	clade_402	N	N
Brevibacterium sp. JC43	428	JF824806	clade_402	N	N
Selenomonas artemidis	1692	HM596274	clade_403	N	N
Selenomonas sp. FOBR9	1704	HQ616378	clade_403	N	N
Selenomonas sp. oral taxon 137	1715	AENV01000007	clade_403	N	N
Desmospora activa	751	AM940019	clade_404	N	N
Desmospora sp. 8437	752	AFHT01000143	clade_404	N	N
Paenibacillus sp. oral taxon F45	1407	HM099647	clade_404	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
<i>Corynebacterium ammoniagenes</i>	682	ADNS01000011	clade_405	N	N
<i>Corynebacterium aurimucosum</i>	687	ACLH01000041	clade_405	N	N
<i>Corynebacterium bovis</i>	688	AF537590	clade_405	N	N
<i>Corynebacterium canis</i>	689	GQ871934	clade_405	N	N
<i>Corynebacterium casei</i>	690	NR_025101	clade_405	N	N
<i>Corynebacterium durum</i>	694	Z97069	clade_405	N	N
<i>Corynebacterium efficiens</i>	695	ACLI01000121	clade_405	N	N
<i>Corynebacterium falsenii</i>	696	Y13024	clade_405	N	N
<i>Corynebacterium flavescens</i>	697	NR_037040	clade_405	N	N
<i>Corynebacterium glutamicum</i>	701	BA000036	clade_405	N	N
<i>Corynebacterium jeikeium</i>	704	ACYW01000001	clade_405	N	OP
<i>Corynebacterium kroppenstedtii</i>	705	NR_026380	clade_405	N	N
<i>Corynebacterium lipophiloflavum</i>	706	ACHJ01000075	clade_405	N	N
<i>Corynebacterium matruchotii</i>	709	ACSH02000003	clade_405	N	N
<i>Corynebacterium minutissimum</i>	710	X82064	clade_405	N	N
<i>Corynebacterium resistens</i>	718	ADGN01000058	clade_405	N	N
<i>Corynebacterium simulans</i>	720	AF537604	clade_405	N	N
<i>Corynebacterium singulare</i>	721	NR_026394	clade_405	N	N
<i>Corynebacterium</i> sp. 1 ex sheep	722	Y13427	clade_405	N	N
<i>Corynebacterium</i> sp. NML 99_0018	726	GU238413	clade_405	N	N
<i>Corynebacterium striatum</i>	727	ACGE01000001	clade_405	N	OP
<i>Corynebacterium urealyticum</i>	732	X81913	clade_405	N	OP
<i>Corynebacterium variabile</i>	734	NR_025314	clade_405	N	N
<i>Aerococcus sanguinicola</i>	98	AY837833	clade_407	N	N
<i>Aerococcus urinae</i>	99	CP002512	clade_407	N	N
<i>Aerococcus urinaequi</i>	100	NR_043443	clade_407	N	N
<i>Aerococcus viridans</i>	101	ADNT01000041	clade_407	N	N
<i>Fusobacterium naviforme</i>	898	HQ223106	clade_408	N	N
<i>Moryella indoligenes</i>	1268	AF527773	clade_408	N	N
<i>Selenomonas genomosp.</i> P5	1697	AY341820	clade_410	N	N
<i>Selenomonas</i> sp. oral clone IQ048	1710	AY349408	clade_410	N	N
<i>Selenomonas sputigena</i>	1717	ACKP02000033	clade_410	N	N
<i>Hyphomicrobium sulfonivorans</i>	1007	AY468372	clade_411	N	N
<i>Methylocella silvestris</i>	1228	NR_074237	clade_411	N	N
<i>Legionella pneumophila</i>	1153	NC_002942	clade_412	N	OP
<i>Lactobacillus coryniformis</i>	1077	NR_044705	clade_413	N	N
<i>Arthrobacter agilis</i>	178	NR_026198	clade_414	N	N
<i>Arthrobacter arilaitensis</i>	179	NR_074608	clade_414	N	N
<i>Arthrobacter bergerei</i>	180	NR_025612	clade_414	N	N
<i>Arthrobacter globiformis</i>	181	NR_026187	clade_414	N	N
<i>Arthrobacter nicotianae</i>	182	NR_026190	clade_414	N	N
<i>Mycobacterium abscessus</i>	1269	AGQU01000002	clade_418	N	OP
<i>Mycobacterium chelonae</i>	1273	AB548610	clade_418	N	OP
<i>Bacteroides salanitronis</i>	291	CP002530	clade_419	N	N
<i>Paraprevotella xylaniphila</i>	1427	AFBR01000011	clade_419	N	N
<i>Barnesiella intestinihominis</i>	336	AB370251	clade_420	N	N
<i>Barnesiella viscericola</i>	337	NR_041508	clade_420	N	N
<i>Parabacteroides</i> sp. NS31_3	1422	JN029805	clade_420	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Porphyromonadaceae bacterium NML 060648	1470	EF184292	clade_420	N	N
Tannerella forsythia	1913	CP003191	clade_420	N	N
Tannerella sp. 6_1_58FAA_CT1	1914	ACWX01000068	clade_420	N	N
Mycoplasma amphoriforme	1311	AY531656	clade_421	N	N
Mycoplasma genitalium	1317	L43967	clade_421	N	N
Mycoplasma pneumoniae	1322	NC_000912	clade_421	N	N
Mycoplasma penetrans	1321	NC_004432	clade_422	N	N
Ureaplasma parvum	1966	AE002127	clade_422	N	N
Ureaplasma urealyticum	1967	AAYN01000002	clade_422	N	N
Treponema genomsp. P1	1927	AY341822	clade_425	N	N
Treponema sp. oral taxon 228	1943	GU408580	clade_425	N	N
Treponema sp. oral taxon 230	1944	GU408603	clade_425	N	N
Treponema sp. oral taxon 231	1945	GU408631	clade_425	N	N
Treponema sp. oral taxon 232	1946	GU408646	clade_425	N	N
Treponema sp. oral taxon 235	1947	GU408673	clade_425	N	N
Treponema sp. ovine footrot	1959	AJ010951	clade_425	N	N
Treponema vincentii	1960	ACYH01000036	clade_425	N	OP
Burkholderiales bacterium 1_1_47	452	ADCQ01000066	clade_432	N	OP
Parasutterella excrementihominis	1429	AFBP01000029	clade_432	N	N
Parasutterella secunda	1430	AB491209	clade_432	N	N
Sutterella morbirenis	1898	AJ832129	clade_432	N	N
Sutterella sanguinus	1900	AJ748647	clade_432	N	N
Sutterella sp. YIT 12072	1901	AB491210	clade_432	N	N
Sutterella stercoricanis	1902	NR_025600	clade_432	N	N
Sutterella wadsworthensis	1903	ADMF01000048	clade_432	N	N
Propionibacterium freudenreichii	1572	NR_036972	clade_433	N	N
Propionibacterium sp. oral taxon 192	1580	GQ422728	clade_433	N	N
Tessaracoccus sp. oral taxon F04	1917	HM099640	clade_433	N	N
Peptoniphilus ivorii	1445	Y07840	clade_434	N	N
Peptoniphilus sp. gpac007	1448	AM176517	clade_434	N	N
Peptoniphilus sp. gpac018A	1449	AM176519	clade_434	N	N
Peptoniphilus sp. gpac148	1451	AM176535	clade_434	N	N
Flexispira rappini	887	AY126479	clade_436	N	N
Helicobacter bilis	993	ACDN01000023	clade_436	N	N
Helicobacter cinaedi	995	ABQT01000054	clade_436	N	N
Helicobacter sp. None	998	U44756	clade_436	N	N
Brevundimonas subvibrioides	429	CP002102	clade_438	N	N
Hyphomonas neptunium	1008	NR_074092	clade_438	N	N
Phenylobacterium zucineum	1465	AY628697	clade_438	N	N
Streptococcus downei	1793	AEKN01000002	clade_441	N	N
Streptococcus sp. SHV515	1848	Y07601	clade_441	N	N
Acinetobacter sp. CIP 53.82	40	JQ638584	clade_443	N	N
Halomonas elongata	990	NR_074782	clade_443	N	N
Halomonas johnsoniae	991	FR775979	clade_443	N	N
Butyrivibrio fibrisolvens	456	U41172	clade_444	N	N
Roseburia sp. 11SE37	1640	FM954975	clade_444	N	N
Roseburia sp. 11SE38	1641	FM954976	clade_444	N	N
Shuttleworthia satellites	1728	ACIP02000004	clade_444	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Shuttleworthia sp. MSX8B	1729	HQ616383	clade_444	N	N
Shuttleworthia sp. oral taxon G69	1730	GU432167	clade_444	N	N
Bdellovibrio sp. MPA	344	AY294215	clade_445	N	N
Desulfobulbus sp. oral clone CH031	755	AY005036	clade_445	N	N
Desulfovibrio desulfuricans	757	DQ092636	clade_445	N	N
Desulfovibrio fairfieldensis	758	U42221	clade_445	N	N
Desulfovibrio piger	759	AF192152	clade_445	N	N
Desulfovibrio sp. 3_1_syn3	760	ADDR01000239	clade_445	N	N
Geobacter bemidjiensis	941	CP001124	clade_445	N	N
Brachybacterium alimentarium	401	NR_026269	clade_446	N	N
Brachybacterium conglomeratum	402	AB537169	clade_446	N	N
Brachybacterium tyrofermentans	403	NR_026272	clade_446	N	N
Dermabacter hominis	749	FJ263375	clade_446	N	N
Aneurinibacillus thermoaerophilus	171	NR_029303	clade_448	N	N
Brevibacillus agri	409	NR_040983	clade_448	N	N
Brevibacillus centrosporus	411	NR_043414	clade_448	N	N
Brevibacillus choshinensis	412	NR_040980	clade_448	N	N
Brevibacillus invocatus	413	NR_041836	clade_448	N	N
Brevibacillus parabrevis	415	NR_040981	clade_448	N	N
Brevibacillus reuszeri	416	NR_040982	clade_448	N	N
Brevibacillus sp. pH8	417	JN837488	clade_448	N	N
Brevibacillus thermoruber	418	NR_026514	clade_448	N	N
Lactobacillus murinus	1100	NR_042231	clade_449	N	N
Lactobacillus oeni	1102	NR_043095	clade_449	N	N
Lactobacillus ruminis	1115	ACGS02000043	clade_449	N	N
Lactobacillus vini	1141	NR_042196	clade_449	N	N
Gemella haemolysans	924	ACDZ02000012	clade_450	N	N
Gemella morbillorum	925	NR_025904	clade_450	N	N
Gemella morbillorum	926	ACRX01000010	clade_450	N	N
Gemella sanguinis	927	ACRY01000057	clade_450	N	N
Gemella sp. oral clone ASCE02	929	AY923133	clade_450	N	N
Gemella sp. oral clone ASCF04	930	AY923139	clade_450	N	N
Gemella sp. oral clone ASCF12	931	AY923143	clade_450	N	N
Gemella sp. WAL 1945J	928	EU427463	clade_450	N	N
Sporolactobacillus nakayamae	1753	NR_042247	clade_451	N	N
Gluconacetobacter entanii	945	NR_028909	clade_452	N	N
Gluconacetobacter europaeus	946	NR_026513	clade_452	N	N
Gluconacetobacter hansenii	947	NR_026133	clade_452	N	N
Gluconacetobacter oboediens	949	NR_041295	clade_452	N	N
Gluconacetobacter xylinus	950	NR_074338	clade_452	N	N
Auritibacter ignavus	193	FN554542	clade_453	N	N
Dermacoccus sp. Ellin185	750	AEIQ01000090	clade_453	N	N
Janibacter limosus	1013	NR_026362	clade_453	N	N
Janibacter melonis	1014	EF063716	clade_453	N	N
Acetobacter aceti	7	NR_026121	clade_454	N	N
Acetobacter fabarum	8	NR_042678	clade_454	N	N
Acetobacter lovaniensis	9	NR_040832	clade_454	N	N
Acetobacter malorum	10	NR_025513	clade_454	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Acetobacter orientalis	11	NR_028625	clade_454	N	N
Acetobacter pasteurianus	12	NR_026107	clade_454	N	N
Acetobacter pomorum	13	NR_042112	clade_454	N	N
Acetobacter syzygii	14	NR_040868	clade_454	N	N
Acetobacter tropicalis	15	NR_036881	clade_454	N	N
Gluconacetobacter azotocaptans	943	NR_028767	clade_454	N	N
Gluconacetobacter diazotrophicus	944	NR_074292	clade_454	N	N
Gluconacetobacter johannae	948	NR_024959	clade_454	N	N
Nocardia brasiliensis	1351	AIHV01000038	clade_455	N	N
Nocardia cyriacigeorgica	1352	HQ009486	clade_455	N	N
Nocardia puris	1354	NR_028994	clade_455	N	N
Nocardia sp. 01_Je_025	1355	GU574059	clade_455	N	N
Rhodococcus equi	1623	ADNW01000058	clade_455	N	N
Oceanobacillus caeni	1358	NR_041533	clade_456	N	N
Oceanobacillus sp. Ndiop	1359	CAER01000083	clade_456	N	N
Ornithinibacillus bavariensis	1384	NR_044923	clade_456	N	N
Ornithinibacillus sp. 7_10AIA	1385	FN397526	clade_456	N	N
Virgibacillus proomii	2005	NR_025308	clade_456	N	N
Corynebacterium amycolatum	683	ABZU01000033	clade_457	N	OP
Corynebacterium hansenii	702	AM946639	clade_457	N	N
Corynebacterium xerosis	735	FN179330	clade_457	N	OP
Staphylococcaceae bacterium NML_92_0017	1756	AY841362	clade_458	N	N
Staphylococcus fleurettii	1766	NR_041326	clade_458	N	N
Staphylococcus sciuri	1774	NR_025520	clade_458	N	N
Staphylococcus vitulinus	1779	NR_024670	clade_458	N	N
Stenotrophomonas maltophilia	1782	AAVZ01000005	clade_459	N	N
Stenotrophomonas sp. FG_6	1783	EF017810	clade_459	N	N
Mycobacterium africanum	1270	AF480605	clade_46	N	OP
Mycobacterium alsiensis	1271	AJ938169	clade_46	N	OP
Mycobacterium avium	1272	CP000479	clade_46	N	OP
Mycobacterium colombiense	1274	AM062764	clade_46	N	OP
Mycobacterium gordonae	1276	GU142930	clade_46	N	OP
Mycobacterium intracellulare	1277	GQ153276	clade_46	N	OP
Mycobacterium kansasii	1278	AF480601	clade_46	N	OP
Mycobacterium lacus	1279	NR_025175	clade_46	N	OP
Mycobacterium leprae	1280	FM211192	clade_46	N	OP
Mycobacterium lepromatosis	1281	EU203590	clade_46	N	OP
Mycobacterium mantenii	1283	FJ042897	clade_46	N	OP
Mycobacterium marinum	1284	NC_010612	clade_46	N	OP
Mycobacterium microti	1285	NR_025234	clade_46	N	OP
Mycobacterium parascrofulaceum	1287	ADNV01000350	clade_46	N	OP
Mycobacterium seoulense	1290	DQ536403	clade_46	N	OP
Mycobacterium sp. 1761	1292	EU703150	clade_46	N	N
Mycobacterium sp. 1791	1295	EU703148	clade_46	N	N
Mycobacterium sp. 1797	1296	EU703149	clade_46	N	N
Mycobacterium sp. B10_07.09.0206	1298	HQ174245	clade_46	N	N
Mycobacterium sp. NLA001000736	1305	HM627011	clade_46	N	N
Mycobacterium sp. W	1306	DQ437715	clade_46	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Mycobacterium tuberculosis	1307	CP001658	clade_46	N	Category -C
Mycobacterium ulcerans	1308	AB548725	clade_46	N	OP
Mycobacterium vulneris	1309	EU834055	clade_46	N	OP
Xanthomonas campestris	2016	EF101975	clade_461	N	N
Xanthomonas sp. kmd_489	2017	EU723184	clade_461	N	N
Dietzia natronolimnaea	769	GQ870426	clade_462	N	N
Dietzia sp. BBDP51	770	DQ337512	clade_462	N	N
Dietzia sp. CA149	771	GQ870422	clade_462	N	N
Dietzia timorensis	772	GQ870424	clade_462	N	N
Gordonia bronchialis	951	NR_027594	clade_463	N	N
Gordonia polyisoprenivorans	952	DQ385609	clade_463	N	N
Gordonia sp. KTR9	953	DQ068383	clade_463	N	N
Gordonia sputi	954	FJ536304	clade_463	N	N
Gordonia terrae	955	GQ848239	clade_463	N	N
Leptotrichia goodfellowii	1167	ADAD01000110	clade_465	N	N
Leptotrichia sp. oral clone IK040	1174	AY349387	clade_465	N	N
Leptotrichia sp. oral clone P2PB_51 P1	1175	AY207053	clade_465	N	N
Bacteroidales genomosp. P7 oral clone MB3_P19	264	DQ003623	clade_466	N	N
Butyrlicimonas virosa	454	AB443949	clade_466	N	N
Odoribacter laneus	1363	AB490805	clade_466	N	N
Odoribacter splanchnicus	1364	CP002544	clade_466	N	N
Capnocytophaga gingivalis	478	ACLQ01000011	clade_467	N	N
Capnocytophaga granulosa	479	X97248	clade_467	N	N
Capnocytophaga sp. oral clone AH015	483	AY005074	clade_467	N	N
Capnocytophaga sp. oral strain S3	487	AY005073	clade_467	N	N
Capnocytophaga sp. oral taxon 338	488	AEXX01000050	clade_467	N	N
Capnocytophaga canimorsus	476	CP002113	clade_468	N	N
Capnocytophaga sp. oral clone ID062	485	AY349368	clade_468	N	N
Lactobacillus cateniformis	1075	M23729	clade_469	N	N
Lactobacillus vitulinus	1142	NR_041305	clade_469	N	N
Cetobacterium somerae	501	AJ438155	clade_470	N	N
Fusobacterium gonidiaformans	896	ACET01000043	clade_470	N	N
Fusobacterium mortiferum	897	ACDB02000034	clade_470	N	N
Fusobacterium necrogenes	899	X55408	clade_470	N	N
Fusobacterium necrophorum	900	AM905356	clade_470	N	N
Fusobacterium sp. 12_1B	905	AGWJ01000070	clade_470	N	N
Fusobacterium sp. 3_1_5R	911	ACDD01000078	clade_470	N	N
Fusobacterium sp. D12	918	ACDG02000036	clade_470	N	N
Fusobacterium ulcerans	921	ACDH01000090	clade_470	N	N
Fusobacterium varium	922	ACIE01000009	clade_470	N	N
Mycoplasma arthritidis	1312	NC_011025	clade_473	N	N
Mycoplasma faucium	1314	NR_024983	clade_473	N	N
Mycoplasma hominis	1318	AF443616	clade_473	N	N
Mycoplasma orale	1319	AY796060	clade_473	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Mycoplasma salivarium	1324	M24661	clade_473	N	N
Mitsuokella jalaludinii	1247	NR_028840	clade_474	N	N
Mitsuokella multacida	1248	ABWK02000005	clade_474	N	N
Mitsuokella sp. oral taxon 521	1249	GU413658	clade_474	N	N
Mitsuokella sp. oral taxon G68	1250	GU432166	clade_474	N	N
Selenomonas genomsp. C1	1695	AY278627	clade_474	N	N
Selenomonas genomsp. P8 oral clone MB5_P06	1700	DQ003628	clade_474	N	N
Selenomonas ruminantium	1703	NR_075026	clade_474	N	N
Veillonellaceae bacterium oral taxon 131	1994	GU402916	clade_474	N	N
Alloscardovia omnicolens	139	NR_042583	clade_475	N	N
Alloscardovia sp. OB7196	140	AB425070	clade_475	N	N
Bifidobacterium urinalis	366	AJ278695	clade_475	N	N
Prevotella loescheii	1503	JN867231	clade_48	N	N
Prevotella sp. oral clone ASCG12	1530	DQ272511	clade_48	N	N
Prevotella sp. oral clone GU027	1540	AY349398	clade_48	N	N
Prevotella sp. oral taxon 472	1553	ACZS01000106	clade_48	N	N
Selenomonas diana	1693	GQ422719	clade_480	N	N
Selenomonas flueggei	1694	AF287803	clade_480	N	N
Selenomonas genomsp. C2	1696	AY278628	clade_480	N	N
Selenomonas genomsp. P6 oral clone MB3_C41	1698	DQ003636	clade_480	N	N
Selenomonas genomsp. P7 oral clone MB5_C08	1699	DQ003627	clade_480	N	N
Selenomonas infelix	1701	AF287802	clade_480	N	N
Selenomonas noxia	1702	GU470909	clade_480	N	N
Selenomonas sp. oral clone FT050	1705	AY349403	clade_480	N	N
Selenomonas sp. oral clone GI064	1706	AY349404	clade_480	N	N
Selenomonas sp. oral clone GT010	1707	AY349405	clade_480	N	N
Selenomonas sp. oral clone HU051	1708	AY349406	clade_480	N	N
Selenomonas sp. oral clone IK004	1709	AY349407	clade_480	N	N
Selenomonas sp. oral clone JI021	1711	AY349409	clade_480	N	N
Selenomonas sp. oral clone JS031	1712	AY349410	clade_480	N	N
Selenomonas sp. oral clone OH4A	1713	AY947498	clade_480	N	N
Selenomonas sp. oral clone P2PA_80 P4	1714	AY207052	clade_480	N	N
Selenomonas sp. oral taxon 149	1716	AEEJ01000007	clade_480	N	N
Veillonellaceae bacterium oral taxon 155	1995	GU470897	clade_480	N	N
Agrococcus jenensis	117	NR_026275	clade_484	N	N
Microbacterium gubbeenense	1232	NR_025098	clade_484	N	N
Pseudoclavibacter sp. Timone	1590	FJ375951	clade_484	N	N
Tropheryma whipplei	1961	BX251412	clade_484	N	N
Zimmermannella bifida	2031	AB012592	clade_484	N	N
Legionella hackeliae	1151	M36028	clade_486	N	OP
Legionella longbeachae	1152	M36029	clade_486	N	OP
Legionella sp. D3923	1154	JN380999	clade_486	N	OP

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Legionella sp. D4088	1155	JN381012	clade_486	N	OP
Legionella sp. H63	1156	JF831047	clade_486	N	OP
Legionella sp. NML 93L054	1157	GU062706	clade_486	N	OP
Legionella steelei	1158	HQ398202	clade_486	N	OP
Tatlockia micdadei	1915	M36032	clade_486	N	N
Helicobacter pullorum	996	ABQU01000097	clade_489	N	N
Acetobacteraceae bacterium AT_5844	16	AGEZ01000040	clade_490	N	N
Roseomonas cervicalis	1643	ADVL01000363	clade_490	N	N
Roseomonas mucosa	1644	NR_028857	clade_490	N	N
Roseomonas sp. NML94_0193	1645	AF533357	clade_490	N	N
Roseomonas sp. NML97_0121	1646	AF533359	clade_490	N	N
Roseomonas sp. NML98_0009	1647	AF533358	clade_490	N	N
Roseomonas sp. NML98_0157	1648	AF533360	clade_490	N	N
Rickettsia akari	1627	CP000847	clade_492	N	OP
Rickettsia conorii	1628	AE008647	clade_492	N	OP
Rickettsia prowazekii	1629	M21789	clade_492	N	Category -B
Rickettsia rickettsii	1630	NC_010263	clade_492	N	OP
Rickettsia slovaca	1631	L36224	clade_492	N	OP
Rickettsia typhi	1632	AE017197	clade_492	N	OP
Anaeroglobus geminatus	160	AGCJ01000054	clade_493	N	N
Megasphaera genomsp. C1	1201	AY278622	clade_493	N	N
Megasphaera micronuciformis	1203	AECS01000020	clade_493	N	N
Clostridiales genomsp. BVAB3	540	CP001850	clade_495	N	N
Tsukamurella paurometabola	1963	X80628	clade_496	N	N
Tsukamurella tyrosinosolvens	1964	AB478958	clade_496	N	N
Abiotrophia para_adiacens	2	AB022027	clade_497	N	N
Carnobacterium divergens	492	NR_044706	clade_497	N	N
Carnobacterium maltaromaticum	493	NC_019425	clade_497	N	N
Enterococcus avium	800	AF133535	clade_497	N	N
Enterococcus caccae	801	AY943820	clade_497	N	N
Enterococcus casseliflavus	802	AEWT01000047	clade_497	N	N
Enterococcus durans	803	AJ276354	clade_497	N	N
Enterococcus faecalis	804	AE016830	clade_497	N	N
Enterococcus faecium	805	AM157434	clade_497	N	N
Enterococcus gallinarum	806	AB269767	clade_497	N	N
Enterococcus gilvus	807	AY033814	clade_497	N	N
Enterococcus hawaiiensis	808	AY321377	clade_497	N	N
Enterococcus hirae	809	AF061011	clade_497	N	N
Enterococcus italicus	810	AEPV01000109	clade_497	N	N
Enterococcus mundtii	811	NR_024906	clade_497	N	N
Enterococcus raffinosus	812	FN600541	clade_497	N	N
Enterococcus sp. BV2CASA2	813	JN809766	clade_497	N	N
Enterococcus sp. CCRI_16620	814	GU457263	clade_497	N	N
Enterococcus sp. F95	815	FJ463817	clade_497	N	N
Enterococcus sp. RfL6	816	AJ133478	clade_497	N	N
Enterococcus thailandicus	817	AY321376	clade_497	N	N
Fusobacterium canifelinum	893	AY162222	clade_497	N	N
Fusobacterium genomsp. C1	894	AY278616	clade_497	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Fusobacterium genomosp. C2	895	AY278617	clade_497	N	N
Fusobacterium periodonticum	902	ACJY01000002	clade_497	N	N
Fusobacterium sp. 1_1_41FAA	906	ADGG01000053	clade_497	N	N
Fusobacterium sp. 11_3_2	904	ACUO01000052	clade_497	N	N
Fusobacterium sp. 2_1_31	907	ACDC02000018	clade_497	N	N
Fusobacterium sp. 3_1_27	908	ADGF01000045	clade_497	N	N
Fusobacterium sp. 3_1_33	909	ACQE01000178	clade_497	N	N
Fusobacterium sp. 3_1_36A2	910	ACPU01000044	clade_497	N	N
Fusobacterium sp. AC18	912	HQ616357	clade_497	N	N
Fusobacterium sp. ACB2	913	HQ616358	clade_497	N	N
Fusobacterium sp. AS2	914	HQ616361	clade_497	N	N
Fusobacterium sp. CM1	915	HQ616371	clade_497	N	N
Fusobacterium sp. CM21	916	HQ616375	clade_497	N	N
Fusobacterium sp. CM22	917	HQ616376	clade_497	N	N
Fusobacterium sp. oral clone ASCF06	919	AY923141	clade_497	N	N
Fusobacterium sp. oral clone ASCF11	920	AY953256	clade_497	N	N
Granulicatella adiacens	959	ACKZ01000002	clade_497	N	N
Granulicatella elegans	960	AB252689	clade_497	N	N
Granulicatella paradiacens	961	AY879298	clade_497	N	N
Granulicatella sp. oral clone ASC02	963	AY923126	clade_497	N	N
Granulicatella sp. oral clone ASCA05	964	DQ341469	clade_497	N	N
Granulicatella sp. oral clone ASCB09	965	AY953251	clade_497	N	N
Granulicatella sp. oral clone ASCG05	966	AY923146	clade_497	N	N
Tetragenococcus halophilus	1918	NR_075020	clade_497	N	N
Tetragenococcus koreensis	1919	NR_043113	clade_497	N	N
Vagococcus fluvialis	1973	NR_026489	clade_497	N	N
Chryseobacterium anthropi	514	AM982793	clade_498	N	N
Chryseobacterium gleum	515	ACKQ02000003	clade_498	N	N
Chryseobacterium hominis	516	NR_042517	clade_498	N	N
Treponema refringens	1936	AF426101	clade_499	N	OP
Treponema sp. oral clone JU031	1941	AY349416	clade_499	N	N
Treponema sp. oral taxon 239	1948	GU408738	clade_499	N	N
Treponema sp. oral taxon 271	1955	GU408871	clade_499	N	N
Alistipes finegoldii	129	NR_043064	clade_500	N	N
Alistipes onderdonkii	131	NR_043318	clade_500	N	N
Alistipes putredinis	132	ABFK02000017	clade_500	N	N
Alistipes shahii	133	FP929032	clade_500	N	N
Alistipes sp. HGB5	134	AENZ01000082	clade_500	N	N
Alistipes sp. JC50	135	JF824804	clade_500	N	N
Alistipes sp. RMA 9912	136	GQ140629	clade_500	N	N
Mycoplasma agalactiae	1310	AF010477	clade_501	N	N
Mycoplasma bovoculi	1313	NR_025987	clade_501	N	N
Mycoplasma fermentans	1315	CP002458	clade_501	N	N
Mycoplasma flocculare	1316	X62699	clade_501	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Mycoplasma ovipneumoniae	1320	NR_025989	clade_501	N	N
Arcobacter butzleri	176	AEPT01000071	clade_502	N	N
Arcobacter cryaerophilus	177	NR_025905	clade_502	N	N
Campylobacter curvus	461	NC_009715	clade_502	N	OP
Campylobacter rectus	467	ACFU01000050	clade_502	N	OP
Campylobacter showae	468	ACVQ01000030	clade_502	N	OP
Campylobacter sp. FOBRC14	469	HQ616379	clade_502	N	OP
Campylobacter sp. FOBRC15	470	HQ616380	clade_502	N	OP
Campylobacter sp. oral clone BB120	471	AY005038	clade_502	N	OP
Campylobacter sputorum	472	NR_044839	clade_502	N	OP
Bacteroides ureolyticus	330	GQ167666	clade_504	N	N
Campylobacter gracilis	463	ACYG01000026	clade_504	N	OP
Campylobacter hominis	464	NC_009714	clade_504	N	OP
Dialister invisus	762	ACIM02000001	clade_506	N	N
Dialister microaerophilus	763	AFBB01000028	clade_506	N	N
Dialister microaerophilus	764	AENT01000008	clade_506	N	N
Dialister propionificiens	766	NR_043231	clade_506	N	N
Dialister succinatiphilus	768	AB370249	clade_506	N	N
Megasphaera elsdenii	1200	AY038996	clade_506	N	N
Megasphaera genomosp. type_1	1202	ADGP01000010	clade_506	N	N
Megasphaera sp. BLPYG_07	1204	HM990964	clade_506	N	N
Megasphaera sp. UPII 199_6	1205	AFIJ01000040	clade_506	N	N
Chromobacterium violaceum	513	NC_005085	clade_507	N	N
Laribacter hongkongensis	1148	CP001154	clade_507	N	N
Methylophilus sp. ECd5	1229	AY436794	clade_507	N	N
Finegoldia magna	883	ACHM02000001	clade_509	N	N
Parvimonas micra	1431	AB729072	clade_509	N	N
Parvimonas sp. oral taxon 110	1432	AFII01000002	clade_509	N	N
Peptostreptococcus micros	1456	AM176538	clade_509	N	N
Peptostreptococcus sp. oral clone FJ023	1460	AY349390	clade_509	N	N
Peptostreptococcus sp. P4P_31 P3	1458	AY207059	clade_509	N	N
Helicobacter pylori	997	CP000012	clade_510	N	OP
Anaplasma marginale	165	ABOR01000019	clade_511	N	N
Anaplasma phagocytophilum	166	NC_007797	clade_511	N	N
Ehrlichia chaffeensis	783	AAIF01000035	clade_511	N	OP
Neorickettsia risticii	1349	CP001431	clade_511	N	N
Neorickettsia sennetsu	1350	NC_007798	clade_511	N	N
Pseudoramibacter alactolyticus	1606	AB036759	clade_512	N	N
Veillonella montpellierensis	1977	AF473836	clade_513	N	N
Veillonella sp. oral clone ASCA08	1988	AY923118	clade_513	N	N
Veillonella sp. oral clone ASCB03	1989	AY923122	clade_513	N	N
Inquilinus limosus	1012	NR_029046	clade_514	N	N
Sphingomonas sp. oral clone FZ016	1746	AY349412	clade_514	N	N
Anaerococcus lactolyticus	145	ABY001000217	clade_515	N	N
Anaerococcus prevotii	147	CP001708	clade_515	N	N
Anaerococcus sp. gpac104	152	AM176528	clade_515	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Anaerococcus sp. gpac126	153	AM176530	clade_515	N	N
Anaerococcus sp. gpac155	154	AM176536	clade_515	N	N
Anaerococcus sp. gpac199	155	AM176539	clade_515	N	N
Anaerococcus tetradius	157	ACGC01000107	clade_515	N	N
Bacteroides coagulans	271	AB547639	clade_515	N	N
Clostridiales bacterium 9403326	534	HM587324	clade_515	N	N
Clostridiales bacterium ph2	539	JN837487	clade_515	N	N
Peptostreptococcus sp. 9succ1	1457	X90471	clade_515	N	N
Peptostreptococcus sp. oral clone AP24	1459	AB175072	clade_515	N	N
Tissierella praeacuta	1924	NR_044860	clade_515	N	N
Helicobacter canadensis	994	ABQS01000108	clade_518	N	N
Peptostreptococcus anaerobius	1455	AY326462	clade_520	N	N
Peptostreptococcus stomatis	1461	ADGQ01000048	clade_520	N	N
Bilophila wadsworthia	367	ADCP01000166	clade_521	N	N
Desulfovibrio vulgaris	761	NR_074897	clade_521	N	N
Actinomyces nasicola	64	AJ508455	clade_523	N	N
Cellulosimicrobium funkei	500	AY501364	clade_523	N	N
Lactococcus raffinolactis	1146	NR_044359	clade_524	N	N
Bacteroidales genomosp. P1	258	AY341819	clade_529	N	N
Bacteroidales genomosp. P2 oral clone MB1_G13	259	DQ003613	clade_529	N	N
Bacteroidales genomosp. P3 oral clone MB1_G34	260	DQ003615	clade_529	N	N
Bacteroidales genomosp. P4 oral clone MB2_G17	261	DQ003617	clade_529	N	N
Bacteroidales genomosp. P5 oral clone MB2_P04	262	DQ003619	clade_529	N	N
Bacteroidales genomosp. P6 oral clone MB3_C19	263	DQ003634	clade_529	N	N
Bacteroidales genomosp. P8 oral clone MB4_G15	265	DQ003626	clade_529	N	N
Bacteroidetes bacterium oral taxon D27	333	HM099638	clade_530	N	N
Bacteroidetes bacterium oral taxon F31	334	HM099643	clade_530	N	N
Bacteroidetes bacterium oral taxon F44	335	HM099649	clade_530	N	N
Flavobacterium sp. NF2_1	885	FJ195988	clade_530	N	N
Myroides odoratimimus	1326	NR_042354	clade_530	N	N
Myroides sp. MY15	1327	GU253339	clade_530	N	N
Chlamydiales bacterium NS16	507	JN606076	clade_531	N	N
Chlamydophila pecorum	508	D88317	clade_531	N	OP
Parachlamydia sp. UWE25	1423	BX908798	clade_531	N	N
Fusobacterium russii	903	NR_044687	clade_532	N	N
Streptobacillus moniliformis	1784	NR_027615	clade_532	N	N
Eubacteriaceae bacterium P4P_50 P4	833	AY207060	clade_533	N	N
Abiotrophia defectiva	1	ACIN02000016	clade_534	N	N
Abiotrophia sp. oral clone P4PA_155 P1	3	AY207063	clade_534	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Catonella genomosp. P1 oral clone MB5_P12	496	DQ003629	clade_534	N	N
Catonella morbi	497	ACIL02000016	clade_534	N	N
Catonella sp. oral clone FL037	498	AY349369	clade_534	N	N
Eremococcus coleocola	818	AENN01000008	clade_534	N	N
Facklamia hominis	879	Y10772	clade_534	N	N
Granulicatella sp. M658_99_3	962	AJ271861	clade_534	N	N
Campylobacter coli	459	AAFL01000004	clade_535	N	OP
Campylobacter concisus	460	CP000792	clade_535	N	OP
Campylobacter fetus	462	ACLG01001177	clade_535	N	OP
Campylobacter jejuni	465	AL139074	clade_535	N	Category -B
Campylobacter upsaliensis	473	AEPU01000040	clade_535	N	OP
Atopobium minutum	183	HM007583	clade_539	N	N
Atopobium parvulum	184	CP001721	clade_539	N	N
Atopobium rimae	185	ACFE01000007	clade_539	N	N
Atopobium sp. BS2	186	HQ616367	clade_539	N	N
Atopobium sp. F0209	187	EU592966	clade_539	N	N
Atopobium sp. ICM42b10	188	HQ616393	clade_539	N	N
Atopobium sp. ICM57	189	HQ616400	clade_539	N	N
Atopobium vaginae	190	AEDQ01000024	clade_539	N	N
Coriobacteriaceae bacterium BV3Ac1	677	JN809768	clade_539	N	N
Actinomyces naeslundii	63	X81062	clade_54	N	N
Actinomyces oricola	67	NR_025559	clade_54	N	N
Actinomyces oris	69	BABV01000070	clade_54	N	N
Actinomyces sp. 7400942	70	EU484334	clade_54	N	N
Actinomyces sp. ChDC B197	72	AF543275	clade_54	N	N
Actinomyces sp. GEJ15	73	GU561313	clade_54	N	N
Actinomyces sp. M2231_94_1	79	AJ234063	clade_54	N	N
Actinomyces sp. oral clone GU067	83	AY349362	clade_54	N	N
Actinomyces sp. oral clone IO077	85	AY349364	clade_54	N	N
Actinomyces sp. oral clone IP073	86	AY349365	clade_54	N	N
Actinomyces sp. oral clone JA063	88	AY349367	clade_54	N	N
Actinomyces sp. oral taxon 170	89	AFBL01000010	clade_54	N	N
Actinomyces sp. oral taxon 171	90	AECW01000034	clade_54	N	N
Actinomyces urogenitalis	95	ACFH01000038	clade_54	N	N
Actinomyces viscosus	96	ACRE01000096	clade_54	N	N
Orientia tsutsugamushi	1383	AP008981	clade_541	N	OP
Megamonas funiformis	1198	AB300988	clade_542	N	N
Megamonas hypermegale	1199	AJ420107	clade_542	N	N
Aeromicrobium marinum	102	NR_025681	clade_544	N	N
Aeromicrobium sp. JC14	103	JF824798	clade_544	N	N
Luteococcus sanguinis	1190	NR_025507	clade_544	N	N
Propionibacteriaceae bacterium NML 02_0265	1568	EF599122	clade_544	N	N
Rhodococcus corynebacterioides	1622	X80615	clade_546	N	N
Rhodococcus erythropolis	1624	ACNO01000030	clade_546	N	N
Rhodococcus fascians	1625	NR_037021	clade_546	N	N
Segniliparus rotundus	1690	CP001958	clade_546	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Segniliparus rugosus	1691	ACZI01000025	clade_546	N	N
Exiguobacterium acetylicum	878	FJ970034	clade_547	N	N
Macrococcus caseolyticus	1194	NR_074941	clade_547	N	N
Streptomyces sp. 1 AIP_2009	1890	FJ176782	clade_548	N	N
Streptomyces sp. SD 524	1892	EU544234	clade_548	N	N
Streptomyces sp. SD 528	1893	EU544233	clade_548	N	N
Streptomyces thermoviolaceus	1895	NR_027616	clade_548	N	N
Borrelia afzelii	388	ABCU01000001	clade_549	N	OP
Borrelia crociduræ	390	DQ057990	clade_549	N	OP
Borrelia duttonii	391	NC_011229	clade_549	N	OP
Borrelia hermsii	393	AY597657	clade_549	N	OP
Borrelia hispanica	394	DQ057988	clade_549	N	OP
Borrelia persica	395	HM161645	clade_549	N	OP
Borrelia recurrentis	396	AF107367	clade_549	N	OP
Borrelia spielmanii	398	ABKB01000002	clade_549	N	OP
Borrelia turicatae	399	NC_008710	clade_549	N	OP
Borrelia valaisiana	400	ABCY01000002	clade_549	N	OP
Providencia alcalifaciens	1586	ABXW01000071	clade_55	N	N
Providencia rettgeri	1587	AM040492	clade_55	N	N
Providencia rustigianii	1588	AM040489	clade_55	N	N
Providencia stuartii	1589	AF008581	clade_55	N	N
Treponema pallidum	1932	CP001752	clade_550	N	OP
Treponema phagedenis	1934	AEFH01000172	clade_550	N	N
Treponema sp. clone DDKL_4	1939	Y08894	clade_550	N	N
Acholeplasma laidlawii	17	NR_074448	clade_551	N	N
Mycoplasma putrefaciens	1323	U26055	clade_551	N	N
Mycoplasmataceae genomosp. P1 oral clone MB1_G23	1325	DQ003614	clade_551	N	N
Spiroplasma insolitum	1750	NR_025705	clade_551	N	N
Collinsella intestinalis	660	ABXH02000037	clade_553	N	N
Collinsella stercoris	661	ABXJ01000150	clade_553	N	N
Collinsella tanakaei	662	AB490807	clade_553	N	N
Caminiella sporogenes	458	NR_025485	clade_554	N	N
Acidaminococcus fermentans	21	CP001859	clade_556	N	N
Acidaminococcus intestini	22	CP003058	clade_556	N	N
Acidaminococcus sp. D21	23	ACGB01000071	clade_556	N	N
Phascolarctobacterium faecium	1462	NR_026111	clade_556	N	N
Phascolarctobacterium sp. YIT 12068	1463	AB490812	clade_556	N	N
Phascolarctobacterium succinatutens	1464	AB490811	clade_556	N	N
Acidithiobacillus ferrivorans	25	NR_074660	clade_557	N	N
Xanthomonadaceae bacterium NML 03_0222	2015	EU313791	clade_557	N	N
Catabacter hongkongensis	494	AB671763	clade_558	N	N
Christensenella minuta	512	AB490809	clade_558	N	N
Clostridiales bacterium oral clone P4PA_66 P1	536	AY207065	clade_558	N	N
Clostridiales bacterium oral taxon 093	537	GQ422712	clade_558	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Heliobacterium modesticaldum	1000	NR_074517	clade_560	N	N
Alistipes indistinctus	130	AB490804	clade_561	N	N
Bacteroidales bacterium ph8	257	JN837494	clade_561	N	N
Candidatus Sulcia muelleri	475	CP002163	clade_561	N	N
Cytophaga xylanolytica	742	FR733683	clade_561	N	N
Flavobacteriaceae genomosp. C1	884	AY278614	clade_561	N	N
Gramella forsetii	958	NR_074707	clade_561	N	N
Sphingobacterium faecium	1740	NR_025537	clade_562	N	N
Sphingobacterium mizutaii	1741	JF708889	clade_562	N	N
Sphingobacterium multivorum	1742	NR_040953	clade_562	N	N
Sphingobacterium spiritivorum	1743	ACHA02000013	clade_562	N	N
Jonquetella anthropi	1017	ACOO02000004	clade_563	N	N
Pyramidobacter pisciolens	1614	AY207056	clade_563	N	N
Synergistes genomosp. C1	1904	AY278615	clade_563	N	N
Synergistes sp. RMA 14551	1905	DQ412722	clade_563	N	N
Synergistetes bacterium ADV897	1906	GQ258968	clade_563	N	N
Candidatus Arthromitus sp. SFB_mouse_Yit	474	NR_074460	clade_564	N	N
Gracilibacter thermotolerans	957	NR_043559	clade_564	N	N
Brachyspira aalborgi	404	FM178386	clade_565	N	N
Brachyspira sp. HIS3	406	FM178387	clade_565	N	N
Brachyspira sp. HIS4	407	FM178388	clade_565	N	N
Brachyspira sp. HIS5	408	FM178389	clade_565	N	N
Adlercreutzia equolifaciens	97	AB306661	clade_566	N	N
Coriobacteriaceae bacterium JC110	678	CAEM01000062	clade_566	N	N
Coriobacteriaceae bacterium phl	679	JN837493	clade_566	N	N
Cryptobacterium curtum	740	GQ422741	clade_566	N	N
Eggerthella sinensis	779	AY321958	clade_566	N	N
Eggerthella sp. 1_3_56FAA	780	ACWN01000099	clade_566	N	N
Eggerthella sp. HGA1	781	AEXR01000021	clade_566	N	N
Eggerthella sp. YY7918	782	AP012211	clade_566	N	N
Gordonibacter pamelaeeae	680	AM886059	clade_566	N	N
Gordonibacter pamelaeeae	956	FP929047	clade_566	N	N
Slackia equolifaciens	1732	EU377663	clade_566	N	N
Slackia exigua	1733	ACUX01000029	clade_566	N	N
Slackia faecicanis	1734	NR_042220	clade_566	N	N
Slackia heliotrinireducens	1735	NR_074439	clade_566	N	N
Slackia isoflavoniconvertens	1736	AB566418	clade_566	N	N
Slackia piriformis	1737	AB490806	clade_566	N	N
Slackia sp. NATTS	1738	AB505075	clade_566	N	N
Chlamydiales bacterium NS13	506	JN606075	clade_567	N	N
Victivallaceae bacterium NML 080035	2003	FJ394915	clade_567	N	N
Victivallis vadensis	2004	ABDE02000010	clade_567	N	N
Streptomyces griseus	1889	NR_074787	clade_573	N	N
Streptomyces sp. SD 511	1891	EU544231	clade_573	N	N
Streptomyces sp. SD 534	1894	EU544232	clade_573	N	N
Cloacibacillus evryensis	530	GQ258966	clade_575	N	N
Deferribacteres sp. oral clone	743	AY349370	clade_575	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
JV001					
Deferribacteres sp. oral clone JV023	745	AY349372	clade_575	N	N
Synergistetes bacterium LBVCM1157	1907	GQ258969	clade_575	N	N
Synergistetes bacterium oral taxon 362	1909	GU410752	clade_575	N	N
Synergistetes bacterium oral taxon D48	1910	GU430992	clade_575	N	N
Peptococcus sp. oral clone JM048	1439	AY349389	clade_576	N	N
Helicobacter winhamensis	999	ACDO01000013	clade_577	N	N
Wolinella succinogenes	2014	BX571657	clade_577	N	N
Olsenella genomsp. C1	1368	AY278623	clade_578	N	N
Olsenella profusa	1369	FN178466	clade_578	N	N
Olsenella sp. F0004	1370	EU592964	clade_578	N	N
Olsenella sp. oral taxon 809	1371	ACVE01000002	clade_578	N	N
Olsenella uli	1372	CP002106	clade_578	N	N
Nocardiopsis dassonvillei	1356	CP002041	clade_579	N	N
Peptococcus niger	1438	NR_029221	clade_580	N	N
Peptococcus sp. oral taxon 167	1440	GQ422727	clade_580	N	N
Akkermansia muciniphila	118	CP001071	clade_583	N	N
Opitutus terrae	1373	NR_074978	clade_583	N	N
Clostridiales bacterium oral taxon F32	538	HM099644	clade_584	N	N
Leptospira borgpetersenii	1161	NC_008508	clade_585	N	OP
Leptospira broomii	1162	NR_043200	clade_585	N	OP
Leptospira interrogans	1163	NC_005823	clade_585	N	OP
Methanobrevibacter gottschalkii	1213	NR_044789	clade_587	N	N
Methanobrevibacter millerae	1214	NR_042785	clade_587	N	N
Methanobrevibacter oralis	1216	HE654003	clade_587	N	N
Methanobrevibacter thaueri	1219	NR_044787	clade_587	N	N
Methanobrevibacter smithii	1218	ABYV02000002	clade_588	N	N
Deinococcus radiodurans	746	AE000513	clade_589	N	N
Deinococcus sp. R_43890	747	FR682752	clade_589	N	N
Thermus aquaticus	1923	NR_025900	clade_589	N	N
Actinomyces sp. c109	81	AB167239	clade_590	N	N
Syntrophomonadaceae genomsp. P1	1912	AY341821	clade_590	N	N
Anaerobaculum hydrogeniformans	141	ACJX02000009	clade_591	N	N
Microcystis aeruginosa	1246	NC_010296	clade_592	N	N
Prochlorococcus marinus	1567	CP000551	clade_592	N	N
Methanobrevibacter acididurans	1208	NR_028779	clade_593	N	N
Methanobrevibacter arboriphilus	1209	NR_042783	clade_593	N	N
Methanobrevibacter curvatus	1210	NR_044796	clade_593	N	N
Methanobrevibacter cuticularis	1211	NR_044776	clade_593	N	N
Methanobrevibacter filiformis	1212	NR_044801	clade_593	N	N
Methanobrevibacter woesei	1220	NR_044788	clade_593	N	N
Roseiflexus castenholzii	1642	CP000804	clade_594	N	N
Methanobrevibacter olleyae	1215	NR_043024	clade_595	N	N
Methanobrevibacter ruminantium	1217	NR_042784	clade_595	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Methanobrevibacter wolinii	1221	NR_044790	clade_595	N	N
Methanosphaera stadtmanae	1222	AY196684	clade_595	N	N
Chloroflexi genomosp. P1	511	AY331414	clade_596	N	N
Halorubrum lipolyticum	992	AB477978	clade_597	N	N
Methanobacterium formicicum	1207	NR_025028	clade_597	N	N
Acidilobus saccharovorans	24	AY350586	clade_598	N	N
Hyperthermus butylicus	1006	CP000493	clade_598	N	N
Ignicoccus islandicus	1011	X99562	clade_598	N	N
Metallosphaera sedula	1206	D26491	clade_598	N	N
Thermophilum pendens	1922	X14835	clade_598	N	N
Prevotella melaninogenica	1506	CP002122	clade_6	N	N
Prevotella sp. ICM1	1520	HQ616385	clade_6	N	N
Prevotella sp. oral clone FU048	1535	AY349393	clade_6	N	N
Prevotella sp. oral clone GI030	1537	AY349395	clade_6	N	N
Prevotella sp. SEQ116	1526	JN867246	clade_6	N	N
Streptococcus anginosus	1787	AECT01000011	clade_60	N	N
Streptococcus milleri	1812	X81023	clade_60	N	N
Streptococcus sp. 16362	1829	JN590019	clade_60	N	N
Streptococcus sp. 69130	1832	X78825	clade_60	N	N
Streptococcus sp. AC15	1833	HQ616356	clade_60	N	N
Streptococcus sp. CM7	1839	HQ616373	clade_60	N	N
Streptococcus sp. OBRC6	1847	HQ616352	clade_60	N	N
Burkholderia ambifaria	442	AAUZ01000009	clade_61	N	OP
Burkholderia cenocepacia	443	AAHI01000060	clade_61	N	OP
Burkholderia cepacia	444	NR_041719	clade_61	N	OP
Burkholderia mallei	445	CP000547	clade_61	N	Category -B
Burkholderia multivorans	446	NC_010086	clade_61	N	OP
Burkholderia oklahomensis	447	DQ108388	clade_61	N	OP
Burkholderia pseudomallei	448	CP001408	clade_61	N	Category -B
Burkholderia rhizoxinica	449	HQ005410	clade_61	N	OP
Burkholderia sp. 383	450	CP000151	clade_61	N	OP
Burkholderia xenovorans	451	U86373	clade_61	N	OP
Prevotella buccae	1488	ACRB01000001	clade_62	N	N
Prevotella genomosp. P8 oral clone MB3_P13	1498	DQ003622	clade_62	N	N
Prevotella sp. oral clone FW035	1536	AY349394	clade_62	N	N
Prevotella bivia	1486	ADFO01000096	clade_63	N	N
Prevotella disiens	1494	AEDO01000026	clade_64	N	N
Bacteroides faecis	276	GQ496624	clade_65	N	N
Bacteroides fragilis	279	AP006841	clade_65	N	N
Bacteroides nordii	285	NR_043017	clade_65	N	N
Bacteroides salyersiae	292	EU136690	clade_65	N	N
Bacteroides sp. 1_1_14	293	ACRP01000155	clade_65	N	N
Bacteroides sp. 1_1_6	295	ACIC01000215	clade_65	N	N
Bacteroides sp. 2_1_56FAA	298	ACWI01000065	clade_65	N	N
Bacteroides sp. AR29	316	AF139525	clade_65	N	N
Bacteroides sp. B2	317	EU722733	clade_65	N	N
Bacteroides thetaiotaomicron	328	NR_074277	clade_65	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
<i>Actinobacillus minor</i>	45	ACFT01000025	clade_69	N	N
<i>Haemophilus parasuis</i>	978	GU226366	clade_69	N	N
<i>Vibrio cholerae</i>	1996	AAUR01000095	clade_71	N	Category -B
<i>Vibrio fluvialis</i>	1997	X76335	clade_71	N	Category -B
<i>Vibrio furnissii</i>	1998	CP002377	clade_71	N	Category -B
<i>Vibrio mimicus</i>	1999	ADAF01000001	clade_71	N	Category -B
<i>Vibrio parahaemolyticus</i>	2000	AAWQ01000116	clade_71	N	Category -B
<i>Vibrio</i> sp. RC341	2001	ACZT01000024	clade_71	N	Category -B
<i>Vibrio vulnificus</i>	2002	AE016796	clade_71	N	Category -B
<i>Lactobacillus acidophilus</i>	1067	CP000033	clade_72	N	N
<i>Lactobacillus amylolyticus</i>	1069	ADNY01000006	clade_72	N	N
<i>Lactobacillus amylovorus</i>	1070	CP002338	clade_72	N	N
<i>Lactobacillus crispatus</i>	1078	ACOG01000151	clade_72	N	N
<i>Lactobacillus delbrueckii</i>	1080	CP002341	clade_72	N	N
<i>Lactobacillus helveticus</i>	1088	ACLM01000202	clade_72	N	N
<i>Lactobacillus kalixensis</i>	1094	NR_029083	clade_72	N	N
<i>Lactobacillus kefirifaciens</i>	1095	NR_042440	clade_72	N	N
<i>Lactobacillus leichmannii</i>	1098	JX986966	clade_72	N	N
<i>Lactobacillus</i> sp. 66c	1120	FR681900	clade_72	N	N
<i>Lactobacillus</i> sp. KLDS 1.0701	1122	EU600905	clade_72	N	N
<i>Lactobacillus</i> sp. KLDS 1.0712	1130	EU600916	clade_72	N	N
<i>Lactobacillus</i> sp. oral clone HT070	1136	AY349383	clade_72	N	N
<i>Lactobacillus ultunensis</i>	1139	ACGU01000081	clade_72	N	N
<i>Prevotella intermedia</i>	1502	AF414829	clade_81	N	N
<i>Prevotella nigrescens</i>	1511	AFPX01000069	clade_81	N	N
<i>Prevotella pallens</i>	1515	AFPY01000135	clade_81	N	N
<i>Prevotella</i> sp. oral taxon 310	1551	GQ422737	clade_81	N	N
<i>Prevotella</i> genomosp. C1	1495	AY278624	clade_82	N	N
<i>Prevotella</i> sp. CM38	1519	HQ610181	clade_82	N	N
<i>Prevotella</i> sp. oral taxon 317	1552	ACQH01000158	clade_82	N	N
<i>Prevotella</i> sp. SG12	1527	GU561343	clade_82	N	N
<i>Prevotella denticola</i>	1493	CP002589	clade_83	N	N
<i>Prevotella</i> genomosp. P7 oral clone MB2_P31	1497	DQ003620	clade_83	N	N
<i>Prevotella histicola</i>	1501	JN867315	clade_83	N	N
<i>Prevotella multiformis</i>	1508	AEWX01000054	clade_83	N	N
<i>Prevotella</i> sp. JCM 6330	1522	AB547699	clade_83	N	N
<i>Prevotella</i> sp. oral clone GI059	1539	AY349397	clade_83	N	N
<i>Prevotella</i> sp. oral taxon 782	1555	GQ422745	clade_83	N	N
<i>Prevotella</i> sp. oral taxon G71	1559	GU432180	clade_83	N	N
<i>Prevotella</i> sp. SEQ065	1524	JN867234	clade_83	N	N
<i>Prevotella veroralis</i>	1565	ACVA01000027	clade_83	N	N
<i>Bacteroides acidifaciens</i>	266	NR_028607	clade_85	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Bacteroides cellulosilyticus	269	ACCH01000108	clade_85	N	N
Bacteroides clarus	270	AFBM01000011	clade_85	N	N
Bacteroides eggertii	275	ACWG01000065	clade_85	N	N
Bacteroides oleiciplenus	286	AB547644	clade_85	N	N
Bacteroides pyogenes	290	NR_041280	clade_85	N	N
Bacteroides sp. 315_5	300	FJ848547	clade_85	N	N
Bacteroides sp. 31SF15	301	AJ583248	clade_85	N	N
Bacteroides sp. 31SF18	302	AJ583249	clade_85	N	N
Bacteroides sp. 35AE31	303	AJ583244	clade_85	N	N
Bacteroides sp. 35AE37	304	AJ583245	clade_85	N	N
Bacteroides sp. 35BE34	305	AJ583246	clade_85	N	N
Bacteroides sp. 35BE35	306	AJ583247	clade_85	N	N
Bacteroides sp. WH2	324	AY895180	clade_85	N	N
Bacteroides sp. XB12B	325	AM230648	clade_85	N	N
Bacteroides stercoris	327	ABFZ02000022	clade_85	N	N
Actinobacillus pleuropneumoniae	46	NR_074857	clade_88	N	N
Actinobacillus ureae	48	AEVG01000167	clade_88	N	N
Haemophilus aegyptius	969	AFBC01000053	clade_88	N	N
Haemophilus ducreyi	970	AE017143	clade_88	N	OP
Haemophilus haemolyticus	973	JN175335	clade_88	N	N
Haemophilus influenzae	974	AADP01000001	clade_88	N	OP
Haemophilus parahaemolyticus	975	GU561425	clade_88	N	N
Haemophilus parainfluenzae	976	AEWU01000024	clade_88	N	N
Haemophilus paraphrophaemolyticus	977	M75076	clade_88	N	N
Haemophilus somnus	979	NC_008309	clade_88	N	N
Haemophilus sp. 70334	980	HQ680854	clade_88	N	N
Haemophilus sp. HK445	981	FJ685624	clade_88	N	N
Haemophilus sp. oral clone ASCA07	982	AY923117	clade_88	N	N
Haemophilus sp. oral clone ASCG06	983	AY923147	clade_88	N	N
Haemophilus sp. oral clone BJ021	984	AY005034	clade_88	N	N
Haemophilus sp. oral clone BJ095	985	AY005033	clade_88	N	N
Haemophilus sp. oral taxon 851	987	AGRK01000004	clade_88	N	N
Haemophilus sputorum	988	AFNK01000005	clade_88	N	N
Histophilus somni	1003	AF549387	clade_88	N	N
Mannheimia haemolytica	1195	ACZX01000102	clade_88	N	N
Pasteurella bettyae	1433	L06088	clade_88	N	N
Moellerella wisconsensis	1253	JN175344	clade_89	N	N
Morganella morganii	1265	AJ301681	clade_89	N	N
Morganella sp. JB_T16	1266	AJ781005	clade_89	N	N
Proteus mirabilis	1582	ACLE01000013	clade_89	N	N
Proteus penneri	1583	ABVP01000020	clade_89	N	N
Proteus sp. HS7514	1584	DQ512963	clade_89	N	N
Proteus vulgaris	1585	AJ233425	clade_89	N	N
Oribacterium sinus	1374	ACKX01000142	clade_90	N	N
Oribacterium sp. ACB1	1375	HM120210	clade_90	N	N
Oribacterium sp. ACB7	1376	HM120211	clade_90	N	N
Oribacterium sp. CM12	1377	HQ616374	clade_90	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
Oribacterium sp. ICM51	1378	HQ616397	clade_90	N	N
Oribacterium sp. OBRC12	1379	HQ616355	clade_90	N	N
Oribacterium sp. oral taxon 108	1382	AFIH01000001	clade_90	N	N
Actinobacillus actinomycetemcomitans	44	AY362885	clade_92	N	N
Actinobacillus succinogenes	47	CP000746	clade_92	N	N
Aggregatibacter actinomycetemcomitans	112	CP001733	clade_92	N	N
Aggregatibacter aphrophilus	113	CP001607	clade_92	N	N
Aggregatibacter segnis	114	AEPS01000017	clade_92	N	N
Averyella dalhousiensis	194	DQ481464	clade_92	N	N
Bisgaard Taxon	368	AY683487	clade_92	N	N
Bisgaard Taxon	369	AY683489	clade_92	N	N
Bisgaard Taxon	370	AY683491	clade_92	N	N
Bisgaard Taxon	371	AY683492	clade_92	N	N
Buchnera aphidicola	440	NR_074609	clade_92	N	N
Cedecea davisae	499	AF493976	clade_92	N	N
Citrobacter amalonaticus	517	FR870441	clade_92	N	N
Citrobacter braakii	518	NR_028687	clade_92	N	N
Citrobacter farmeri	519	AF025371	clade_92	N	N
Citrobacter freundii	520	NR_028894	clade_92	N	N
Citrobacter gillienii	521	AF025367	clade_92	N	N
Citrobacter koseri	522	NC_009792	clade_92	N	N
Citrobacter murlinae	523	AF025369	clade_92	N	N
Citrobacter rodentium	524	NR_074903	clade_92	N	N
Citrobacter sedlakii	525	AF025364	clade_92	N	N
Citrobacter sp. 30_2	526	ACDJ01000053	clade_92	N	N
Citrobacter sp. KMSI_3	527	GQ468398	clade_92	N	N
Citrobacter werkmanii	528	AF025373	clade_92	N	N
Citrobacter youngae	529	ABWL02000011	clade_92	N	N
Cronobacter malonaticus	737	GU122174	clade_92	N	N
Cronobacter sakazakii	738	NC_009778	clade_92	N	N
Cronobacter turicensis	739	FN543093	clade_92	N	N
Enterobacter aerogenes	786	AJ251468	clade_92	N	N
Enterobacter asburiae	787	NR_024640	clade_92	N	N
Enterobacter cancerogenus	788	Z96078	clade_92	N	N
Enterobacter cloacae	789	FP929040	clade_92	N	N
Enterobacter cowanii	790	NR_025566	clade_92	N	N
Enterobacter hormaechei	791	AFHR01000079	clade_92	N	N
Enterobacter sp. 247BMC	792	HQ122932	clade_92	N	N
Enterobacter sp. 638	793	NR_074777	clade_92	N	N
Enterobacter sp. JC163	794	JN657217	clade_92	N	N
Enterobacter sp. SCSS	795	HM007811	clade_92	N	N
Enterobacter sp. TSE38	796	HM156134	clade_92	N	N
Enterobacteriaceae bacterium 9_2_54FAA	797	ADCU01000033	clade_92	N	N
Enterobacteriaceae bacterium CF01Ent_1	798	AJ489826	clade_92	N	N
Enterobacteriaceae bacterium Smarlab 3302238	799	AY538694	clade_92	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
<i>Escherichia albertii</i>	824	ABKX01000012	clade_92	N	N
<i>Escherichia coli</i>	825	NC_008563	clade_92	N	Category -B
<i>Escherichia fergusonii</i>	826	CU928158	clade_92	N	N
<i>Escherichia hermannii</i>	827	HQ407266	clade_92	N	N
<i>Escherichia</i> sp. 1_1_43	828	ACID01000033	clade_92	N	N
<i>Escherichia</i> sp. 4_1_40B	829	ACDM02000056	clade_92	N	N
<i>Escherichia</i> sp. B4	830	EU722735	clade_92	N	N
<i>Escherichia vulneris</i>	831	NR_041927	clade_92	N	N
<i>Ewingella americana</i>	877	JN175329	clade_92	N	N
<i>Haemophilus genomosp.</i> P2 oral clone MB3_C24	971	DQ003621	clade_92	N	N
<i>Haemophilus genomosp.</i> P3 oral clone MB3_C38	972	DQ003635	clade_92	N	N
<i>Haemophilus</i> sp. oral clone JM053	986	AY349380	clade_92	N	N
<i>Hafnia alvei</i>	989	DQ412565	clade_92	N	N
<i>Klebsiella oxytoca</i>	1024	AY292871	clade_92	N	OP
<i>Klebsiella pneumoniae</i>	1025	CP000647	clade_92	N	OP
<i>Klebsiella</i> sp. AS10	1026	HQ616362	clade_92	N	N
<i>Klebsiella</i> sp. Co9935	1027	DQ068764	clade_92	N	N
<i>Klebsiella</i> sp. enrichment culture clone SRC_DSD25	1036	HM195210	clade_92	N	N
<i>Klebsiella</i> sp. OBRC7	1028	HQ616353	clade_92	N	N
<i>Klebsiella</i> sp. SP_BA	1029	FJ999767	clade_92	N	N
<i>Klebsiella</i> sp. SRC_DSD1	1033	GU797254	clade_92	N	N
<i>Klebsiella</i> sp. SRC_DSD11	1030	GU797263	clade_92	N	N
<i>Klebsiella</i> sp. SRC_DSD12	1031	GU797264	clade_92	N	N
<i>Klebsiella</i> sp. SRC_DSD15	1032	GU797267	clade_92	N	N
<i>Klebsiella</i> sp. SRC_DSD2	1034	GU797253	clade_92	N	N
<i>Klebsiella</i> sp. SRC_DSD6	1035	GU797258	clade_92	N	N
<i>Klebsiella variicola</i>	1037	CP001891	clade_92	N	N
<i>Kluyvera ascorbata</i>	1038	NR_028677	clade_92	N	N
<i>Kluyvera cryocrescens</i>	1039	NR_028803	clade_92	N	N
<i>Leminorella grimontii</i>	1159	AJ233421	clade_92	N	N
<i>Leminorella richardii</i>	1160	HF558368	clade_92	N	N
<i>Pantoea agglomerans</i>	1409	AY335552	clade_92	N	N
<i>Pantoea ananatis</i>	1410	CP001875	clade_92	N	N
<i>Pantoea brenneri</i>	1411	EU216735	clade_92	N	N
<i>Pantoea citrea</i>	1412	EF688008	clade_92	N	N
<i>Pantoea conspicua</i>	1413	EU216737	clade_92	N	N
<i>Pantoea septica</i>	1414	EU216734	clade_92	N	N
<i>Pasteurella dagmatis</i>	1434	ACZR01000003	clade_92	N	N
<i>Pasteurella multocida</i>	1435	NC_002663	clade_92	N	N
<i>Plesiomonas shigelloides</i>	1469	X60418	clade_92	N	N
<i>Raoultella ornithinolytica</i>	1617	AB364958	clade_92	N	N
<i>Raoultella planticola</i>	1618	AF129443	clade_92	N	N
<i>Raoultella terrigena</i>	1619	NR_037085	clade_92	N	N
<i>Salmonella bongori</i>	1683	NR_041699	clade_92	N	Category -B
<i>Salmonella enterica</i>	1672	NC_011149	clade_92	N	Category

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
					-B
<i>Salmonella enterica</i>	1673	NC_011205	clade_92	N	Category -B
<i>Salmonella enterica</i>	1674	DQ344532	clade_92	N	Category -B
<i>Salmonella enterica</i>	1675	ABEH02000004	clade_92	N	Category -B
<i>Salmonella enterica</i>	1676	ABAK02000001	clade_92	N	Category -B
<i>Salmonella enterica</i>	1677	NC_011080	clade_92	N	Category -B
<i>Salmonella enterica</i>	1678	EU118094	clade_92	N	Category -B
<i>Salmonella enterica</i>	1679	NC_011094	clade_92	N	Category -B
<i>Salmonella enterica</i>	1680	AE014613	clade_92	N	Category -B
<i>Salmonella enterica</i>	1682	ABFH02000001	clade_92	N	Category -B
<i>Salmonella enterica</i>	1684	ABEM01000001	clade_92	N	Category -B
<i>Salmonella enterica</i>	1685	ABAM02000001	clade_92	N	Category -B
<i>Salmonella typhimurium</i>	1681	DQ344533	clade_92	N	Category -B
<i>Salmonella typhimurium</i>	1686	AF170176	clade_92	N	Category -B
<i>Serratia fonticola</i>	1718	NR_025339	clade_92	N	N
<i>Serratia liquefaciens</i>	1719	NR_042062	clade_92	N	N
<i>Serratia marcescens</i>	1720	GU826157	clade_92	N	N
<i>Serratia odorifera</i>	1721	ADBY01000001	clade_92	N	N
<i>Serratia proteamaculans</i>	1722	AAUN01000015	clade_92	N	N
<i>Shigella boydii</i>	1724	AAKA01000007	clade_92	N	Category -B
<i>Shigella dysenteriae</i>	1725	NC_007606	clade_92	N	Category -B
<i>Shigella flexneri</i>	1726	AE005674	clade_92	N	Category -B
<i>Shigella sonnei</i>	1727	NC_007384	clade_92	N	Category -B
<i>Tatumella ptyseos</i>	1916	NR_025342	clade_92	N	N
<i>Trabulsiella guamensis</i>	1925	AY373830	clade_92	N	N
<i>Yersinia aldovae</i>	2019	AJ871363	clade_92	N	OP
<i>Yersinia aleksiciae</i>	2020	AJ627597	clade_92	N	OP
<i>Yersinia bercovieri</i>	2021	AF366377	clade_92	N	OP
<i>Yersinia enterocolitica</i>	2022	FR729477	clade_92	N	Category -B
<i>Yersinia frederiksenii</i>	2023	AF366379	clade_92	N	OP
<i>Yersinia intermedia</i>	2024	AF366380	clade_92	N	OP
<i>Yersinia kristensenii</i>	2025	ACCA01000078	clade_92	N	OP
<i>Yersinia mollaretii</i>	2026	NR_027546	clade_92	N	OP
<i>Yersinia pestis</i>	2027	AE013632	clade_92	N	Category

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
					-A
<i>Yersinia pseudotuberculosis</i>	2028	NC_009708	clade_92	N	OP
<i>Yersinia rohdei</i>	2029	ACCD01000071	clade_92	N	OP
<i>Yokenella regensburgei</i>	2030	AB273739	clade_92	N	N
<i>Conchiformibius kuhniae</i>	669	NR_041821	clade_94	N	N
<i>Morococcus cerebrosus</i>	1267	JN175352	clade_94	N	N
<i>Neisseria bacilliformis</i>	1328	AFAY01000058	clade_94	N	N
<i>Neisseria cinerea</i>	1329	ACDY01000037	clade_94	N	N
<i>Neisseria flavescens</i>	1331	ACQV01000025	clade_94	N	N
<i>Neisseria gonorrhoeae</i>	1333	CP002440	clade_94	N	OP
<i>Neisseria lactamica</i>	1334	ACEQ01000095	clade_94	N	N
<i>Neisseria macacae</i>	1335	AFQE01000146	clade_94	N	N
<i>Neisseria meningitidis</i>	1336	NC_003112	clade_94	N	OP
<i>Neisseria mucosa</i>	1337	ACDX01000110	clade_94	N	N
<i>Neisseria pharyngis</i>	1338	AJ239281	clade_94	N	N
<i>Neisseria polysaccharea</i>	1339	ADBE01000137	clade_94	N	N
<i>Neisseria sicca</i>	1340	ACKO02000016	clade_94	N	N
<i>Neisseria</i> sp. KEM232	1341	GQ203291	clade_94	N	N
<i>Neisseria</i> sp. oral clone AP132	1344	AY005027	clade_94	N	N
<i>Neisseria</i> sp. oral strain B33KA	1346	AY005028	clade_94	N	N
<i>Neisseria</i> sp. oral taxon 014	1347	ADEA01000039	clade_94	N	N
<i>Neisseria</i> sp. TM10_1	1343	DQ279352	clade_94	N	N
<i>Neisseria subflava</i>	1348	ACEO01000067	clade_94	N	N
<i>Okadaella gastrococcus</i>	1365	HQ699465	clade_98	N	N
<i>Streptococcus agalactiae</i>	1785	AAJO01000130	clade_98	N	N
<i>Streptococcus alactolyticus</i>	1786	NR_041781	clade_98	N	N
<i>Streptococcus australis</i>	1788	AEQR01000024	clade_98	N	N
<i>Streptococcus bovis</i>	1789	AEEL01000030	clade_98	N	N
<i>Streptococcus canis</i>	1790	AJ413203	clade_98	N	N
<i>Streptococcus constellatus</i>	1791	AY277942	clade_98	N	N
<i>Streptococcus cristatus</i>	1792	AEVC01000028	clade_98	N	N
<i>Streptococcus dysgalactiae</i>	1794	AP010935	clade_98	N	N
<i>Streptococcus equi</i>	1795	CP001129	clade_98	N	N
<i>Streptococcus equinus</i>	1796	AEVB01000043	clade_98	N	N
<i>Streptococcus gallolyticus</i>	1797	FR824043	clade_98	N	N
<i>Streptococcus genomosp.</i> C1	1798	AY278629	clade_98	N	N
<i>Streptococcus genomosp.</i> C2	1799	AY278630	clade_98	N	N
<i>Streptococcus genomosp.</i> C3	1800	AY278631	clade_98	N	N
<i>Streptococcus genomosp.</i> C4	1801	AY278632	clade_98	N	N
<i>Streptococcus genomosp.</i> C5	1802	AY278633	clade_98	N	N
<i>Streptococcus genomosp.</i> C6	1803	AY278634	clade_98	N	N
<i>Streptococcus genomosp.</i> C7	1804	AY278635	clade_98	N	N
<i>Streptococcus genomosp.</i> C8	1805	AY278609	clade_98	N	N
<i>Streptococcus gordonii</i>	1806	NC_009785	clade_98	N	N
<i>Streptococcus infantarius</i>	1807	ABJK02000017	clade_98	N	N
<i>Streptococcus infantis</i>	1808	AFNN01000024	clade_98	N	N
<i>Streptococcus intermedius</i>	1809	NR_028736	clade_98	N	N
<i>Streptococcus lutetiensis</i>	1810	NR_037096	clade_98	N	N
<i>Streptococcus massiliensis</i>	1811	AY769997	clade_98	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
<i>Streptococcus mitis</i>	1813	AM157420	clade_98	N	N
<i>Streptococcus oligofermentans</i>	1815	AY099095	clade_98	N	N
<i>Streptococcus oralis</i>	1816	ADMV01000001	clade_98	N	N
<i>Streptococcus parasanguinis</i>	1817	AEKM01000012	clade_98	N	N
<i>Streptococcus pasteurianus</i>	1818	AP012054	clade_98	N	N
<i>Streptococcus peroris</i>	1819	AEVF01000016	clade_98	N	N
<i>Streptococcus pneumoniae</i>	1820	AE008537	clade_98	N	N
<i>Streptococcus porcinus</i>	1821	EF121439	clade_98	N	N
<i>Streptococcus pseudopneumoniae</i>	1822	FJ827123	clade_98	N	N
<i>Streptococcus pseudoporcinus</i>	1823	AENS01000003	clade_98	N	N
<i>Streptococcus pyogenes</i>	1824	AE006496	clade_98	N	OP
<i>Streptococcus ratti</i>	1825	X58304	clade_98	N	N
<i>Streptococcus sanguinis</i>	1827	NR_074974	clade_98	N	N
<i>Streptococcus sinensis</i>	1828	AF432857	clade_98	N	N
<i>Streptococcus</i> sp. 2_1_36FAA	1831	ACOI01000028	clade_98	N	N
<i>Streptococcus</i> sp. 2285_97	1830	AJ131965	clade_98	N	N
<i>Streptococcus</i> sp. ACS2	1834	HQ616360	clade_98	N	N
<i>Streptococcus</i> sp. AS20	1835	HQ616366	clade_98	N	N
<i>Streptococcus</i> sp. BS35a	1836	HQ616369	clade_98	N	N
<i>Streptococcus</i> sp. C150	1837	ACRI01000045	clade_98	N	N
<i>Streptococcus</i> sp. CM6	1838	HQ616372	clade_98	N	N
<i>Streptococcus</i> sp. ICM10	1840	HQ616389	clade_98	N	N
<i>Streptococcus</i> sp. ICM12	1841	HQ616390	clade_98	N	N
<i>Streptococcus</i> sp. ICM2	1842	HQ616386	clade_98	N	N
<i>Streptococcus</i> sp. ICM4	1844	HQ616387	clade_98	N	N
<i>Streptococcus</i> sp. ICM45	1843	HQ616394	clade_98	N	N
<i>Streptococcus</i> sp. M143	1845	ACRK01000025	clade_98	N	N
<i>Streptococcus</i> sp. M334	1846	ACRL01000052	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASB02	1849	AY923121	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASCA03	1850	DQ272504	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASCA04	1851	AY923116	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASCA09	1852	AY923119	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASCB04	1853	AY923123	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASCB06	1854	AY923124	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASCC04	1855	AY923127	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASCC05	1856	AY923128	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASCC12	1857	DQ272507	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASCD01	1858	AY923129	clade_98	N	N
<i>Streptococcus</i> sp. oral clone ASCD09	1859	AY923130	clade_98	N	N
<i>Streptococcus</i> sp. oral clone	1860	DQ272509	clade_98	N	N

OTU	SEQ ID Number	Public DB Accession	Clade	Spore Former	Pathogen Status
ASCD10					
Streptococcus sp. oral clone ASCE03	1861	AY923134	clade_98	N	N
Streptococcus sp. oral clone ASCE04	1862	AY953253	clade_98	N	N
Streptococcus sp. oral clone ASCE05	1863	DQ272510	clade_98	N	N
Streptococcus sp. oral clone ASCE06	1864	AY923135	clade_98	N	N
Streptococcus sp. oral clone ASCE09	1865	AY923136	clade_98	N	N
Streptococcus sp. oral clone ASCE10	1866	AY923137	clade_98	N	N
Streptococcus sp. oral clone ASCE12	1867	AY923138	clade_98	N	N
Streptococcus sp. oral clone ASCF05	1868	AY923140	clade_98	N	N
Streptococcus sp. oral clone ASCF07	1869	AY953255	clade_98	N	N
Streptococcus sp. oral clone ASCF09	1870	AY923142	clade_98	N	N
Streptococcus sp. oral clone ASCG04	1871	AY923145	clade_98	N	N
Streptococcus sp. oral clone BW009	1872	AY005042	clade_98	N	N
Streptococcus sp. oral clone CH016	1873	AY005044	clade_98	N	N
Streptococcus sp. oral clone GK051	1874	AY349413	clade_98	N	N
Streptococcus sp. oral clone GM006	1875	AY349414	clade_98	N	N
Streptococcus sp. oral clone P2PA_41 P2	1876	AY207051	clade_98	N	N
Streptococcus sp. oral clone P4PA_30 P4	1877	AY207064	clade_98	N	N
Streptococcus sp. oral taxon 071	1878	AEEP01000019	clade_98	N	N
Streptococcus sp. oral taxon G59	1879	GU432132	clade_98	N	N
Streptococcus sp. oral taxon G62	1880	GU432146	clade_98	N	N
Streptococcus sp. oral taxon G63	1881	GU432150	clade_98	N	N
Streptococcus suis	1882	FM252032	clade_98	N	N
Streptococcus thermophilus	1883	CP000419	clade_98	N	N
Streptococcus salivarius	1826	AGBV01000001	clade_98	N	N
Streptococcus uberis	1884	HQ391900	clade_98	N	N
Streptococcus urinalis	1885	DQ303194	clade_98	N	N
Streptococcus vestibularis	1886	AEKO01000008	clade_98	N	N
Streptococcus viridans	1887	AF076036	clade_98	N	N
Synergistetes bacterium oral clone 03 5 D05	1908	GU227192	clade_98	N	N

Table 2**Mouse studies with bacterial compositions**

	Mortality Score	D3 Weight Score	Morbidity >3 Score	Summary Score
Treatment 1	3	3.0	3.0	9
Treatment 2	0	0.6	0.0	1
Treatment 3	0	-0.5	0.0	-1
Treatment 4	0.5	2.4	0.6	3
Treatment 5	0	0.5	0.0	0
Treatment 6	1	2.0	0.6	4
Treatment 7	0.5	0.7	0.4	2
Treatment 8	0	0.6	0.0	1
Treatment 9	0.5	1.3	0.6	2
Treatment 10	0.5	1.5	0.6	3
Treatment 11	0.5	1.0	0.6	2
Treatment 12	0	1.3	0.0	1
Treatment 13	0.5	1.3	0.4	2
Treatment 14	0.5	1.2	0.6	2

Table 3A**Table 3A. Mouse studies with bacterial compositions**

	Mortality Score	D3 Weight Score	Morbidity >3 Score	Summary Score
Treatment 1	3	3.0	3.0	9
Treatment 2	0	0.0	0.0	0
Treatment 3	3	2.1	2.7	8
Treatment 4	1.5	1.1	1.1	4
Treatment 5	0	0.7	0.2	1
Treatment 6	0	1.2	0.0	1
Treatment 7	3	2.4	2.1	8
Treatment 8	0	0.8	0.6	1
Treatment 9	0	0.9	0.3	1
Treatment 10	1.5	2.5	2.7	7
Treatment 11	0	1.3	0.8	2
Treatment 12	0	0.1	0.0	0
Treatment 13	3	1.6	0.3	5
Treatment 14	0	0.4	2.3	3
Treatment 15	1.5	3.4	2.6	7

Table 3B**Table 3B. Mouse studies with bacterial compositions**

	Mortality Score	D3 Weight Score	Morbidity >3 Score	Summary Score
Treatment 1	3	3.0	3.0	9
Treatment 2	1.8	0.7	2.1	5
Treatment 3	0	0.0	0.0	0
Treatment 4	0	0.5	0.0	0
Treatment 5	0	0.7	0.0	1
Treatment 6	0.6	2.3	0.7	4
Treatment 7	0.6	1.7	0.6	3
Treatment 8	2.4	3.0	2.0	7
Treatment 9	0.6	1.4	0.6	3
Treatment 10	0	1.1	0.0	1
Treatment 11	0	1.7	0.6	2
Treatment 12	3	3.1	3.2	9

Table 4**Table 4: Species isolated from ethanol treated spore preparation preparation before (left) and after (right) CsCl gradient step**

Isolates	ethanol treated spore preparation	ethanol treated, gradient purified spore preparation
<i>Bacillus coagulans</i>	7	2
<i>Blautia luti</i>	1	1
<i>Blautia</i> sp	14	13
<i>Blautia wexlerae</i>	3	1
<i>Ruminococcus obeum</i>	4	2
<i>Clostridiales</i> sp	1	2
<i>Clostridium aerotolerans</i>	1	2
<i>Clostridium disporicum</i>	0	1
<i>Clostridium</i> sp	1	1
<i>Clostridium symbiosum</i>	0	1
<i>Dorea longicatena</i>	8	6
<i>Eubacterium cellulosolvens</i>	1	0
<i>Eubacterium ventriosum</i>	2	2
<i>Gemmiger formicilis</i>	0	1
<i>Robinsoniella peoriensis</i>	0	1
<i>Roseburia hominis</i>	3	6
<i>Roseburia intestinalis</i>	9	7
<i>Ruminococcus</i> sp	5	2
<i>Syntrophococcus sucromutans</i>	1	1
<i>Turicibacter sanguinis</i>	3	4
<i>Clostridiales</i> sp	7	9
<i>Clostridium bartlettii</i>	8	11
<i>Clostridium irregulare</i>	0	1

Clostridium sordellii	4	6
Lachnospiraceae sp	1	0

Table 5

Mortality and weight change in mice challenged with *C. difficile* with or without ethanol treated, spore preparation treatment.

Test article	mortality (n=10)	% weight change on Day 3
vehicle (negative control)	20%	-10.5%
Donor feces (positive control)	0	-0.1%
EtOH-treated spore preparation 1x	0	2.3%
EtOH-treated spore preparation 0.1x	0	2.4%
EtOH-treated spore preparation 0.01x	0	-3%
heat-treated spore preparation	0	0.1%

Table 6

Table 6 shows spore quantitation for ethanol treated spore preparations using spore CFU (SCFU) assay and DPA assay.

Preparation	SCFU / 30 capsules	DPA SEq / 30 capsules	Ratio SCFU / DPA
Preparation 1	4.0×10^5	6.8×10^7	5.9×10^{-3}
Preparation 2	2.1×10^7	9.2×10^8	0.023
Preparation 3	6.9×10^9	9.6×10^9	0.72

Table 7

DPA doses in Table 7 when normalized to 4×10^5 SCFU per dose

Preparation	SCFU / 30 capsules	DPA SEq / 30 capsules	Fraction of Preparation 1 Dose
Preparation 1	4.0×10^5	6.8×10^7	1.0
Preparation 2	4.0×10^5	1.8×10^7	0.26
Preparation 3	4.0×10^5	5.6×10^5	0.0082

Table 8

SPC1	SPC2	SPC3	OTU1	OTU2	OTU3	Results
SPC10325	SPC10415	SPC10567	Clostridium_b olteae	Blautia producta	Eubacterium_rectal e	++++
SPC10325	SPC10355	SPC10415	Clostridium_b olteae	Clostridium_sym biosum	Blautia producta	++++
SPC10325	SPC10355	SPC10567	Clostridium_b olteae	Clostridium_sym biosum	Eubacterium_rectal e	-
SPC10325	SPC10355	SPC10386	Clostridium_b olteae	Clostridium_sym biosum	Faecalibacterium_p rausnitzii	-
SPC10325	SPC10355	SPC10390	Clostridium_b olteae	Clostridium_sym biosum	Lachnospiraceae_b acterium_5_1_57F AA	
SPC10325	SPC10386	SPC10415	Clostridium_b olteae	Faecalibacterium prausnitzii	Blautia producta	++++
SPC10325	SPC10386	SPC10567	Clostridium_b olteae	Faecalibacterium prausnitzii	Eubacterium_rectal e	
SPC10325	SPC10386	SPC10390	Clostridium_b olteae	Faecalibacterium prausnitzii	Lachnospiraceae_b acterium_5_1_57F AA	++++
SPC10325	SPC10390	SPC10415	Clostridium_b olteae	Lachnospiraceae _bacterium_5_1_ 57FAA	Blautia producta	++++
SPC10325	SPC10390	SPC10567	Clostridium_b olteae	Lachnospiraceae _bacterium_5_1_ 57FAA	Eubacterium_rectal e	+
SPC10355	SPC10415	SPC10567	Clostridium_sy mbiosum	Blautia producta	Eubacterium_rectal e	++++
SPC10355	SPC10386	SPC10415	Clostridium_sy mbiosum	Faecalibacterium prausnitzii	Blautia producta	++++
SPC10355	SPC10386	SPC10567	Clostridium_sy mbiosum	Faecalibacterium prausnitzii	Eubacterium_rectal e	
SPC10355	SPC10386	SPC10390	Clostridium_sy mbiosum	Faecalibacterium prausnitzii	Lachnospiraceae_b acterium_5_1_57F AA	+
SPC10355	SPC10390	SPC10415	Clostridium_sy mbiosum	Lachnospiraceae _bacterium_5_1_ 57FAA	Blautia producta	++++
SPC10355	SPC10390	SPC10567	Clostridium_sy mbiosum	Lachnospiraceae _bacterium_5_1_ 57FAA	Eubacterium_rectal e	
SPC10097	SPC10415	SPC10567	Collinsella_aer ofaciens	Blautia producta	Eubacterium_rectal e	++++
SPC10097	SPC10325	SPC10415	Collinsella_aer ofaciens	Clostridium_bolte ae	Blautia producta	++++
SPC10097	SPC10325	SPC10355	Collinsella_aer ofaciens	Clostridium_bolte ae	Clostridium_symbio sum	++++
SPC10097	SPC10325	SPC10567	Collinsella_aer ofaciens	Clostridium_bolte ae	Eubacterium_rectal e	++++
SPC10097	SPC10325	SPC10386	Collinsella_aer ofaciens	Clostridium_bolte ae	Faecalibacterium_p rausnitzii	++++
SPC10097	SPC10325	SPC10390	Collinsella_aer ofaciens	Clostridium_bolte ae	Lachnospiraceae_b acterium_5_1_57F AA	++++
SPC10097	SPC10355	SPC10415	Collinsella_aer ofaciens	Clostridium_sym biosum	Blautia producta	++++
SPC10097	SPC10355	SPC10567	Collinsella_aer ofaciens	Clostridium_sym biosum	Eubacterium_rectal e	

SPC1	SPC2	SPC3	OTU1	OTU2	OTU3	Results
SPC10097	SPC10355	SPC10386	Collinsella_aerofaciens	Clostridium_symbiosum	Faecalibacterium_prausnitzii	
SPC10097	SPC10355	SPC10390	Collinsella_aerofaciens	Clostridium_symbiosum	Lachnospiraceae_bacterium_5_1_57F AA	+
SPC10097	SPC10304	SPC10415	Collinsella_aerofaciens	Coprococcus_comes	Blautia producta	++++
SPC10097	SPC10304	SPC10325	Collinsella_aerofaciens	Coprococcus_comes	Clostridium_bolteae	++++
SPC10097	SPC10304	SPC10355	Collinsella_aerofaciens	Coprococcus_comes	Clostridium_symbiosum	+++
SPC10097	SPC10304	SPC10567	Collinsella_aerofaciens	Coprococcus_comes	Eubacterium_rectale	+++
SPC10097	SPC10304	SPC10386	Collinsella_aerofaciens	Coprococcus_comes	Faecalibacterium_prausnitzii	++++
SPC10097	SPC10304	SPC10390	Collinsella_aerofaciens	Coprococcus_comes	Lachnospiraceae_bacterium_5_1_57F AA	+++
SPC10097	SPC10386	SPC10415	Collinsella_aerofaciens	Faecalibacterium_prausnitzii	Blautia producta	++++
SPC10097	SPC10386	SPC10567	Collinsella_aerofaciens	Faecalibacterium_prausnitzii	Eubacterium_rectale	+++
SPC10097	SPC10386	SPC10390	Collinsella_aerofaciens	Faecalibacterium_prausnitzii	Lachnospiraceae_bacterium_5_1_57F AA	+++
SPC10097	SPC10390	SPC10415	Collinsella_aerofaciens	Lachnospiraceae_bacterium_5_1_57FAA	Blautia producta	++++
SPC10097	SPC10390	SPC10567	Collinsella_aerofaciens	Lachnospiraceae_bacterium_5_1_57FAA	Eubacterium_rectale	++++
SPC10304	SPC10415	SPC10567	Coprococcus_comes	Blautia producta	Eubacterium_rectale	++++
SPC10304	SPC10325	SPC10415	Coprococcus_comes	Clostridium_bolteae	Blautia producta	++++
SPC10304	SPC10325	SPC10355	Coprococcus_comes	Clostridium_bolteae	Clostridium_symbiosum	
SPC10304	SPC10325	SPC10567	Coprococcus_comes	Clostridium_bolteae	Eubacterium_rectale	--
SPC10304	SPC10325	SPC10386	Coprococcus_comes	Clostridium_bolteae	Faecalibacterium_prausnitzii	+++
SPC10304	SPC10325	SPC10390	Coprococcus_comes	Clostridium_bolteae	Lachnospiraceae_bacterium_5_1_57F AA	+++
SPC10304	SPC10355	SPC10415	Coprococcus_comes	Clostridium_symbiosum	Blautia producta	++++
SPC10304	SPC10355	SPC10567	Coprococcus_comes	Clostridium_symbiosum	Eubacterium_rectale	---
SPC10304	SPC10355	SPC10386	Coprococcus_comes	Clostridium_symbiosum	Faecalibacterium_prausnitzii	
SPC10304	SPC10355	SPC10390	Coprococcus_comes	Clostridium_symbiosum	Lachnospiraceae_bacterium_5_1_57F AA	
SPC10304	SPC10386	SPC10415	Coprococcus_comes	Faecalibacterium_prausnitzii	Blautia producta	++++
SPC10304	SPC10386	SPC10567	Coprococcus_comes	Faecalibacterium_prausnitzii	Eubacterium_rectale	-
SPC10304	SPC10386	SPC10390	Coprococcus_comes	Faecalibacterium_prausnitzii	Lachnospiraceae_bacterium_5_1_57F	

SPC1	SPC2	SPC3	OTU1	OTU2	OTU3	Results
					AA	
SPC10304	SPC10390	SPC10415	Coprococcus_ comes	Lachnospiraceae_ bacterium_5_1_ 57FAA	Blautia producta	++++
SPC10304	SPC10390	SPC10567	Coprococcus_ comes	Lachnospiraceae_ bacterium_5_1_ 57FAA	Eubacterium_rectal e	
SPC10386	SPC10415	SPC10567	Faecalibacteri um_prausnitzii	Blautia producta	Eubacterium_rectal e	++++
SPC10386	SPC10390	SPC10415	Faecalibacteri um_prausnitzii	Lachnospiraceae_ bacterium_5_1_ 57FAA	Blautia producta	++++
SPC10386	SPC10390	SPC10567	Faecalibacteri um_prausnitzii	Lachnospiraceae_ bacterium_5_1_ 57FAA	Eubacterium_rectal e	
SPC10390	SPC10415	SPC10567	Lachnospirace ae_bacterium _5_1_57FAA	Blautia producta	Eubacterium_rectal e	++++

Table 9

SPC1	SPC2	OTU1	OTU2	Result
SPC10414	SPC10414	Alistipes_shahii	Alistipes_shahii	
SPC10211	SPC10414	Bacteroides_caccae	Alistipes_shahii	
SPC10213	SPC10414	Bacteroides_eggerthii	Alistipes_shahii	--
SPC10030	SPC10414	Bacteroides_ovatus	Alistipes_shahii	
SPC00006	SPC10414	Bacteroides_sp_1_1_6	Alistipes_shahii	++++
SPC00007	SPC10414	Bacteroides_sp_3_1_23	Alistipes_shahii	+
SPC10019	SPC10414	Bacteroides_sp_D20	Alistipes_shahii	-
SPC00005	SPC10414	Bacteroides_vulgatus	Alistipes_shahii	+++
SPC10081	SPC10414	Bacteroides_vulgatus	Alistipes_shahii	+
SPC10301	SPC10414	Bifidobacterium_adolescentis	Alistipes_shahii	++++
SPC10298	SPC10414	Bifidobacterium_pseudocatenulatum	Alistipes_shahii	
SPC00021	SPC10414	Blautia_producta	Alistipes_shahii	++++
SPC10403	SPC10414	Blautia_schinkii	Alistipes_shahii	
SPC10243	SPC10414	Clostridium_hathewayi	Alistipes_shahii	++++
SPC00026	SPC10414	Clostridium_nexile	Alistipes_shahii	
SPC00027	SPC10414	Clostridium_sp_HGF2	Alistipes_shahii	
SPC10355	SPC10414	Clostridium_symbiosum	Alistipes_shahii	
SPC10097	SPC10414	Collinsella_aerofaciens	Alistipes_shahii	++++
SPC00009	SPC10414	Coprobacillus_sp_D7	Alistipes_shahii	++++
SPC00080	SPC10414	Coprococcus_catus	Alistipes_shahii	-
SPC10304	SPC10414	Coprococcus_comes	Alistipes_shahii	
SPC00018	SPC10414	Dorea_formicigenerans	Alistipes_shahii	----
SPC00057	SPC10414	Dorea_longicatena	Alistipes_shahii	++++
SPC00008	SPC10414	Enterococcus_faecalis	Alistipes_shahii	++++
SPC10001	SPC10414	Erysipelotrichaceae_bacterium	Alistipes_shahii	---
SPC00001	SPC10414	Escherichia_coli	Alistipes_shahii	++++
SPC10110	SPC10414	Escherichia_coli	Alistipes_shahii	++++
SPC00022	SPC10414	Eubacterium_eligens	Alistipes_shahii	--
SPC10363	SPC10414	Eubacterium_rectale	Alistipes_shahii	
SPC00054	SPC10414	Faecalibacterium_prausnitzii	Alistipes_shahii	
SPC10386	SPC10414	Faecalibacterium_prausnitzii	Alistipes_shahii	+
SPC10390	SPC10414	Lachnospiraceae_bacterium_5_1_57FAA	Alistipes_shahii	
SPC00056	SPC10414	Odoribacter_splanchnicus	Alistipes_shahii	
SPC10388	SPC10414	Odoribacter_splanchnicus	Alistipes_shahii	
SPC10048	SPC10414	Parabacteroides_merdae	Alistipes_shahii	

SPC1	SPC2	OTU1	OTU2	Result
SPC00061	SPC10414	Roseburia_intestinalis	Alistipes_shahii	-
SPC10197	SPC10414	Ruminococcus_obeum	Alistipes_shahii	
SPC10233	SPC10414	Ruminococcus_torques	Alistipes_shahii	
SPC00015	SPC10414	Streptococcus_thermophilus	Alistipes_shahii	
SPC10211	SPC10211	Bacteroides_caccae	Bacteroides_caccae	++++
SPC10030	SPC10211	Bacteroides_ovatus	Bacteroides_caccae	
SPC00006	SPC10211	Bacteroides_sp_1_1_6	Bacteroides_caccae	++++
SPC00007	SPC10211	Bacteroides_sp_3_1_23	Bacteroides_caccae	+++
SPC10019	SPC10211	Bacteroides_sp_D20	Bacteroides_caccae	+++
SPC00005	SPC10211	Bacteroides_vulgatus	Bacteroides_caccae	++++
SPC10081	SPC10211	Bacteroides_vulgatus	Bacteroides_caccae	+
SPC00021	SPC10211	Blautia_producta	Bacteroides_caccae	++++
SPC00026	SPC10211	Clostridium_nexile	Bacteroides_caccae	
SPC00027	SPC10211	Clostridium_sp_HGF2	Bacteroides_caccae	
SPC10097	SPC10211	Collinsella_aerofaciens	Bacteroides_caccae	++++
SPC00009	SPC10211	Coprobacillus_sp_D7	Bacteroides_caccae	+++
SPC00080	SPC10211	Coprococcus_catus	Bacteroides_caccae	++++
SPC00018	SPC10211	Dorea_formicigenerans	Bacteroides_caccae	+++
SPC00057	SPC10211	Dorea_longicatena	Bacteroides_caccae	
SPC00008	SPC10211	Enterococcus_faecalis	Bacteroides_caccae	++++
SPC10001	SPC10211	Erysipelotrichaceae_bacterium	Bacteroides_caccae	++
SPC00001	SPC10211	Escherichia_coli	Bacteroides_caccae	++++
SPC10110	SPC10211	Escherichia_coli	Bacteroides_caccae	++++
SPC00022	SPC10211	Eubacterium_eligens	Bacteroides_caccae	++
SPC00054	SPC10211	Faecalibacterium_prausnitzii	Bacteroides_caccae	-
SPC00056	SPC10211	Odoribacter_splanchnicus	Bacteroides_caccae	
SPC10048	SPC10211	Parabacteroides_merdae	Bacteroides_caccae	+
SPC00061	SPC10211	Roseburia_intestinalis	Bacteroides_caccae	+
SPC10197	SPC10211	Ruminococcus_obeum	Bacteroides_caccae	++++
SPC00015	SPC10211	Streptococcus_thermophilus	Bacteroides_caccae	++
SPC10211	SPC10213	Bacteroides_caccae	Bacteroides_eggerthii	++++
SPC10213	SPC10213	Bacteroides_eggerthii	Bacteroides_eggerthii	++++
SPC10030	SPC10213	Bacteroides_ovatus	Bacteroides_eggerthii	
SPC00006	SPC10213	Bacteroides_sp_1_1_6	Bacteroides_eggerthii	+++
SPC00007	SPC10213	Bacteroides_sp_3_1_23	Bacteroides_eggerthii	++
SPC10019	SPC10213	Bacteroides_sp_D20	Bacteroides_eggerthii	
SPC00005	SPC10213	Bacteroides_vulgatus	Bacteroides_eggerthii	++++
SPC10081	SPC10213	Bacteroides_vulgatus	Bacteroides_eggerthii	+

SPC1	SPC2	OTU1	OTU2	Result
SPC00021	SPC10213	Blautia_producta	Bacteroides_eggerthii	++++
SPC00026	SPC10213	Clostridium_nexile	Bacteroides_eggerthii	
SPC00027	SPC10213	Clostridium_sp_HGF2	Bacteroides_eggerthii	-
SPC10097	SPC10213	Collinsella_aerofaciens	Bacteroides_eggerthii	++++
SPC00009	SPC10213	Coprobaillus_sp_D7	Bacteroides_eggerthii	
SPC00080	SPC10213	Coprococcus_catus	Bacteroides_eggerthii	+
SPC00018	SPC10213	Dorea_formicigenerans	Bacteroides_eggerthii	
SPC00057	SPC10213	Dorea_longicatena	Bacteroides_eggerthii	-
SPC00008	SPC10213	Enterococcus_faecalis	Bacteroides_eggerthii	++++
SPC10001	SPC10213	Erysipelotrichaceae_bacterium	Bacteroides_eggerthii	
SPC00001	SPC10213	Escherichia_coli	Bacteroides_eggerthii	++++
SPC10110	SPC10213	Escherichia_coli	Bacteroides_eggerthii	++++
SPC00022	SPC10213	Eubacterium_eligens	Bacteroides_eggerthii	
SPC00054	SPC10213	Faecalibacterium_prausnitzii	Bacteroides_eggerthii	
SPC00056	SPC10213	Odoribacter_splanchnicus	Bacteroides_eggerthii	
SPC10048	SPC10213	Parabacteroides_merdae	Bacteroides_eggerthii	
SPC00061	SPC10213	Roseburia_intestinalis	Bacteroides_eggerthii	
SPC10197	SPC10213	Ruminococcus_obeum	Bacteroides_eggerthii	++++
SPC00015	SPC10213	Streptococcus_thermophilus	Bacteroides_eggerthii	
SPC10030	SPC10030	Bacteroides_ovatus	Bacteroides_ovatus	+++
SPC00006	SPC10030	Bacteroides_sp_1_1_6	Bacteroides_ovatus	++++
SPC00007	SPC10030	Bacteroides_sp_3_1_23	Bacteroides_ovatus	
SPC10019	SPC10030	Bacteroides_sp_D20	Bacteroides_ovatus	-
SPC00005	SPC10030	Bacteroides_vulgatus	Bacteroides_ovatus	+
SPC00021	SPC10030	Blautia_producta	Bacteroides_ovatus	++++
SPC00026	SPC10030	Clostridium_nexile	Bacteroides_ovatus	
SPC00027	SPC10030	Clostridium_sp_HGF2	Bacteroides_ovatus	
SPC00009	SPC10030	Coprobaillus_sp_D7	Bacteroides_ovatus	
SPC00080	SPC10030	Coprococcus_catus	Bacteroides_ovatus	
SPC00018	SPC10030	Dorea_formicigenerans	Bacteroides_ovatus	
SPC00057	SPC10030	Dorea_longicatena	Bacteroides_ovatus	-
SPC00008	SPC10030	Enterococcus_faecalis	Bacteroides_ovatus	++++
SPC10001	SPC10030	Erysipelotrichaceae_bacterium	Bacteroides_ovatus	
SPC00001	SPC10030	Escherichia_coli	Bacteroides_ovatus	++++
SPC00022	SPC10030	Eubacterium_eligens	Bacteroides_ovatus	-
SPC00054	SPC10030	Faecalibacterium_prausnitzii	Bacteroides_ovatus	
SPC00056	SPC10030	Odoribacter_splanchnicus	Bacteroides_ovatus	
SPC00061	SPC10030	Roseburia_intestinalis	Bacteroides_ovatus	

SPC1	SPC2	OTU1	OTU2	Result
SPC00015	SPC10030	Streptococcus_thermophilus	Bacteroides_ovatus	++
SPC00006	SPC00006	Bacteroides_sp_1_1_6	Bacteroides_sp_1_1_6	++++
SPC00005	SPC00006	Bacteroides_vulgatus	Bacteroides_sp_1_1_6	++++
SPC00001	SPC00006	Escherichia_coli	Bacteroides_sp_1_1_6	++++
SPC00006	SPC00007	Bacteroides_sp_1_1_6	Bacteroides_sp_3_1_2_3	++++
SPC00007	SPC00007	Bacteroides_sp_3_1_23	Bacteroides_sp_3_1_2_3	
SPC00005	SPC00007	Bacteroides_vulgatus	Bacteroides_sp_3_1_2_3	+++
SPC00001	SPC00007	Escherichia_coli	Bacteroides_sp_3_1_2_3	++++
SPC00006	SPC10019	Bacteroides_sp_1_1_6	Bacteroides_sp_D20	++++
SPC00007	SPC10019	Bacteroides_sp_3_1_23	Bacteroides_sp_D20	++++
SPC10019	SPC10019	Bacteroides_sp_D20	Bacteroides_sp_D20	
SPC00005	SPC10019	Bacteroides_vulgatus	Bacteroides_sp_D20	+
SPC00021	SPC10019	Blautia_producta	Bacteroides_sp_D20	++++
SPC00026	SPC10019	Clostridium_nexile	Bacteroides_sp_D20	-
SPC00027	SPC10019	Clostridium_sp_HGF2	Bacteroides_sp_D20	
SPC00009	SPC10019	Coprobacillus_sp_D7	Bacteroides_sp_D20	
SPC00080	SPC10019	Coprococcus_catus	Bacteroides_sp_D20	
SPC00018	SPC10019	Dorea_formicigenerans	Bacteroides_sp_D20	-
SPC00057	SPC10019	Dorea_longicatena	Bacteroides_sp_D20	
SPC00008	SPC10019	Enterococcus_faecalis	Bacteroides_sp_D20	++++
SPC10001	SPC10019	Erysipelotrichaceae_bacterium	Bacteroides_sp_D20	
SPC00001	SPC10019	Escherichia_coli	Bacteroides_sp_D20	++++
SPC00022	SPC10019	Eubacterium_eligens	Bacteroides_sp_D20	-
SPC00054	SPC10019	Faecalibacterium_prausnitzii	Bacteroides_sp_D20	
SPC00056	SPC10019	Odoribacter_splanchnicus	Bacteroides_sp_D20	
SPC00061	SPC10019	Roseburia_intestinalis	Bacteroides_sp_D20	-
SPC00015	SPC10019	Streptococcus_thermophilus	Bacteroides_sp_D20	+
SPC10030	SPC10081	Bacteroides_ovatus	Bacteroides_vulgatus	
SPC00006	SPC10081	Bacteroides_sp_1_1_6	Bacteroides_vulgatus	
SPC00007	SPC10081	Bacteroides_sp_3_1_23	Bacteroides_vulgatus	-
SPC10019	SPC10081	Bacteroides_sp_D20	Bacteroides_vulgatus	
SPC00005	SPC00005	Bacteroides_vulgatus	Bacteroides_vulgatus	+
SPC00005	SPC10081	Bacteroides_vulgatus	Bacteroides_vulgatus	++
SPC10081	SPC10081	Bacteroides_vulgatus	Bacteroides_vulgatus	
SPC00021	SPC10081	Blautia_producta	Bacteroides_vulgatus	++++
SPC00026	SPC10081	Clostridium_nexile	Bacteroides_vulgatus	
SPC00027	SPC10081	Clostridium_sp_HGF2	Bacteroides_vulgatus	+++

SPC1	SPC2	OTU1	OTU2	Result
SPC00009	SPC10081	Coprobacillus_sp_D7	Bacteroides_vulgatus	-
SPC00080	SPC10081	Coprococcus_catus	Bacteroides_vulgatus	++
SPC00018	SPC10081	Dorea_formicigenerans	Bacteroides_vulgatus	
SPC00057	SPC10081	Dorea_longicatena	Bacteroides_vulgatus	
SPC00008	SPC10081	Enterococcus_faecalis	Bacteroides_vulgatus	++++
SPC10001	SPC10081	Erysipelotrichaceae_bacterium	Bacteroides_vulgatus	
SPC00001	SPC00005	Escherichia_coli	Bacteroides_vulgatus	++++
SPC00001	SPC10081	Escherichia_coli	Bacteroides_vulgatus	++++
SPC00022	SPC10081	Eubacterium_eligens	Bacteroides_vulgatus	
SPC00054	SPC10081	Faecalibacterium_prausnitzii	Bacteroides_vulgatus	
SPC00056	SPC10081	Odoribacter_splanchnicus	Bacteroides_vulgatus	
SPC10048	SPC10081	Parabacteroides_merdae	Bacteroides_vulgatus	+
SPC00061	SPC10081	Roseburia_intestinalis	Bacteroides_vulgatus	
SPC00015	SPC10081	Streptococcus_thermophilus	Bacteroides_vulgatus	--
SPC10211	SPC10301	Bacteroides_caccae	Bifidobacterium_adolescentis	++++
SPC10213	SPC10301	Bacteroides_eggerthii	Bifidobacterium_adolescentis	++++
SPC10030	SPC10301	Bacteroides_ovatus	Bifidobacterium_adolescentis	++++
SPC00006	SPC10301	Bacteroides_sp_1_1_6	Bifidobacterium_adolescentis	++++
SPC00007	SPC10301	Bacteroides_sp_3_1_23	Bifidobacterium_adolescentis	++++
SPC10019	SPC10301	Bacteroides_sp_D20	Bifidobacterium_adolescentis	++++
SPC00005	SPC10301	Bacteroides_vulgatus	Bifidobacterium_adolescentis	++++
SPC10081	SPC10301	Bacteroides_vulgatus	Bifidobacterium_adolescentis	++++
SPC10301	SPC10301	Bifidobacterium_adolescentis	Bifidobacterium_adolescentis	++++
SPC10298	SPC10301	Bifidobacterium_pseudocatenulatum	Bifidobacterium_adolescentis	++++
SPC00021	SPC10301	Blautia_producta	Bifidobacterium_adolescentis	++++
SPC10243	SPC10301	Clostridium_hathewayi	Bifidobacterium_adolescentis	++++
SPC00026	SPC10301	Clostridium_nexile	Bifidobacterium_adolescentis	++++
SPC00027	SPC10301	Clostridium_sp_HGF2	Bifidobacterium_adolescentis	++++
SPC10097	SPC10301	Collinsella_aerofaciens	Bifidobacterium_adolescentis	++++
SPC00009	SPC10301	Coprobacillus_sp_D7	Bifidobacterium_adolescentis	++++
SPC00080	SPC10301	Coprococcus_catus	Bifidobacterium_adolescentis	
SPC00018	SPC10301	Dorea_formicigenerans	Bifidobacterium_adolescentis	++++

SPC1	SPC2	OTU1	OTU2	Result
SPC00057	SPC10301	Dorea_longicatena	Bifidobacterium_adolescentis	++++
SPC00008	SPC10301	Enterococcus_faecalis	Bifidobacterium_adolescentis	++++
SPC10001	SPC10301	Erysipelotrichaceae_bacterium	Bifidobacterium_adolescentis	++++
SPC00001	SPC10301	Escherichia_coli	Bifidobacterium_adolescentis	++++
SPC10110	SPC10301	Escherichia_coli	Bifidobacterium_adolescentis	++++
SPC00022	SPC10301	Eubacterium_eligens	Bifidobacterium_adolescentis	++++
SPC00054	SPC10301	Faecalibacterium_prausnitzii	Bifidobacterium_adolescentis	+
SPC00056	SPC10301	Odoribacter_splanchnicus	Bifidobacterium_adolescentis	+++
SPC10048	SPC10301	Parabacteroides_merdae	Bifidobacterium_adolescentis	++++
SPC00061	SPC10301	Roseburia_intestinalis	Bifidobacterium_adolescentis	+++
SPC10197	SPC10301	Ruminococcus_obeum	Bifidobacterium_adolescentis	++++
SPC10233	SPC10301	Ruminococcus_torques	Bifidobacterium_adolescentis	++++
SPC00015	SPC10301	Streptococcus_thermophilus	Bifidobacterium_adolescentis	++++
SPC10211	SPC10298	Bacteroides_caccae	Bifidobacterium_pseudocatenulatum	++++
SPC10213	SPC10298	Bacteroides_eggerthii	Bifidobacterium_pseudocatenulatum	++++
SPC10030	SPC10298	Bacteroides_ovatus	Bifidobacterium_pseudocatenulatum	++++
SPC00006	SPC10298	Bacteroides_sp_1_1_6	Bifidobacterium_pseudocatenulatum	++++
SPC00007	SPC10298	Bacteroides_sp_3_1_23	Bifidobacterium_pseudocatenulatum	++++
SPC10019	SPC10298	Bacteroides_sp_D20	Bifidobacterium_pseudocatenulatum	--
SPC00005	SPC10298	Bacteroides_vulgatus	Bifidobacterium_pseudocatenulatum	++++
SPC10081	SPC10298	Bacteroides_vulgatus	Bifidobacterium_pseudocatenulatum	++++
SPC10298	SPC10298	Bifidobacterium_pseudocatenulatum	Bifidobacterium_pseudocatenulatum	++++
SPC00021	SPC10298	Blautia_producta	Bifidobacterium_pseudocatenulatum	+
SPC10243	SPC10298	Clostridium_hathewayi	Bifidobacterium_pseudocatenulatum	++++
SPC00026	SPC10298	Clostridium_nexile	Bifidobacterium_pseudocatenulatum	++++
SPC00027	SPC10298	Clostridium_sp_HGF2	Bifidobacterium_pseudocatenulatum	+++
SPC10097	SPC10298	Collinsella_aerofaciens	Bifidobacterium_pseudocatenulatum	++++
SPC00009	SPC10298	Coprobacillus_sp_D7	Bifidobacterium_pseudocatenulatum	+++
SPC00080	SPC10298	Coprococcus_catus	Bifidobacterium_pseudocatenulatum	

SPC1	SPC2	OTU1	OTU2	Result
SPC00018	SPC10298	Dorea_formicigenerans	Bifidobacterium_pseudocatenulatum	+++
SPC00057	SPC10298	Dorea_longicatena	Bifidobacterium_pseudocatenulatum	++++
SPC00008	SPC10298	Enterococcus_faecalis	Bifidobacterium_pseudocatenulatum	++++
SPC10001	SPC10298	Erysipelotrichaceae_bacterium	Bifidobacterium_pseudocatenulatum	
SPC00001	SPC10298	Escherichia_coli	Bifidobacterium_pseudocatenulatum	++++
SPC10110	SPC10298	Escherichia_coli	Bifidobacterium_pseudocatenulatum	++++
SPC00022	SPC10298	Eubacterium_eligens	Bifidobacterium_pseudocatenulatum	++++
SPC00054	SPC10298	Faecalibacterium_prausnitzii	Bifidobacterium_pseudocatenulatum	++
SPC00056	SPC10298	Odoribacter_splanchnicus	Bifidobacterium_pseudocatenulatum	+
SPC10048	SPC10298	Parabacteroides_merdae	Bifidobacterium_pseudocatenulatum	++++
SPC00061	SPC10298	Roseburia_intestinalis	Bifidobacterium_pseudocatenulatum	+++
SPC10197	SPC10298	Ruminococcus_obeum	Bifidobacterium_pseudocatenulatum	++++
SPC10233	SPC10298	Ruminococcus_torques	Bifidobacterium_pseudocatenulatum	++++
SPC00015	SPC10298	Streptococcus_thermophilus	Bifidobacterium_pseudocatenulatum	++++
SPC10414	SPC10415	Alistipes_shahii	Blautia_producta	
SPC10211	SPC10415	Bacteroides_caccae	Blautia_producta	+
SPC10213	SPC10415	Bacteroides_eggerthii	Blautia_producta	
SPC10030	SPC10415	Bacteroides_ovatus	Blautia_producta	-
SPC00006	SPC00021	Bacteroides_sp_1_1_6	Blautia_producta	++++
SPC00006	SPC10415	Bacteroides_sp_1_1_6	Blautia_producta	++++
SPC00007	SPC00021	Bacteroides_sp_3_1_23	Blautia_producta	++++
SPC00007	SPC10415	Bacteroides_sp_3_1_23	Blautia_producta	++
SPC10019	SPC10415	Bacteroides_sp_D20	Blautia_producta	
SPC00005	SPC00021	Bacteroides_vulgatus	Blautia_producta	++++
SPC00005	SPC10415	Bacteroides_vulgatus	Blautia_producta	++++
SPC10081	SPC10415	Bacteroides_vulgatus	Blautia_producta	++++
SPC10301	SPC10415	Bifidobacterium_adolescentis	Blautia_producta	++++
SPC10298	SPC10415	Bifidobacterium_pseudocatenulatum	Blautia_producta	
SPC00021	SPC00021	Blautia_producta	Blautia_producta	++++
SPC00021	SPC10415	Blautia_producta	Blautia_producta	++++
SPC10415	SPC10415	Blautia_producta	Blautia_producta	+
SPC10415	SPC10415	Blautia_producta	Blautia_producta	++++
SPC10403	SPC10415	Blautia_schinkii	Blautia_producta	

SPC1	SPC2	OTU1	OTU2	Result
SPC10256	SPC10415	Clostridium butyricum	Blautia_producta	++++
SPC10358	SPC10415	Clostridium orbiscindens	Blautia_producta	++++
SPC10325	SPC10415	Clostridium bolteae	Blautia_producta	++++
SPC10167	SPC10415	Clostridium disporicum	Blautia_producta	++++
SPC10243	SPC10415	Clostridium hathewayi	Blautia_producta	+++
SPC10313	SPC10415	Clostridium hylemonae	Blautia_producta	++++
SPC10202	SPC10415	Clostridium innocuum	Blautia_producta	++++
SPC10238	SPC10415	Clostridium mayombeii	Blautia_producta	++++
SPC00026	SPC10415	Clostridium nexile	Blautia_producta	-
SPC00027	SPC10415	Clostridium_sp_HGF2	Blautia_producta	
SPC10355	SPC10415	Clostridium symbiosum	Blautia_producta	
SPC10355	SPC10415	Clostridium symbiosum	Blautia_producta	++++
SPC10155	SPC10415	Clostridium tertium	Blautia_producta	++++
SPC10097	SPC10415	Collinsella aerofaciens	Blautia_producta	++++
SPC10097	SPC10415	Collinsella aerofaciens	Blautia_producta	++++
SPC00009	SPC00021	Coprobacillus_sp_D7	Blautia_producta	++++
SPC00009	SPC10415	Coprobacillus_sp_D7	Blautia_producta	++++
SPC00080	SPC10415	Coprococcus catus	Blautia_producta	----
SPC10304	SPC10415	Coprococcus comes	Blautia_producta	
SPC10304	SPC10415	Coprococcus comes	Blautia_producta	++++
SPC00018	SPC00021	Dorea formicigenerans	Blautia_producta	++++
SPC00018	SPC10415	Dorea formicigenerans	Blautia_producta	--
SPC00057	SPC10415	Dorea longicatena	Blautia_producta	+++
SPC00008	SPC00021	Enterococcus faecalis	Blautia_producta	++++
SPC00008	SPC10415	Enterococcus faecalis	Blautia_producta	++++
SPC10001	SPC10415	Erysipelotrichaceae_bacterium	Blautia_producta	---
SPC00001	SPC00021	Escherichia coli	Blautia_producta	++++
SPC00001	SPC10415	Escherichia coli	Blautia_producta	++++
SPC10110	SPC10415	Escherichia coli	Blautia_producta	++++
SPC00022	SPC10415	Eubacterium eligens	Blautia_producta	---
SPC10363	SPC10415	Eubacterium rectale	Blautia_producta	+
SPC00054	SPC10415	Faecalibacterium prausnitzii	Blautia_producta	
SPC10386	SPC10415	Faecalibacterium prausnitzii	Blautia_producta	+
SPC10386	SPC10415	Faecalibacterium prausnitzii	Blautia_producta	++++
SPC10390	SPC10415	Lachnospiraceae_bacterium_5_1_57FAA	Blautia_producta	+
SPC10390	SPC10415	Lachnospiraceae_bacterium_5_1_57FAA	Blautia_producta	++++
SPC00056	SPC10415	Odoribacter_splanchnicus	Blautia_producta	-

SPC1	SPC2	OTU1	OTU2	Result
SPC10388	SPC10415	Odoribacter_splanchnicus	Blautia_producta	+
SPC10048	SPC10415	Parabacteroides_merdae	Blautia_producta	+++
SPC00061	SPC10415	Roseburia_intestinalis	Blautia_producta	--
SPC10468	SPC10415	Ruminococcus_gnavus	Blautia_producta	++++
SPC10197	SPC10415	Ruminococcus_obeum	Blautia_producta	
SPC10233	SPC10415	Ruminococcus_torques	Blautia_producta	
SPC00015	SPC00021	Streptococcus_thermophilus	Blautia_producta	++++
SPC00015	SPC10415	Streptococcus_thermophilus	Blautia_producta	
SPC10211	SPC10403	Bacteroides_caccae	Blautia_schinkii	
SPC10213	SPC10403	Bacteroides_eggerthii	Blautia_schinkii	--
SPC10030	SPC10403	Bacteroides_ovatus	Blautia_schinkii	-
SPC00006	SPC10403	Bacteroides_sp_1_1_6	Blautia_schinkii	+++
SPC00007	SPC10403	Bacteroides_sp_3_1_23	Blautia_schinkii	+
SPC10019	SPC10403	Bacteroides_sp_D20	Blautia_schinkii	--
SPC00005	SPC10403	Bacteroides_vulgatus	Blautia_schinkii	++
SPC10081	SPC10403	Bacteroides_vulgatus	Blautia_schinkii	
SPC10301	SPC10403	Bifidobacterium_adolescentis	Blautia_schinkii	++
SPC10298	SPC10403	Bifidobacterium_pseudocatenulatum	Blautia_schinkii	-
SPC00021	SPC10403	Blautia_producta	Blautia_schinkii	++++
SPC10403	SPC10403	Blautia_schinkii	Blautia_schinkii	
SPC10243	SPC10403	Clostridium_hathewayi	Blautia_schinkii	++++
SPC00026	SPC10403	Clostridium_nexile	Blautia_schinkii	--
SPC00027	SPC10403	Clostridium_sp_HGF2	Blautia_schinkii	
SPC10355	SPC10403	Clostridium_symbiosum	Blautia_schinkii	
SPC10097	SPC10403	Collinsella_aerofaciens	Blautia_schinkii	++++
SPC00009	SPC10403	Coprobacillus_sp_D7	Blautia_schinkii	++++
SPC00080	SPC10403	Coprococcus_catus	Blautia_schinkii	---
SPC10304	SPC10403	Coprococcus_comes	Blautia_schinkii	+
SPC00018	SPC10403	Dorea_formicigenerans	Blautia_schinkii	
SPC00057	SPC10403	Dorea_longicatena	Blautia_schinkii	+++
SPC00008	SPC10403	Enterococcus_faecalis	Blautia_schinkii	++++
SPC10001	SPC10403	Erysipelotrichaceae_bacterium	Blautia_schinkii	---
SPC00001	SPC10403	Escherichia_coli	Blautia_schinkii	++++
SPC10110	SPC10403	Escherichia_coli	Blautia_schinkii	++++
SPC00022	SPC10403	Eubacterium_eligens	Blautia_schinkii	-
SPC10363	SPC10403	Eubacterium_rectale	Blautia_schinkii	+
SPC00054	SPC10403	Faecalibacterium_prausnitzii	Blautia_schinkii	
SPC10386	SPC10403	Faecalibacterium_prausnitzii	Blautia_schinkii	

SPC1	SPC2	OTU1	OTU2	Result
SPC10390	SPC10403	Lachnospiraceae_bacterium_5_1_57FAA	Blautia_schinkii	
SPC00056	SPC10403	Odoribacter_splanchnicus	Blautia_schinkii	-
SPC10388	SPC10403	Odoribacter_splanchnicus	Blautia_schinkii	
SPC10048	SPC10403	Parabacteroides_merdae	Blautia_schinkii	
SPC00061	SPC10403	Roseburia_intestinalis	Blautia_schinkii	-
SPC10197	SPC10403	Ruminococcus_obeum	Blautia_schinkii	
SPC10233	SPC10403	Ruminococcus_torques	Blautia_schinkii	
SPC00015	SPC10403	Streptococcus_thermophilus	Blautia_schinkii	
SPC10256	SPC10256	Clostridium_butyricum	Clostridium_butyricum	++++
SPC10167	SPC10256	Clostridium_disporicum	Clostridium_butyricum	++++
SPC10202	SPC10256	Clostridium_innocuum	Clostridium_butyricum	++++
SPC10238	SPC10256	Clostridium_mayombeii	Clostridium_butyricum	++++
SPC10155	SPC10256	Clostridium_tertium	Clostridium_butyricum	++++
SPC10097	SPC10256	Collinsella_aerofaciens	Clostridium_butyricum	++++
SPC10304	SPC10256	Coproccoccus_comes	Clostridium_butyricum	++++
SPC10256	SPC10358	Clostridium_butyricum	Clostridium_orbiscindens	++++
SPC10358	SPC10358	Clostridium_orbiscindens	Clostridium_orbiscindens	+
SPC10325	SPC10358	Clostridium_bolteae	Clostridium_orbiscindens	++++
SPC10167	SPC10358	Clostridium_disporicum	Clostridium_orbiscindens	++++
SPC10313	SPC10358	Clostridium_hylemonae	Clostridium_orbiscindens	
SPC10202	SPC10358	Clostridium_innocuum	Clostridium_orbiscindens	++++
SPC10238	SPC10358	Clostridium_mayombeii	Clostridium_orbiscindens	++++
SPC10355	SPC10358	Clostridium_symbiosum	Clostridium_orbiscindens	++++
SPC10155	SPC10358	Clostridium_tertium	Clostridium_orbiscindens	++++
SPC10097	SPC10358	Collinsella_aerofaciens	Clostridium_orbiscindens	++++
SPC10304	SPC10358	Coproccoccus_comes	Clostridium_orbiscindens	++++
SPC10386	SPC10358	Faecalibacterium_prausnitzii	Clostridium_orbiscindens	
SPC10256	SPC10325	Clostridium_butyricum	Clostridium_bolteae	++++
SPC10325	SPC10325	Clostridium_bolteae	Clostridium_bolteae	++++
SPC10167	SPC10325	Clostridium_disporicum	Clostridium_bolteae	++++
SPC10313	SPC10325	Clostridium_hylemonae	Clostridium_bolteae	
SPC10202	SPC10325	Clostridium_innocuum	Clostridium_bolteae	++++
SPC10238	SPC10325	Clostridium_mayombeii	Clostridium_bolteae	++++
SPC10355	SPC10325	Clostridium_symbiosum	Clostridium_bolteae	++++

SPC1	SPC2	OTU1	OTU2	Result
SPC10155	SPC10325	Clostridium_tertium	Clostridium_bolteae	++++
SPC10097	SPC10325	Collinsella_aerofaciens	Clostridium_bolteae	++++
SPC10304	SPC10325	Coprococcus_comes	Clostridium_bolteae	++++
SPC10167	SPC10167	Clostridium_disporicum	Clostridium_disporicum	+++
SPC10202	SPC10167	Clostridium_innocuum	Clostridium_disporicum	+++
SPC10155	SPC10167	Clostridium_tertium	Clostridium_disporicum	++++
SPC10097	SPC10167	Collinsella_aerofaciens	Clostridium_disporicum	-
SPC10211	SPC10243	Bacteroides_caccae	Clostridium_hathewayi	++++
SPC10213	SPC10243	Bacteroides_eggerthii	Clostridium_hathewayi	++++
SPC10030	SPC10243	Bacteroides_ovatus	Clostridium_hathewayi	++++
SPC00006	SPC10243	Bacteroides_sp_1_1_6	Clostridium_hathewayi	++++
SPC00007	SPC10243	Bacteroides_sp_3_1_23	Clostridium_hathewayi	++++
SPC10019	SPC10243	Bacteroides_sp_D20	Clostridium_hathewayi	++++
SPC00005	SPC10243	Bacteroides_vulgatus	Clostridium_hathewayi	++++
SPC10081	SPC10243	Bacteroides_vulgatus	Clostridium_hathewayi	++++
SPC00021	SPC10243	Blautia_producta	Clostridium_hathewayi	++++
SPC10243	SPC10243	Clostridium_hathewayi	Clostridium_hathewayi	++++
SPC00026	SPC10243	Clostridium_nexile	Clostridium_hathewayi	
SPC00027	SPC10243	Clostridium_sp_HGF2	Clostridium_hathewayi	
SPC10097	SPC10243	Collinsella_aerofaciens	Clostridium_hathewayi	++++
SPC00009	SPC10243	Coprobacillus_sp_D7	Clostridium_hathewayi	++++
SPC00080	SPC10243	Coprococcus_catus	Clostridium_hathewayi	+++
SPC00018	SPC10243	Dorea_formicigenerans	Clostridium_hathewayi	++++
SPC00057	SPC10243	Dorea_longicatena	Clostridium_hathewayi	+
SPC00008	SPC10243	Enterococcus_faecalis	Clostridium_hathewayi	++++
SPC10001	SPC10243	Erysipelotrichaceae_bacterium	Clostridium_hathewayi	++++
SPC00001	SPC10243	Escherichia_coli	Clostridium_hathewayi	++++
SPC10110	SPC10243	Escherichia_coli	Clostridium_hathewayi	++++
SPC00022	SPC10243	Eubacterium_eligens	Clostridium_hathewayi	+
SPC00054	SPC10243	Faecalibacterium_prausnitzii	Clostridium_hathewayi	
SPC00056	SPC10243	Odoribacter_splanchnicus	Clostridium_hathewayi	
SPC10048	SPC10243	Parabacteroides_merdae	Clostridium_hathewayi	+
SPC00061	SPC10243	Roseburia_intestinalis	Clostridium_hathewayi	+++
SPC10197	SPC10243	Ruminococcus_obeum	Clostridium_hathewayi	++++
SPC10233	SPC10243	Ruminococcus_torques	Clostridium_hathewayi	++++
SPC00015	SPC10243	Streptococcus_thermophilus	Clostridium_hathewayi	++
SPC10256	SPC10313	Clostridium_butyricum	Clostridium_hylemonae	++++
SPC10325	SPC10313	Clostridium_bolteae	Clostridium_hylemonae	

SPC1	SPC2	OTU1	OTU2	Result
			e	
SPC10167	SPC10313	Clostridium_disporicum	Clostridium_hylemonae	
SPC10313	SPC10313	Clostridium_hylemonae	Clostridium_hylemonae	
SPC10202	SPC10313	Clostridium_innocuum	Clostridium_hylemonae	++++
SPC10238	SPC10313	Clostridium_mayombeii	Clostridium_hylemonae	++++
SPC10155	SPC10313	Clostridium_tertium	Clostridium_hylemonae	++++
SPC10097	SPC10313	Collinsella_aerofaciens	Clostridium_hylemonae	+++
SPC10304	SPC10313	Coprococcus_comes	Clostridium_hylemonae	+
SPC10167	SPC10202	Clostridium_disporicum	Clostridium_innocuum	+++
SPC10202	SPC10202	Clostridium_innocuum	Clostridium_innocuum	++++
SPC10238	SPC10202	Clostridium_mayombeii	Clostridium_innocuum	++++
SPC10155	SPC10202	Clostridium_tertium	Clostridium_innocuum	++++
SPC10097	SPC10202	Collinsella_aerofaciens	Clostridium_innocuum	+++
SPC10256	SPC10238	Clostridium_butyricum	Clostridium_mayombeii	++++
SPC10167	SPC10238	Clostridium_disporicum	Clostridium_mayombeii	++++
SPC10202	SPC10238	Clostridium_innocuum	Clostridium_mayombeii	++++
SPC10238	SPC10238	Clostridium_mayombeii	Clostridium_mayombeii	++++
SPC10155	SPC10238	Clostridium_tertium	Clostridium_mayombeii	++++
SPC10097	SPC10238	Collinsella_aerofaciens	Clostridium_mayombeii	++++
SPC00006	SPC00026	Bacteroides_sp_1_1_6	Clostridium_nexile	++++
SPC00007	SPC00026	Bacteroides_sp_3_1_23	Clostridium_nexile	++++
SPC00005	SPC00026	Bacteroides_vulgatus	Clostridium_nexile	++++
SPC00021	SPC00026	Blautia_producta	Clostridium_nexile	++++
SPC00026	SPC00026	Clostridium_nexile	Clostridium_nexile	++
SPC00009	SPC00026	Coprobacillus_sp_D7	Clostridium_nexile	
SPC00018	SPC00026	Dorea_formicigenerans	Clostridium_nexile	
SPC00008	SPC00026	Enterococcus_faecalis	Clostridium_nexile	++++
SPC00001	SPC00026	Escherichia_coli	Clostridium_nexile	++++
SPC00022	SPC00026	Eubacterium_eligens	Clostridium_nexile	+
SPC00015	SPC00026	Streptococcus_thermophilus	Clostridium_nexile	+
SPC00006	SPC00027	Bacteroides_sp_1_1_6	Clostridium_sp_HGF2	++++
SPC00007	SPC00027	Bacteroides_sp_3_1_23	Clostridium_sp_HGF2	++++
SPC00005	SPC00027	Bacteroides_vulgatus	Clostridium_sp_HGF2	++
SPC00021	SPC00027	Blautia_producta	Clostridium_sp_HGF2	++++
SPC00026	SPC00027	Clostridium_nexile	Clostridium_sp_HGF2	++++
SPC00027	SPC00027	Clostridium_sp_HGF2	Clostridium_sp_HGF2	++++

SPC1	SPC2	OTU1	OTU2	Result
SPC00009	SPC00027	Coprobacillus_sp_D7	Clostridium_sp_HGF2	-
SPC00018	SPC00027	Dorea_formicigenerans	Clostridium_sp_HGF2	
SPC00008	SPC00027	Enterococcus_faecalis	Clostridium_sp_HGF2	++++
SPC00001	SPC00027	Escherichia_coli	Clostridium_sp_HGF2	++++
SPC00022	SPC00027	Eubacterium_eligens	Clostridium_sp_HGF2	
SPC00015	SPC00027	Streptococcus_thermophilus	Clostridium_sp_HGF2	+
SPC10211	SPC10355	Bacteroides_caccae	Clostridium_symbiosu m	+++
SPC10213	SPC10355	Bacteroides_eggerthii	Clostridium_symbiosu m	++++
SPC10030	SPC10355	Bacteroides_ovatus	Clostridium_symbiosu m	
SPC00006	SPC10355	Bacteroides_sp_1_1_6	Clostridium_symbiosu m	++++
SPC00007	SPC10355	Bacteroides_sp_3_1_23	Clostridium_symbiosu m	++++
SPC10019	SPC10355	Bacteroides_sp_D20	Clostridium_symbiosu m	
SPC00005	SPC10355	Bacteroides_vulgatus	Clostridium_symbiosu m	+++
SPC10081	SPC10355	Bacteroides_vulgatus	Clostridium_symbiosu m	
SPC10301	SPC10355	Bifidobacterium_adolescentis	Clostridium_symbiosu m	++++
SPC10298	SPC10355	Bifidobacterium_pseudocatenulat um	Clostridium_symbiosu m	+
SPC00021	SPC10355	Blautia_producta	Clostridium_symbiosu m	++++
SPC10256	SPC10355	Clostridium_butyricum	Clostridium_symbiosu m	++++
SPC10358	SPC10355	Clostridium_orbiscindens	Clostridium_symbiosu m	++++
SPC10325	SPC10355	Clostridium_bolteae	Clostridium_symbiosu m	++++
SPC10167	SPC10355	Clostridium_disporicum	Clostridium_symbiosu m	++++
SPC10243	SPC10355	Clostridium_hathewayi	Clostridium_symbiosu m	++++
SPC10313	SPC10355	Clostridium_hylemonae	Clostridium_symbiosu m	+++
SPC10202	SPC10355	Clostridium_innocuum	Clostridium_symbiosu m	++++
SPC10238	SPC10355	Clostridium_mayombeii	Clostridium_symbiosu m	++++
SPC00026	SPC10355	Clostridium_nexile	Clostridium_symbiosu m	+
SPC00027	SPC10355	Clostridium_sp_HGF2	Clostridium_symbiosu m	
SPC10355	SPC10355	Clostridium_symbiosum	Clostridium_symbiosu m	+
SPC10355	SPC10355	Clostridium_symbiosum	Clostridium_symbiosu m	++++
SPC10155	SPC10355	Clostridium_tertium	Clostridium_symbiosu m	+

SPC1	SPC2	OTU1	OTU2	Result
SPC10097	SPC10355	Collinsella_aerofaciens	Clostridium_symbiosu m	+++
SPC10097	SPC10355	Collinsella_aerofaciens	Clostridium_symbiosu m	++++
SPC00009	SPC10355	Coprobacillus_sp_D7	Clostridium_symbiosu m	
SPC00080	SPC10355	Coprococcus_catus	Clostridium_symbiosu m	-
SPC10304	SPC10355	Coprococcus_comes	Clostridium_symbiosu m	
SPC10304	SPC10355	Coprococcus_comes	Clostridium_symbiosu m	++++
SPC00018	SPC10355	Dorea_formicigenerans	Clostridium_symbiosu m	
SPC00057	SPC10355	Dorea_longicatena	Clostridium_symbiosu m	++++
SPC00008	SPC10355	Enterococcus_faecalis	Clostridium_symbiosu m	++++
SPC10001	SPC10355	Erysipelotrichaceae_bacterium	Clostridium_symbiosu m	
SPC00001	SPC10355	Escherichia_coli	Clostridium_symbiosu m	++++
SPC10110	SPC10355	Escherichia_coli	Clostridium_symbiosu m	++++
SPC00022	SPC10355	Eubacterium_eligens	Clostridium_symbiosu m	+
SPC00054	SPC10355	Faecalibacterium_prausnitzii	Clostridium_symbiosu m	
SPC00056	SPC10355	Odoribacter_splanchnicus	Clostridium_symbiosu m	
SPC10048	SPC10355	Parabacteroides_merdae	Clostridium_symbiosu m	-
SPC00061	SPC10355	Roseburia_intestinalis	Clostridium_symbiosu m	--
SPC10197	SPC10355	Ruminococcus_obeum	Clostridium_symbiosu m	++++
SPC10233	SPC10355	Ruminococcus_torques	Clostridium_symbiosu m	++
SPC00015	SPC10355	Streptococcus_thermophilus	Clostridium_symbiosu m	
SPC10167	SPC10155	Clostridium_disporicum	Clostridium_tertium	++++
SPC10155	SPC10155	Clostridium_tertium	Clostridium_tertium	++++
SPC10097	SPC10155	Collinsella_aerofaciens	Clostridium_tertium	
SPC10030	SPC10097	Bacteroides_ovatus	Collinsella_aerofaciens	++++
SPC00006	SPC10097	Bacteroides_sp_1_1_6	Collinsella_aerofaciens	++++
SPC00007	SPC10097	Bacteroides_sp_3_1_23	Collinsella_aerofaciens	++++
SPC10019	SPC10097	Bacteroides_sp_D20	Collinsella_aerofaciens	++++
SPC00005	SPC10097	Bacteroides_vulgatus	Collinsella_aerofaciens	++++
SPC10081	SPC10097	Bacteroides_vulgatus	Collinsella_aerofaciens	++++
SPC00021	SPC10097	Blautia_producta	Collinsella_aerofaciens	++++
SPC00026	SPC10097	Clostridium_nexile	Collinsella_aerofaciens	+
SPC00027	SPC10097	Clostridium_sp_HGF2	Collinsella_aerofaciens	++++

SPC1	SPC2	OTU1	OTU2	Result
SPC10155	SPC10097	<i>Clostridium_tertium</i>	<i>Collinsella_aerofaciens</i>	
SPC10097	SPC10097	<i>Collinsella_aerofaciens</i>	<i>Collinsella_aerofaciens</i>	++++
SPC10097	SPC10097	<i>Collinsella_aerofaciens</i>	<i>Collinsella_aerofaciens</i>	
SPC00009	SPC10097	<i>Coprobacillus_sp_D7</i>	<i>Collinsella_aerofaciens</i>	+++
SPC00080	SPC10097	<i>Coprococcus_catus</i>	<i>Collinsella_aerofaciens</i>	++++
SPC00018	SPC10097	<i>Dorea_formicigenerans</i>	<i>Collinsella_aerofaciens</i>	++
SPC00057	SPC10097	<i>Dorea_longicatena</i>	<i>Collinsella_aerofaciens</i>	++++
SPC00008	SPC10097	<i>Enterococcus_faecalis</i>	<i>Collinsella_aerofaciens</i>	++++
SPC10001	SPC10097	<i>Erysipelotrichaceae_bacterium</i>	<i>Collinsella_aerofaciens</i>	++++
SPC00001	SPC10097	<i>Escherichia_coli</i>	<i>Collinsella_aerofaciens</i>	++++
SPC00022	SPC10097	<i>Eubacterium_eligens</i>	<i>Collinsella_aerofaciens</i>	+++
SPC00054	SPC10097	<i>Faecalibacterium_prausnitzii</i>	<i>Collinsella_aerofaciens</i>	+++
SPC00056	SPC10097	<i>Odoribacter_splanchnicus</i>	<i>Collinsella_aerofaciens</i>	+++
SPC10048	SPC10097	<i>Parabacteroides_merdae</i>	<i>Collinsella_aerofaciens</i>	++++
SPC00061	SPC10097	<i>Roseburia_intestinalis</i>	<i>Collinsella_aerofaciens</i>	++
SPC00015	SPC10097	<i>Streptococcus_thermophilus</i>	<i>Collinsella_aerofaciens</i>	+
SPC00006	SPC00009	<i>Bacteroides_sp_1_1_6</i>	<i>Coprobacillus_sp_D7</i>	+++
SPC00007	SPC00009	<i>Bacteroides_sp_3_1_23</i>	<i>Coprobacillus_sp_D7</i>	
SPC00005	SPC00009	<i>Bacteroides_vulgatus</i>	<i>Coprobacillus_sp_D7</i>	+
SPC00009	SPC00009	<i>Coprobacillus_sp_D7</i>	<i>Coprobacillus_sp_D7</i>	-
SPC00008	SPC00009	<i>Enterococcus_faecalis</i>	<i>Coprobacillus_sp_D7</i>	++++
SPC00001	SPC00009	<i>Escherichia_coli</i>	<i>Coprobacillus_sp_D7</i>	++
SPC00006	SPC00080	<i>Bacteroides_sp_1_1_6</i>	<i>Coprococcus_catus</i>	++++
SPC00007	SPC00080	<i>Bacteroides_sp_3_1_23</i>	<i>Coprococcus_catus</i>	
SPC00005	SPC00080	<i>Bacteroides_vulgatus</i>	<i>Coprococcus_catus</i>	+
SPC00021	SPC00080	<i>Blautia_producta</i>	<i>Coprococcus_catus</i>	++++
SPC00026	SPC00080	<i>Clostridium_nexile</i>	<i>Coprococcus_catus</i>	
SPC00027	SPC00080	<i>Clostridium_sp_HGF2</i>	<i>Coprococcus_catus</i>	---
SPC00009	SPC00080	<i>Coprobacillus_sp_D7</i>	<i>Coprococcus_catus</i>	---
SPC00080	SPC00080	<i>Coprococcus_catus</i>	<i>Coprococcus_catus</i>	
SPC00018	SPC00080	<i>Dorea_formicigenerans</i>	<i>Coprococcus_catus</i>	
SPC00057	SPC00080	<i>Dorea_longicatena</i>	<i>Coprococcus_catus</i>	
SPC00008	SPC00080	<i>Enterococcus_faecalis</i>	<i>Coprococcus_catus</i>	++++
SPC00001	SPC00080	<i>Escherichia_coli</i>	<i>Coprococcus_catus</i>	++++
SPC00022	SPC00080	<i>Eubacterium_eligens</i>	<i>Coprococcus_catus</i>	
SPC00054	SPC00080	<i>Faecalibacterium_prausnitzii</i>	<i>Coprococcus_catus</i>	
SPC00056	SPC00080	<i>Odoribacter_splanchnicus</i>	<i>Coprococcus_catus</i>	
SPC00061	SPC00080	<i>Roseburia_intestinalis</i>	<i>Coprococcus_catus</i>	

SPC1	SPC2	OTU1	OTU2	Result
SPC00015	SPC00080	Streptococcus_thermophilus	Coprococcus_catus	
SPC10211	SPC10304	Bacteroides_caccae	Coprococcus_comes	+++
SPC10213	SPC10304	Bacteroides_eggerthii	Coprococcus_comes	+++
SPC10030	SPC10304	Bacteroides_ovatus	Coprococcus_comes	
SPC00006	SPC10304	Bacteroides_sp_1_1_6	Coprococcus_comes	+++
SPC00007	SPC10304	Bacteroides_sp_3_1_23	Coprococcus_comes	++++
SPC10019	SPC10304	Bacteroides_sp_D20	Coprococcus_comes	
SPC00005	SPC10304	Bacteroides_vulgatus	Coprococcus_comes	++++
SPC10081	SPC10304	Bacteroides_vulgatus	Coprococcus_comes	
SPC10301	SPC10304	Bifidobacterium_adolescentis	Coprococcus_comes	++++
SPC10298	SPC10304	Bifidobacterium_pseudocatenulatum	Coprococcus_comes	++++
SPC00021	SPC10304	Blautia_producta	Coprococcus_comes	++++
SPC10256	SPC10304	Clostridium_butyricum	Coprococcus_comes	++++
SPC10167	SPC10304	Clostridium_disporicum	Coprococcus_comes	++++
SPC10243	SPC10304	Clostridium_hathewayi	Coprococcus_comes	++++
SPC10313	SPC10304	Clostridium_hylemonae	Coprococcus_comes	+
SPC10202	SPC10304	Clostridium_innocuum	Coprococcus_comes	++++
SPC10238	SPC10304	Clostridium_mayombi	Coprococcus_comes	++++
SPC00026	SPC10304	Clostridium_nexile	Coprococcus_comes	
SPC00027	SPC10304	Clostridium_sp_HGF2	Coprococcus_comes	
SPC10155	SPC10304	Clostridium_tertium	Coprococcus_comes	++++
SPC10097	SPC10304	Collinsella_aerofaciens	Coprococcus_comes	++++
SPC10097	SPC10304	Collinsella_aerofaciens	Coprococcus_comes	+++
SPC00009	SPC10304	Coprobacillus_sp_D7	Coprococcus_comes	+++
SPC00080	SPC10304	Coprococcus_catus	Coprococcus_comes	--
SPC10304	SPC10304	Coprococcus_comes	Coprococcus_comes	
SPC10304	SPC10304	Coprococcus_comes	Coprococcus_comes	++
SPC00018	SPC10304	Dorea_formicigenerans	Coprococcus_comes	
SPC00057	SPC10304	Dorea_longicatena	Coprococcus_comes	
SPC00008	SPC10304	Enterococcus_faecalis	Coprococcus_comes	++++
SPC10001	SPC10304	Erysipelotrichaceae_bacterium	Coprococcus_comes	-
SPC00001	SPC10304	Escherichia_coli	Coprococcus_comes	++++
SPC10110	SPC10304	Escherichia_coli	Coprococcus_comes	++++
SPC00022	SPC10304	Eubacterium_eligens	Coprococcus_comes	++
SPC00054	SPC10304	Faecalibacterium_prausnitzii	Coprococcus_comes	
SPC00056	SPC10304	Odoribacter_splanchnicus	Coprococcus_comes	
SPC10048	SPC10304	Parabacteroides_merdae	Coprococcus_comes	-
SPC00061	SPC10304	Roseburia_intestinalis	Coprococcus_comes	-

SPC1	SPC2	OTU1	OTU2	Result
SPC10197	SPC10304	Ruminococcus_obeum	Coprococcus_comes	++++
SPC10233	SPC10304	Ruminococcus_torques	Coprococcus_comes	++++
SPC00015	SPC10304	Streptococcus_thermophilus	Coprococcus_comes	++
SPC00006	SPC00018	Bacteroides_sp_1_1_6	Dorea_formicigenerans	+++
SPC00007	SPC00018	Bacteroides_sp_3_1_23	Dorea_formicigenerans	
SPC00005	SPC00018	Bacteroides_vulgatus	Dorea_formicigenerans	++
SPC00009	SPC00018	Coprobacillus_sp_D7	Dorea_formicigenerans	-
SPC00018	SPC00018	Dorea_formicigenerans	Dorea_formicigenerans	--
SPC00008	SPC00018	Enterococcus_faecalis	Dorea_formicigenerans	++++
SPC00001	SPC00018	Escherichia_coli	Dorea_formicigenerans	++
SPC00015	SPC00018	Streptococcus_thermophilus	Dorea_formicigenerans	
SPC00006	SPC00057	Bacteroides_sp_1_1_6	Dorea_longicatena	++++
SPC00007	SPC00057	Bacteroides_sp_3_1_23	Dorea_longicatena	+++
SPC00005	SPC00057	Bacteroides_vulgatus	Dorea_longicatena	++++
SPC00021	SPC00057	Blautia_producta	Dorea_longicatena	++++
SPC00026	SPC00057	Clostridium_nexile	Dorea_longicatena	
SPC00027	SPC00057	Clostridium_sp_HGF2	Dorea_longicatena	--
SPC00009	SPC00057	Coprobacillus_sp_D7	Dorea_longicatena	
SPC00018	SPC00057	Dorea_formicigenerans	Dorea_longicatena	++
SPC00057	SPC00057	Dorea_longicatena	Dorea_longicatena	-
SPC00008	SPC00057	Enterococcus_faecalis	Dorea_longicatena	++++
SPC00001	SPC00057	Escherichia_coli	Dorea_longicatena	++++
SPC00022	SPC00057	Eubacterium_eligens	Dorea_longicatena	++
SPC00054	SPC00057	Faecalibacterium_prausnitzii	Dorea_longicatena	-
SPC00056	SPC00057	Odoribacter_splanchnicus	Dorea_longicatena	
SPC00015	SPC00057	Streptococcus_thermophilus	Dorea_longicatena	+
SPC00006	SPC00008	Bacteroides_sp_1_1_6	Enterococcus_faecalis	++++
SPC00007	SPC00008	Bacteroides_sp_3_1_23	Enterococcus_faecalis	++++
SPC00005	SPC00008	Bacteroides_vulgatus	Enterococcus_faecalis	++++
SPC00008	SPC00008	Enterococcus_faecalis	Enterococcus_faecalis	++++
SPC00001	SPC00008	Escherichia_coli	Enterococcus_faecalis	++++
SPC00006	SPC10001	Bacteroides_sp_1_1_6	Erysipelotrichaceae_bacterium	++++
SPC00007	SPC10001	Bacteroides_sp_3_1_23	Erysipelotrichaceae_bacterium	
SPC00005	SPC10001	Bacteroides_vulgatus	Erysipelotrichaceae_bacterium	+
SPC00021	SPC10001	Blautia_producta	Erysipelotrichaceae_bacterium	++++
SPC00026	SPC10001	Clostridium_nexile	Erysipelotrichaceae_bacterium	

SPC1	SPC2	OTU1	OTU2	Result
SPC00027	SPC10001	Clostridium_sp_HGF2	Erysipelotrichaceae_bacterium	--
SPC00009	SPC10001	Coprobacillus_sp_D7	Erysipelotrichaceae_bacterium	-
SPC00080	SPC10001	Coprococcus_catus	Erysipelotrichaceae_bacterium	
SPC00018	SPC10001	Dorea_formicigenerans	Erysipelotrichaceae_bacterium	--
SPC00057	SPC10001	Dorea_longicatena	Erysipelotrichaceae_bacterium	
SPC00008	SPC10001	Enterococcus_faecalis	Erysipelotrichaceae_bacterium	++++
SPC10001	SPC10001	Erysipelotrichaceae_bacterium	Erysipelotrichaceae_bacterium	-
SPC00001	SPC10001	Escherichia_coli	Erysipelotrichaceae_bacterium	++++
SPC00022	SPC10001	Eubacterium_eligens	Erysipelotrichaceae_bacterium	-
SPC00054	SPC10001	Faecalibacterium_prausnitzii	Erysipelotrichaceae_bacterium	-
SPC00056	SPC10001	Odoribacter_splanchnicus	Erysipelotrichaceae_bacterium	
SPC00061	SPC10001	Roseburia_intestinalis	Erysipelotrichaceae_bacterium	-
SPC00015	SPC10001	Streptococcus_thermophilus	Erysipelotrichaceae_bacterium	
SPC10030	SPC10110	Bacteroides_ovatus	Escherichia_coli	++++
SPC00006	SPC10110	Bacteroides_sp_1_1_6	Escherichia_coli	++++
SPC00007	SPC10110	Bacteroides_sp_3_1_23	Escherichia_coli	++++
SPC10019	SPC10110	Bacteroides_sp_D20	Escherichia_coli	++++
SPC00005	SPC10110	Bacteroides_vulgatus	Escherichia_coli	++++
SPC10081	SPC10110	Bacteroides_vulgatus	Escherichia_coli	++++
SPC00021	SPC10110	Blautia_producta	Escherichia_coli	++++
SPC00026	SPC10110	Clostridium_nexile	Escherichia_coli	++++
SPC00027	SPC10110	Clostridium_sp_HGF2	Escherichia_coli	++++
SPC10097	SPC10110	Collinsella_aerofaciens	Escherichia_coli	++++
SPC00009	SPC10110	Coprobacillus_sp_D7	Escherichia_coli	++
SPC00080	SPC10110	Coprococcus_catus	Escherichia_coli	++++
SPC00018	SPC10110	Dorea_formicigenerans	Escherichia_coli	++++
SPC00057	SPC10110	Dorea_longicatena	Escherichia_coli	++++
SPC00008	SPC10110	Enterococcus_faecalis	Escherichia_coli	++++
SPC10001	SPC10110	Erysipelotrichaceae_bacterium	Escherichia_coli	++++
SPC00001	SPC00001	Escherichia_coli	Escherichia_coli	++++
SPC00001	SPC10110	Escherichia_coli	Escherichia_coli	++++
SPC10110	SPC10110	Escherichia_coli	Escherichia_coli	++++
SPC00022	SPC10110	Eubacterium_eligens	Escherichia_coli	++++
SPC00054	SPC10110	Faecalibacterium_prausnitzii	Escherichia_coli	+++

SPC1	SPC2	OTU1	OTU2	Result
SPC00056	SPC10110	Odoribacter_splanchnicus	Escherichia_coli	+++
SPC10048	SPC10110	Parabacteroides_merdae	Escherichia_coli	++++
SPC00061	SPC10110	Roseburia_intestinalis	Escherichia_coli	+++
SPC00015	SPC10110	Streptococcus_thermophilus	Escherichia_coli	+++
SPC00006	SPC00022	Bacteroides_sp_1_1_6	Eubacterium_eligens	++++
SPC00007	SPC00022	Bacteroides_sp_3_1_23	Eubacterium_eligens	
SPC00005	SPC00022	Bacteroides_vulgatus	Eubacterium_eligens	+++
SPC00021	SPC00022	Blautia_producta	Eubacterium_eligens	++++
SPC00009	SPC00022	Coprobaecillus_sp_D7	Eubacterium_eligens	
SPC00018	SPC00022	Dorea_formicigenans	Eubacterium_eligens	--
SPC00008	SPC00022	Enterococcus_faecalis	Eubacterium_eligens	++++
SPC00001	SPC00022	Escherichia_coli	Eubacterium_eligens	++
SPC00022	SPC00022	Eubacterium_eligens	Eubacterium_eligens	
SPC00015	SPC00022	Streptococcus_thermophilus	Eubacterium_eligens	
SPC10211	SPC10363	Bacteroides_caccae	Eubacterium_rectale	
SPC10213	SPC10363	Bacteroides_eggerthii	Eubacterium_rectale	
SPC10030	SPC10363	Bacteroides_ovatus	Eubacterium_rectale	
SPC00006	SPC10363	Bacteroides_sp_1_1_6	Eubacterium_rectale	++++
SPC00007	SPC10363	Bacteroides_sp_3_1_23	Eubacterium_rectale	+++
SPC10019	SPC10363	Bacteroides_sp_D20	Eubacterium_rectale	--
SPC00005	SPC10363	Bacteroides_vulgatus	Eubacterium_rectale	++++
SPC10081	SPC10363	Bacteroides_vulgatus	Eubacterium_rectale	
SPC10301	SPC10363	Bifidobacterium_adolescentis	Eubacterium_rectale	++++
SPC10298	SPC10363	Bifidobacterium_pseudocatenulatum	Eubacterium_rectale	
SPC00021	SPC10363	Blautia_producta	Eubacterium_rectale	++++
SPC10415	SPC10567	Blautia_producta	Eubacterium_rectale	++++
SPC10256	SPC10567	Clostridium_butyricum	Eubacterium_rectale	++++
SPC10358	SPC10567	Clostridium_orbiscindens	Eubacterium_rectale	+
SPC10325	SPC10567	Clostridium_bolteae	Eubacterium_rectale	++
SPC10167	SPC10567	Clostridium_disporicum	Eubacterium_rectale	++++
SPC10243	SPC10363	Clostridium_hathewayi	Eubacterium_rectale	++++
SPC10313	SPC10567	Clostridium_hylemonae	Eubacterium_rectale	
SPC10202	SPC10567	Clostridium_innocuum	Eubacterium_rectale	++++
SPC10238	SPC10567	Clostridium_mayombeii	Eubacterium_rectale	++++
SPC00026	SPC10363	Clostridium_nexile	Eubacterium_rectale	-
SPC00027	SPC10363	Clostridium_sp_HGF2	Eubacterium_rectale	--
SPC10355	SPC10363	Clostridium_symbiosum	Eubacterium_rectale	++
SPC10355	SPC10567	Clostridium_symbiosum	Eubacterium_rectale	+

SPC1	SPC2	OTU1	OTU2	Result
SPC10155	SPC10567	Clostridium_tertium	Eubacterium_rectale	++++
SPC10097	SPC10363	Collinsella_aerofaciens	Eubacterium_rectale	++++
SPC10097	SPC10567	Collinsella_aerofaciens	Eubacterium_rectale	++++
SPC00009	SPC10363	Coprobacillus_sp_D7	Eubacterium_rectale	+++
SPC00080	SPC10363	Coprococcus_catus	Eubacterium_rectale	---
SPC10304	SPC10363	Coprococcus_comes	Eubacterium_rectale	+
SPC10304	SPC10567	Coprococcus_comes	Eubacterium_rectale	++++
SPC00018	SPC10363	Dorea_formicigenerans	Eubacterium_rectale	-
SPC00057	SPC10363	Dorea_longicatena	Eubacterium_rectale	++++
SPC00008	SPC10363	Enterococcus_faecalis	Eubacterium_rectale	++++
SPC10001	SPC10363	Erysipelotrichaceae_bacterium	Eubacterium_rectale	-
SPC00001	SPC10363	Escherichia_coli	Eubacterium_rectale	++++
SPC10110	SPC10363	Escherichia_coli	Eubacterium_rectale	++++
SPC00022	SPC10363	Eubacterium_eligens	Eubacterium_rectale	
SPC10363	SPC10363	Eubacterium_rectale	Eubacterium_rectale	+++
SPC10567	SPC10567	Eubacterium_rectale	Eubacterium_rectale	
SPC00054	SPC10363	Faecalibacterium_prausnitzii	Eubacterium_rectale	--
SPC10386	SPC10567	Faecalibacterium_prausnitzii	Eubacterium_rectale	
SPC10390	SPC10567	Lachnospiraceae_bacterium_5_1_57FAA	Eubacterium_rectale	+++
SPC00056	SPC10363	Odoribacter_splanchnicus	Eubacterium_rectale	-
SPC10048	SPC10363	Parabacteroides_merdae	Eubacterium_rectale	-
SPC00061	SPC10363	Roseburia_intestinalis	Eubacterium_rectale	----
SPC10470	SPC10567	Ruminococcus_bromii	Eubacterium_rectale	+
SPC10468	SPC10567	Ruminococcus_gnavus	Eubacterium_rectale	++++
SPC10197	SPC10363	Ruminococcus_obeum	Eubacterium_rectale	++
SPC10233	SPC10363	Ruminococcus_torques	Eubacterium_rectale	+
SPC00015	SPC10363	Streptococcus_thermophilus	Eubacterium_rectale	
SPC10211	SPC10386	Bacteroides_caccae	Faecalibacterium_prausnitzii	
SPC10213	SPC10386	Bacteroides_eggerthii	Faecalibacterium_prausnitzii	-
SPC10030	SPC10386	Bacteroides_ovatus	Faecalibacterium_prausnitzii	-
SPC00006	SPC00054	Bacteroides_sp_1_1_6	Faecalibacterium_prausnitzii	++++
SPC00006	SPC10386	Bacteroides_sp_1_1_6	Faecalibacterium_prausnitzii	+++
SPC00007	SPC00054	Bacteroides_sp_3_1_23	Faecalibacterium_prausnitzii	++
SPC00007	SPC10386	Bacteroides_sp_3_1_23	Faecalibacterium_prausnitzii	
SPC10019	SPC10386	Bacteroides_sp_D20	Faecalibacterium_prausnitzii	--

SPC1	SPC2	OTU1	OTU2	Result
SPC00005	SPC00054	Bacteroides_vulgatus	Faecalibacterium_prau snitzii	++++
SPC00005	SPC10386	Bacteroides_vulgatus	Faecalibacterium_prau snitzii	+++
SPC10081	SPC10386	Bacteroides_vulgatus	Faecalibacterium_prau snitzii	---
SPC10301	SPC10386	Bifidobacterium_adolescentis	Faecalibacterium_prau snitzii	+
SPC10298	SPC10386	Bifidobacterium_pseudocatenulat um	Faecalibacterium_prau snitzii	
SPC00021	SPC00054	Blautia_producta	Faecalibacterium_prau snitzii	++++
SPC00021	SPC10386	Blautia_producta	Faecalibacterium_prau snitzii	++++
SPC10256	SPC10386	Clostridium_butyricum	Faecalibacterium_prau snitzii	++++
SPC10358	SPC10386	Clostridium_orbiscindens	Faecalibacterium_prau snitzii	
SPC10325	SPC10386	Clostridium_bolteae	Faecalibacterium_prau snitzii	++
SPC10167	SPC10386	Clostridium_disporicum	Faecalibacterium_prau snitzii	
SPC10243	SPC10386	Clostridium_hathewayi	Faecalibacterium_prau snitzii	+++
SPC10313	SPC10386	Clostridium_hylemonae	Faecalibacterium_prau snitzii	
SPC10202	SPC10386	Clostridium_innocuum	Faecalibacterium_prau snitzii	++++
SPC10238	SPC10386	Clostridium_mayombeii	Faecalibacterium_prau snitzii	++++
SPC00026	SPC00054	Clostridium_nexile	Faecalibacterium_prau snitzii	
SPC00026	SPC10386	Clostridium_nexile	Faecalibacterium_prau snitzii	-
SPC00027	SPC00054	Clostridium_sp_HGF2	Faecalibacterium_prau snitzii	++
SPC00027	SPC10386	Clostridium_sp_HGF2	Faecalibacterium_prau snitzii	--
SPC10355	SPC10386	Clostridium_symbiosum	Faecalibacterium_prau snitzii	+++
SPC10355	SPC10386	Clostridium_symbiosum	Faecalibacterium_prau snitzii	++++
SPC10155	SPC10386	Clostridium_tertium	Faecalibacterium_prau snitzii	++++
SPC10097	SPC10386	Collinsella_aerofaciens	Faecalibacterium_prau snitzii	++++
SPC10097	SPC10386	Collinsella_aerofaciens	Faecalibacterium_prau snitzii	++++
SPC00009	SPC00054	Coprobacillus_sp_D7	Faecalibacterium_prau snitzii	---
SPC00009	SPC10386	Coprobacillus_sp_D7	Faecalibacterium_prau snitzii	
SPC00080	SPC10386	Coprococcus_catus	Faecalibacterium_prau snitzii	---
SPC10304	SPC10386	Coprococcus_comes	Faecalibacterium_prau snitzii	
SPC10304	SPC10386	Coprococcus_comes	Faecalibacterium_prau snitzii	+++

SPC1	SPC2	OTU1	OTU2	Result
SPC00018	SPC00054	Dorea_formicigenerans	Faecalibacterium_prau snitzii	
SPC00018	SPC10386	Dorea_formicigenerans	Faecalibacterium_prau snitzii	---
SPC00057	SPC10386	Dorea_longicatena	Faecalibacterium_prau snitzii	+++
SPC00008	SPC00054	Enterococcus_faecalis	Faecalibacterium_prau snitzii	++++
SPC00008	SPC10386	Enterococcus_faecalis	Faecalibacterium_prau snitzii	++++
SPC10001	SPC10386	Erysipelotrichaceae_bacterium	Faecalibacterium_prau snitzii	--
SPC00001	SPC00054	Escherichia_coli	Faecalibacterium_prau snitzii	++++
SPC00001	SPC10386	Escherichia_coli	Faecalibacterium_prau snitzii	++++
SPC10110	SPC10386	Escherichia_coli	Faecalibacterium_prau snitzii	++
SPC00022	SPC00054	Eubacterium_eligens	Faecalibacterium_prau snitzii	
SPC00022	SPC10386	Eubacterium_eligens	Faecalibacterium_prau snitzii	
SPC10363	SPC10386	Eubacterium_rectale	Faecalibacterium_prau snitzii	+
SPC00054	SPC00054	Faecalibacterium_prausnitzii	Faecalibacterium_prau snitzii	+
SPC00054	SPC10386	Faecalibacterium_prausnitzii	Faecalibacterium_prau snitzii	
SPC10386	SPC10386	Faecalibacterium_prausnitzii	Faecalibacterium_prau snitzii	+
SPC10386	SPC10386	Faecalibacterium_prausnitzii	Faecalibacterium_prau snitzii	
SPC10390	SPC10386	Lachnospiraceae_bacterium_5_1 57FAA	Faecalibacterium_prau snitzii	++++
SPC00056	SPC10386	Odoribacter_splanchnicus	Faecalibacterium_prau snitzii	--
SPC10048	SPC10386	Parabacteroides_merdae	Faecalibacterium_prau snitzii	-
SPC00061	SPC10386	Roseburia_intestinalis	Faecalibacterium_prau snitzii	
SPC10197	SPC10386	Ruminococcus_obeum	Faecalibacterium_prau snitzii	
SPC10233	SPC10386	Ruminococcus_torques	Faecalibacterium_prau snitzii	
SPC00015	SPC00054	Streptococcus_thermophilus	Faecalibacterium_prau snitzii	
SPC00015	SPC10386	Streptococcus_thermophilus	Faecalibacterium_prau snitzii	
SPC10211	SPC10390	Bacteroides_caccae	Lachnospiraceae_bact erium_5_1_57FAA	
SPC10213	SPC10390	Bacteroides_eggerthii	Lachnospiraceae_bact erium_5_1_57FAA	
SPC10030	SPC10390	Bacteroides_ovatus	Lachnospiraceae_bact erium_5_1_57FAA	-
SPC00006	SPC10390	Bacteroides_sp_1_1_6	Lachnospiraceae_bact erium_5_1_57FAA	+++
SPC00007	SPC10390	Bacteroides_sp_3_1_23	Lachnospiraceae_bact erium_5_1_57FAA	

SPC1	SPC2	OTU1	OTU2	Result
SPC10019	SPC10390	Bacteroides_sp_D20	Lachnospiraceae_bacterium_5_1_57FAA	---
SPC00005	SPC10390	Bacteroides_vulgatus	Lachnospiraceae_bacterium_5_1_57FAA	+++
SPC10081	SPC10390	Bacteroides_vulgatus	Lachnospiraceae_bacterium_5_1_57FAA	--
SPC10301	SPC10390	Bifidobacterium_adolescentis	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10298	SPC10390	Bifidobacterium_pseudocatenulatum	Lachnospiraceae_bacterium_5_1_57FAA	
SPC00021	SPC10390	Blautia_producta	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10415	SPC10390	Blautia_producta	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10256	SPC10390	Clostridium_butyricum	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10358	SPC10390	Clostridium_orbiscindens	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10325	SPC10390	Clostridium_bolteae	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10167	SPC10390	Clostridium_disporicum	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10243	SPC10390	Clostridium_hathewayi	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10313	SPC10390	Clostridium_hylemonae	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10202	SPC10390	Clostridium_innocuum	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10238	SPC10390	Clostridium_mayombeii	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC00026	SPC10390	Clostridium_nexile	Lachnospiraceae_bacterium_5_1_57FAA	-
SPC00027	SPC10390	Clostridium_sp_HGF2	Lachnospiraceae_bacterium_5_1_57FAA	-
SPC10355	SPC10390	Clostridium_symbiosum	Lachnospiraceae_bacterium_5_1_57FAA	+
SPC10355	SPC10390	Clostridium_symbiosum	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10155	SPC10390	Clostridium_tertium	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10097	SPC10390	Collinsella_aerofaciens	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10097	SPC10390	Collinsella_aerofaciens	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC00009	SPC10390	Coprobacillus_sp_D7	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC00080	SPC10390	Coprococcus_catus	Lachnospiraceae_bacterium_5_1_57FAA	
SPC10304	SPC10390	Coprococcus_comes	Lachnospiraceae_bacterium_5_1_57FAA	
SPC10304	SPC10390	Coprococcus_comes	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC00018	SPC10390	Dorea_formicigenerans	Lachnospiraceae_bacterium_5_1_57FAA	--
SPC00057	SPC10390	Dorea_longicatena	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC00008	SPC10390	Enterococcus_faecalis	Lachnospiraceae_bacterium_5_1_57FAA	++++

SPC1	SPC2	OTU1	OTU2	Result
SPC10001	SPC10390	Erysipelotrichaceae_bacterium	Lachnospiraceae_bacterium_5_1_57FAA	---
SPC00001	SPC10390	Escherichia_coli	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10110	SPC10390	Escherichia_coli	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC00022	SPC10390	Eubacterium_eligens	Lachnospiraceae_bacterium_5_1_57FAA	
SPC10363	SPC10390	Eubacterium_rectale	Lachnospiraceae_bacterium_5_1_57FAA	
SPC00054	SPC10390	Faecalibacterium_prausnitzii	Lachnospiraceae_bacterium_5_1_57FAA	
SPC10386	SPC10390	Faecalibacterium_prausnitzii	Lachnospiraceae_bacterium_5_1_57FAA	
SPC10386	SPC10390	Faecalibacterium_prausnitzii	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC10390	SPC10390	Lachnospiraceae_bacterium_5_1_57FAA	Lachnospiraceae_bacterium_5_1_57FAA	
SPC10390	SPC10390	Lachnospiraceae_bacterium_5_1_57FAA	Lachnospiraceae_bacterium_5_1_57FAA	++++
SPC00056	SPC10390	Odoribacter_splanchnicus	Lachnospiraceae_bacterium_5_1_57FAA	--
SPC10388	SPC10390	Odoribacter_splanchnicus	Lachnospiraceae_bacterium_5_1_57FAA	
SPC10048	SPC10390	Parabacteroides_merdae	Lachnospiraceae_bacterium_5_1_57FAA	-
SPC00061	SPC10390	Roseburia_intestinalis	Lachnospiraceae_bacterium_5_1_57FAA	
SPC10197	SPC10390	Ruminococcus_obeum	Lachnospiraceae_bacterium_5_1_57FAA	
SPC10233	SPC10390	Ruminococcus_torques	Lachnospiraceae_bacterium_5_1_57FAA	
SPC00015	SPC10390	Streptococcus_thermophilus	Lachnospiraceae_bacterium_5_1_57FAA	
SPC10211	SPC10388	Bacteroides_caccae	Odoribacter_splanchnicus	
SPC10213	SPC10388	Bacteroides_eggerthii	Odoribacter_splanchnicus	-
SPC10030	SPC10388	Bacteroides_ovatus	Odoribacter_splanchnicus	--
SPC00006	SPC00056	Bacteroides_sp_1_1_6	Odoribacter_splanchnicus	++++
SPC00006	SPC10388	Bacteroides_sp_1_1_6	Odoribacter_splanchnicus	+
SPC00007	SPC00056	Bacteroides_sp_3_1_23	Odoribacter_splanchnicus	+
SPC00007	SPC10388	Bacteroides_sp_3_1_23	Odoribacter_splanchnicus	
SPC10019	SPC10388	Bacteroides_sp_D20	Odoribacter_splanchnicus	---
SPC00005	SPC00056	Bacteroides_vulgatus	Odoribacter_splanchnicus	+++
SPC00005	SPC10388	Bacteroides_vulgatus	Odoribacter_splanchnicus	+++
SPC10081	SPC10388	Bacteroides_vulgatus	Odoribacter_splanchnicus	-
SPC10301	SPC10388	Bifidobacterium_adolescentis	Odoribacter_splanchnicus	++++

SPC1	SPC2	OTU1	OTU2	Result
SPC10298	SPC10388	Bifidobacterium_pseudocatenulatum	Odoribacter_splanchnicus	+++
SPC00021	SPC00056	Blautia_producta	Odoribacter_splanchnicus	++++
SPC00021	SPC10388	Blautia_producta	Odoribacter_splanchnicus	++++
SPC10243	SPC10388	Clostridium_hathewayi	Odoribacter_splanchnicus	++++
SPC00026	SPC00056	Clostridium_nexile	Odoribacter_splanchnicus	
SPC00026	SPC10388	Clostridium_nexile	Odoribacter_splanchnicus	---
SPC00027	SPC00056	Clostridium_sp_HGF2	Odoribacter_splanchnicus	
SPC00027	SPC10388	Clostridium_sp_HGF2	Odoribacter_splanchnicus	---
SPC10355	SPC10388	Clostridium_symbiosum	Odoribacter_splanchnicus	++
SPC10097	SPC10388	Collinsella_aerofaciens	Odoribacter_splanchnicus	++++
SPC00009	SPC00056	Coprobacillus_sp_D7	Odoribacter_splanchnicus	-
SPC00009	SPC10388	Coprobacillus_sp_D7	Odoribacter_splanchnicus	+++
SPC00080	SPC10388	Coprococcus_catus	Odoribacter_splanchnicus	--
SPC10304	SPC10388	Coprococcus_comes	Odoribacter_splanchnicus	
SPC00018	SPC00056	Dorea_formicigenerans	Odoribacter_splanchnicus	
SPC00018	SPC10388	Dorea_formicigenerans	Odoribacter_splanchnicus	-
SPC00057	SPC10388	Dorea_longicatena	Odoribacter_splanchnicus	++++
SPC00008	SPC00056	Enterococcus_faecalis	Odoribacter_splanchnicus	++++
SPC00008	SPC10388	Enterococcus_faecalis	Odoribacter_splanchnicus	++++
SPC10001	SPC10388	Erysipelotrichaceae_bacterium	Odoribacter_splanchnicus	--
SPC00001	SPC00056	Escherichia_coli	Odoribacter_splanchnicus	++++
SPC00001	SPC10388	Escherichia_coli	Odoribacter_splanchnicus	++++
SPC10110	SPC10388	Escherichia_coli	Odoribacter_splanchnicus	++++
SPC00022	SPC00056	Eubacterium_eligens	Odoribacter_splanchnicus	
SPC00022	SPC10388	Eubacterium_eligens	Odoribacter_splanchnicus	
SPC10363	SPC10388	Eubacterium_rectale	Odoribacter_splanchnicus	+
SPC00054	SPC00056	Faecalibacterium_prausnitzii	Odoribacter_splanchnicus	
SPC00054	SPC10388	Faecalibacterium_prausnitzii	Odoribacter_splanchnicus	-
SPC10386	SPC10388	Faecalibacterium_prausnitzii	Odoribacter_splanchnicus	+

SPC1	SPC2	OTU1	OTU2	Result
SPC00056	SPC00056	Odoribacter_splanchnicus	Odoribacter_splanchnicus	
SPC00056	SPC10388	Odoribacter_splanchnicus	Odoribacter_splanchnicus	---
SPC10388	SPC10388	Odoribacter_splanchnicus	Odoribacter_splanchnicus	+
SPC10048	SPC10388	Parabacteroides_merdae	Odoribacter_splanchnicus	
SPC00061	SPC10388	Roseburia_intestinalis	Odoribacter_splanchnicus	
SPC10197	SPC10388	Ruminococcus_obeum	Odoribacter_splanchnicus	+
SPC10233	SPC10388	Ruminococcus_torques	Odoribacter_splanchnicus	
SPC00015	SPC00056	Streptococcus_thermophilus	Odoribacter_splanchnicus	
SPC00015	SPC10388	Streptococcus_thermophilus	Odoribacter_splanchnicus	+
SPC10030	SPC10048	Bacteroides_ovatus	Parabacteroides_merdae	
SPC00006	SPC10048	Bacteroides_sp_1_1_6	Parabacteroides_merdae	++++
SPC00007	SPC10048	Bacteroides_sp_3_1_23	Parabacteroides_merdae	+++
SPC10019	SPC10048	Bacteroides_sp_D20	Parabacteroides_merdae	
SPC00005	SPC10048	Bacteroides_vulgatus	Parabacteroides_merdae	++++
SPC00021	SPC10048	Blautia_producta	Parabacteroides_merdae	++++
SPC00026	SPC10048	Clostridium_nexile	Parabacteroides_merdae	++
SPC00027	SPC10048	Clostridium_sp_HGF2	Parabacteroides_merdae	+++
SPC00009	SPC10048	Coprobaillus_sp_D7	Parabacteroides_merdae	-
SPC00080	SPC10048	Coprococcus_catus	Parabacteroides_merdae	+++
SPC00018	SPC10048	Dorea_formicigenerans	Parabacteroides_merdae	
SPC00057	SPC10048	Dorea_longicatena	Parabacteroides_merdae	
SPC00008	SPC10048	Enterococcus_faecalis	Parabacteroides_merdae	++++
SPC10001	SPC10048	Erysipelotrichaceae_bacterium	Parabacteroides_merdae	
SPC00001	SPC10048	Escherichia_coli	Parabacteroides_merdae	++++
SPC00022	SPC10048	Eubacterium_eligens	Parabacteroides_merdae	
SPC00054	SPC10048	Faecalibacterium_prausnitzii	Parabacteroides_merdae	+
SPC00056	SPC10048	Odoribacter_splanchnicus	Parabacteroides_merdae	
SPC10048	SPC10048	Parabacteroides_merdae	Parabacteroides_merdae	+++
SPC00061	SPC10048	Roseburia_intestinalis	Parabacteroides_merdae	

SPC1	SPC2	OTU1	OTU2	Result
SPC00015	SPC10048	Streptococcus_thermophilus	Parabacteroides_merd ae	
SPC00006	SPC00061	Bacteroides_sp_1_1_6	Roseburia_intestinalis	++++
SPC00007	SPC00061	Bacteroides_sp_3_1_23	Roseburia_intestinalis	+
SPC00005	SPC00061	Bacteroides_vulgatus	Roseburia_intestinalis	+
SPC00021	SPC00061	Blautia_producta	Roseburia_intestinalis	++++
SPC00026	SPC00061	Clostridium_nexile	Roseburia_intestinalis	-
SPC00027	SPC00061	Clostridium_sp_HGF2	Roseburia_intestinalis	---
SPC00009	SPC00061	Coprobacillus_sp_D7	Roseburia_intestinalis	-
SPC00018	SPC00061	Dorea_formicigenerans	Roseburia_intestinalis	
SPC00057	SPC00061	Dorea_longicatena	Roseburia_intestinalis	-
SPC00008	SPC00061	Enterococcus_faecalis	Roseburia_intestinalis	++++
SPC00001	SPC00061	Escherichia_coli	Roseburia_intestinalis	++++
SPC00022	SPC00061	Eubacterium_eligens	Roseburia_intestinalis	
SPC00054	SPC00061	Faecalibacterium_prausnitzii	Roseburia_intestinalis	
SPC00056	SPC00061	Odoribacter_splanchnicus	Roseburia_intestinalis	-
SPC00061	SPC00061	Roseburia_intestinalis	Roseburia_intestinalis	
SPC00015	SPC00061	Streptococcus_thermophilus	Roseburia_intestinalis	
SPC10415	SPC10470	Blautia_producta	Ruminococcus_bromii	++++
SPC10256	SPC10470	Clostridium_butyricum	Ruminococcus_bromii	++++
SPC10358	SPC10470	Clostridium_orbiscindens	Ruminococcus_bromii	
SPC10325	SPC10470	Clostridium_bolteae	Ruminococcus_bromii	+++
SPC10167	SPC10470	Clostridium_disporicum	Ruminococcus_bromii	
SPC10313	SPC10470	Clostridium_hylemonae	Ruminococcus_bromii	
SPC10202	SPC10470	Clostridium_innocuum	Ruminococcus_bromii	++++
SPC10238	SPC10470	Clostridium_mayombeii	Ruminococcus_bromii	++++
SPC10355	SPC10470	Clostridium_symbiosum	Ruminococcus_bromii	++++
SPC10155	SPC10470	Clostridium_tertium	Ruminococcus_bromii	++++
SPC10097	SPC10470	Collinsella_aerofaciens	Ruminococcus_bromii	++++
SPC10304	SPC10470	Coprococcus_comes	Ruminococcus_bromii	++++
SPC10567	SPC10470	Eubacterium_rectale	Ruminococcus_bromii	+
SPC10386	SPC10470	Faecalibacterium_prausnitzii	Ruminococcus_bromii	
SPC10390	SPC10470	Lachnospiraceae_bacterium_5_1_57FAA	Ruminococcus_bromii	++++
SPC10470	SPC10470	Ruminococcus_bromii	Ruminococcus_bromii	-
SPC10468	SPC10470	Ruminococcus_gnavus	Ruminococcus_bromii	++++
SPC10415	SPC10468	Blautia_producta	Ruminococcus_gnavus	++++
SPC10256	SPC10468	Clostridium_butyricum	Ruminococcus_gnavus	++++
SPC10358	SPC10468	Clostridium_orbiscindens	Ruminococcus_gnavus	++++

SPC1	SPC2	OTU1	OTU2	Result
SPC10325	SPC10468	Clostridium_bolteae	Ruminococcus_gnavus	++++
SPC10167	SPC10468	Clostridium_disporicum	Ruminococcus_gnavus	++++
SPC10313	SPC10468	Clostridium_hylemonae	Ruminococcus_gnavus	+++
SPC10202	SPC10468	Clostridium_innocuum	Ruminococcus_gnavus	++++
SPC10238	SPC10468	Clostridium_mayombeii	Ruminococcus_gnavus	++++
SPC10355	SPC10468	Clostridium_symbiosum	Ruminococcus_gnavus	++++
SPC10155	SPC10468	Clostridium_tertium	Ruminococcus_gnavus	++++
SPC10097	SPC10468	Collinsella_aerofaciens	Ruminococcus_gnavus	++++
SPC10304	SPC10468	Coprococcus_comes	Ruminococcus_gnavus	++++
SPC10386	SPC10468	Faecalibacterium_prausnitzii	Ruminococcus_gnavus	++++
SPC10390	SPC10468	Lachnospiraceae_bacterium_5_1_57FAA	Ruminococcus_gnavus	++++
SPC10470	SPC10468	Ruminococcus_bromii	Ruminococcus_gnavus	++++
SPC10468	SPC10468	Ruminococcus_gnavus	Ruminococcus_gnavus	+++
SPC10030	SPC10197	Bacteroides_ovatus	Ruminococcus_obeum	
SPC00006	SPC10197	Bacteroides_sp_1_1_6	Ruminococcus_obeum	+++
SPC00007	SPC10197	Bacteroides_sp_3_1_23	Ruminococcus_obeum	+++
SPC10019	SPC10197	Bacteroides_sp_D20	Ruminococcus_obeum	
SPC00005	SPC10197	Bacteroides_vulgatus	Ruminococcus_obeum	++++
SPC10081	SPC10197	Bacteroides_vulgatus	Ruminococcus_obeum	
SPC00021	SPC10197	Blautia_producta	Ruminococcus_obeum	++++
SPC00026	SPC10197	Clostridium_nexile	Ruminococcus_obeum	-
SPC00027	SPC10197	Clostridium_sp_HGF2	Ruminococcus_obeum	--
SPC10097	SPC10197	Collinsella_aerofaciens	Ruminococcus_obeum	++++
SPC00009	SPC10197	Coprobacillus_sp_D7	Ruminococcus_obeum	+
SPC00080	SPC10197	Coprococcus_catus	Ruminococcus_obeum	
SPC00018	SPC10197	Dorea_formicigenerans	Ruminococcus_obeum	++++
SPC00057	SPC10197	Dorea_longicatena	Ruminococcus_obeum	-
SPC00008	SPC10197	Enterococcus_faecalis	Ruminococcus_obeum	++++
SPC10001	SPC10197	Erysipelotrichaceae_bacterium	Ruminococcus_obeum	
SPC00001	SPC10197	Escherichia_coli	Ruminococcus_obeum	+++
SPC10110	SPC10197	Escherichia_coli	Ruminococcus_obeum	++++
SPC00022	SPC10197	Eubacterium_eligens	Ruminococcus_obeum	+
SPC00054	SPC10197	Faecalibacterium_prausnitzii	Ruminococcus_obeum	
SPC00056	SPC10197	Odoribacter_splanchnicus	Ruminococcus_obeum	-
SPC10048	SPC10197	Parabacteroides_merdae	Ruminococcus_obeum	
SPC00061	SPC10197	Roseburia_intestinalis	Ruminococcus_obeum	
SPC10197	SPC10197	Ruminococcus_obeum	Ruminococcus_obeum	++++
SPC00015	SPC10197	Streptococcus_thermophilus	Ruminococcus_obeum	+++

SPC1	SPC2	OTU1	OTU2	Result
SPC10211	SPC10233	Bacteroides_caccae	Ruminococcus_torque s	++++
SPC10213	SPC10233	Bacteroides_eggerthii	Ruminococcus_torque s	++++
SPC10030	SPC10233	Bacteroides_ovatus	Ruminococcus_torque s	++++
SPC00006	SPC10233	Bacteroides_sp_1_1_6	Ruminococcus_torque s	++++
SPC00007	SPC10233	Bacteroides_sp_3_1_23	Ruminococcus_torque s	++++
SPC10019	SPC10233	Bacteroides_sp_D20	Ruminococcus_torque s	++
SPC00005	SPC10233	Bacteroides_vulgatus	Ruminococcus_torque s	++++
SPC10081	SPC10233	Bacteroides_vulgatus	Ruminococcus_torque s	++++
SPC00021	SPC10233	Blautia_producta	Ruminococcus_torque s	++++
SPC00026	SPC10233	Clostridium_nexile	Ruminococcus_torque s	+
SPC00027	SPC10233	Clostridium_sp_HGF2	Ruminococcus_torque s	
SPC10097	SPC10233	Collinsella_aerofaciens	Ruminococcus_torque s	++++
SPC00009	SPC10233	Coprobacillus_sp_D7	Ruminococcus_torque s	++++
SPC00080	SPC10233	Coprococcus_catus	Ruminococcus_torque s	+
SPC00018	SPC10233	Dorea_formicigenerans	Ruminococcus_torque s	++++
SPC00057	SPC10233	Dorea_longicatena	Ruminococcus_torque s	
SPC00008	SPC10233	Enterococcus_faecalis	Ruminococcus_torque s	++++
SPC10001	SPC10233	Erysipelotrichaceae_bacterium	Ruminococcus_torque s	+
SPC00001	SPC10233	Escherichia_coli	Ruminococcus_torque s	++++
SPC10110	SPC10233	Escherichia_coli	Ruminococcus_torque s	++++
SPC00022	SPC10233	Eubacterium_eligens	Ruminococcus_torque s	++
SPC00054	SPC10233	Faecalibacterium_prausnitzii	Ruminococcus_torque s	
SPC00056	SPC10233	Odoribacter_splanchnicus	Ruminococcus_torque s	
SPC10048	SPC10233	Parabacteroides_merdae	Ruminococcus_torque s	+
SPC00061	SPC10233	Roseburia_intestinalis	Ruminococcus_torque s	+
SPC10197	SPC10233	Ruminococcus_obeum	Ruminococcus_torque s	++++
SPC10233	SPC10233	Ruminococcus_torques	Ruminococcus_torque s	++++
SPC00015	SPC10233	Streptococcus_thermophilus	Ruminococcus_torque s	+
SPC00006	SPC00015	Bacteroides_sp_1_1_6	Streptococcus_thermo philus	+++

SPC1	SPC2	OTU1	OTU2	Result
SPC00007	SPC00015	Bacteroides_sp_3_1_23	Streptococcus_thermo philus	+++
SPC00005	SPC00015	Bacteroides_vulgatus	Streptococcus_thermo philus	+
SPC00009	SPC00015	Coprobacillus_sp_D7	Streptococcus_thermo philus	+
SPC00008	SPC00015	Enterococcus_faecalis	Streptococcus_thermo philus	++++
SPC00001	SPC00015	Escherichia_coli	Streptococcus_thermo philus	+
SPC00015	SPC00015	Streptococcus_thermophilus	Streptococcus_thermo philus	

CLAIMS

What is claimed is:

1. A therapeutic composition comprising a bacterial population comprising at least three but fewer than nine bacterial strains selected from the group consisting of *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*, wherein the composition is formulated for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.
2. The composition of claim 1, wherein at least one of the bacterial strains is not a colonic bacterium.
3. The composition of claim 1, wherein at least one of the bacterial strains is not obtained from a fecal culture.
4. The composition of claim 1, wherein at least one *Bacteroides* species is detectably present in the mammalian subject prior to administration of the composition.
5. The composition of claim 1, wherein at least one *Bacteroides* species is not detectably present in the mammalian subject prior to administration of the composition, but is detectably present in the mammalian subject at least one hour after administration of the composition.
6. The composition of claim 1, wherein the mammalian subject has not received at least two doses of vancomycin, metronidazole and/or or similar antibiotic compound within one week prior to administration of the therapeutic composition.
7. The composition of claim 1, wherein a single administration is substantially effective to reduce *C. difficile* and/or *C. difficile* toxin content in a mammalian subject to whom the composition is administered.

8. The composition of claim 1, wherein one strain of *E. coli* is present in amounts at least 2, 5, 10, 50, 100 or more than 100 times greater than any other strain of *E. coli* present in the composition.
9. The composition of claim 1, wherein at least three bacterial strains are not present in the composition in equal ratios.
10. The composition of claim 1, wherein at least three bacterial strains are present in a ratio equivalent to the ratio of the bacterial strains in a reference mammalian subject.
11. The composition of claim 1, wherein at least one of the bacterial strains is provided in a concentration of greater than 1×10^9 viable bacteria per gram of composition
12. The composition of claim 1, wherein at least one of the bacterial strains is provided in a concentration of less than 1×10^8 viable bacteria per gram of composition.
13. The composition of claim 1, wherein a plurality of the bacterial strains is provided in a concentration of less than 1×10^8 viable bacteria per gram of composition.
14. The composition of claim 1, comprising no more than nine different bacterial strains, wherein at least two strains are from the group selected from: *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*
15. The composition of claim 1, formulated for oral administration as a solid, semi-solid, gel, or liquid form.
16. The composition of claim 1, formulated in the form of a pill, tablet, capsule, or lozenge.
17. The composition of claim 1, wherein the bacterial strains are substantially encapsulated in an enteric coating.
18. The composition of claim 1, wherein the bacterial strains are substantially inactive prior to localization in the gastrointestinal tract of a mammalian subject to whom the composition is administered.

19. The composition of claim 1, wherein no more than two of the bacterial strains are strains whose growth is substantially inhibited by an equivalent amount of *C. difficile* bacteria.
20. A method of treating a mammalian subject suffering from or at risk of developing a gastrointestinal disease, disorder or condition, comprising the step of administering to the mammalian subject a therapeutic composition comprising a bacterial population comprising at least three bacterial strains, wherein no greater than nine of the bacterial strains are members of bacterial species selected from the group consisting of *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*, wherein the composition is formulated for oral or gastric administration.
21. The method of claim 20, wherein the gastrointestinal disease, disorder or condition is selected from the group consisting of relapsing diarrhea caused by *C. difficile*, ulcerative colitis, colitis, Crohn's disease, and irritable bowel disease.
22. The method of claim 20, wherein the mammalian subject is an agricultural mammal.
23. The method of claim 20, wherein the bacterial population comprises at least six bacterial strains.
24. The method of claim 20, wherein the bacterial population comprises at least six but fewer than ten bacterial strains.
25. The method of claim 20, wherein the therapeutic composition is administered only once prior to improvement of the disease, disorder or condition.
26. The method of claim 20, wherein the therapeutic composition is administered at intervals greater than two days.
27. The method of claim 20, wherein the mammalian subject has not received at least two doses of vancomycin, metronidazole and/or or similar antibiotic compound within one week prior to administration of the therapeutic composition.
28. The method of claim 20, wherein the mammalian subject is not suffering from relapsing diarrhea caused by *C. difficile*.

29. The method of claim 20, wherein the mammalian subject has not previously received an antibiotic compound in the one month prior to administration of the therapeutic composition.
30. A method of treating a mammalian subject suffering from or at risk of developing a gastrointestinal disease, disorder or condition, comprising the step of administering to the mammalian subject the therapeutic composition of any one of claims 1-19.
31. A method of treating a mammalian subject suffering from or at risk of developing a gastrointestinal disease, disorder or condition, or a metabolic disease, disorder or condition selected from the group consisting of diabetes and autism, comprising the step of administering to the mammalian subject a therapeutic composition comprising a bacterial population comprising at least three bacterial strains, wherein no greater than nine of the bacterial strains are members of a bacterial species selected from the group consisting of *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*, wherein the composition is formulated for oral or gastric administration.
32. The method of claim 31, further comprising the step of detecting one or more of the administered bacterial strains in the mammalian subject subsequent to administration.
33. The method of claim 31, wherein the detecting step comprises detecting a 16S nucleic acid sequence in at least one administered bacterial strain.
34. A therapeutic composition comprising a bacterial population comprising at least three but fewer than nine bacterial strains, wherein the bacterial strains comprise 16S nucleic acid sequences at least 97% identical to reference 16S nucleic acid sequences in bacterial strains selected from the group consisting of *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*, wherein the composition is formulated for

- oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.
35. A therapeutic composition comprising a bacterial population comprising at least three but fewer than nine bacterial strains, wherein the bacterial strains comprise *Clostridium innocuum*, *Clostridium ramosum*, and *Clostridium bifermentans*, wherein the composition is formulated for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.
36. A therapeutic composition comprising a bacterial population comprising at least three but fewer than nine bacterial strains, wherein the bacterial strains do not comprise detectable amounts of *Bacteroides ovatus*, *Bacteroides vulgatus*, or *Bacteroides thetaiotaomicron*, wherein the composition is formulated for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition.
37. A method of increasing diversity of a gastrointestinal microbiota in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutic composition comprising a bacterial population comprising at least three but fewer than nine bacterial strains, wherein the bacterial strains comprise 16S nucleic acid sequences at least 97% identical to reference 16S nucleic acid sequences in bacterial strains selected from the group consisting of *Escherichia coli*, *Enterococcus faecalis*, *Clostridium innocuum*, *Clostridium ramosum*, *Clostridium bifermentans*, *Bacteroides ovatus*, *Bacteroides vulgatus*, *Bacteroides thetaiotaomicron*, and *Blautia producta*, wherein the composition is formulated for oral or gastric administration to a mammalian subject in an effective amount for increasing the diversity of the gastrointestinal microbiota of the mammalian subject subsequent to administration.
38. The method of claim 37, wherein the diversity is increased for at least 1 day after administration.
39. The method of claim 37, wherein the diversity is increased for at least 4 days after administration.

40. The method of claim 37, wherein the diversity is increased for at least 7 days after administration.
41. The method of claim 37, wherein the diversity is increased for at least 14 days after administration.
42. The method of claim 37, wherein the diversity is increased for at least 21 days after administration.
43. The method of claim 37, wherein the mammalian subject is suffering from or at risk of developing a disease, disorder or condition other than a gastrointestinal disease, disorder or condition.




Figure 1A

2/7

1 AAATTGAAGAGTTTGATCATGGCTCAGATTGAACGCTGGCGGCAGGCCTA
51 ACACATGCAAGTCGAACG**GTAACAGGAAGAAGCTTGCTCTTTGCTGACGA**
101 GTGGCGGACGGGTGAGTAATGTCTGGGAAACTGCCT**GATGGAGGGGGATA**
151 **ACTACTGGAAACGGTAGCTAATACCGCATAACGTCGCAAGACCAAAGAGG**
201 **GGGACCTTCGGGCCTCTTGCCATCGGATGTGCCAGATGGGATTAGCTAG**
251 TAGGTGGGGTAACGGCTCACCTAGGCGACGATCCCTAGCTGGTCTGAGAG
301 GATGACCAGCCACACTGGAAGTGAAGACACGGTCCAGACTCCTACGGGAGG
351 CAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCCATGCC
401 GCGTGTATGAAGAAGGCCTTCGGGTTGTAAAG**TACTTTCAGCGGGGAGGA**
451 **AGGGAGTAAAGTTAATACCTTTGCTCATTGACGTTACCCGCAGAAGAAGC**
501 ACCGGCTAACTCGTGCCAGGCATGCGCAGGAATACGGAGGTGCAAGCGT
551 TAATCGGAATTACTGGGCGTAAAGCG**CACGCAGGCGGTTTGTTAAGTCAG**
601 **ATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATCTGATACTGGCAAGC**
651 **TTGAGTCTCGTAGAGGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGT**
701 AGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACT
751 CACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGT
801 AGTCCACGCCGTAAACGATGT**CGACTTGAGGTTGTGCCCTTGAGGCGTG**
851 **GCTTCCGGAGCTAACGCGTTAAGTCGACCGCCTGGGGAGTACGGCCGCAA**
901 GGTATAAACTCAAATGAATTGACGGGGGCCCGCACAAAGCGGTGGAGCATG
951 TGGTTTAATTTCGATGCAACGCGAAGAACCTTACCT**GGTCTTGACATCCAC**
1001 **GGAAGTTTTTCAGAGATGAGAATGTGCCTTCGGGAACCGTGAGACAGGTGC**
1051 TGCATGGCTGTCGTCAGCTCGTGTTGTGAAATGTTGGGTAAAGTCCCGCA
1101 ACGAGCGCAACCCTTAT**TCCTTTGTTGCCAGCGGTCCGGCCGGGAAC TCA**
1151 **AGGAGACTGCCAGTGATAAACTGGAGGAAGGTGGGGATGACGTCAAGTCA**
1201 TCATGGCCCTTACGACCAGGGCTACACACGTGCTACAATGGCG**GCATACAA**
1251 **AGAGAAGCGACCTCGCGAGAGCAAGCGGACCTCATAAAGTGCCTCGTAGT**
1301 CCGGATTGGAGTCTGCAACTCGACTCCATGAAGTCGGAATCGCTAGTAAT
1351 CGTGATCAGAATGCCACGGTGAATACGTTCCCGGGCCTTGTACACACCG
1401 CCCGMCACACCATGGGAGTGGGTTGCAAAAGAAG**TAGGTAGCTTAACCTT**
1451 **CGGGAGGGCGCTTAC**CACTTTGTGATTCATGACTGGGGTGAAGTCGTAAC
1501 AAGGTAACCGTAGGGGAACCTGCGGTTGGATCACCTCCTTA

Figure 1B

3/7




Figure 2

4/7




Figure 3




Figure 4




Figure 5




Figure 6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US14/14747

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C12N 1/00 (2014.01)

USPC - 435/252.33, 243, 252.7

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): C12N 1/20, 1/00 (2014.01)

USPC: 435/252.33, 252.1, 243, 252.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MicroPatent (US-G, US-A, EP-A, EP-B, WO, JP-bib, DE-C,B, DE-A, DE-T, DE-U, GB-A, FR-A); Pubmed; Google Scholar; ScienceDirect; bacteroides, clostridium, coli, gastrointestinal, probiotic, composition, dose, administration

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	US 2004/0028689 A1 (BORODY, TJ) February 12, 2004; paragraphs [0002], [0016], [0025]-[0029], [0040]-[0047], [0049], [0085]; Table 1	1, 3-6, 9, 10, 14-24, 27-29, 30/3-30/6, 30/9, 30/10, 30/14-30/19, 31, 35 ----- 2, 7, 8, 11-13, 25, 26, 30/2, 30/7, 30/8, 30/11-30/13, 30/25, 32, 33, 34, 36-43
Y	US 7981411 B2 (NADEAU, E et al.) July 19, 2011; column 1, lines 6-10	7, 25, 30/7, 30/25
Y	US 5,965,128 (DOYLE, M et al.) October 12, 1999; abstract; column 6, lines 32-47	8, 30/8, 36
Y	US 2012/0315249 A1 (OLMSTEAD, SF) December 13, 2012; paragraph [0001], Claims 4, 5	11-13, 30/11-30/13
Y	US 7998473 B2 (BOILEAU, TWM et al.) August 16, 2011; abstract; column 2, lines 8-24; column 10, lines 20-22	26
Y	US 2009/0197249 A1 (GILLEVET, P) August 6, 2009; paragraphs [0009], [0011], [0017], [0018]	32, 33
Y	BROSIOUS, J et al. Complete Nucleotide Sequence Of A 16S Ribosomal RNA Gene From Escherichia coli. PNAS. October 1978; Vol. 75, No. 10; pages 4801-4805; page 4804, figure 4.	34, 37-43

☒ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

09 May 2014 (09.05.2014)

Date of mailing of the international search report

13 JUN 2014

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Shane Thomas

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US14/14747

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BHATIA, A. et al. Propionibacterium Acnes And Chronic Diseases. The Infectious Etiology Of Chronic Diseases: Defining The Relationship, Enhancing The Research, And Mitigating the Effects: Workshop Summary. Editors: Stacey L. Knobler, Siobhan O'Connor, Stanley M. Lemon Marjan Najafi. 2004, pages 74-80; page 74, paragraph 2; downloaded from http://www.nap.edu/catalog/11026.html . ISBN: 0-309-52672-8.	2, 30/2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US14/14747

Box No. 1 **Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:

a. (means)

☐

on paper

☒

in electronic form

b. (time)

☒

in the international application as filed

☐

together with the international application in electronic form

☒

subsequently to this Authority for the purposes of search

2. ☒ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments: